ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 9
ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 9
ii
CONTRIBUTORS
. ....... Amer. M . S . . . . . . . . . Archer. R . A . . . . . . . . Bindra. J . S . . . . . . . . Bloch. A . . . . . . . . . . Campbell. W . C. . . . . . . Carlson. R . G . . . . . . . . Chang. A . Y . . . . . . . . . Chignell. C . F . . . . . . . Claridge. C . A . . . . . . . Daly. J . W . . . . . . . . . Dean. R . R . . . . . . . . . DuCharme. D . W . . . . . . . Eargle. D . H., Jr . . . . . . Flanders. L . E . . . . . . . Fleming. J . S . . . . . . . . Francis. J . E . . . . . . . . Fullerton. D . S . . . . . . . Giles. R . E. . . . . . . . . Gordon. M . . . . . . . . . . Gylys. J . A . . . . . . . . . Harbert. C. A . . . . . . . . Hardy. R . A., Jr . . . . . . Adelstein. G W
67 203 253 214 139 115 270 182 280 95 290 67 50 260 162 75 57 260 85 38 27
1
11
........ Hodson. A . . . . . . . . . Holland. G . F . . . . . . . Jerina. D . M . . . . . . . . Johnson. A . G . . . . . . . Katzenellenbogen. J . A . . . Kenyon. G . L . . . . . . . . Leitner. F . . . . . . . . . MacNintch. J . .E. . . . . . McKinney. G . R . . . . . . . Metcalf. R . L . . . . . . . Mrozik. H . . . . . . . . . Mueller. R . A . . . . . . . Partyka. R . A . . . . . . . Pereira. J . N . . . . . . . Rando. R . R . . . . . . . . Rosenthale. M . E. . . . . . Schwartz. A . R . . . . . . . Shadomy. S . . . . . . . . . Tomeszewski. J . E . . . . . Vernier. V . G . . . . . . . Welch. W . M . . . . . . . . Wheelock. E . F . . . . . . . Herzig. D . J
85 151 172 290 244 222 260 95 75 203 300 115 162 27 172 234 193 128 107 290 19
1 151
ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 9 Sponsored by the Division of Medicinal Chemistry of the American Chemical Society Editor-in- Chief: RICHARD V. HEINZELMAN THE UPJOHN COMPANY KALAMAZOO, MICHIGAN
SECTION EDITORS MAXWELL GORDON
FRANK CLARKE
WALTER MORELAND
WILLIAM WECHTER
ACADEMIC PRESS
@
GEORGE WARREN ROBERT WILEY
New York and London 1974
A Subsidiary of Harcourt Brace Jovanovich, Publishers
ACADEMIC PRESS RAPID MANUSCRIPT REPRODUCTION
COPYRIGHT 0 1974, BY ACADEMIC PRESS, INC. ALL RIGHTS RESERVED. NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION I N WRITING FROM THE PUBLISHER.
ACADEMIC PRESS, INC. 111 Fifth Avenue, New
York. New York 10003
United Kingdom Edition published by ACADEMIC PRESS, INC. (LONDON) LTD. 24/28 Oval Road, London NWl
LIBRARY OF CONGRESS CATALOG CARD NUMBER:66- 26843
PRINTED IN THE UNITED STATES O F AMERICA
V
CONTENTS
............................. ...............................
Contributors
ii
Preface
xi
I. CNS AGENTS Section Editor: Maxwell Gordon, Bristol Laboratories, Syracuse, New York
..............
1
...............
11
1.
Antipsychotic and Antianxiety Agents. Charles A. Harbert and Willard M. Welch, Pfizer, Inc., Groton, Connecticut
2.
Narcotic Antagonists and Analgesics Robert A. Hardy, Jr., Lederle Laboratories, A Division of American Cyanamid Company, Pearl River, New York
3.
Antiparkinsonism Drugs. Vernon G. Vernier, E. I. Du Pont de Nemours & Co., Inc., Newark, Delaware
4.
Psychotomimetic Agents. Richard A. Partyka and Jonas A. Gylys, Bristol Laboratories Syracuse, New York
5.
Abuse of CNS Agents Maxwell Gordon, Bristol Laboratories, Syracuse, New York
.....................
19
.....................
27
.......................
38
11.
Section Editor: 6.
PHARMACODYNAMIC AGENTS
Frank H. Clarke, Ciba-Geigy Corporation, Ardsley, New York
..................
The Etiology of Hypertension. Donald W. DuCharme, The Upjohn Company, Kalamazoo, Michigan
50
vi CONTENTS 7.
.....................
Antihypertensive Agents John E. Francis, Research Department, Pharmaceuticals Division, CIBA-GEIGY Corporation, Ardsley, New York
..............
8. Antiarrhythmic and Antianginal Agents Gilbert W. Adelstein and Richard R. Dean, Searle Laboratories, Chicago, Illinois 9.
......................
Antithrombotic Agents J. Stuart Fleming and John E. MacNintch, Bristol Laboratories, Syracuse, New York
.................
10. Pulmonary and Antiallergy Drugs Ralph E. Giles and David J. Herzig, Warner-Lambert Research Institute, Morris Plains, New Jersey
57
67
75
85
111. CHEMOTHERAPEUTIC AGENTS
Section Editor: George H. Warren, Wyeth Laboratories, Inc., Philadelphia, Pennsylvania
...........................
95
........................
107
......................
115
........................
128
11. Antibiotics F. Leitner and C. A. Claridge, Bristol Laboratories, Syracuse, New York
12. Antifungal Agents Smith Shadomy, Medical College of Virginia, Richmond, Virginia 13. Antiparasitic Agents. W. C. Campbell and H. Mrozik, Merck Institute for Therapeutic Research, Rahway, New Jersey
14. Antiviral Agents.
Andrew R. Schwartz, Hahnemann Medical College and Hospital, Philadelphia, Pennsylvania
vii CONTENTS
......................
139
.....................
151
15. Antineoplastic Agents A. Bloch, Roswell Park Memorial Institute, Buffalo, New York
16. Immunotherapy of Cancer Anita Hodson and E. Frederick Wheelock, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
IV. METABOLIC DISEASES AND ENDOCRINE FUNCTION Section Editor: Walter T. Moreland, Pfizer Inc., Groton, Connecticut
. . . . . . . . . . . . . . 162
17. Prostaglandins and Related Compounds. Richard A. Mueller and Lloyd E. Flanders, G. D. Searle and Co., Chicago, Illinois
. . . . . . . . . . . . . . . . . . 172
18. Disorders of Lipid Metabolism Gerald F. Holland and Joseph N. Pereira, Pfizer Inc., Groton, Connecticut
........................
19. Diabetes Mellitus Albert Y. Chang, The Upjohn Company, Kalamazoo Michigan
182
. . . . . . . . . . . . . . 193
20.
Non-steroidal Antiinflamatory Agents Marvin E. Rosenthale, Wyeth Laboratories, Inc., Radnor, Pennsylvania
21.
Cyclic Nucleotides and Drug Discovery M. Samir h e r and Gordon R. McKinney, Mead Johnson Research Center, Evansville, Indiana
. . . . . . . . . . . . . . 203
viii CONTENTS
V.
TOPICS IN BIOLOGY
Section Editor: William J. Wechter, The Upjohn Company, Kalamazoo, Michigan Section Editorial
........................
213
........................
214
22.
Anti-aging Drugs. Jasjit S. Bindra, Pfizer, Inc., Groton, Connecticut
23.
Affinity Labeling of Hormone Binding Sites. John A. Katzenellenbogen, Department of Chemistry, University of Illinois, Urbana, Illinois
24.
Mechanism-Based Irreversible Enzyme Inhibitors. Robert R. Rando, Dept. of Pharmacology, Harvard Medical School, Boston, Massachusetts
25.
Adjuvants to the Immune System. Arthur G. Johnson, University of Michigan Medical School, Ann Arbor, Michigan
26.
The Cannabinoids: Therapeutic Potentials Robert A. Archer, Lilly Research Laboratories, Indianapolis, Indiana
. . . . . . . . . . . 222
. . . . . . . . . 234
. . . . . . . . . . . . . . . . . 244 . . . . . . . . . . . . 253
VI. Section Editor: 27.
TOPICS IN CHEMISTRY
Robert A. Wiley, University of Kansas, Lawrence, Kansas
. . . . . . . . . . 260
Reactions of Interest in Medicinal Chemistry. Dwight S. Fullerton, George L. Kenyon and Dolan H. Eargle, Jr., Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota and University of California, San Francisco, California
ix CONTENTS 28.
29.
The Intramolecular Diels-Alder Reaction in Organic Synthesis. Robert G. Carlson, Department of Chemistry, University of Kansas, Lawrence, Kansas
. . 270
. . . . . . . . . . . . . . . 280
Drug Binding and Drug Action. . . . Colin F. Chignell, National Heart and Lung Institute, Bethesda, Maryland
. . . . . . . . 290
30. Cytochrome P-450 Monoxygenases in Drug Metabolism J. E. Tomeszewski, D. M. Jerina and J. W. Daly, National Institute of Arthritis, Metabolism and Digestive Diseases, National Institutes of Health, Bethesda, Maryland
31. Use of Chemical Relationships in Design of DDT-Type Insecticides. 300 Robert L. Metcalf, Department of Entomology, University of Illinois, Urbana-Champaign, Illinois
COMPOUND NAME AND CODE NUMBER INDEX.
. . . . . . . . . . . . . . . . . 309
This Page Intentionally Left Blank
xi
PREFACE Our editorial policy continues to be to report annually on the more active fields of interest to medicinal chemists and to cover less regularly new or maturing biomedical topics or fields which have passed their prime. Less than half of this year's topics appeared also in last year's Annual Reports. It may be well to remind the reader that it is not our intent to provide comprehensive literature coverage for the expert in the field; plenty of other publications already serve this purpose. Our aim is to report significant highlights to enable the worker in a related field to recognize developments or concepts which may broaden his approach to his own area or even cause him to delve into a new one. Just as the increasing availability of massive computer-generated bibliographies on a particular topic poses a growing problem for a researcher who wishes to read selectively in a new field, so this same capability makes it more difficult for our chapter authors to be selective in what they choose to discuss. In fact this problem constitutes the editor's most arduous task; the ten-page chapter limit is designed both to achieve desired selectivity of subject matter and to keep the volume within a reasonable price range in this era of soaring costs. For the first time section editors have been given the opportunity to include one-page editorial overviews of their sections; among the objectives of these overviews are to highlight major new developments, emphasize common features in drug actions or disease etiologies or just to permit speculation as a stimulus for new ideas. While only one section editor chose to accept the invitation this year, it is hoped that more will do so in future volumes. A s always, your constructive suggestions for improvement or for new topics are earnestly solicited.
Kalamazoo, Michigan June, 1974
This Page Intentionally Left Blank
Section I
-
CNS Agents
E d i t o r : Maxwell Gordon B r i s t o l L a b o r a t o r i e s , Syracuse, New York Chapter 1. A n t i p s y c h o t i c and A n t i a n x i e t y Agents Charles A. Harbert and W i l l a r d M. Welch P f i z e r I n c . , Groton, Conn. 06340 I n t r o d u c t i o n - Although s e v e r a l promising a g e n t s have p r o g r e s s e d t o advanced c l i n i c a l s t a g e s , no fundamentally new a n t i p s y c h o t i c o r a n t i a n x i e t y a g e n t s w e r e i n t r o d u c e d i n t h e U.S. i n 1973. Clozapine has emerged as t h e focus of c l i n i c a l and t h e o r e t i c a l i n t e r e s t i n t h e a n t i p s y c h o t i c area based on i t s extremely low i n c i d e n c e of e x t r a p y r a m i d a l s i d e r e a c t i o n s . This d i s c o v e r y h a s given new impetus t o r e s e a r c h d i r e c t e d toward an und e r s t a n d i n g of t h e biochemical and n e u r o p h y s i o l o g i c a l c o r r e l a t e s of a n t i p s y c h o t i c a c t i o n and e x t r a p y r a m i d a l m a n i f e s t a t i o n s . A c t 2 v i t y i n t h e a n t i a n x i e t y area a g a i n l a r g e l y focused on a g e n t s s t r u c t u r a l l y and mechani s t i c a l l y r e l a t e d t o t h e benzodiazepines. Extensive treatises have covered t h e c h e m i s t r y , b i o c h e m i s t r y , pharmacology and c l i n i c a l u t i l i t y of t h e b e n z o d i a z e p i n e s l and t h e n e u r o l e p t i c s . 2 A n t i p s y c h o t i c Agents - T r i c y c l i c s - S t r u c t u r e - a c t i v i t y r e l a t i o n s h i p s (SAR) of t h e t r i c y c l i c p s y c h o t h e r a p e u t i c s 3 and c l i n i c a l e x p e r i e n c e w i t h t h e l o n g - a c t i n g n e u r o l e p t i c s 4 9 5 have been reviewed. Emphasis continued t o s h i f t from s t r u c t u r e s w i t h 6 , 6 , 6 r i n g systems t o t h e 6 , 7 , 6 - t r i c y c l i c s . Among t h e l a t t e r , c l o z a p i n e (A) h a s a t t r a c t e d t h e most i n t e r e s t . A r e c e n t review6 h i g h l i g h t s t h e unique p r o f i l e of t h i s agent and t h e a u t h o r p o i n t s out some troublesome s i d e e f f e c t s (hypotension, t a c h y c a r d i a ) t h a t may l i m i t i t s c l i n i c a l use. Regardless, t h e emergence of c l o z a p i n e has reemphasized t h e f e a s i b i l i t y of d i s a s s o c i a t i n g a n t i p s y c h o t i c a c t i v i t y from t h e c a t a l e p t i c p r o p e r t i e s t h a t have been c l a s s i c a l l y regarded as a prerequisite f o r c l i n i c a l therapeutic activity. 7 a)XmH ;ZICH b ) X r C l ; Z n C H c ) X = H ; Z = N d) X I C1 ; Z = N e ) X = O E t ; Z = CH f ) X I OCH3;Z = CH _.
H
6
4
Continuing SAR s t u d i e s i n t h e d i b e n z o [ b , f ] t h i e p i n and r e l a t e d 6 , 7 , 6 systems have shown t h a t s u b s t i t u t i o n by c h l o r i n e i n t h e 9 - p o s i t i o n of p e r a t h i e p i n (&) r e s u l t s i n diminished a c t i v i t y .8 A l l e i g h t p o s s i b l e aryl-monochloro isomers of p e r a t h i e p i n have now been s y n t h e s i z e d , and of
2 -
Sect. I
-
CNS Agents
Gordon, Ed.
t h e s e only t h e 8 - C 1 isomer ( o c t o c l o t h e p i n , &) i s more p o t e n t t h a n t h e p a r e n t compound. Octoclothepin enantiomers and t h e racemate were found t o d i f f e r l i t t l e from each o t h e r i n CNS d e p r e s s a n t e f f e c t s o r i n t o x i c i t y . ' The 4-aza a n a l o g s & and 2d showed markedly reduced depress a n t and c a t a l e p t i c a c t i v i t y compared w i t h 3 and 2, r e s p e c t i v e l y . l O , l l Among s e v e r a l 8-alkoxy analogs prepared, o n l y t h e 8 - E t 0 isomer (&) e x h i b i t e d a c t i v i t y (1OX chlorpromazine [CPZ] i n t h e r o t a t i n g rod t e s t ) e q u i v a l e n t t o t h e known 8-Me0 d e r i v a t i v e ( 2 f , octometothepin) .I2 Oxid a t i o n of t h e S atom and/or 4'-N atom i n a number of d i b e n z o [ b , f ] t h i e p i n s r e l a t e d t o 1. r e s u l t e d i n a uniform l o s s of CNS d e p r e s s a n t a c t i v i t y . 1 3 EX 11-582A (3) p o s s e s s e s p o t e n t a c t i v i t y i n t h e f i g h t i n g mouse (ED50 0.9 mg/kg) and antiamphetamine t o x i c i t y (ED50 0.28 mg/kg) t e s t s . 1 4 Like c l o z a p i n e , t h i s compound was i n a c t i v e a g a i n s t apomorphine-induced emesis.
q y
a) R CF3
c1
CHCHzCHzN(CH3
3 -
)2
-
a;Q CH,;
Z
I
N
I
R
b) R
-4
I
L c1
S
C H 2 9 ; Z
=
N (CH, ) 2
S
-5
A r e c e n t paper of t h e o r e t i c a l i n t e r e s t r e p o r t e d p o t e n t n e u r o l e p t i c a c t i v i t y f o r a number of p i p e r i d y l i d e n e t h i o x a n t h e n e s (4,Z=S) and r e l a t e d s t r u c t u r e s (4, Z=O o r NCH3); f o r example, 4a and 4b were r e s p e c t i v e l y 7 and 1 8 X CPZ i n t h e r a t p t o s i s t e s t . 1 5 S i g n i f i c a n t l y , many of t h e s e compounds were more p o t e n t t h a n t h e i r corresponding t r i c y c l i c congeners w i t h nonr i g i d s i d e c h a i n s . Since k cannot assume t h e s o l i d s t a t e c o n f i g u r a t i o n t h e a u t h o r s q u e s t i o n e d earlier s p e c u l a t i o n s t h a t t h e a c t i v e of CPZ c o n f i g u r a t i o n of a n t i p s y c h o t i c s resembles t h a t of c r y s t a l l i n e CPZ. Rather, t h e i r f i n d i n g s are c o n s i s t e n t w i t h t h e S - c o n f i g u r a t i o n of a n t i p s y c h o t i c d r u g s f r e q u e n t l y d e p i c t e d by Janssen.7 I n a r e l a t e d paper, NMR s h i f t r e a g e n t s were used t o determine t h e s t e r e o c h e m i s t r y of and t r a n s aminoalkylidene xanthenes and thioxanthenes . I 6 As expected, n e u r o l e p t i c a c t i v i t y predominated i n t h e cis series.
(z),
An i m p o r t a n t pharmacokinetic s t u d y c o r r e l a t e d CPZ plasma l e v e l s w i t h t h e r a p e u t i c response and found t h a t plasma l e v e l s i n t h e range of 150-300 ng/ml u s u a l l y corresponded t o c l i n i c a l improvement . I 7 S i g n i f i c a n t l y , concomitant a d m i n i s t r a t i o n of an a n t i p a r k i n s o n agent ( t r i h e x y p h e n i d y l ) tended t o lower plasma l e v e l s of CPZ, an e f f e c t a s c r i b e d t o reduced g a s t r i c mot i l i t y and d e c r e a s e d a b s o r p t i o n of CPZ. Butyrophenones, P h e n y l p i p e r a z i n e s , and R e l a t e d Compounds - Bromoperidol (&) i s e s s e n t i a l l y e q u a l t o h a l o p e r i d o l i n potency and d u r a t i o n of a c t i o n . 1 8 The trans-4-aryl-4-methoxycyclohexylaminobutyrophenone 6b exceeded h a l o p e r i d o l on s e v e r a l b e h a v i o r a l e n d p o i n t s and exhibitedh i g h l y s e l e c t i v e (vs. 5-HT) NE uptake blockade.19 Compound &, t h e most p o t e n t (15X CPZ i n c o n d i t i o n e d avoidance response [CAR]) i n a series of s u b s t i t u t e d pyrazino[2',1':6,l]pyrido[3,4-b]indoles, was r e p o r t e d t o have a prolonged d u r a t i o n of a c t i o n and few c a r d i o v a s c u l a r
Antipsychotic and Antianxiety Agents Harbert, Welch 2
Chap. 1
effects .20 Centpyraquin (6d, compound 69-183) combined neuroleptic activity (ca. CPZ in CAR) with significant hypotensive effects.21 AHR-2277 (lenperone, 6 e ) exerted a rapid and favorable effect on psychotic symptomatology, and was claimed to produce a very low incidence of neurological side reactions.22 A double-blind study of AL-1021 (6f) in hospitalized schizophrenics failed to confirm earlier encouraging results obtained in pilot study.23 Milipertine (&) produced troublesome EPS side effects in schizophrenics at doses well below those required to produce antipsychotic activity.24 Compound j’&was one of a series reported to exhibit CNS depressant activity in animals roughly in the CPZ range.25 Oxazolidinone 7c blocked isolation-induced aggression in mice (ca. 0 . 5 X CPZ);26 a similar level of activity in this test was seen with the related compounds 8a and &.27
-6
H
7 m
7b) X
I
OCH3; Y
= H; R =
-
R
-8
COCH3 CH2CHOHCH206
8b)
R
(CH,),OCONHCH,
Miscellaneous Compounds - A benzodiazep ne, SCH- 2,041 (2, halazepam), showed evidence of efficacy against acute psychotic symptoms in an uncontrolled tria1.28 CI-686 (10)was predicted to have major tranquilizer activity of short duration on the basis of quantitative pharmaco-EEG studies.29 Butaclamol (11, - AY-23,028) possessed pharmacological actions resembling fluphenazine, with activity residing solely in the (+)-enantiomer.30,31 The SAR of several cannabinoids nas been reexamined and
Sect. I
4 -
-
CNS Agents
Gordon, Ed.
found to differ significantly from earlier reports.32 A comparison study in the same paper showed 12 to be 3-15X CPZ in decreasing motor activity and in blocking fighting behavior in mice.
10 -
-9
11 -
OH
12 -
Antianxiety Agents-Benzodiazepines and Related Compounds - The drug therapy of anxiety33~34 and the effect of benzodiazepines in controlling aggressive behavior35 were reviewed. It was argued that conformational similarities between diphenylhydantoin and diazepam36 do not constitute an appropriate basis for comparing their biological activities.37 A series of benzodiazepines with a,a-dihydroperfluoroalkyl groups at N-1 were found to successfully block metabolism at N-1 as predicted. One of these, nalazepam (Sch 12,041, 2 ) , appeared to be more specific than diazepam in anticonvulsant (pentylenetetrazole, PTZ) and traction endpoints, with lower side effect potential (therapeutic index 4X diazepam). 38 The ,39 and ID-540 (13b)hO related compound, fletazepam (Sch 15,698, were claimed to be skeletal muscle relaxants. Clonazepam (Ro 5-4023, 13c) was more active against seizures induced by i.v. lidocaine than Ro 8-4192 (E) or diazepam.41 Compound from a novel series =her of 7-azidobenzodiazepines, demonstrated sedative and anticonvulsant properties equivalent to diazepam.42
e)
e,
1 ‘
2
7 5
13 2
K 3 -N
c1
14a) 2 -NHOCH2CH2=CH2 14b) 2-NHCONHCOOC2 Hcj 14c) 2 - N 7 - H
\’. 14 -
0
Chap. 1
Antipsychotic and Antianxiety Agents
Harbert, Welch
2
Pharmacological studies indicated uldazepam (U-31,920, 3) to be an effective antianxiety drug with weak sedative and muscle relaxant prowas nearly equivalent to diazepam in perties.43 The urea derivative several behavioral and convulsant (thiosemicarbazide) end points ,44 wherewere less active in the same tests. as the related 2-imidazolidones (&) A number of 1,3-dialkylpyrazolo[4,3-e]diazepinones exhibited potent CNS activity and one of these, pyrazapon (CI-683, 2) showed anxiolytic activity equivalent to diazepam in man.45 SAR studies showed that hydrogen is preferred at N-4 and that 1,3-dialkyl substitution is superior to the 2,3-pattern of the isomeric series (16).
=
15 -
16 -
18 -
Several series of triazolobenzodiazepines (17) with CNS depressant the most potent of the 3activity have been reported. D-40TA (E), unsubstituted triazoles, was highly active as a tranquilizer, sedativehypnotic and muscle relaxant in animal^.^^-^^ Triazolam (U-33,030, =) exhibited hypnotic activity in man at 0.25-2.0 mg. 49 The anticonvulsant and antiaggressive potencies of U-31,957 (G) and U-35,005 (G) exceeded those of the corresponding diazepam analogs, but they were only weakly active in end points measuring overt depression (traction, EtOH) .50 Alprazolam (U-31,889, 17e)51 demonstrated a marked and rapid anxiolytic effect in man as had been predicted from its EEG profile.52 Chlordiazepoxide isosteres in the triazolobenzodiazepine series (e.g. 17f) were consistently inactive.46,53 The triazinodione 18was equal to diazepam on several behavioral end points and was 0.3X diazepam against PTZ convulsions and EtOH narcosis.44 The 1,5-benzodiazepine triflubazepam (ORF-8063, =)possessed antianxiety properties in man at 40-160 mg/day,54,55 with a profile similar to diazepam.56 Like most lY4-benzodiazepines it was primarily metabolized through N-dealkylation, but was otherwise hydroxylated in the N-phenyl ring rather than at C-3.57 Pharmacokinetic studies with
6 -
Sect. I
-
CNS Agents
Gordon, Ed.
t r i f l u b a z e p a m showed c l i n i c a l improvement t o b e c o r r e l a t e d w i t h blood l e v e l s of 0.5 t o 1 . 0 ng/m1.58 Clobazam w a s claimed t o be b e t t e r t o l e r a t e d t h a n c h l o r d i a z e p o x i d e i n pharmacological and t o x i c o l o g i c a l s t u d i e s . 59 The 1,5-benzodiazepine r e l a t i v e s of c h l o r d i a z e p o x i d e , 20a and E , p r o t e c t e d mice a g a i n s t c o n v u l s i o n s produced by PTZ, s t r y c h n i n e (ST) and t r e m o r i n e , and were less d i s r u p t i v e t h a n c h l o r d i a z e p o x i d e on tests of motor c o o r d i n a t i o n . 6 0
(w)
2
CH3
7
Q;Jo I 19
C6H5
OZN
19a) 7-CF3 19b) 7-C1
l o C6H5
20 -
20a) 2-M12 20b) 2-N(CH3 )2
Other S t r u c t u r e s w i t h A n t i a n x i e t y A c t i v i t y - The o x y p e r t i n e a n a l o g s 21a and 21b induced a t a x i a , d e c r e a s e d locomotor a c t i v i t y and antagonizede l e c t r o s h o c k (ES) and ST c o n v u l s i o n s i n mice 0.25 diazepam).61 I n d o l e d e r i v a t i v e s U-5092 and U-13,625 (G) p r o t e c t e d mice a g a i n s t ES-induced c o n v u l s i o n s and produced a CPZ-like t r a n q u i l i z i n g e f f e c t . 62 I n a double-blind s t u d y a g a i n s t a n x i e t y , 200 mg opipramol (22) w a s e q u i v a l e n t t o 30 mg c h l o r d i a z e p o x i d e .63 The i s o q u i n o l i n e d e r i v a t i v e 23 and t h e b e n z o t h i a z e p i n e d e r i v a t i v e 2 4 possessed marked CNS a c t i v i t y i n mice c h a r a c t e r i z e d by g e n e r a l d e p r e s s i o n and a n t i c o n v u l s a n t (ES, PTZ, ST) a c t i v i t y . 6 4 , 6 5 The R enantiomers of a series of 1 - a m i n o t e t r a l i n s (e.g. 25) s u p p r e s s e d c o n d i t i o n e d emotional response (CER) i n rats a t 10 I n t e r e s t i n g l y , t h e S isomers were devoid of CER a c t i v i t y , b u t mg/kg. possessed marked a n t i c a t a l e p t i c ( t e t r a b e n a z i n e ) a c t i v i t y . 66 Although 26a and 26b resemble known m e t a b o l i t e s of 1,4-benzodiazepine t r a n q u i l i z e r s , t h e y e x h i b i t e d o n l y v e r y weak anti-PTZ and ES a c t i v i t y , and showed no taming e f f e c t i n i s o l a t e d mice.67
(z)
2l a
(=.
Chap. 1
A n t i p s y c h o t i c and A n t i a n x i e t y Agents
H a r b e r t , Welch
7
$yJ 0
OCH3 25
-
26 -
b)
1-OH
B i o l o g i c a l Observations and Hypotheses - The r o l e of dopamine r e c e p t o r b l o c k i n g a g e n t s i n t h e t r e a t m e n t of schizophrenia68 and t h e m e c h a n i s t i c r e l a t i o n s h i p of t h e a n t i p s y c h o t i c e f f e c t s of n e u r o l e p t i c s t o t h e i r e x t r a pyramidal (EPS) e f f e c t s @ have been reviewed. S e v e r a l hypotheses have been advanced t o account f o r c l o z a p i n e ' s low i n c i d e n c e of EPS r e a c t i o n s , 6 most of which invoke i t s a t r o p i n e - l i k e a n t i c h o l i n e r g i c a c t i v i t y . For example, c l o z a p i n e causes a g r e a t e r i n c r e a s e i n homovanillic a c i d l e v e l s i n t h e l i m b i c system than i n t h e s t r i a t u m , w h i l e h a l o p e r i d o l shows no s e l e c t i v i t y i n t h e s e p o r t i o n s of t h e b r a i n . However, when an a n t i c h o l i n e r g i c agent is coadministered w i t h h a l o p e r i d o l an e f f e c t resembling t h a t of c l o z a p i n e i s o b t a i n e d , 70 c o n s i s t e n t with r e c e n t evidence t h a t c h o l i n e r g i c pathways modulate dopaminergic a c t i v i t y i n t h e s t r i a t u m , but n o t i n t h e l i m b i c system. 7 l T h e r e f o r e , c l o z a p i n e ' s a n t i c h o l i n e r g i c properties may f o r t u i t o u s l y balance i t s EPS e f f e c t i n t h e s t r i a t u m w i t h o u t a t t e n u a t i n g i t s a n t i p s y c h o t i c e f f e c t . The r e c e n t observation72 t h a t CPZ enhances a c e t y l c h o l i n e output i n t h e s t r i a t u m of cannulated c a t s provides t h e f i r s t d i r e c t evidence t h a t n e u r o l e p t i c drugs a c t i v a t e t h e c h o l i n e r g i c s y s t e m and s u p p o r t s t h e p o s t u l a t e d e x i s t e n c e of an interdependent and a n t a g o n i s t i c c h o l i n e r g i c-d op aminer g i c neuronal network .73 F u r t h e r evidence f o r t h e e x i s t e n c e of a neuronal feedback mechanism c o n t r o l l i n g DA t u r n o v e r i n b r a i n came from a r e p o r t t h a t a n t i p s y c h o t i c drugs i n c r e a s e t h e r a t e of f i r i n g of dopaminergic neurons i n t h e s u b s t a n t i a n i g r a and t h e v e n t r a l tegmental area. 74 Recent papers a l s o suggested t h a t y-hydroxybutyric a c i d (GHB) 75,76 and y-aminobutyric a c i d (GABA) 77 may r e g u l a t e t h i s feedback mechanism. I f t h e s e f i n d i n g s are s u b s t a n t i a t e d GHB and GABA w i l l provide v a l u a b l e t o o l s t o s t u d y t h i s feedback mechanism and i t s r e l a t i o n s h i p t o n e u r o l o g i c a l m a n i f e s t a t i o n s such as c a t a l e p s y i n animals, and EPS s i d e e f f e c t s and t a r d i v e d y s k i n e s i a i n man. The import a n c e of i d e n t i f y i n g e x i s t i n g o r new b i o l o g i c a l tests t h a t r e l a t e more s p e c i f i c a l l y t o a n t i p s y c h o t i c a c t i v i t y i n man was emphasized i n two r e c e n t papers which claimed t h a t b i o l o g i c a l endpoints showing t o l e r a n c e (e.g. s t e r e o t y p e d behavior) do n o t assess p o t e n t i a l a n t i p s y c h o t i c e f f e c t s i n man, b u t r a t h e r only measure p r o p e n s i t y t o cause EPS e f f e c t s . 7 8 9 7 9 A new technique t o assess changes i n NE s y n t h e s i s i n rat b r a i n measures t h e accumulation of 3-methoxy-4-hydroxyphenylethyleneglycol (MOPEG), a major NE m e t a b o l i t e . 8 0 This method w a s claimed t o be more convenient than c o n v e n t i o n a l methods u t i l i z i n g exogeneous a-methylp-tyrosine o r l a b e l e d t y r o s i n e , and t o avoid e r r o r s t h a t might b e
8
Sect. I
-
CNS Agents
Gordon, Ed.
introduced by i n t e r a c t i o n of t h e s e agents w i t h t h e t e s t compound. The s e d a t i v e a c t i v i t y of n e u r o l e p t i c s appears t o c o r r e l a t e w e l l w i t h t h e i r a b i l i t y t o i n c r e a s e MOPEG levels i n b r a i n . 8 1 S e v e r a l r e c e n t r e p o r t s have i m p l i c a t e d enzyme def i c i e n c e s o r a b n o r m a l i t i e s i n t h e pathophysiology of s c h i z o p h r e n i a . Post-mortem b r a i n specimens of s c h i z o p h r e n i c s showed a s i g n i f i c a n t r e d u c t i o n i n dopamine-8-hydroxylase a c t i v i t y vs. normals i n a l l b r a i n r e g i o n s examined.82 Monoamine oxidase (MAO) a c t i v i t y w a s found t o be s i g n i f i c a n t l y lower i n t h e p l a t e l e t s of s c h i z o p h r e n i c and non-schizophrenic monozygotic twin p a i r s when compared t o normal c o n t r o l s , s u g g e s t i n g t h a t decreased MA0 a c t i v i t y might be a g e n e t i c marker f o r v u l n e r a b i l i t y t o s c h i z o p h r e n i a . 83 An N-methyltransferase capable of forming dimethyltryptamine (DMT) , a known h a l l u c i n o g e n , was found i n human red blood c e l l s , plasma, and p l a t e l e t s . 8 4 S i g n i f i c a n t l y t h e a c t i v i t y of t h i s enzyme i n p l a t e l e t s w a s h i g h e r i n p s y c h o t i c s u b j e c t s than i n nonpsychotics, a f i n d i n g a p p a r e n t l y r e l a t e d t o an u n i d e n t i f i e d d i a l y z a b l e i n h i b i t o r pres e n t i n normal s u b j e c t s , b u t n o t i n p s y c h o t i c s . A non-specific N-methylt r a n s f e r a s e i s o l a t e d from rat b r a i n w a s found t o be s i m i l a r l y c o n t r o l l e d by a d i a l y z a b l e i n h i b i t o r . 8 5 DMT and b u f o t e n i n have been i d e n t i f i e d i n t h e u r i n e of a u t i s t i c c h i l d r e n 8 6 and c h r o n i c s c h i z o p h r e n i c s , 87 b u t no d i f f e r e n c e between plasma DMT l e v e l s i n c o n t r o l s and s c h i z o p h r e n i c s w a s e v i d e n t i n a r e c e n t study.88 Although S-adenosylmethionine h a s been viewed f o r many y e a r s as t h e methyl donor r e s p o n s i b l e f o r t h e 0- and N-methylation of b i o g e n i c amines, t h e involvement of 5-methyltetrahydrof o l i c a c i d i n t h e s e t r a n s f o r m a t i o n s h a s now been f i r m l y e s t a b l i s h e d . 8 9 , g 0 Accordingly, i t h a s been p o s t u l a t e d r e c e n t l y t h a t t h e cause of schizop h r e n i a might b e an overabundance of f o l a t e coenzymes, r e s u l t i n g i n e x c e s s i v e N-methylation of b i o g e n i c amines i n b r a i n . 8 9 Diazepam appears t o e x e r t a d i r e c t a c t i o n a t t h e s p i n a l level by i n c r e a s i n g segmental p r e s y n a p t i c i n h i b i t i o n and by d e c r e a s i n g o r s u p p r e s s i n g p r e s y n a p t i c c o n t r o l s of s u p r a s p i n a l o r i g i n . 91 Benzod i a z e p i n e s appear t o d e c r e a s e NE turnover by reducing impulse a c t i v i t y i n t h e l o c u s coeruleus r a t h e r t h a n by a d i r e c t i n t e r f e r e n c e w i t h release of NE from t h e nerve terminals.92 R e p e t i t i v e dosing may, however, r e v e r s e t h i s i n h i b i t o r y e f f e c t i n t h e "reward s t r u c t u r e s " w h i l e m a i n t a i n i n g t h e i n h i b i t o r y e f f e c t upon t h e "aversive s t r u c t u r e s .'Ig3 Benzodiazepines may f o r t i f y t h e mechanisms of p h y s i o l o g i c a l s t a b i l i z a t i o n of n e u r o n a l nerve t e r m i n a l membranes by f a c i l i t a t i n g t h e formation, release o r a c t i o n of p r o s t a g l a n d i n s .94 A combination of i n h i b i t i o n of 2-M phosphodiesterase a c t i v i t y and i n h i b i t i o n of 5-HT turnover i n t h e midbrain raph6 region i n rats may be r e s p o n s i b l e f o r c h l o r d i a z e p o x i d e ' s a b i l i t y t o s u p p r e s s a g g r e s s i v e behavior .95 REFERENCES
1 2.
"The Benzodiazepines", Eds. S . Garattini, E . Mussini and L . 0 . Randall, Raven Press, New York. 1 9 7 3 , 685 pp. " I c r d u t r l a l Pharmacology, Neuroleptics", Vol. 1, Eds. S . Fielding and H . Lal, Futura Publishing (ompauy, Mount Kisro, New York, 1974. 349 pp.
Chap. 1
3. 4. 5. 6. 7. 8.
9. 10. 11. 12 * 13.
14. 15. 16. 17. 18.
10. 20. 21. 22 *
23. 24. 25. 26. 21.
28. 29.
30.
31. 32.
33. 34. 35. 36. 37.
38. 39. 40. 41.
42. 4).
44. 45. 40.
47. 48. 49.
SO. 51.
52.
Antipsychotic and Antianxiety Agents
Harbert, Welch
J. Schumtz, Pharm. Acta. Helv., 68, 117 (1973). 0 . Bakke, Acta P s y c h i a t . Scand. 9, Suppl. 246,32 (1973) and o t h e r articles i n Suppl. 246. N . W . lmlah and K. P. Murphy, T h e r a p i e , 28, 587 (1973) and o t h e r a r t i c l e s i n T h e r a p i e . 28, No. 3 (1973). F. J. Ayd, J r . , I n t . Drug Ther. Newsletter, E ( 2 - 3 , 5 (1974). P. A. J. Janssen i n "Modern Problems in Pharmecopsychiatry. The Neuroleptcis". Vol. 5 , D. P. Bobon, P. A. J. Janssen, and J. Bobon, Eds., S. Karger, Baael, 1970, p. 33. K. S i n d e l l r , B. Kaklc, J. Metysovl. and M. P r o t i v a , Farmaco, Ed. S c i . , 28. 256 (1973). J . 0. J f l e k , K. S i n d e l l r , J. Pomykdcek, 0. Horesovekf. K. P e l z , E. S v l t z , 8 . Knklc. J. Holubek, J. Metysovl and M. P r o t i v a , C o l l e c t . Czech. Chem. Comun., 38, 115 (1973). V. B d r t l , J. Metysovl. and M. P r o t i v a , 38, 1693 (1973). 38, 2778 (1973). V . B d r t l , J. Metysovl and M. P r o t i v a , S., K. S i n d e l l r , B. KakBc, E. S v l t e k , J. Metysov6 and M. P r o t i v a , 38, 1579 (1973). J . 0. J f l e k , K. Metysovl. E. S v l t e k , F. J a n f i k , J. Pomykdcek and M. P r o t i v a , 38. 599 (1973). F. P. Miller, D. Gauger and G. Garske. Fed. Proc., Fed. Amer. S O C . Exp. B i o l . , 32, 785 Abs. (1973). L. Kaiser, P. J. Fowler, D. H . Tedeschi, 8. M. Lester. E. Garvey, C. L. Z i r k l e . E . A. N o d i f f , and A. J. Saggiomo, J. Med. Chem., 17,57 (1974). L. K a i s e r , R. J. Warren and 5. L. Z i r k l e , J. Med. Chem., l7, 1 3 1 (1974). L. Rivera-Calimlim, L. Castaneda and L. Lasagna, Clin. Pharmcol. Therap.. 16, 978 (1973). c. J. E. Niemegeers and P. A, J. J a n s s e n , Arnzeim.-Forech., 24, 45 (1974). u. L e d n i c e r , D. E. Enmert, R. L a h t i and A. D. Rudzik, J. Med. Chem., 16. 1251 (1973). A. K . Saxena, P. C. J a i n , N. Anand and P. R. Dua, l6, 560 (1973). G . u. Singh, S. Nityanand, R. C. S r i m a l , V. A. Rao. P. C. J a i n and 8. ti. Dhawan. E x p e r i e n t i a , 29, 1529 (1973). H. C. Denber, Ann. Med. Psychol., 131, 1 3 1 (1973). J. L. Gendron, R. L. Zimmerman and B. C. S c h i e l e , Curr. Therap. Res., C l i n . Exp.. 2, 333 (1973). I). Mielke, D. M. G a l l a n t and M. P. Bishop, g,324 (1973). 5 . N . R a s t o g i , N. Anand. P. P. Gupta and J. N . Sharma, J. Mad. Chem., 16, 797 (1973). M. L. F i e l d e n , W. J . Welstead, J r . , N. D. Dawson. Y.-H. (hen, R. P. Mays, J. P. DaVanzo and C . D. Lunsford, .6, 1124 (1973). W . 1 . Welstead, J r . , G . C. H e l s l e y , C. R. T a y l o r , L. B. T u r n b u l l . J. P. DaVmtO, W. H. Funderburk and R. S. Alphin, g,1129 (19731. K. Y . Ota, A. A. Kurland and P. Ferro-Diaz, Curr. Therap. Res.. C l i n . Em., 15, 327 (19731. T . M. I t i l , J. Maraaa, A. Bigelow and 8. S a l e t u , 16,80 (1974). K . Voith, Abstr. of Papers. 167th Nat. Mtg. Amer. Chem. SOC., Loa Angafep. C a l i f o r n i a . March 31-April 5 , MEDI 6 , 1974. 1 . G . Humher and F. B r u d e r l e i n , MEDI 5 , 1974. R. Loev, P. E. Bender, F. Dowalo, E . Macko and P. J . Fowler, J. Med. Chem., 16. 1200 (1973). G . N . Aagaard and H. W. E l l i o t , P o s t g r a d u a t e Medicine, & 159 (1973). u . Kelly, P r a c t i t i o n e r , 210, 44 (1973). A. DiMascio, Psychopharmacologia, 2,95 (1973). A . Camerman and N . Camerman, J. Amr. Chem. SOC., 96, 268 (1972). I . It. Sternbach, F. D. S a n c i l l i o and J . F. Blount, J . Med. Chem., 17,374 (J974). M . steinman, J. G . T o p l i s s , R. A l e k e l , Y . - S . Wong, and E. E . York, 16. 1354 (1973). 1 . Aner. Med. Assor., 227. 938 (1974). U n l i s t e d Drugs, 22. 2 (1974). (,. Gogollk, C h . Stwnpf and Ch. T s c h a k a l o f f , Arzneim.-Forech., 23, 545 (1973). R . Y . Ning and L. 0 . R a n d a l l , 1 . Med. Chem., 16,879 (1973). J. 8. H e e t e r , Jr. and A. D. Rudzik, G., 17, 293 (1974). R . 8. Moffett and A. D. Rudzik, W., 1 6 , 1256 (1973). H . A . DeWald, I . C. Nordin, Y. J. L ' I t a E e n and R. F. P a r c e l l . 16,1346 (1973). K . Meguro and Y . Kuwada, Chem. Phann. B u l l . (Tokyo), 21, 2375 (1973). rake, Y. I t o h and Y . Nagawa, Jap. J. Pharmacol., 23. Suppl., 77 (1973). Ikeda, Y. H. 5 . Chiba and Y. Nagawa, G., 2,83 (1973). r . Roth, M. Kramer and J. L. Schwartz, Curr. Ther. Res., C l i n . Exp., 16,1 1 7 (1974). 205 (1973). A . I). Rudzik, J. B. H e s t e r and W. F r i i s , Pharmacologist. g, T . M. I t i l , N. Polvan, S. Egilmez, B. S a l e t u and J. Marasa. Curr. Ther. M a . , C l h . Exp., 15, 603 (1973). T. PI. I t i l , B. S a l r t u , J . Mnrasa and A. N . Mucciardi, Pharmakopsychist., 2, 225 (1972).
w..
u.,
s.,
u.,
-
a.,
m.,
w.,
a..
a.,
s.,
w.,
9
10 -
53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78 * 79. 80. 81. 82 * 83. 84. 85.
86. 87. 88.
89. 90. 91.
92. 93.
94. 95.
Sect.
I
-
CNS Agents
Gordon, Ed.
Y. Kuwada, Chem. Pharm. B u l l . (Tokyo), 2382 (1973). L). M. G a l l a n t , W. C. Swanson, D. H. Mielke and R. Guerrero-Figueroa. Curr. Therap. Res.. Clin. Exp., 14, 664 (1972). S . Gershon, Psychopharm. B u l l . 9, 92 (1973). R. D. Heilman, E. W. Bauer and J. P. DaVanzo, Pharmacologist, 15. 254 (1973). R. M. Grimes, K. B. A l t o n and C. Shaw, Is, 254 (1973). G. S a k a l i s , E. Pearson. E. Kermani and S . Gerahon. Curr. Ther. Us.. C l i n . Erp., Is, 268 (1973). F. Barzaghi, R. Fournex and P. Mantegazza. Armelm.-Forsch., 23. 683 (1973). A. Bauer, P. Danneberg, K.-H. Weber and K. Minck, J. Med. Chem., l6, 1 0 1 1 (1973). G. R. A l l e n , J r . , V. G. De Vries, E. N. G r e e n b l a t t , R. L i t t e l l . F. J. HcEvoy and D. 8 . %ran, ibii., 1 6 , 949 (1973). K . P. S z g h and 0. S. Bhandari, Arzneim.-Forach., 23, 973 (1973). K . Jepson and G. Beaumont, J. I n t . Mad. Rea., 1 .145 (1973). J. L. Neumeyer and K . K . Weinhardt, J. Med. Chem., 2,808 (1973). V . Nacci, G. F i l a c c h i o n i , G. C. P o r r e t t a . G. S t e f a n c i c h and A. G u a i t a n i , Farmaco, Ed. Sci.. 28, 949 (1973). R. S a r g e s , J. R. T r e t t e r , S. S . Tenen and A. Weissman, J. Med. Chem., l6. 1003 (1973). H . OelschlYger, W. A. Behrendt and H. Hoffmann, Arzneim.-Forsch., 23, 802 (1973). J . R. Stevens, Arch. Gen. P s y c h i a t r y , 29. 177 (1973). S . Matthysse, Fed. P r o c . , Fed. Amr. SOC. Exp. B i o l . , 32, 200 (1973). N.-E. Anden and G. S t o c k , J. Pharm. Pharmacol., 25, 346 (1973). G. B a r t h o l i n i , K . G. Lloyd and H. S t a d l e r , L i f e Sci., l3. No. 4 , v i (1973). H . S t a d l e r , K. G. Lloyd, 14. Gadea-Ciria and G. B a r t h o l i n i . B r a i n R e 8 . . 55, 476 (1973). H. Corrodi, K . Fuxe and P. Lindbrink, 43, 397 (1972). B. S . Bunney. J . R. Walters. R. H . Roth and .K.G Aghajanian. J. Pharmacol. Exp. Ther.. 560 (1973). G. S t o c k , T. Magnusson and N.-E. Anden, Naunyn-Schmiedeberg'a Arch. F'harmakol. Exp. P a t h o l . 278, 347 (1973). R. Roth, J. R. Waltars and G. K . Aghajanian, L i f e S c i . , 12, No. 8. CxXXiX (1973). R. A. L a h t i and E. G. Losey, Res. Cormrmn. Chem. P a t h . Pharmacol.. 1. 31 (1974). H . Asper, M. B a g g i o l i n i . H. R. Burki, H. Lauener, W. Ruch and G. S t i l l e , 287 (1973). I. M. N i e l s e n , B. F j a l l a n d , V. Pedersen and M. Nymark, Psychopharmecologia. 2,195 (1974). J. L. Meek and N . H. Neff, J. Pharmacol. Exp. Ther.. 570 (1973). H. H. Keller, G. B a r t h o l i n i and A. P l e t s c h e r , Eur. J. Pharmacol.. 23, 183 (1973). C. D. Wise and L. S t e i n , S c i e n c e , 181,344 (1973). R. J . Wyatt, D. L. Murphy, R. Belmaker, S . Cohen, C. H. Donnelly and W. P o l l i n , 1 7 9 , 916 (1973). R. J. Wyatt, J. M. Saavedra and J. Axelrod, Am. J. P s y c h i a t r y , 130, 754 (1973). J. M. Saavedra, J. T. Coyle and J. Axelrod, J. Neurochem., 0, 743 (1973). N . Narasimhachari and H. E. Himrich, L i f e S c i . XI, g, 475 (1973). H . E . Himwich, N . Naraaimhachari, B. Heller, J. S. Spaide, L. Haakovec, M. Fujimori and K. Tabushi, "Chem1C.d l i o d i f i c a t i o n of Brain Function", Ed. H. C. S a b e l l i , R a w n P r e s s , New York, 1973. p. 297. R. J. Wyatt, L. R. Mandell, H. S. Ahn, R. W. Walker and W. J. A. Vanden Heuvel, Peychopharmacologia, 31, 265 (1973). P. Ladiiron, L i f e S c i . , 12,No. 6 , x c i i i (1973). W. C. Korevaar, M. A. Geyer, S. Knapp, L. L. Hsu and A. J. Mandell, Nature, Nev B i o l . , 245, 244 (1973). D. hlen6trey. J. Decaud-Gasarabwe and J. N. Besson, Eur. J. Pharmacol.. 2 4 , 158 (1973). P. Lidbrink and L.-0. Farnebo, Neuropharmacology, l2, 1087 (1973). R . Guerrero-Figueroa. E . Guerreo-Figueroa, G. A. Sneed and M. J. Kennedy, Curr. Ther. Res., C l i n . Exp., Ifr. 137 (1974). M. Doteuchi and E . Costa, N e u r o p h a m c o l o g y . 12,1059 (1973). L. F. Quenzer, R. S. Feldman and J. W. Moore, Psychopharmacologia. 3, 8 1 (1974). K. Meguro, H . Tawada. H. Miyano. Y. S a t 0 and
u.,
u.,
185,
w...g,
184.
-
u..
Chapter 2.
Narcotic Antagonists and Analgesics
Robert A. Hardy, Jr., Lederle Laboratories, A Division of American Cyanamid Company, Pearl River, New York
-
m i n g 1973, c l i n i c a l t r i a l reports on new agents remained Introduction few. Further d e t a i l s on agonists and antagonists described i n 1972 abs t r a c t s and preliminary reports appeared, indicating continuation of these investigations. !Be variety of new s t r u c t u r e types with analgesic or antagonist a c t i v i t y appears t o have declined i n 1973. Ebth analgesics and antagonists are t r e a t e d together i n s t r u c t u r e - a c t i v i t y discussion as d i f ferences between them remain very subtle indeed (e.g. diastereomers and enantiomers w i t h opposite actions ). Several reviews are noteworthy: IIhe well known analgesic publicat i o n s of the l a t e Dr. &than B. Eddy were brought t o a close w i t h an overview of 75 years of research toward solutions f o r morphine-type drug dependence .1 m e proceedings of an International Symposium on Agonists and Antagonists (1971) were published.2 Reviews on pentazocine3,4 and strong analgesics5 appeared.
-
New Clinical Studies Current reports do not provide d e f i n i t i v e informat i o n on any new compounds. Previous investigations a r e continuing and it remains premature t o assess t h e i r c l i n i c a l importance. However, the outlook is optimistic that significant c l i n i c a l advances a r e i n progress considering the variety of agonist and antagonist agents being studied. A 1O:l thadone:naloxone combination evaluated i n man provoked few side effects? advancing t o c l i n i c a l trials the previously described concept of using a parenterally e f f e c t i v e antagonist co bined with an o r a l l y a c t i v e narcotic t o prevent abuse of o r a l medication.
7
b, -c%j
H Q---
I
I1
An e a r l y c l i n i c a l t r i a l of oxilorphan [(- )-Bc-2605, Ia] as an antagonist f o r potential narcotic ad i c t i o n treatment indicated a d i u r e t i c e f f e c t a t low doses (2-4 mg sc).' In laboratory animals Ia was a naloxone-like antagonist, w a s almost equally e f f e c t i v e o r a l l y as parenterally, and had a prolonged d ~ r a t i o n . ~Preliminary c l i n i c a l r e s u l t s a r e cons i s t e n t with this p r o f i l e . Ihe N-cyclobutylmethyl analog (-)-I3 was a highly potent, dependence-free agonist i n animals, and preliminary c l i n i c a l t ials have been i n i t i a t e d with r e s u l t s comparable t o the animal model5 (See a l s o m p t e r 5 1.
12
Sect. I
-
CNS Agents
Gordon, Ed.
Structure-Activity; Agents under Investigation iates and Wrphinans - Details of the total synthesis of the BC-2605 zries (1)were described.9 A new synthetic approach was utilized representing a &jor advance in synthetic methods for Grphinans and related compounds, including isomorphinans and hasubanan analogs. It provides naloxone analogs which are not derived from the opium alkaloid thebaine, but which have comparable activities. (- )-Ib shared antagonist signs in monkeys, and was a potent analgesic equivalent to morphine in mice (hotplate and Nilsen tests).1° Ib racemate was morphine-like in monkeys (suppression of abstinence) and was similar to (-)-Ib in mice.1° The (+)isomer was morphine-like in monkeys, less potent but somewhat longer acting, and was weak to inactive in mice. From a series of morphine derivatives recently synthesized in Hungary, azidomorphine (IIa)and azidocodeine (IIb) proved to be about 300 times and about 1 times more potent than morphine, respectively (rat hotplate).113’ -ever, physical dependence capacity (pDc) in mice, rats and monkeys was low at equianalgesic doses, unusual for a potent N-methyl opiate structure. A levallorphan metabolite isolated from rat urine was established by X-ray analysis as the @-hydroxy derivative 111.13 It was then synthesized and, like the parent drug, was an antagonist without analgesic activity. An analogous 68-h oxy metabolite of naltrexone, formed by mese examples represent the first reports reduction, was found in of C-6 isomorphine configuration metabolites.
-.IF
The bicyclic 5-;-hydroxyphenylmorphan series was extended to include the N-propyl, N-cyclopropylmethyl (CPM and N-ally1 derivatives Na,b,c, both as racemates and the (+)-is0mers.~5 They were pentazocine-like analgesics with weak or no antagonist actions, and showed no PDC in monkeys. Thus, potent antagonists cannot be obtained in this series by replacing the N-methyl group of a potent agonist with claseical antagonist substituents (IVd-3 x morphine; high PM:). 6,7-%nzomorphans - Very little new structure-activity information concerning benzomorphans appeared during 1973. The s=-amine @-hydroxy6,7-benzomorphan had analgesic activity about 4 that of codeine (mouse hot-plate) while the corresponding N-methyl derivative was inactive, the reverse of the usual relative potency.16 Rntazocine underwent a chemical change in aqueous acid conditions used to hydrolize glucuronides.17 The mass spectral fragmentation of 93- and gg-alkyl-6,7-benzomorphans, including pentazocine, indicated that the configuration at C-9 could be assigned even when only one isomer of a diastereomeric pair was
Chap. 2
Narcotic Antagonists, Analgesics
Hardy
13
18
available.
Aminotetralins - Additional details of the synthesis of 49 1,3-bridged-2aminotetralins (V) were pub1ished;lg several were equal to or more potent than morphine (rat tail-flick). V was the longest acting a tagonist tested in the Univ. of Michigan morphine-dependent monkeys." It displayed twice the duration of cyclazocine and was about 1/5 as potent as nalorphine as an antagonist. In mice it was equivalent to morphine (hotplate ).
C,
-OH
VI
V
Three diastereomeric pairs of tetralins VI were synthesized as methadone analogs.20 VIa were analgesics comparable to meperidine (mouse hotplate) with little differences-in the potency of the hiastereonkrs; substitution of hydroxyl for hydrogen increased potency somewhat. Among a series of potential antiparkinson agents, 2-methylamino-5-methoxytetralin shared analgesic activity in the codeine-propoxyphene range (mouse tailpinch), but was more toxic.21 Piperidines and Pyrrolidines - New antagonist-analgesics were reported in the N-alkyl-norketobemidone series.22 The N-awl, hexyl and heptyl compounds VIIa,b,c were strong agonists with weak antagonist properties, and no PIX! in monkeys. VIIa was an analgesic nearly 3 times more potent than the parent VIId (mouse hot-plate). This contrasts with the more traditional N-propyl, CPM and allyl analogs which were not antegonists but weak to medium strength agonists with high mX:.
c, -Heptyl d, - M VII
VIII, (- )-isomer
In the pyrrolidine series, additional details of the selective antagonist actions of N-CPM and N-ally1 analogs of profadol appeared,23,24 and CI-747 (VIII) was selected for detailed evaluation. Its analgesic potency was 40-50 times pentazocine (mouse antiwrithing ) with antagonist properties 5-6 times pentazocine. Ihe absolute stereochemistry and analgesic properties of the diastereomeric 3-allyl-prodine analogs who deduced similar conclusions. M was 13-15 times more potent than morphine (mouse hot-plate), and its (+)-enantiomer was 40 times morphine and 260 times its (-)-isomer. It was suggested that the equatorial allyl group enhanced receptor association.
14
Sect. I
-
CNS Agents
Gordon, Ed.
Similar a solute stereochemical studies of other prodines were also described.2 r29
ll
CON(C5
l2
(c6'5 a, R
-
L
R X p-C1; b, R = 3-CF -4-Cl 3
A series of 2,2-diphenyl-4-piperidinobutyramides (X) were studied in which the goal was separation of analgesic and antidiarrheal (constipating) activities.3° Ioperamide (Xa) and fluperamide ( X b ) were selected for further investigation each being more potent than diphenoxylate and codeine in protecting against castor-oil-induced diarrhea and very weak analgesics (rat,warm water tail-withdrawal). Closely related analogs combined strong analgesic properties with strong antidiarrheal activity. In this study, potent analgesic activity was an unwanted side effect. Several additional piperidines were active analgesics. The 3-methyl derivative of the potent narcotic fentanyl was 10 times more potent than the parent drug .3l N-[2- (2-Oxazolidinone-5-yl)ethyl]-4-phenyl-4-propionoxypiperidine shared morphine-like analgesic$ t e n ~ y , 3and ~ an N-(2indanyl )-analog had meperidine-like potency.
Diphenylpropylamines and Mscellaneous Compoundg - Among a series of thiophthalanes studied for analgesic activity,j4 Iu 6-062 (XI) was the most active. It was approximately equal to morphine (mice, hot-plate, tail-pinch and Nilsen tests ), produced a Straub-tail reaction and was antagonized by nalorphine. Similar thiophthalanes with a propylamino side chain had been previously studied as antidepressants, but were not analgesics and did not produce a Straub-tail.
XI
XI1
Another approach to the separation of antidiarrheal from narcotic analgesic activity was the comparison of Straub-tai V8. CoMtipating effects.35 CI-750 (XII), selected for evaluation,3 did not produce a Straub-tail, showed only weak analgesic activity and had a constipating effect about equal to diphenoxylate. Piperidinoethyl and pyrrolidinoethyl analogs of XI1 with a 1-dimethylamino group had potent narcotic actions.
2
Agonist and antagonist properties of vimi 1 stereoisomers (XIII, previously known as diviminol) were described.j? This compound has 3 asymmetric centers and 6 stereoisomers. Analgesic activity resided in a
Chap. 2
Narcotic Antagonists, Analgesics
Hardy
15
(-)-isomer (€$; several times morphine, some PDC) and antagonist activity in a (+)-isomer (S,; nalorphine-like)which were not enantiomers of each other. No other isomers had analgesic or antagonist activity. In the
racemate, the agonistic activity of % is apparently partially opposed by the antagonistic E$ isomer. The result is a racemate with codeine-range analgesic activity and a low order of pzx;'. Analgesic activity was found in a group of N-substituted cyclohexylmethylbenzamides, and AH 791 (XIV) was equipotent to morphine (mice, antiwrithing and hot-plate) and showed high PDC in monkeys. !Bis represents a structurg distinctly different from previous high PDC narcotic-like compounds . 3 The dissociative anesthetic etoxadrol ( X V ) produced analgesia at low subanesthetic doses (0.5-1 mg), measured by elevation of the electrical stimlation threshold in monkeys.39 It was comparable to morphine,but shorter in duration. XV was not active in mice (antiwrithing), perhaps since dissociative anesthetics produce different effects in rodents vg. higher species. Further studies as a parenteral analgesic were suggested. 0
(c21f,
xv
XVI A study of 24 monoaryl- and diarylphosphorus analogs of methadone revealed moderate analgesic activity in several compounds; XV was 1/4-1/5 the potency of morphine (mice, hot-plate and antiwrithing Unfortunately, the toxicity was highest in compounds with the best analgesic activity. Pharmacological implicat of the conformations of methadone and isomethadone were analyzed. Aniinflanmttory Analgesics - !&is class of compounds is discussed in detail in Chapter 20. Studies of arylalkanoic acids and derivatives continue unabated. Details of analgesic testing of these agents are frequently incomplete PharmacolORy, Biochemistry and bktabolism - !be variety of studies covering methods, mechanism of action, biochemistry, etc. continues to increase. Detailed discussion of these is outside the scope of this review; however, the following selected examples are illustrative of current trends. A full paper on biodegradable poly-lactic acid long-acting delivery
.
16
Sect. I
-
CNS Agents
Gordon, Ed.
systems f o r narcotic antagonists a ~ p e a r e d , ~following 3 up the i n i t i a l a b s t r a c t s . The use of chronic spinal dogs dependent on morphine w a s described f o r quantitative assays of antagonists .44 &tho@ f o r producing antibodies t o morphine f o r radioinnnunoassay were reviewed. F’urther studies of specific opiate rece or s i t e s based on stereos p e c i f i c binding i n nervous t i s s u e a eared.a The i n i t i a l r e s u l t s were confirmed by other investigators. 471@ m e r o l e of sodium i n enhancing antagonist binding but decreasing agonist binding i n v i t r o w a s found as an important q u a l i t a t i v e difference t h a t may be relevant t o the divergent pharmacological properties of antagonists and agonists .46 Several additional metabolic findings a r e of i n t e r e s t . The formation of codeine from morphine (or heroin) w a s observed i n a significant increase of 0-methyl transferase a c t i v i t y leading t o increased codeine i n addict urine could be a specific marker f o r the addiction s t a t e . The long sought primary amine metabolite from levomethadyl acetate was i d e n t i f i e d by combined gas chromatography-mass spectrometry (gc-ms) of r a t t i s s u e and plasma samples, and was found t o be a highly potent analgesic (1.5 mg/kg sc, mouse antiwrithing).5O Thus, the general tendency of mono- and d i demethyl congeners t o have a low order of a c t i v i t y does not apply i n t h i s s e r i e s . Both mono- and di-demethyl metabolites of g-propoxyphene were observed i n man, using combined gc-ms and deuterium-labelled propoxyphenes .51 a-(+)-Norpropoxyphene was the major metabolite, and was about 1/10as active as the parent drug (mouse antiwrithing, and rat t a i l f l i c k ) .52 The r o l e of biogenic amines a8 r e l a t e d t o narcotic e f f e c t s continues t o be an active f i e l d . Further studies appeared concerning enhanced cerebral serotonin turnover ,53 balance w i t h the catecholamine s y ~ t e m , 5 ~ dopamine turnover i n p e striatum,55 and homovanillic acid content i n t h e caudate nucleus .5 Additional d e t a i l s of the cyclic-AMP antagonism of mo phine analgesia,57 and i t s e f f e c t on tolerance and physical dependence5 were a l s o published.
fi
Referenees 1. N. B. Eddy and E. L. b y , Science, 181, 407 (1973). 2. H. W. Kosterlitz, H. 0. J. Collier and J. E. Villarreal (Eds), Agonist and Antagonist Actions of Narcotic Analgesic Ih-ugs, Univ. F’ark Press, Ehltimore (1973). 3. J. P. h p e , h g s , b 1 (1973). 4. R. N. Brogden, T. M. Speight and G. S. Avery, Rrugs, 6 (1973). 5. W. B. b a n and J. D. Wrrison, Drugs, b 108 (1973). 6. S. D. Aarwatikar and R. R. Knowles, Clin. Fharmacol. ?her., 14, 941 (1973) l 230 (1973). 7. I. J. Pachter, Science, & 8. J. G. M t t and D. R. Jasinsky, Rmmacologist, lI_, 240 (1973). 9. I. Wnkovi6, T. T. Conway, H. Wong, Y. G. Fkrron, I. J. Pschter and 7910 (1973); cf a l s o Qem. Abstr., B. Belleau, J. Am. Chem. SOC., 79, 18931~(1973).
Chap. 2
Narcotic Antagonists, Analgesics
17
Hardy
H. H. Swain, J. E. V i l l a r r e a l and M. H. Seevers, Addendum, Report 35th Ann. M t g . Corn. on Problems o f Rrug Dependence, Chapel H i l l , N. c., MY 21-23, 1973. 11. J. Knoll, S. Mrst and K. Kelemen, J. Pharm. pharmacol., 22, 929 (1973 1 12. J. Knoll, pharmacol. Res. Commun., 175 (1973). 13 J. F. Blaunt, E. Mhacsi, F. M. Vane and G. J. Wnnering, J. E d . Chem., 16, 352 (1973). 14. E. J. Cone, Tetrahedron I e t t e r s , 2607 (1973). 1.5 * H. H. Chg, T. a - i s h i and E. L. My, J. E d . Chem., 17 133 (1974). 16. J. J. Fauley and J. B. IaPidus, l6, 181 (1973f 17 * D. P. Vaughan and A. H. Beckett, J. Pharm. Pharmacol., 2_2 993 (1973 1. 18. D. I?. Vaughan and A. H. E c k e t t , i b i d . , 22, 895 (1973). 19. M. E. Freed, J. R. Potoski, E. H. Freed, G. L. Conklin and J. L. &Us, J. E d . Chem., 16, 595 (1973). 20. E. M. Kandeel and A. R. W r t i n , LbL., 16, 947 (1973). 10.
z.,
21. 22. 23
Y. C. W t i n , C. H. Jarboe, R. A. Krause, K. R. I p n , D. k n n i g a n and J. B. W.land, 6, 147 (1973). T. a - i s h i and E. L. Wy, 16,1376 (1973). R. E. B3wman, H. 0. J. C o l l i e r , P. J. Hattersley, I. M. Lockhart, D. J. Peters; C. Schneider, N.-E. Webb and M. Wright, g., 16,
z. , s.,
~
1177 (1973). 24. 25 26. 27. 28. 29.
30
31
33 34.
36 35
38
u.,
u., u., w., u.,
u.,
(19731
W. J. Welstead, Jr., G. C. Helsley, C. R. Taylor, L. B. Turnbull, J. P. DaVanzo, W. H. Funderburk, and R. S. Alphin, J. &d. Chem., 16,
32
37
R. E. EOwman, H. 0. J. Collier, I. M. Lockhart, C. Schneider, N. E. Webb and M. Wright, l6, 1181 (1973). K. H. kll and P. S. Fbrtoghese, 16 203 (1973). K. H. k11 and P. S. Portoghese, 589 (1973). M. A. B r i o , G. Camia and A. F. Casy, 16, 592 (1973). D. L. k s o n and P. S. Portoghese, l6, 1%(1973). P. S. Portoghese, Z. S. D. Gomaa, D. L. k s o n and E. Shefter, ibid., 16, 199 (1973 1. R. A. Stokbroekx, J. Vandenberk, A. H. M. T. Van Heertum, G. M. L. W. van Iaar, M. J. M. C. Van der Aa, W. F. M. Van Ever and P. A. J. Janssen, 16, 782 (1973). T. N. Riley, D. B. Hale and M. C. Wilson, J. Pharm. Sci., 62, 983
-
m9 (1973).
z.,
E. Solomons and J. Sam, l6, 1330 (1973). B. Fjalland, V. Pedersen, N. lassen, P. V. Petersen and I. M l l e r Nielsen, Acta pharmacol. Toxicol., 32, 278 (1973). D. E. J h t l e r , R. F. Myer, S. M. Alexander, P. €kiss and J. A. Kennedy, J. Md. Chem., 16, 49 (1973). P. Ittss, J. A. Kennedy, J. N. Wiley, J. V i l l a r r e a l and D. E. J h t l e r , J. pharmacol. Exp. 'lher., 186, 183 (1973 ). D. Della Bella, V. Ferrari, V. Frigeni and P. Iualdi, Nature New Biol., 241, 282 (1973 ). R. T. Brittain, D. N. Kellett, M. L. Neat and R. Stables, Brit. J. Pharmacol., 158P (1973).
9,
18 39 40. 41. 42. 43
9
Sect. I
- CNS Agents
Gordon, Ed.
A. H. Tang and J. D. Kirch, Anesth. Analg. Curr. Res., 52, 577 (1973). W. H. Shelver, M. Schreibman, N. S. Tanner and V. Subba Rao, J. Md.
Chem., 17, I20 (1974 ). H. B. m g i , J. D. l b n i t z and E. Shefter, Nature New Blol., 244, 186 (1973 ) * J. G. Henkel, K. H. Bell and P. S. Brtoghese, J. Wd. Chem., 17 -, 124
(1974 1
J. H. R. Woodland, S. Yolles, D. A. Blake, M. Eelrich and F. J. Myer, 16, 897 (1973 ) * W. R. Mutin, C. G. Eades and J. A. ?hapson, Fed. Proc. 32, 687 j
44. 45
46. 47. 48. 49 50
(1973 1-
S. Spector, B. Brkowitz, E. J. Flynn and B. Fkskar, pharmacol. Rev. 25, 281 (1973 1. C. B. Fkrt, G. Pasternak and S. H. Snyder, Science, 182, 1359 (1973). E. J. Simon, J. M. Hiller and I. Edelman, €?roc. Natl. Acad. Sci., 70,
1947 (1973 1.
54.
L. Terenius, Acts pharmacol. Toxicol., 377 (1973). U. Edrner and S. Abbott, Experientia, 24, 180 (1973). R. E. BLllings, R. Booher, S. b i t s , A. Pohland and R. E. kbkhon, J. Wd. Chem., l6, 305 (1973). R. E. McMhon, H. R. Sullivan, S. L. lXle and F. J. &shall, Life Sci, 12 Pt 11, 463 (1973). R. Nickander and S. Smits, Pharmacologist, 1L 203 (1973). G. G. Yarbrough, D. M. Bxbaum and E. Sanders-&sh, J. Eharmacol. %P. !her., 14, 328 (1973). D. M. Wbaum, G. G. Yarbrough and M. E. Carter, G., %1 317
55 *
E. Costa, A. Carenzi, A. Guidotti and A. Revuelta, Life Sci.,
52
53
56 57 58.
(1973 1
m i (1973).
12(4),
L. Ahtee and I. Kd&idinen, Amopean J. pharmacol., 22, 206 (1973). I. K. Ho, H. H. Loh and E. L. Way, J. Fharmacol, Ekp. !her., l@j,
336 (1.9731.
I. K. Ho, H. H. Loh and E. L. Way,
u.,%1
347 (3.973).
Chapter 3.
Antiparkinsonism Drugs
Vernon G. V e r n i e r , E. I . du Pont de Nemours
?C
Co., I n c . , Newark, De.
-
General Knowledge of t h e n a t u r e o f t h e biochemical l e s i o n of P a r k i n s o n ' s d i s e a s e and t h e a v a i l a b i l i t y of r a t i o n a l c o r r e c t i v e t h e r a p y c o n t i n u e s t o s p u r a c t i v i t y t o f i n d improved and novel e n t i t i e s w i t h e x i s t i n g and d i f f e r e n t nodes of a c t i o n . Many u s e f u l reviews are a v a i l a b l e i n t h i s f i e l d . T h i s c h a p t e r updates t h e compilation by Vernier1. Levodopa i s reviewed by McDowell' and it and o t h e r developments are covered by Calne3. The l a r g e and growing amantadine l i t e r a t u r e i s w e l l analyzed by P a r k e s 4 . T h i s review w i l l cover t h e r a p e u t i c a g e n t s and leads under f o u r mechanisms of a c t i o n : 1. dopamine replacement, 2. dopamine r e l e a s e , 3. dopamine r e c e p t o r s t i m u l a n t s and 4. a n t i c h o l i n e r g i c s . Each agent w i l l be d i s c u s s e d under i t s presumed major mode of a c t i o n even though t h e evidence f o r it may not be d e f i n i t i v e o r t h e agent may a c t by s e v e r a l mechanisms.
-
Dopamine replacement This most e f f e c t i v e t r e a t m e n t f o r P a r k i n s o n ' s disease i s s u p p l i e d by t h e - n a t u r a l l y - o c c u r r i n g amino a c i d levodopa ( I, L3,4-dihydro~yphenylalanine~'~), I n t h e u s u a l o r a l doses o f 2 . 5 t o 6 g d a i l y it e n t e r s t h e b r a i n and i s decarboxylated t o form dopamine (11)
I
I1
which presumably r e p l e n i s h e s t h e d e f i c i e n t n e u r o t r a n s m i t t e r s t o r e s i n t h e basal g a n g l i a r e s u l t i n g from midbrain s u b s t a n t i a n i g r a l e s i o n s . I n 60 t o 80% o f c a s e s a k i n e s i a , r i g i d i t y and t o a lesser e x t e n t tremor a r e moderately t o markedly improved, b u t management i s d i f f i c u l t . T h i s i s due t o numerous s i d e e f f e c t s , t h e n e c e s s i t y o f g i v i n g many doses d a i l y , and t h e slowly i n c r e a s i n g dose t i t r a t i o n , l e a d i n g t o a long induct i o n time f o r o p t i m a l e f f e c t s . Some p a t i e n t s have a s h o r t and/or v a r i a b l e t i m e of symptomatic r e l i e f f o l l o w i n g each dose. Sudden f r e e z i n g , t h e "ono f f e f f e c t , " i s o f t e n noted0. I t s causes are under study and s e v e r a l approaches t o i t s a l l e v i a t i o n are i n development ( d e t e r m i n a t i o n s o f levodopa plasma l e v e l s f o r optimal t i m e and dose t i t r a t i o n , s u s t a i n e d r e l e a s e formulations, e tc )
..
P r i n c i p a l levodopa s i d e e f f e c t s are i n d e c r e a s i n g o r d e r of incidence: 1. Nausea and vomiting, 2. p o s t u r a l hypotension, 3. c a r d i a c a r r h y t h m i a s , 4. abnormal i n v o l u n t a r y movements and 5. p s y c h i a t r i c d i s t u r b a n c e s . Considerable r e s e a r c h e f f o r t i s d i r e c t e d toward t h e d e t e r m i n a t i o n of how much o f t h e o r i g i n a l t r e a t m e n t r a t i o n a l e can b e s u b s t a n t i a t e d . Although g e n e r a l l y a g r e a t e r t h a n o r i g i n a l l y expected complexity i s being
20
Sect. I
-
Gordon, Ed.
CNS Agents
found, most r e s u l t s a r e consistent with o r i g i n a l expectations. Carbidopa and benserazide, two agents which a r e potent aromatic amino acid decarboxylase i n h i b i t o r s in v i t r o and in V
.
Early r e p o r t s of t h e biochemistry and pharmacology of carbidopa (111, MK 486, t h e L form of MK 485, a l s o r e f e r r e d t o as HMD) indicated i t s
I11
IV
e x t r a c e r e b r a l d i s t r i b u t i o n and potent in v i t r o and in v i v o i n h i b i t i o n of aromatic amino a c i d decarboxylasell. I t s i n t e r a c t i o n s with levodopa i n Carbidopa enhanced t h e animals were characterized by L o t t i and Porter’’. a b i l i t y of levodopa t o increase motor a c t i v i t y of mice and rats and t o reverse reserpine-induced hypothermia and suppression of locomotion and p t o s i s . Brain dopamine l e v e l s were concomitantly enhanced. I n c o n t r a s t levodopa emesis i n dogs and pigeons was attenuated. C l i n i c a l e y e r i e n c e with carbidopa and levodopa has been extensive
and f a ~ o r a b l e l ~, , ~Carbidopa alone had no influence on Parkinsonian p a t i e n t s and i s reported t o be q u i t e non-toxic. It r a i s e d plasma l e v e l s of levodopa about five-fold, thus i n d i c a t i n g about an 80% reduction of t h e required levodopa alone dose. Carbidopa doses of 100-300 mg/day combined with levodopa i n c o n t r o l l e d t r i a l s r e s u l t e d i n a rapid onset of therap e u t i c e f f e c t ( a few days o r weeks compared with months with levodopa alone) , and s t r i k i n g l y reduced t h e incidence of nausea and vomiting. P a t i e n t s on long term combined therapy achieved superior r e l i e f . Combined treatment m a y reduce cardiac arrhythmias , but t h e incidence of involuntary movements i s increased. Several groups found a 1:lO combination most usef u l with a d a i l y dose of carbidopa 100 mg: levodopa 1000 mg. Marsden14 suggests t h a t it may become t h e treatment of choice. The pharmacology of and c l i n i c a l experience with benserazide (IV,
Ro 4-4602) i s generally similar t o t h a t of carbidopalO. It i s somewhat l e s s potent in v i t r o as a decarboxylase i n h i b i t o r but in V i V O and i n t h e ~ ,d~i f~f e.r s i n c l i n i c i t s potency i s similar t o t h a t of c a r b i d ~ p a ~ , ~It penetrating t h e b r a i n i n animals at high doses. Benserazide administrat i o n , l i k e carbidopa, increases absorption of levodopa from t h e g u t , increasing plasma l e v e l s , and blocks p e r i p h e r a l conversion t o dopamine. I n t h e b r a i n t h e i n h i b i t o r s increase levodopa penetration and catecholamine ( dopamine and norepinephrine) l e v e l s .
Chap. 3
Antiparkinsonism Drugs
Vernier
21 -
C l i n i c a l l y benserazide+levodopa treatment improved t h e t h e r a p e u t i c r e s u l t s , decreased t h e required levodopa dose ( t o about 1 / 5 ) and decreased t h e incidence of nausea and vomiting. It generally did not decrease t h e involuntary movements but increased them. Benserazide seems t o be well t o l e r a t e d on a long term administration a t t h e 100-400 mg/day l e v e l s , with few t r a n s i e n t changes i n l i v e r biopsies and enzyme levels15.
-
Dopamine r e l e a s e r s Schwab noted i n 1968 t h e antiparkinsonism e f f e c t of amantadine ( V ) , an a n t i v i r a l agent which has s i n c e been extensively
V
VI
t e s t e d 1 7 and approved f o r t h a t a d d i t i o n a l i n d i c a t i o n . Amantadine a f f e c t s catecholamines, primarily dopamine, and had no a n t i c h o l i n e r g i c e f f e c t s 1 8 . I t caused pressor responses i n t h e dopamine-primed dog with much l e s s e f f e c t upon norepinephrine , suggesting predominately dopamine r e l e a s e l a 3 19. Amantadine antagonized e f f e c t s of major t r a n q u i l i z e r s on s e v e r a l kinds of behavior, including t h e conditioned avoidance response22 , a f f e c t e d t h e r o t a t i o n a l a c t i v i t y of s t r i a t a l - l e s i o n e d rats and mice23 and i n t e r a c t e d wit*h a p ~ m o r p h i n,25. e ~ ~ This and considerable other biochemical and pharmacological evidence i s generally consistent with t h e r e l e a s e of s t o r e d dopamine as a m a o r element i n i t s action together with f a c i l i t a t i o n of neural release2g-28. Amantadine a l s o increased synthesis of levodopa and presumably dopamine i n rat striatum2’. Although many recent r e p o r t s d e a l with t h e s e aspects of t h e animal pharmacology, t h e exact mechanism i s not y e t f u l l y established. I n p a t i e n t s t h e onset of a c t i o n i s prompt, faster than levodopa but of l e s s i n t e n s i t y , with fewer s i d e e f f e c t s than levodopa, p a r t i c u l a r l y nausea and vomiting and dyskinesias. A t doses of 200-300 mg/day maximum b e n e f i t i s achieved soon a f t e r beginning drug and t h i s e f f e c t may be sust a i n e d over long periods, although some r e p o r t s i n d i c a t e a decline i n effect. Although no c l i n i c a l r e p o r t s on D 145 (VI, DMAA) have been found, it i s a c l o s e congener of amantadine which shows catecholamine i n t e r a c t i o n s generally similar t o it, suggesting capacity f o r dopamine r e l e a s e . I t may a l s o have some capacity f o r d i r e c t stimulation of dopamine receptors3’. Moderate t o high i . v . doses of D 145 decreased decerebrate r i g i d i t y i n cats31. Other biochemical findings have been noted32. Carmantadine (VII, Sch 15427) i s s t r u c t u r a l l y r e l a t e d t o amantadine33. It shares some of i t s pharmacological a c t i o n s , w a s e f f e c t i v e i n a
22 -
Sect. I
- CNS Agents
Gordon, Ed. 0
HO VIII v1 I
head-turning t e s t 3 4 , and i s i n e a r l y c l i n i c a l t r i a l s . Dopamantine ( V I I I ) combined elements of both mantadine and dopamine i n i t s s t r u c t u r e , shares some pharmacological e f f e c t s of amantadine and i s i n e a r l y c l i n i c a l trials35.
-
Dopmine receptor stimulants A chemical rearrangement of morphine y i e l d s apomorphine ( I X ) which i s now known t o s t i m u l a t e dopaminergic r e c e p t o r s .
Hd
X
’OH IX
S ~ h w a bdiscovered ~~ i n 1951 t h a t it r e l i e v e d tremor and r i i d i t y of parkinsonism. T h i s has been confirmed by CotziasJ7, Castaignef8 and others. It markedly diminished tremor i n monkeys39. Apomorphine i s not a p r a c t i c a l t h e r a p e u t i c agent (poor o r a l absorption requiring p a r e n t e r a l admini s t r a t i o n , s h o r t duration of a c t i o n , high incidence of nausea and emesis , i n s t a b i l i t y ) but i s an important s y n t h e t i c and b i o l o g i c a l s t a r t i n g point i n t h e search f o r new agents, s i n c e it contains common elements of t h e dopamine s t r u c t u r e . Experiments w i t h apomorphine have shed l i g h t on t h e a c t i o n of levodopa and dopamine i n t h e treatment of parkinsonism and a l s o t h e nature of drug-induced parkinsonism which accompanied t h e use of major t r a n q u i l i z e r s which antagonize apomorphine emesis and stereotypy4’. Originally tested i n cardiovascular disease , t r i v a s t a l (X, ET 495) has been proposed as a dopamine receptor stimulant w i t h b e t t e r o r a l a b s o r p I n. addition t o i t s t i o n and longer duration of a c t i o n t h a n a p ~ m o r p h i n e ~ ~ d i r e c t e f f e c t on t h e receptors t h e data suggested a weak dopamine and norepinephrine r e l e a s i n g e f f e c t . T r i v a s t a l blocked caudate EEG spindles as d i d a p ~ m o r p h i n eand ~ ~ reduced tremor i n monkeys w i t h midbrain lesions43. Others have reported i t s drug dynamics and pharmacological actions44 ,45. Reports of c l i n i c a l t r i a l s 4 6 i n 125 p a t i e n t s at doses of 20 t o 240 mg/day l e d t o p o s i t i v e conclusion of b e n e f i t i n 4 s t u d i e s (involving 83 p a t i e n t s ) and negative assessment i n 3 s t u d i e s (involving 42 p a t i e n t s ) . Side e f f e c t s were s t r i k i n g and seen i n most p a t i e n t s but could be reduced w i t h lowered doses. Dyskinesias, l i k e those w i t h levodopa, were most frequent , w i t h nausea and vomiting, daytime drowsiness ( w i t h insomnia a t
Chap. 3
Antiparkinsonism Drugs
Vernier
23 -
n i g h t ) a l s o found frequently. Less common were confusion, headaches and dizziness. Most t r i v a s t a l t r i a l s continued p a t i e n t s on previous medicat i o n including levodopa s o t h a t t h e t h e r a p e u t i c r o l e of t r i v a s t a l i s not yet clear. P r e c l i n i c a l data suggest t h a t NBTI ( X I ) a t f a i r l y high doses (40 mg/ kg i . p . ) caused tremors and stereotypy i n rodents reminiscent of apomor-
XI
phine, which was blocked by chlorpromazine and other major t r a n q u i l i z e r s but not by a n t i c h o l i n e r g i c s . It r e s t o r e d locomotor a c t i v i t y i n reserpinea ~ ~ It may stimulate dopaminergic depleted rats l i k e l e v o d ~ p ,47. receptors4*. Reports of i t s c l i n i c a l s t a t u s have not appeared.
-
The peripheral a n t i c h o l i n e r g i c e f f e c t s of benapryzine Anticholinergics (XII, BRL 1288) were considerably weaker than those o f trihexyphenidyl
XI1
XI11
In but i t s c e n t r a l e f f e c t s were nearly equivalent i n animals and man4'. a p i l o t t r i a l benapryzine a t higher doses than those of trihexyphenidyl was found t o be equivalent t o i t , but w i t h possibly fewer s i d e e f f e c t s 5 0 . Two o t h e r p a r t i a l l y c o n t r o l l e d t r i a l s (13 and 28 p a t i e n t s ) indicated Benapryzine may represent a t e f f e c t i v e n e s s and s a f e t y a t 200 mg/day5'. least p a r t i a l success i n separating c e n t r a l from p e r i p h e r a l a n t i choliner i c e f f e c t s , possibly as a r e s u l t of d i f f e r e n c e i n pharmacok i n e t i c s f 3 . Direct e f f e c t s have been demonstrated by iontophoretic a p p l i c a t i o n t o c o r t i c a l neurons5". The morphanthridine e l a n t r i n e (XIII, Ex 10-029) has been t e s t e d i n man and i t s pharmacological a c t i o n appears t o be mainly, but not exclus i v e l y , r e l a t e d t o i t s a n t i c h o l i n e r g i c action55. Two c l i n i c a l t r i a l s ( 2 5 and 13 p a t i e n t s ) r e p o r t e f f i c a c y alone a t doses of 30-60 mg/day and w i t h levodopaS6,57, Side e f f e c t s were predominately of t h e a n t i c h o l i n e r g i c type. A recent s u b s t a n t i a l m u l t i c l i n i c c o n t r o l l e d study58 i n 89 p a t i e n t s found t h a t e l a n t r i n e , 40 mg d a i l y , e f f e c t i v e l y reduced tremor and possibly r i g i d i t y more than t h e same dosage of trihexyphenidyl. E l a n t r i n e caused more dry mouth, Thus e l a n t r i n e was e f f e c t i v e but not c l e a r l y more select ive
.
24
Sect. I
-
CNS Agents
Gordon, Ed.
-
Comment E a r l i e r r e s e a r c h i n t e r e s t has s h i f t e d from a n t i c h o l i n e r g i c t o catecholamine a c t i o n s . Is t h e formation o f 6-hydroxydopamine, which causes a d r e n e r g i c nerve t e r m i n a l d e s t r u c t i o n , t h e cause of t h e biochemical l e s i o n of Parkinson's d i s e a s e ? If t r u e , new p o s s i b i l i t i e s f o r c u r e o r p r e v e n t i o n through i n f l u e n c i n g t h e cause could emerge from t h e i n t e n s i v e catecholamine r e s e a r c h e f f o r t . A d d i t i o n a l dopamine releasers w i l l probably be t e s t e d s i n c e t h i s mode of a c t i o n h a s been i d e n t i f i e d . E f f e c t i v e and s e l e c t i v e dopamine reuptake b l o c k e r s should be explored as another t h e r a p e u t i c approach. D i r e c t dopamine r e c e p t o r s t i m u l a t i o n i s probably t h e most a c t i v e p r e s e n t area, I n view o f t h e complex catecholamine physiology o t h e r n e u r o l o g i c a l t a r g e t u s e s f o r t h e s e l e a d s w i l l be sought and undoubtedly found. Comb i n a t i o n s of t h e l a s t 3 approaches w i l l b e p r i m a r i l y i n i t i a t e d by c l i n i cians.
New small animal methods , supplementing oxotremorine tremor , e t c , , have made p o s s i b l e s t u d y of a d r e n e r g i c a c t i o n s based mainly upon t h e changes i n locomotor a c t i v i t y and s t e r e o t y p y e x e r t e d by amphetamine and apomorphine and by drug e f f e c t s upon t u r n i n g behavior a f t e r s t r i a t a l l e s i o n s caused by 6-hydroxydopamine, e l e c t r o l y s i s and s u c t i o n . References V. G. V e r n i e r , i n "Annual Reports i n Medicinal Chemistry, 1970,"
2.
3.
4. 5.
C. K. Cain, ed., Academic P r e s s , N.Y. (1971) p. 42. F. H. McDowell, e d . , Symposium on Levodopa i n P a r k i n s o n ' s Disease, Neurol., 22 (5, P a r t 21, 1 (1972). D. B. Calne, e d . , "Progress i n t h e Treatment o f Parkinsonism," Advances i n Neurol., 2, 1 (1973) Raven P r e s s , N.Y. J . D. P a r k e s , Amantadine, i n Recent Advances i n Drug Research, Academic P r e s s , N.Y. (1974) i n p r e s s . G. C. C o t z i a s , M. H. Van Woert and L. M. S c h i f f e r , New Eng. J . Med.,
276, 374 (1967).
L a n g r a l l and C. Joseph, Neurol. , 22 ( 5 , P a r t 2) , 3 (1972). R. B. Godwin-Austen, Advances i n Neurol., 3, 23 (1973). A. R. Damasio, A. Castro-Caldas and A. L e e , Advances i n Neurol.,
6. H X . 7. 8.
3,
11 (1973).
9. C. C. P o r t e r , Fed. P r o c . , 2,871 (1971). 10. A. P l e t s c h e r , Advances i n Neurol., 2, 49 (1973). 11. C. C . P o r t e r , L. S. Watson, D. C . T i t u s , J. A. Totaro and S . S . Byer, Biochem. Pham,. , l l , 1067 (1962). 12. V. L o t t i and C . C. P o r t e r , J. Pharmacol. Exp. T h e r . , 172, 406 (1970). 13. S. K. Rao and D. B. Calne, Advances i n Neurol. , 2, 7 3 T 9 7 3 ) . 14. C. D. Marsden, J. D. Parkes and J. E. Rees, Advances i n Neurol., 2, 79 (1973).
15.
U. K. Rinne, V. Sonninen and T. S i i r t o l a , Advances i n Neurol.,
. Schwab,
3,
(1973
16.
R. S. A. C . England, D. C . Poskanzer and R. R . Young, J . h e r . Med. ASSOC., 208, 1168 (1969).
59
Chap. 3
18.
Antiparkinsonism Drugs
Vernier
25
J . D. Parkes, R. C. Baxter, A. G a l b r a i t h , C . D . Marsden and J. E. Rees, Advances i n Neurol., 3, 105 (1973). R. P. Grelak, R. C l a r k , J. M. Stump and V. G. V e r n i e r , S c i e n c e , 2,
203 (1970). B. A. S p i l k e r and K. M. Dhasmana, E x p e r i e n t i a , 30, 64 (1974). 20. V. G. V e r n i e r , J. B. Harmon, J . M. Stump, T. E. Lynes, J. P. Marvel and D. H. Smith, Tox. Appl. Pharmacol., 2,642 (1969). 21. J . Offermeier, i n P a r k i n s o n ' s Disease, A New Approach t o Treatment, ed. G. F. B. Birdwood e t al., Academic P r e s s , London (1971)p . 85. 735 22. J. A. Davies, B. Jackson and P. H . Redfern, Neuropharmacol., ,2.l
19
(1973). 23. U. Stromberg and T. H. Svensson, Acta Pharmacol. T o x i c o l . , 30, 161
(1971). 24. R . Hackman, 25.
26. 27.
P. P e n t i k a i n e n , P. J. Neuvonen and H. Vapaatalo, E x p e r i e n t i a , 3, 1524 (1973). B. Cox and S. J . Tha, Europ. J. Pharmacol. , 24, 96 (1973). P. F. Von Voightlander and K. E. Moore, S c i e n c e , I& 408 , (1971). P. F. Von Voightlander and K . E. Moore, J. Pharmacol. Exp. Therap.,
184, 542 (1973). 28. R X , H e i k k i l a and G. Cohen, Europ. J. Pharmacol. , 20, 156 (1972). 29. B. S c a t t o n , A. Cheramy, M. J . Besson and J. Glowinski, Europ. J . Pharmacol. , 2,131 (1970). 30. T. H. Svensson, Europ. J. Pharmacol., 23, 232 (1973). 31. K. H. Sontag and P. Wand, Arzneim.-Forsch. , 23, 1737 (1973). 32. W. Wesemann and J. D. Schollmeyer, Agents and A c t i o n s , 2, 195 (1973). 33. J. Amer. Med. ASSOC., 226, 1117 (1973). 34. A. B a r n e t t , J. Goldstein and E. F i e l d e r , Fed. Proc. , 33, 293 (1974). 35. J . Amer. Med. ASSOC., 228, USAN Council, L i s t 134, May (1974). 36. R . S. Schwab, L. V. Amador and J . Y. L e t t v i n , Trans. Am. Neurol. Assoc. , 76, 251 (1951). 37. G. C. C o t z i a s , P. S. P a p a v a s i l i o u , C. F e h l i n g , B. Kauf'man and I . Mena, New Eng. J. Med. , 282, 31 (1970). 38. P. Castaigne, D. Laplane and G. Dordain, Res. Commun. i n Chem. P a t h o l . Pharmacol. , 2, 154 (1971). 39. V. G. Vernier and K. R . Unna, J. Pharmacol. Exp. T h e r . , 103,365 (1951). 40. J . Maj , M. Grabowska and L. Gajda, Europ. J . Pharmacol. , 17,208 (1972). 41. H. C o r r o d i , K. Fuxe and U. Ungerstedt, J . Pharm. Pharmacol. , 23, 989 42.
.
(1971) . _ . . W . H. Funderburk, D . N . Johnson and J. W. Ward, Fed. Proc.
, 32, 247
(1973). 43. M. G o l d s t e i n , A . F. Battista, T. Ohmoto, B. Anagnoste and K. Fuxe, S c i e n c e , 179, 816 (1973). 44. D. B. Campbell, P. Jenner and A. R. T a y l o r , Advances i n Neurol., 3, 199 (1973). 45. B. C o s t a l l and R. J . Naylor, Advances i n Neurol., 2, 281 (1973). 46. S. D. V a k i l , D. B. Calne, J. L. Reid and C . A. Seymour, Advances i n Neurol. , 2, 121 (1973). 47. M. K. Menon, W. G. Clark and D. Aures, Europ. J. Pharmacol., 19, 43 ( 19-72
.
26
Sect. I
I
48. 49. 50.
51.
- CNS
Agents
Gordon, Ed.
R . M. P i n d e r , Advances i n Neurol. , 3, 295 (1973). D. M. Brown, B. 0. Hughes, C . D. Marsden, J . C. Meadows and B. 476 (1973). S p i c e r , B r i t . J. Pharmacol., 0. P. W. Robinson, Advances i n Neurol., 3, 97 (1973). K. R . Hunter and 0. P. W. Robinson, C l i n i c a l Trials J o u r n a l , 2, 3
9,
(1972). 53.
D . J . Vicary, P. M. Horrocks, J . E. Rees, J , D. Parkes and C . D . Marsden, C l i n i c a l T r i a l s J o u r n a l , l0, 3 (1973). D . J . J e f f e r y , D. M. Brown and P. F. Langley, Xenobiotica, 5 , 169
54. 55.
G. Clark and J . Davies, B r i t . J . Pharmacol., 465 (1973). R . C. U r s i l l o and J. A . McCulloch, Arch. I n t . Pharmacodyn., 197,132
56. 57. 58.
E. A. S p i e g e l and H. T . Wycis, Confinia Neurol., 2,176 (1969). H. T. Wycis, Confinia Neurol. , 34, 130 (1972). E . R. Blonsky, A. D. E r i c s s o n , A . S . McKinney, A. Rix, R . I . H. Wang and A . A. Rim, C l i n i c a l Pharmacol. Therap. , 2, 46 (1974).
52.
(1971).
3,
(1972)
-
Chapter 4.
Psychotomimetic Agents
Richard A. Partyka and JOMS A. Gylys B r i s t o l Laboratories, Syracuse, New York 13201
-
'-'
Comprehensive suryeys on t h e chemistry, pharmacology2 and metabolism o f General The proceedings of conferences d e a l i n g w i t h marihvsna a n n a b i n o i d s have ap7e red. have been published. Governmental p u b l i c a t i o n s which cover t h e b i o l o g i c a l , s o c i a l An e x c e l l e n t account of e r g o t and l e g a l a s u e c t s of marihuana have a l s o appeared.'-'' has been published i n which the t a x o n o q and d i s t r i b u t i o n of the Claviceus s p e c i e s , t h e c o n s t i t u e n t s o f e r g o t and t h e i r b i o s p t h e t i c o r i g i n , and t h e production 3f e r g o t a l k a l o i d s a l l have Seen reviewed.lZ Extensive reviews on t h e ~ h e r n i s t r y ~ a:d ~ - bio~ synthesis15 o f peyote a l k a l o i d s have appeared. The biochemistr] o f psychosesL6 a s w e l l a s t h e r o l e of adrenochromel' a s a psychotomimetic agent have been t h e s u b j e c t s of reviews. -4 review o f che chemistry and pharmacology o f W m e t h v s t i c u m , t h e 18 pepper p l a n t from which t h e n a r c o t i c d r i n k kava-kava i s prepared, has been pubiished.
-
I. Chemistry A. Cinnabinoids A d e f i n i t i v e paper appeared on t h e i s o l a t i o n and s t r u c t u r a l e l u c i d a t i o n o f 1'-retrahydrocannabinol (A1-THC). (2, cannabigerol cannabichromene (3, and cannabicyclol ( 4 A d e s c r i p t i o n o f the a b s o l u f t c o n f i g u r a t i o n 3111 o f both c h i r a l c e n t e r s (C-3 and C-4) i n 1 -THC a s & was also presented. $&fls on t h e t o t 3 1 syntheses o f ( 5 ) cannabidiol (+J d 5 - T H C , (-) d l - T H C , (-) -THC, as well a s t h e racemic and ( + ) l n o d i f i c a t i o n s of t h e l a t t e r two THC'S, were
-
4.
(z),
-
(z),
-3
p
4
-5
-6
published. 20-1 Other cannabinoid r e p a r a t i o n s i n v o l v i n g t h e condensation of terpenoid moieties were a l s o described. 2 2 - 3 ~'32 P opyl and methyl analogs o f cannabinoids 2 and 6 were i s o l a t e d and characterizedz4-' fro111 n a t u r a l sources. A propyl a n a l o g o f 2 was a l s o reported.2i S y n t h e t i c cannabinoids with n i t r o g e n c o n t a i n i n g s i d e chains such a s s t r u c t u r e s i n analogous f a s h i o n according t o p r e v i o u s l y d e s c r i b e d s y n t h e t i c A unique approach t o t h e trans-aza s t r u c t u r e 4 was a l s o reported. 30 routes
7a-c w5gegprepared
L
-8
Unfortunately, b i o l o g i c a l d a t a were n o t reported f o r t h e s e i n t e r e s t i n g s t r u c t u r e s . The ready a v a i l a b i l i t y o f v a r i o u s cannabinoids by i s o l a t i o n and s y n t h e s i s l e d t o a n i n t e n s i f i e d study o f t h e i r metabolism i n v a r i o u s animal specie^.^^'^ I n general, hydroxyIation occurred i n any a v a i l a b l e a l l y l i c o r benzyl o s i t i o n of t h e THC framework with t h e p o t e n t i a l f o r f u r t h e r metabolic conversion."-' I n man, a n important
28
Sect. I
-
CNS Agents
Gordon, Ed.
m e t a b o l i t e o f 4l-TIK was t h e corresponding 7-OH d e r i v a t i v e which a l s o e l i c i t e d p o t e n t cannabinoid-like e f f e c t s . ' 9 - 4 2 S y n t h e t i c developments k e p t pace v i t h t h e i s o l a t i o n and i d e n t i f i c a t i o n the v r i us metaboli p r o ucgs. Thus, procedures f o r t h e s y n t h e s i s of 7-OE-L-f6) -TBCt3-' and 7-GIi4'-THCt6-' were described. 5 8 0 e o g routes. !i9,55,w,
a ed fl-8
m e t a b o l i t e s such a s
9
and l o w e r e a l s o d e r i v e d by s y n t h e t i c
a)
€$-OH;
b)
€$a; R2-OH;
c)
5, R2-=arbanyl;
d)
%dz=H; 1,Za-epoxy;
e)
I(l-Rz=H;
RZM; R fl
3
R34i R3fl
5"
R3.0H
2 a)
5 9 ; R2R3=carbonyl
b)
%<€I3;
c)
\G2H;
OH
R2L,+,
R2-R3=H
10 -
a)
R=OCT(CH3)C5H11
b)
RIC(CH3) <(CH3)C5HI1
c)
RIC(CH3) zC6H13
d)
RG(C5)CH(CH3)C5Hl1
11
3 A v a r i e t y of new 4 -THC d e r i v a t i v e s l l a - c condensation products i n t h e 4' p o s i t i o n . 56-
was prepared i n c l u d i n g Mannich
-
B. Lvsernic Acid S t r u c t u r e s . Sev a 1 u n s u c c e s s f u l a t t e m p t s a t a new s y n t h e s i s of l y s e r g i c a c i d (12a) were sumarized.'f A review on analogs & of. I most of which a r e p a r t i a l s t r u c t u r e s , appeared. 52 An e f f i c i e n t p r o c e s s f o r t h e p r e p a r a t i o n of v a r i o u s secondary and t e r t i a 8 ly5ergamides and t h e corresponding d i - and t e t r a h y d r o d e r i v a Nu-Demethylation o f l y s e r g i c a c i d diethylamide (LSD) was t i v e s was d e s ribed. accomplishedJz 2 s well a s t h e d i F e r i z a t i o n of a wide v a r i e t y o f e r g o t a l k a l o i d d e r i v a t i v e s t o s t r u c t u r e s of type 13.-'5 A convenient p r e p a r a t i o n o f t h e t 7 t g l y s e r g i c a c i d e s t e r 15 from t h e corresponding N-oxide 1L;was d i s c l o s e d . 56 Cyclic o r t h o t h i o esters were used i n a novel F r i e d e l - C r a f t s type approach t o t h e p r e p a r a t i o n o f v a r i o u s 2 - s u b s t i t u t e d 9,lO-dihydrolysergic a c i d d e r i v a t i v e s 12b i n c l u d i n g (R1"CH3). 5 7 A t o t a l s y n t h e s i s of (3- i s o s e t o c l a v i n e (l:c)was described.
RICH2C1,
14
Ls.
C 0 2 9 , cBzcN
13 -
S t u d i e s involving t h e unraveling of t h e complex b i o s y n t h e t i c sequence of t h e review on t h e biosyne r g o t a l h l o i d s continue 20 be r e p ~ r t e d . ~ ~A- ~comprehensive l t h e s i s of e r g o t a l k a l o i d s was publishcd.62 Of p a r t i c u l a r i n t e r e s t w a s t h e d i s c l o s u r e t h a t t h e e n o l a c e t a t e 12d was a n e f f i c i e n t l y s e r g i c a c i d precursor.63 A new a l k a l o l d 1 6 (R=(+) -1ysergyl) from a Claviceps purpurea s t r a i n was i s o l a t e d and c h a r a c t e r i z e d .
-
''
Partyka, Gylys
Psychotomimetic Agents
Chap. 4
2
z
?&.
-
PhenylalXvlaiine T,;?(?s. Anolozs o f Go?I 18a (R=C1 3r,I,X02,NH,)65 as w e l l a s t h e were prepdred. A series o f b-ajor ? - t a b o l i t a s oi ;.C:.l i n t‘.e r a t (18, R.C:12CH, C0,H)’6 bromonethoxyphe=y;isoproplrlamrnes 19 ( n i l , 2) was a l s 6 described, w i t h b r i e f r e f e r e n c e s t o phar2co:oCical a c t i v i t y . 67-i3 A h i s h l y u s e f u l method f o r the a s p e t r i c s y n t h e s i s o f p h e n y l i s o p r o p y l a ~ i n c s a s well as t h e nethodoloFy f o r t h e determination o f t h e i r Numerous analogs o f the psychotonimetic e n a n t i o n e r i c p u r i ? ” Tiere published, pheny1isopropyLznines Irere preoared \:herein the s t r u c t u r a l f e a t u r e s were i n c o r p o r a t e d i n t h e nore c o c s t r a i n e d frans::ork o f a 2-amino-1, 2 3 4-tetrahydronaphthalene ( a n i n o t e t r a l i n ) s y s t e z 21 (R=CH3, OH, @Ke, H, -0CX20-).71-g The aminoindan and aminoC.
20
19 (COH)
a)
R
bj
R
C)
a=ar
a) b)
n-1 D-2
N(W3)
(WET)
(DOJ)
21 -
t e t r a l i n 2(ib analogs o f N M were a l s o prepared.
74
The p r e p a r a t i o n o f t h e s u l f u r analog 22b o f p s i l o c i n (22a) was described. Weak s e d a t i v e and vasopressor a c t i v i t y w a s found.
--
75 -6
I n v i t r o experiments provided evidence f o r t h e bioconversion o f n y r i s t i c i n (23) t o t h e corresponding phenyliso?ropylanine d e r i v a t i v e , PNDA 77 Other workers, u s i n g t h e i n t a c t animal, demonstrated t h e presence o f s t r u c t u r e s m a s major m e t a b o l i t e s
z.
o f t h e r a t and guinea pig, r e s p e c t i v e l y . 7 8 The f u l l i m p l i c a t i o n o f t h e s e bioconvers i o n s with respect t o b e h a v i o r a l o b s e r v a t i o n s i n animals79 a s w e l l a s i n man remains t o be determined. X review on nutmeg was published.80
D.
O t h e r - S t u a i e s continued on t h e measurement o f p h y s i c a l chemical parameters o e l f i d a t e s t r u c t u r e a c t i v i r y p a t t e r n s i n psychotomimetic compounds. Thus X-ray, in ordlif-’ nu& and t o t a l o r b i t a l e n e r g i e s a 4 were used t o study molecular conformation and i t s r e l a t i o n s h i p t o psychotonimetic a c t i v i t y i n t h e l y s e r g i c a c i d series. The conformations o f p s i l o c i n and mescalice we85 examined by molecular o r b i t a l and c l a s s i c a l p o t e n t i a l function calculations C o r r e l a t i o n s o f uv s p e c t r a , ‘6 n a t i v e fluorescence87 and a s s o c i a t i o n constants*8 with t h e psychotomimetic a c t i v i t y of v a r i o u s methoxylated phenylisopropylanines were made. Quantum mechanical s t u d i e s Of
30
Sect. I
- CNS Agents
Gordon, Ed.
t h e r e l a t i o n s h i p between p s y c h o t o n i n e t i a t i v i t y and t h e s t r u c t u r e s o f v a r i o u s a n t i c h o l i n e r g i c a g e n t s were a l s o published. g9-Fo
-
11. Pharnacolow. A. Cannnbinoids. Acute and Fhronic t o x i c i t y , t e r a t o l o g y , and reproduction c, t u d i e s on crude m a r i h u n a e x t r a c t , lL-TMC and o t h e r cannabinoids were p e r f o m e d i n animals. Concrolled human s t u d i e s f a i l e d to r e v e a l any drug r e l a t e d p e m n e n t e f f e c t s 2 * 11, 95althuugh chronic narihuana smokers had impaired 96 c e l l u l a r mediated i m l i n i ty. I n animals, b L - T H C showed s i o n s o f a n a l g e t i c , a n t i p y r e t i c , a n t i i n f l a m a t o 97-100 +f
r,,
and anticonvi?lsant p r o p e r t i e s , lo'-' but no a n t i d e p r e s s a n t e f f e c t s . lo3 I n man, 5 THC was i n a c t i v e a s a n a n a l g e g i c i n experimental ? a i n . l o 4 A'-THC caused hypothermia i n s e v e r a l a n i r a l s p e c i s ? i''-i v h i l e camplex and b i p h a s i c e f f e c t s were seen on rodent a g g r e s s i v e behavior. *L*h-lll ll-THC p o t e n t i a t e d t h e e f f e c t s o f d e p r e s s a n t compounds, 'I2 b u t e x h i b i t e a no c l e a r cut antzgonism towards amphetamine. S i m i l a r f i n d i n g s were a l s o r e p o r t e d f o r s y n c n e t i c cannabinoids. Cannabidiol and cannabinol, which were considered t o b e b i o l o g i c a l l y i n a c t i v e , e x h i b i t e d a n t i c o n w l s a n t a c t i v i 114 and i n t e r a c t e d with J l - T H C both p h a m c o l o g i c a l l y and m e t a b o l i c a l l y i n animals Furthermore, intravenously, cannabinol was found t o be weakly a c t i v e i n man."7 The phannac o l o g i c a l m o p e r t i e s of s e v e r a l s y n t h e t i c 13-THC d e r i v a t i v e s have been d e s c r i b e d i n animals. 7 , f O
'
I n animal o p e r a n t procedures, ?'-THC impaired performince mainly a f f e c t i n g t y p o r a l d i s c r i m i n a t i o n and s h o r t term mecory. 2,5 However, t h e e w re r e p o r t s t h a t A -THC n i g h t f a c i l i t a t e a c q u i s i t i o n of avoidance perfonrance. l l L 1 2 % Tolerance t o t h e e f f e c t s o f LI-THC developed r a p i d l y , was long l a s t i n g , and d i d rigi in.^ Hovev r, t h e r e were s e v e r a l b e h a v i o r a l parameters which f a i l e d t o e x h i b i t tolerance.121'e Thus f a r , only t h e fhesus monkey I n man, e x h i b i t e d s i g n s resen'nling p h y s i c a l dependence upon withdrawal of 1 t o l e r a n c e t o cannabis p r e p a r a t i o n s was less apparent and no t r u e p h y s i c a l dependence The s o - c a l l e d "reverse" t o l e r a n c e p o s t u l a t e d i n Fan could n o t b e was seen.8, lo, r e c e n t l y confirmed.125-6 ll-THC decreased s l e e p d u c t i o n time i n man, however, a Extensive humen s t u d i e s on "hangover" phenomenon was observed the nexc day. cannabinoids d e a l i n g with s u b j e c t i v e e f f e c t s mental function, memory, w t o r and d r i v i n g performance were published. 5 , 11, 128-31
not appear t o b e metabolic i n
'"
The s i m i l a r i t y o f cannabinoids t o o t h e r known psychotomimetic compounds was appeared t o be d i f f e r e n t from LSD i n terms of p h y s i o l o g i c a l i n v e s t i g a t e d . \'-THC and psychotomimetic p r o f i l e s i n man ( r e f . 4 , p. 196). Howe er, c e r t a i n s i m i l a r i t i e s and d i f f e r e n c e s wereaceen between marihuana and e t h a n 0 1 ~ ~w ~ i t h- ~an i n d i c a t i o n o f No c r o s s - t o l e r a n c e could b e demonstrated between ll-THC and c r o s s - t o l e r a n c e . li, IJ5 morphine, mescalice o r LSD. '7 136 I n animals,
;.I -THC produced hypotensive responses, bradycardia
reduced venous
r turn137 and a n t i h y p e r t e n s i v e e f f e c t s i n c e r t a i n l a b o r a t o r y models. 138-9 Xn nan, Ap-THC caused tachycardia, c o n j u n c t i v a l reddening, p r e s s o r e f f e c t s , impairment of Some r e c e n t evidence i n d i c a t e d t h a t ll-THC v a s o r e f l e x e s and ECG changes. reduce i n t r a o c u l a r p r e s s u r e and p u l m n a r y a i r r e s i s t a n c e i n man.
might
S t u d i e s an a b s o r p t i o n , p l a s m l e v e l s orwan d i s t r i b u t i o n , 143-7 u r i n rv and fecal excretio.., and n e t a b o l i c conversion^'^, 3g7 14'-' o f 'll-THC a n d / o r hi$6)-THC i n animals and man were published.3i,33 The c u e s t i o n o f whether A1-THC o r 7-OHdI-THC was m i n l v t e s p n s i b l e f o r t h e e f f e c t s observed w i t h A1-THC ha n o t been resolved.106,1J8 However, i t has been e s t a b l i s h e d t h a t 7-OH-A -THC was p r e s e n t in t h e m u s e b r a i n a f t e r A1-TXC admLnistration, and was found t o be more p o t e n t than L1-THC based on b r a i n concentrations.151-2. On t h e b a s i s of lasma l e v e l s , e x c r e t o r y p a t t e r n s , and concomitant drug e f f e c t s i t appeared t h a t 7+)H-l7-THC most l i k e l y w a s r e s p o n s i b l e hydroxylated m e t a b o l i t e s , such a s s t r u c t u r e s f o r t h a c t i v i t y i n m n . 39, 41, 153 ga.b15&and fi proved t o be inactit:fi31 The metabolism o f DlClP was s t u d i e d i n several animal s p e c i e s . 155
H
The s t r u c t u r e - a c t i v i t y r e l a t i o n s h i p s and r e l a t i v e p o t e n c i e s of v a r i o u s
Chap. 4
Psychotomimetic Agents
31
Partyka, Gylys
cannabinoid; were ?resented. 339156 i t should be noted t h a t d t f f e r e n c e s i n t h e potency of h1-~f1cand .?,1(6)-.IHC, a s w e l l as v a r i o u s 33-T%C d e r i v a t i v e s and analogs, e x i s t e d depending on t h e test animal and procedure ~ s e d . ~ ' , ' ~ ' Despite i n c r e a s e d knowledge, t h e pharmacological c l a s s i f i c a t i o n o f cannabinoids remains e l u s i v e . Any 1.abeling such a s "depressant" o r "hallucinogenic" should be avoided because o f t h e complex and unique p r o p e r t i e s of t h i s c l a s s o f compounds.
-
B. Lyseroic Acid and Tr;ot.-iie Tvxs. I r p o r t a n t c o n t r i b u t i o n s towards t h e unders t a n d i n g of t h e a c t i o n s of psychotomimetic substances, e.g. t h e r o l e o f s e r o t o n e r p i c neurones, s i t e s o f c e n r r a l a c t i o n , and development o f t o l e r a n c e and c r o s s - t o l e r a n c e were revie:ied. 16, 15s-62 The i n f l u e n c e of e q o t a l k a l o i d s on p i c u i c a r y p r o l a c t i n and prolactin-dependent processes :.:as a l s o reviewed. '63 The metabolism o f n i c e r g o l i n e (17) was s t u d i e d i n v a r i o u s a i i m l s p e c i e s , including nan. LSD appeared t o e x e r t s e l e c t i v e e f f e c t s on s e r o t o n e r g i c neurones i n t h e b r a i n stem raphe n u c l e i , however, it i s u?.dctermined whether i t a c t s by blocking o r mi.micking 5-hydroxytryptamine ( 5 - h i ) . 165-r Sufotenin and N, N-dimethyltryptamine (DHT) appeared t o a c t s i m i l a r l y t o LSD on t h e raphe n u c l e i , w h i l e mescaline and DOY appeared t o be d i f f e r e n t . Atropine, 2-3r-LSD, 2nd c h l o r o p r o r a z i n e v e r e i n a c t i v e on raphe The p o s s i b l e involvement o f a c e t y l c h o l i n e , y-aminobutyric a c i d I;A3A) neurones. 1'L-Z -and tryptaminc i n t h e c e n t r a l a c t i o n o f Fsychotomirnetic a g e n t s was imp1icated.l
5'
The phenomena o f t o l e r a n c e and c r o s s - t o l e r a n c e among psychotomimetic a e e n t s were i n t e n s i v tud'ed. A c r o s s - t o l e r a n c e was observed between LSD and tryptamine o r mes a i n e , n4z, Q 7 6 - f b u t n o t Setween LSD o r mescaline and amphetamine o r LSD and DKT. 17'-' I n t e r o c e p t i v e e f f e c t s induced by mescaline, p s i l o c y b i n and LSD were poorly d i f f e r e n t i a t e d by t h e rat. ls'-l D e s p i t e s t r u c t u r a l h e t e r o g e n e i t y , t h e psychoto2imetic a g e n t s i n
e n e r a l caused
an i n c r e a s e i n b r a i n 5-;iT l e v e l s and a decrease i n i t s turnover rate.1'9,184-5 The e f f e c t s on b r a i n norepinephrine (NE) and dopamine were l e s s c l e a r l y defined, b u t a l o v e r i n g o f b r a i n l e v e l s and h i g h e r turnover r a t e s o f NE have been reported. i82-5 S p e c i f i c and s e n s i t i v e r a d i o i m u n e a s s a y s were developed f o r a n a l y s i s o f LSD and mescaline i n b i o l o g i c z i f l u i d s . 186-8 Turthermore, a n t i b o d i e s were o b t a i n e d which e x h i b i t e d high s p e c i f i c i t y t o LSD and c r o s s - r e a c t i v i t y t o o t h e r psychotomimetics r e l a t e d t o tryptarnine and phenethylamine. ls9
The d i s t r i b u t i o n o f LSD i n t h e r a t b r a i n e x h i b i t e d p a t t e r n s mimicking r e g i o n a l l o c a l i z a t i o n o f g-kT.l'o The c e n t r a l e f f e c t s of LSD were antagonized by s e v e r a l s t e r o i d a l agentsAg1 and 3, N-diethyl-l-methyl-l,Z, 5 , 6 - t e t r a h y d r o n i c o t i n a n i d e . 192 Furthermore, an a c t i v e i m u n i z a t i o n by p r o t e i n c o n j u g a t e s coPtaining l y s e r g i c a c i d o r tryptophan prevented c e r t a i n c e n t r a l e f f e c t s of LSD i n mice. L53 LSD f a c i l i t a t e d a c q u i s i t i o n of l e a cd behavior and improved l i g h t d i s c r i m i n a t i o n and r e c e n t memory i n rats and monkeys. 1'e-7 There TJBS l i t t l e w e l l &ocumented evidence t o i m p l i c a t e LSD f o r causing chromsomal damage and t e r a t o l o g i c e f f e c t s b o t h i n r a n and animals. The d e t e r m i n a t i o n of a N-ethyltransferase i n h m n blood1" and brainzo0 t h a t was capable o f converting t r y p t a n i n e i n t o DMT vas d e s c r i b e d . The presence o f a n endogenous substance capable of E e t a b o l i z i n q C:T i n normal s u b j e c t s was p o s t u l a t e d . lg9 Chronic schizophrenics excreted EXC and bufotenin i n t h e i r urine, v h i l e normal s u b j e c t s d i d not. 201-2
-
C. Phenvlnlkvlamine Types. The human p h a m c o l o g y of mescaline, i t s congeners and phenylisopropylamine a n a l o s s was reviewed. '03 X comprehensive study on t h e a c u t e t o x i c i t i e s 0 5 mescaline and i t s d e r i v a t i v e s revealed t h a t t h e do was n o r e s e n s i t i v e than t h e rhesus monkev t o t h e t o x i c e f f e c t s o f t h e s e compounds. 264 Rats f a i l e d t o d i f f e r e n t i a t e 2,3,4-trimetho?cyphen lethylamine, a non-psychotomimetic a n a l o g of mescaline, from mescaline i t s e l f . 25'
A e e o s e l e c t i v i t y o f LSD, DO31& tl DOB !8c. and DOET 18b f o r c e n t r a l ::ns demonstrated i n t h a t the g - c o n f i g u r a t i o n e l i c i t e d t h e n o t e p o t e n t effects2"-' e f f e c t , w h i l e p e r i p h e r a l l y such a d i f f e r e n t i a t i o n w a s not shown. 209-10 110 such clear
32
Sect. I
_.
-
Gordon, Ed.
CNS Agents
d i f f e r e n t i a t i o n with r e s p e c t t o psychotomimetic e f f e c t s could be shown w i t h g-(-) o r 5-(+)-am hetamine, although t h e 2 - i s o s e r was more p o t e n t a s a s t i m u l a n t than t h e 11isomer. 2P1
-
S t r u c t u r e - a c t i v i t y requirements i n t h e phenylisopropjllamine s e r l e s were presented. 203 R e l a t i v e potency r e l a t i o n s h i p s i n v a r i o u s experimental procedures f o r phenylisopropylsmine and D>fT analogs were discussed. 212-3 A t r a n s o i d conformation f o r mescaline a t t h e r e c e p t o r l e v e l was supported by t h e g r e a t e r b e h a v i o r a l e f f e c t s o f 28a over 28b i n t h e
'''
W M caused a b e r r a n t g r o s s b e h a v i o r a l p a t t e r n s w i t h a concomitant h persynchronous i t a l s o produced a l e t h a l hyperthermia i n r a b b i t s . The c a r d i o v a s c u l a r a c t i v i t y of X?.lwas c h a r a c t e r i z e d by z p r e s s o r response, tachyphylsxis and p e r i p h e r a l v a s o d i l a t i o 2 folloved by v z s o c o n s t r i c t i o n . 217 The e n t r a l and p e r i p h e r a l e f f e c t s induced by 3 O Y 57ere s u s c e p t i b l e t o 5-iiT a n t a g o n i s t s . 21s-7 Or%3n d i s t r i b u t i o n , , metabolic conversions and t h e e x c r e t o r y p a t t e r n o f 20014 were s t u d i e d i n l a b o r a t o r y ~ d t o b e responsible f o r the a c t i v i t y animals.218-22G The unchanoed C O ~ ? D O U E appear observed. 219 I n man, 30XT,r23E0B221 and M..DA2'2 caused a d l d euphoria a l o n ? w i t h a f e e l i n g of enhanced awareness a t r e l a t i v e l y lot.! doses. Various a m i n o t e t r a l i n s produced smooth muscle c o n t r a c t i o n s i n v i t r o probably through 5-HT r e c e p t o r s . 223 2 h i n o - 7 - h y d r o x y t e t r a l i n caused c e n t r a l e f f e c t s s i m i l a r t o those seen with mescaline and LSD i n rats. 224
EEG i n t h e cat.215
-
A new thebaine d e r i v a t i v e 2 6 p r o v e d t o be a n extremely p o t e n t psychotoD. Other mimetic agent, q u a l i t a t i v e l y mimickinz cyclazocine i n man 225 A novel c h o l i n e s t e r a s e inhibitor caused s e v e r e sensory d i s t u r b a n c e s i n man. 2i6 Low doses of N, N-dipropyltryptamine were evaluated a s a p o t e n t i a l a d j u n c t i n psychothera v 227 The biochemical e f f e c t s o f psychotomimetic a n t i c h o l i n e r g i c drugs were reviewed. 52i I n man, sensory d i s r u p t i v e e f f e c t s produced by a t r o p i n e , scopolamine and D i t r a n were similar and could
a
27 -
20 -
b e c l a s s i f i e d a s simple d e l i r i u m r a t h e r than a s psychotomimetic syndromes. 229
In rats,
c y c l a ~ o c i n e 2 3and ~ l e ~ a l l o r p h a nproduced ~~~ similar e f f e c t s t o t h o s e seen w i t h LSD.
Chap. 4
Psychotomimetic Agents
Partyka, Gylys
33
References
1. 2.
3. 4.
5. 6. 7. 8.
9.
10. 11. 12.
13. 14. 15. 16. 17. 18.
19. 20. 21. 22.
23. 24.
25. 26. 27. 28. 29. 30.
31. 32.
33. 34.
as. 36. 37.
38. 39. 40.
41. 42. 43.
66. 45. 46. 47.
R. K. Razdan, i n "Progress i n Organic Chemistry," Vol. 8, W. C a r r u t h e r s and J. K. S u t h e r l a n d , Eds., B u t t e r u o r t h s , London, 1973, C h a p t e r 3. L. Hills and P. Brawley, Agents and A c t i o n s , & 201 (1972). R Hechoulam, Ed., "Harijuana, I' Acadenic P r e s s , New York, N.Y., 1973. A. S i n g e r , Ed., "Y!riJuana: Chemistry, PharmacoloRy, a n d P a t t e r n s o f S o c i a l Use," Vol. 191, New York Academy o f S c i e n c e s , Xew York, N.Y. 1971. M. P. Lewis, Ed., "Current Research i n Marijuane," Academic P r e s s , New York, N.Y. 1972. W. Paton and J. Crown, Eds., "Cannabis and i t s D e r i v a t i v e s , Pharmacology and Experimental Psychology, " Oxford U n i v e r s i t y Press, London, 1972. M. deV. Cotten, Ed.. P h a m a c o l . Rev. 2_?, (1971). " M a r i h u n a : A S i c r u l of ?lisunderstanding, t h e T e c h n i c a l P a p e r s o f t h e F i r s t Report o f t h e N a t i o n a l C o m i s s i o n o n ?larihuana and Drug Abuse" Appendix, Vol. 1, U.S. Government P r f n t i n g O f f i c e , 1972. "Cannabis-A Report o f t h e Comnission of I n q u i r y i n t o t h e Non-Medical Use o f Drugs," I n f o r m a t i o n Canada, Ottawa, O n t a r i o , 1972. "Marihuana and H e a l t h , " Second Annual Report t o Congress, U.S. Government P r i n t i n g O f f i c e , 1972. "Marihuana and Health, " T h i r d Annual Report t o Congress, U. S. Government P r i n t i n g O f f i c e , 1974. D. Groger i n "Microbial Toxins,'' Vol. 8, S. Kadis, A. C i e g l e r , and S. A j l , Eds., Academic P r e s s , New York, X.Y., 1972, Chapter 12. J. McLaughlin, Lloydia, 1 (1973). G. Knpadia and M. i a y e z , Lloydia, 9 (1973). A. G. Paul, Lloydia, 36 (1973). H. Weil-Malherbe and S. I. Szara, "The B i o c h e m i s t r y of F u n c t i o n a l a n d E x p e r i m e n t a l Psychoses, " C. C. Thomas, S p r i n g f i e l d , I l l i n o i s , 1971, C h a p t e r 17. R A. Heacock, Chin. Ther., 5 300 (1971). A. T. Shulgin, B u l l . N a r c o t i c s , 25, 59 (1973). Y. Caoni and R. Hechoulam, J. Amer. Chem. Soc., fi 217 (1971). R Hechoulam, P. Braun, and Y. Caoni, ibfd. 6159 (1972). R. Mechoulam, 2. Ben-Zvi, H. Varconi, and Y. Samuelov, Tetrahedron, 3 1615 (1973), L. Cronbie and R. Ponsford, J. Chem. SOC. C, 796 (1971). B. C a r d i l l o , L. H e r l i n i and S. S e m i , T e t r a h e d r o n Lett., 945 (1972). E. W. G i l l , J. Chen. SOC. C, 579 (1971). T. Vree, D. Breimer, C. van Ginneken and J. van Rossurn, J. Pharm. Pharmacol., 2i?, 7 (1972). R. d e Zeeuw, J. Wijsbeek, D. Breimer, T. Vree, C. van Ginneken and J. van R o s s q S c i e n c e f75. 778 (1972). R d e Zeeuw, T. Vree, D. Breimer, and C. van Ginneken, E x p e r i e n t i a , 3 260 (1973). T. P e t r z i l k a a n d W. Lusuardi, Helv. Chim. A c t a , 510 (1973). T. P e t r z i l k a , M. Demuth and W. Lusuardi, i m . , 519 (1973). K Cushman and N. C a s t a g n o l i , Jr., J. Org. Chem., 440 (1973). L. Lemberger, Advan. P h a n a c o l . Chemother. &l 221 (1972). R Mechoulam, H. Varconi, 2. Ben-Zvi, H. Edery, a n d Y. G r u n f e l d , J. h e r . Chem. SOC., 7930 (1972). M. Wall, Ann. N. Y. Acad. S c i . , 191. 23 (1971). 0. Gurny, D. Maynard, R P i t c h e r , and R. K i e r s t e a d , J. h e r . Chem. SOC., 7928 (1972). R. Mechoulan, 2. Ben-Zvi, S. A g u r e l l , I. Nilsson, J. Nilsson, 8. Edery, and Y. C r u n f e l d , Experientia, 1193 (1973). I. Nilsson. S. ARurell. J. Nilsson. A. Ohlsson. J. Lindgren a n d R. Hechoulam. Acta. Pharm. Suecica, &I 97 (1973): D. Maynard. 0. Gurny. .. R. P i t c h e r , and R. K i e r s t e a d . w e r i e n t i a , 21. 1154 (1971). V. Esievez; L. E n g l e r t , a. T. Ho; Res. Comrmn. Chek. Pnthol. P h a G c o l . , & 8 2 1 (1973). L. Lemberger, R. C r a b t r e e , a n d H. M. Rowe, Science, 177. 62 (1972). L. Lemberger, N. Tanurkin, J. Axelrod, and 1. Kopin, Science, 173. 72 (1971). L. Lemberger, J. Weiss, A. Watanabe, I. G a l a n t e r , R Wyatt, a n d P. Cardon, New Eng. J. Med. 286. 685 (1972). M. Wall, D. Brine, C. P i t t , M. Perez-Reyes, J. h e r . Chem. SOC., & 8579 (1972). K. Weinhardt, R. Razdan, and H. D a l z e l l b T e t r a h e d r o n L e t t . , 4827 (1971). J. Nilsson, I. Nilsson, S. A g u r e l l , B. Akenmrk a n d I. Lagerlund, Acta Chem. Scand., 2 768 (1971). T. P e t r z f l k a , M. Demuth, and W. Lusuardi, Acta Pharm. Suecica, 5 679 (1971). 8578 (1972). C. P i t t , F. Hauser, R. Hawks, S. S a t h e K. I l a l l , J. Anar. Chem. SOC., 2361 (1973). R. Razdan, D . U l i s s , H. D a l z e l l ,
a
,
u.,
34
48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63.
64. 65. 66. 67. 68. 69.
70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87.
88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98.
Sect.
I
-
CNS Agents
Gordon, Ed.
K. Fahrenholtz, J. Org. Chem., 22, 2204 (1972). 2. Ben-Zvi, R. Mechoulam, H. Edety, and G. Porath, Science, 174. 951 (1971). B. Loev, P. Bender, F. Dowalo, E. a c k o , and P. Fowler, J. Wed. Chem., & 1200 (1973). It. Bovrun, D. Evans, J. Cuyett, J. Weale, and A. White, J. Chem. SOC., Perkin Trans 1, 760 (1973). E. Canmicne and D. k p p , J. Pharm. Sci., 809 (1971). F. Johnson, 1. A r y , D. Tciqer, and R. Kassel, J. Med. Chem., 532 (1973). Y. Nakahara and T. !:fwaquchi, Chen. Pharm Bull., 2337 (1971). N. Bach and E. Kornfeld, Tetrahedron Lett., 3315 (1973). P. S t u t z and P. S t a d l e r , ,.-I 5095 (1973). P. S t u t z and P. S t a d l e r , Helv. Chin. Acta, 75 (1972). E. Kornfeld and N. Sach, Ckern. and Ind. (London), 1233 (1971). C. Abou-Chaar, H. Guenther, M. Manuel, J. Robbers, and H. Floss, Lloydia, 3_1, 272 (1972’1 R. Floss, G. Basmadjian, ?L Tcheng, C. Spalla, and A. Minqhetti, fbid.,& 442 (1971). R. Bassett, E. Chain, and K. Corbett, Biochem, J., 134. 1 (1973). R. Thorns and R. Bassett. Progr. Phytochem., 2, 47 (1972). C. L e s l i e Lin, C. BLair,.J. Cassady, D. GrogeK W. Maier, and A. Floss, J. Org. Chem., - 2249 (1973). P. Stutz, R. Brunner, and P. S t a d l e r , Experientia, 2 936 (1973). R Courts and J. I b l i c k y , Can. J. Chem., I I , 1402 (1973). B. Ho and L. Tnnsey, J. Med. Chem., LLt, 156 (1971). C. Barfknecht and D. Nichols, 370 (1971). S. Seplilveda, R. Valenzuela, and B. Cassels, 413 (1972). D. Nichols, C. Barrknecht, D. Rusterholtz, F. Benington, and R. Motin, & 480 (1973). L. Pohl and W. Trager, $& 475 (1973). R. Violland, N. Violland-Duperret, H. Pacheco, C. T r o u i l l e r , and A. Leblanc, Chim. Ther., 4 196 (1971). L V i o l l a n d , N. Violland-Duperret, B. Pacheco, M. Chazarian, B u l l SOC. Chim. Fr., 307(1971). C. Barfknecht, D. Nichols, D. Rusterholtz, J. Long, J. Engelbrecht, J. Beaton, R Bradley, and 3. Dyer, J. Med. Chem.. 804 (1973). D. Nichols, C. Barfknecht, J. Long,.R-Standridge, R. Howell, R. Partytu, and D. Dyer, fbfd., II, 161 (1974). E. Campaigne and R Rogers. J. Heterocycl. Chem.. , 10. 297 (1973). N. Chapan, R. Scrowston, and T. Sutton, J. Chem. S O ~ . , Perkin Trans. 1, 3011 (1972). U. Braun and D. Kalbhen, Pharmacology, % 312 (1973). E. Oswald, L. Fishbein, B. Corbett, and M. Walker, Biochim. Biophys. Act., 244. 322 (1971). A. deMello and E. C a r l i n i , Psychophamcologia, 349 (1973). J. F o r r e s t and R. Heacock, Lloydia, 35, 440 (1972). R. Baker, C. Chothia, P. Pauling, and H. Weber, Mol. Pharmacol., % 23 (1973). R Baker, C. Chothia, P. Pauling, and H. Weber, Science, 178. 614 (1972). K Bailey and A. Grey, Can. J. Chem., 3 3876 (1972). M. Kumbar and D. V. Siva Sankar, Res. Cormun. Chem. Pathol Phannacol., & 65 (1973). S. Ksng, C. Johnson, and J. Green, Ebl. Pharmacol., 640 (1973). K. Bailey and D. Verner, J. Pharm. Sci., 480 (1972). P. Antun, J. Smythies, F. Benington, R. Morin, C. Barfknecht, and D. Nichols, Experientia, 3 62 (1971). M. Sung and J. Parker, Proc. Nat. Acad. Sci., 1346 (1972). S. Ehayani, H. Weinstein, S. Cohen, and M. Sokolovsky, Proc. Nat. Acad. Sci., 3 3103 (1973). li. Weinstein, S. Maayani, S. Srebrenik, S. Cohen, and M. Sokolovsky, Mol. Pharnucol., 820 (1973). C. Thcmpson, H. Rosenkrantz, U. Schaeppi, M. Braude, M. Mason, Toxicol. Awl. P h a m c o l . , 3 363 (1973). C. Thompson, EL Phson, H. Rosenkrantz, and M. Braude, fbid., 25, 373 (1973). L. Borgcn, W. Davis, and H. Pace,Phamucol. Biochem and Behav., 203 (1973). H. Replinger, H. Braude, and J. Calandra, Toxicol. Appl. Phamicol., 450 (1973). M. B o m n , and R. Pihl, PsychophamucoloRia, 159 (1973). C. N a b s , N. Suciu-Foca, J. Arnund, and A. Ebrishima, Science, 163. 419 (1974). U. Dewey, L. Harris, and J. Kennedy, Arch. I n t . Phamcodyn. Ther., 133 (1972). D. Bwtbaum, Psychophamcologia, 275 (1972).
a
u.,& u.,
u.,
u.,
a
a
a
a
a
Chap. 4
Psychotomimetic Agents
Partyka, Gylys
35
Dewey, and L. Hnrris, Eur. J. Pharmacol., 24, 1 (1973). R Sofia, S. Nalepa, J. Harakal, and H. Vassar, J. Phannacol. Exp. Ther., 186. 646 (1973). 429 (1973). 101. P. Conaroe and D. Kin, L i f e Sci, 102. W. Bopran, R. S t e e l e , and D. Freedmin, Psychonhennacolopia, 3 101 (1973). 103. R. Sofia, R. Kubena, and H. Barry, tbfd., 2 1 2 1 (1973). 104. S. H i l l , R. Schwin, D. Goodwin, and B. Powell, J. Pharmacol. Exp. Ther., 188. 415 (1974). 105. R. Sofia, Res. C o m n . Chem. Pathol. P h a m c o l . , 4, 281 (1972). 106. C. Haavik and H. Hardnun, L i f e Scf., 3 1 7 7 1 (1973). 107. C. Haavik and H. Hilrdmn, J. P h a M c o l . Exp. Ther., 187. 568 (1973). 108. E. C a r l i n i , A. kmaoui, and R. h r t z , B r i t . J. P h a m c o l . , & 794 (1972). 585 (1972). 109. S. Uekf, M. Fujiwara, and N. Ogawa, Physiol. Behav., 110. B. Carder and J. Olson, Physiol. Behav., 4 599 (1972). 157 (1973). 111. M. Kilbey, J. Moore, 3nd X. Hall, Psychophamcologia, 185 (1973). 112. R. Sofia and L. Knobloch, 113. J. Howes, Res. Comnun. Chen. Pathot P h a m c o l . , 5 895 (1973). 1527 (1973). 114. R. Karler, W. Cely, and S. Turkanis, L i f e Sci., 115. 1. Karniol and E. C a r l i n i , Psychophamcologia, 12, 53 (1973). 116. C. Jones and R. Pertwee, B r i t . J. Phannacol., 9 375 (1972). 1368 (1973). 117. El Perez-Reyes, X Timons, K. Davis, and E. Wall, Experientia, 401 (1972). 118. B. Herring, Psychophamcologia, 119. J. Pirch, K. Osterholm, E. B a r r a t t , and R. Cohn, Proc. Soc. Exp. Biol. Med., 141. 590 (1972). 1 (1973). 120. R Robichaud, M. Hefner, J. Anderson, and K Coldberg, Pharmacology, 297 (1972). 121. R Harris, W. Waters, and D. MeLendon, P s y c h o p h a ~ c o l o g i a , 122. D. Ferraro and D. C r i l l y , Science, 179. 490 (1973). 171 (1973). 123. M. tenHam and J. van Noordwijk, Psychophamacologia, 373 (1973). 124. D. Lawrence and R. Pertwee, Brit. J. P h a m c o l . , 125. L. H o l l i s t e r and J. Tinklenberg, Psychopharmacologia, 3 247 (1973). 126. S. Casswell and D. Marks, Science, 179. 803 (1973). 127. K. Cousens and A. DiMascio, Psychophannacologia, 22, 355 (1973). 373 (1973). 128. P. Bech, L. Rafaelsen, and 0. Rafaelsen, 129. 0. Rafaelsen, P. Bech, J. Chrfstiansen, H. Christrup, J. Nyboe, and L. Rafaelsen, Science, 179. 920 (1973). 130. M. Hosko. M. Kochar, and R Wang, Clin. Pharnncol. Ther.,. -& 344 (1973). 131. H. Evans; R. b h r t z , - D . Brown, B..Rodda, C. Kiplinger, L. Lemberger, and R Forney, Ik, 936 (1973). 132. L.- Rafaelsen, H. Christrup, P. Bech, and 0. Rafaelren, Nature (London), 242. 117 (1973). 812 133. J. Tinklenberg, B. Kopell, F. Helges, and L. t l o l l i s t e r , Arch. Cen. Psychfat.,= (1972). 134. H. Cappell, C. Webster, B. Herring, and R Cinsberg, J. Pharmacol. Exp. Ther., 182. 195 (1972). 1022 (1972). 135. L. N e m n , M. Lutz, M. Could, and E. Domino, Science, & I 831 (1972). 136. P. Bailey and S. Pradhan, Neurophannacology, &I 137. I. Cavero, J. Buckley and B. Jandhyala, Eur. J. Pharmacol., 3 243 (1973). 138. C. Nahas, I. Schwartz, J. Adanec, and W. Manger, Proc. Soc. Exp. Biol. Pkd., && 58 (1973). 169 (1073). 139. I% Biwfngham, Brit. J. P h a m c o l . , 140. W. Roth, J. Tinklenberg, B. Kopell, and L. H o l l i s t e r , C l i n Pharmacol. Ther., 533 (1973). 3 671 (1972). 141. J. Weiss, A. Watanabe, L. Lcmberger, N. Tawrkin, and P. Cardon, 142. M. Kochar and M. Hosko, J. h e r . Med. Ass., 225. 25 (1973). 1613 (1973). 143. E. Leighty, Biochem. P h a m c o l . , 144. 1. Ryrfcldt, C. Ramsay, I. Nilsson, M. Widmn, and S. Agurell, Acta Pham. Suecica, && 13 (1973). 4 244 (1972). 145. R Freudenthal, J. Martin, and M. Wall., Brit. J. P h a m c o l . , & 146. M. Shannon and P. Fried, Psychophararacologia, 22, 141 (1972). 147. E. G i l l and D. Lawrence, J. Phnna. Pharmacol., 3 948 (1973). 148. M. Perez-Reyes. , M. Lipton. M. Timons. M. Wall. D. Brine. and K. Davis, Clin. P h a ~ c o l .Ther., & .48 (1973). 488 (1973). 149. B. Ho, V. Estever, L. Englert, J. Pharm. Pharmacol., 99. 100.
D. Kosersky, W.
m.,
a
a
a
a
a
w.,
u.,
a
u.,
a
36 150.
151. 152. 153. 154.
155. 156. 157.
158. 159. 160. 161. 162. 163.
164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184.
185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200.
Sect.
I - CNS Agents
Gordon, Ed.
H. Perez-Reyes, M. T i m n s , H. Lipton, K. Davis, and H. Wall, S c i e n c e , 127, 633 (1972). H. C h r i s t e n s e n , R. F r e u d c n t h s l , J. Gidley, R. Rosrnfeld, C. Boe pli, L. T e s t i n o , D. Brine, C. P i t t , a n d M. iia11, Science, 172, 165 (1971). E. G i l l , C. Jones, and D. Lawrence, fllochern. P h a m c o l . , 22, 175 (1973). L. Lemberger, R. % r t z , B. Rodds, R. Forney, and H. Rowe, J. Clin. I n v e s t . 2411 (1973). M. Perez-Reycs, .sL Tirr.ons, M. Lipton, 11. C h r i s t e n s e n , K. Davis, and M. Wall, E x p c r i entia, 1009 (1373). L. L e r b e r c e r , R. YcPhhon, R. Archer, K. Matsunoto, and H. Rowe, J. P h a m c o l . Exp. Ther., 187, 169 (1973). H. Edery, Y. C r u n f e l d , G. Porath, Z. Ben-Zvi, A. Shani and R. Mechoulam, ArzneinForsch., 1995 (1972). I. K a r n i o l and E. C a r l i n i , Pharnacolor;y, % 115 (1973). S. Cohen, Progr. Drug Res., _II, 68 (1971). P. B r z v l e y and J. D u f f i e l d , P h a m c o l . Rev., 3 31 (1972). C. Aghajanfan, A m . N.Y. Acad. Sci., 193. 86 (1972). C. Aghajanian, Annu. Rev. P h a m c o l . , 157 (1972). Symposium o n " F u n c t i o n a l S i q n i f i c a n c e of S e r o t o n i n in Neuronal Systems': in Fed. Proc. Fed. h e r . Soc. 30.Biol., 2 81 (1972). H. F l o s s , J. Cassady, and J. Robbers, J. Phann. Sci., 699 (1973). F. Arcamone, A. Glasser, J. G r a f n e t t e r o v a , A. Minghetti, a n d V. N i c o l e l l a , Bfochem. 2205 (1972). Pharmacol., -Zl P. Bradley, Progr. B r a i n Res., 3 183 (1972). G. Bramwell and T. Gonye, Brit. J. Pbarmacol., 9 3573 (1973). H. H a i g l e r and C. Aghajanian, Fed. Proc., Fed. Amer. SOC. Exp. Biol., 22, 492 Abs. (1973). R. SamaniqL. V a l z e l l i and W. Gumulka, Psychophamacologia, 373 (1972). G. Guilbaud, J. Besson, J. O l i v e r a s , a n d J. Liebeskind, B r a i n Res., 417 (1973). H. H a i g l e r a n d G. Aghajanian, Eur. J. Pharmacol., & 5 3 (1973). H. Haigler andC. Aghaianian, Fed. Proc,Fcd. Amer. SOC. Exp. Biol, 2 2170 Abs. (1972). G. Aghajanian, W. Foote, and M. Sheard, J. Pharmacol. Exp. Ther., 171. 178 (1970). N. Scholes, Proc. SOC. Exp. Biol. Wed., 144. 623 (1973). W. M a r t i n and C. Eades, Psychopharmacologia, 2L, 93 (1972). E. Domfno and A. B a r t o l i n i , Neurophamacology, & 703 (1972). J. Winter, J. Pharmacol. Exp. Ther., 178. 625 (1971). IL T i l s o n , and S. Sparber, ibfd., 184. 376 (1973). J. Cole and W. P i e p e r , Psychophannacologia, 2 107 (1973). S. S p a r b e r and H. T i l s o n , 3 220 (1972). M. S c h e c h t e r and 3. Rosecrans, 3 313 (1972). 0. Cameron and J. Appel, 22, 117 (1973). J. Stolk, J. Barchas, M. C o l d s t e i n , W. Boggan and D. Freedman, J. Pharmacof. Exp. Ther., (1974), in p r e s s . H. Rosengarten and H. Denber, Psychopharmacologia, !a (Suppl. ) 1 2 1 (1972). N. Anddn, H. Corrodi, and K. Fuxe, J. Pharmacol. E x p . Ther., 179. 236 (1971). B. Leonard, Psychopharmacologia, 2 33 (1973). A. Taunton-Rigby, S. Sher, and P. Kelley, Science, 181. 165 (1973). A. C a s t r o , 2. C r e t t i e , F. Bartos, and D. Eartos, Res. Commun. Cheai. Tathol. P h a m c o l . , 5 879 (1973). S. S c h n o l l , W. Vogel, C. O d s t r c h e l , Fed. Proc., Fed. Amer. SOC. Exp. Biol., 2852 Abs. (1973). 8. VanVunakis, J. Farrow, H. C j i k a and L. Levine, Proc. Nat. Acad. Sci., 3 1483 (1971). I. Diab, D. Freedmn, and L. Roth, Science, 173. 1022 (1971). H. Selye, L i f e Sci., ( P a r t I), 1135 (1971). J. Smythies, J. Beaton, F. Benington, and R. Morin, Eur. J. Pharmacol., 11, 270 (1972). E. W. Voss and 8. Berger, P s y c h o p h a m c o l o g i a , 3 140 (1972). C. Bignami, 146 (1972). H. S c h e c h t e r and J. Winter, Arch. I n t . Pharmacodyn. Ther., 196, 64 (1972). A. King, I. : a r t i n , and K. Seymour, B r i t . J. P h a m c o l . , l 6 l P (1972). P. 8. Bradley in "Hcmory and T r a n s f e r of Information," H. Zippel, Ed., Plenum P r e s s , Nev York, 1973. S. Y. Long, Teratology.. & _ 75 (1972).
a
a
a
u., u., u.,
a
a
u., a
R. Wyntt, J. Saavedra, and J . Axelrod, Amcr. J. Psychiat., J. Saavedra and J. Axelrod, Science,
175. 1365
(1972).
130. 754
(1973).
Chap. 4 201. 202.
Psychotomimetic Agents
Partyka, Gylys
37
N. Narasimhacharl and H. Hinwich, J. Psychfat. Res., $ 113 (1972).
N. Narasfmhacharl, J. Avalos, H. F u j i m r l and H. H i m i c h , Biol. P s y c h i a t . ,
311
(1972).
203. 204. 205. 201. 207. 208. 209.
A. T. Shulgln, Lloydfa, & 46 (1973). H. Hardmn, C. I h a v i k , and M, S e e v e r s , Toxicol. Appl. P h a m c o l . , 3 299 (1973). J. C. Winter, J. P h n r n i c o l . Exp. Thcr., 185. I01 (1973). H. Depoorterc and D. Loew, B r i t . J. P h a m c o l . , 354P (1972). A. T. ShulRin, J. Pharm. P h a m c o l . , 21, 271 (1973). F. BenfnEton. R. Porin. J. Beaton. J. Smythles. a n d R Bradley, .. K a t u r e (London). Hew Biol., i 8 S (1973): H. Cheng, J. Long, D. Nichols, and C. Barfknecht, J. Pharmacol. Exp. Ther., 116
",
&
.--.
(1914) I
210. 211. 212. 213. 214. 215. 216. 217.
D.
B. E. A.
P.
M. A.
E
~
-
Dyer, D. Kichols, D. R u s t e r h o l z and C. Barfknecht, L i f e S c i . , E, 885 (1973). A n g r i s t , B. Shopsin, and S. Cershon, Nature (London), 152 (1971). Uyeno, P s y c h o p h n m c o l o g i a , 381 (1971). Kulkarni, Biol. Psychiat., 177 (1973). Cooper and G. W a l t e r s , Nature (London), 238. 96 (1972). Wallach, E. F r i e d m n , and S. Cershon, J. Phannacol. Exp. Ther., 182. 145 (1972). H o r i t a and A. H a n i l t o n , Proc. West. Pharnacol. SOC., & 104 (1972). Cheng, J. Long, C. BarRtnecht, and D. Nichols, J. P h a G c o l . Exp. Ther., 186.
a
345 (1973). 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229.
230. 231. 232.
B. Ro. V. Estevez. L. Tansev. - , L. E n-z l e r tr. P. C r e a v e a and W. *Isaac.
&
J. Med. Chem..
158 (1971). ' 8. Ho. V. E s t e v e z and G. F r i t c h i e . B r a i n Res.. 29. 166 (1971). S. S n i d e r , H. Weingartner, and L . . F a i l l a c e , Arch. Cen. P s y c h i a t . , 3 50 (1971). A. T. Shulgin, T. S a r g e n t , and C. Naranfo, Pharmacology, 103 (1971). A. T. Shulgin, T. S a r g e n t , and C. Naranjo, Pharmacology, u, 12 (1973). 8. Cheng, J. Long, D. Nichols, C. Barf.mecht, P h a r u l c o l o g i s t , 326 Abs. (1973). J. Green, K. D r e s s l e r , and N. Khazan, L i f e Sci., 12 ( P a r t I), 475 (1973). B. A n g r i s t and S. Cershon, Psychophamacologia, 2 109 (1973). S. Wray and A. Comn, Neuropharnecology, Iz, 397 (1973). R Soskin, S. Grof and W. Richards, Arch. Cen. P s y c h i a t , 817 (1973). J. O ' N e i l l , T. T e r n i n i , and J. Walker, Advan. Biochem. Psychophannacol., 4 203 (1972). J, Ketchum, F. S i d e l l , E. Crowell, Jr., G. Aghafanira, and A. Hayes, Jr., Psychop b r m a c o l o g i a , &2 ~. 121 (1973). S. Wray, &2 29 (1972). S. Wray, i b i d . , 251 (1973). S. Houry, R. Mechoulam, P. Fowler, E. M a c h , B. Loev, J. Hed. Chem., 11, 287 (1974). r
-
a
m., a
Chapter 5.
Abuse of CNS Agents
Maxwell Gordon, Bristol Laboratories, Syracuse, New York Introduction. The p a s t few years have seen a marked increase i n t h e abuse of CNS agents around the world. It has a l s o seen the passing of Nathan Browne Eddy, who f o r t h i r t y years had done so much t o put a s c i e n t i f i c pharmacological b a s i s 54,55,233(see a l s o 4,8,17,45,58,87,88,131,140,172, 185 under much of the heroin abuse research being done today. Abuse of drugs, both l i c i t and i l l i c i t has been a worldwide e idemic and has involved agents as d i v e r s e as o i a t e s 2,21,31,73,78,83,8~1105,1i6, B7,1 8 8 9 190, 191,215 am hetarnine 5,117,178,307, LSD 16,189,201,202, barbitur a t e s 59,60,61,9bs288, o t h e r hallucino ens 5O,52,93,95,182,183,184,193,2O4 marihuana 20,399 68,85,93, 95 109 110,11f, 141 142,198,211, cocaine 7 1, e t c . , i n a d d i t i o n t o a spate of glue s n i f f i n g , abuse of nutmeg, snuff, oregano and, of course, the ancient scourge alcohol 6. The hallucinogens a r e covered i n chapter 4 of t h i s volume. The l i t e r a t u r e of alcoholism is so v a s t t h a t no attempt can be made i n t h i s limited space t o cover i t . Furthermore t h e r e is a r e a l question i n our s o c i e t y whether w e consider i t t o be a drug s i n c e , f o r example, i t s use is not regulated by the Food and Drug Administration. Sedative abuse (hypnotics, t r a n q u i l i z e r s ) is a serious, much studied problem. However, not even suggestions of a s o l u t i o n a r e a t hand,so t h i s c l a s s of drugs too w i l l not be reviewed.
=ate Abuse. The o p i a t e area of abuse q u a l i f i e s f o r review i n these pages on two counts. F i r s t , i t is one of t h e most s e r i o u s medicallsociological1 legal/economic problems of our times, and secondly, approaches t o the treatment o r prevention of o p i a t e abuse have yielded c o n t r i b u t i o n s t o medicinal chemistry of the c l a s s i c a l kind, and thus a review of t h e s e approaches is appropriate t o t h e readership of t h i s volume. Economic Aspects of Opiate Abuse. One of the driving forces behind t h e rapid expansion of heroin abuse has been the enormous p r o f i t 92,128,132 t o be made from heroin processing, smuggling 9s99, and s a l e . This p r o f i t motive, when added t o t h e ease of contagion of the heroin h a b i t among s u s c e p t i b l e populations (e.g. peer groups), has made the drug abuse battle a d i f f i c u l t one f o r a l l concerned. Only now, a f t e r extensive e f f o r t s t o i n t e r d i c t heroin t r a f f i c , t o a r r e s t and convict t r a f f i c k e r s , and t o e n r o l l as many a d d i c t s as possible i n t o treatment programs, has the explosive growth of heroin abuse shown signs of leveling o f f . Regrettably t h e t o t a l number of a d d i c t s is s t i l l r i s i n g , a l b e i t more slowly, and estimates of t h e number of heroin a d d i c t s i n the U.S. range as high a s 800,000 38, a l though estimates of 300,000 t o 400,000 a d d i c t s are more coarmonly c i t e d . Opium harvesting i s q u i t e labor i n t e n s i v e (about 200 man-hours per kg opium 92 a d hence opium tends t o be grown commercially i n a r e a s where lowc o s t , short-term labor is a v a i l a b l e . Climatic requirements f o r the opium poppy a r e not g r e a t , and Papaver somniferum grows i n areas as d i v e r s e as Bulgaria, China, Greece, India, I r a n , Laos, Mexico, North Africa, Pakistan, Thailand, Turkey, and t h e U.S.S.R.
Chap. 5
Abuse of CNS Agents
Gordon
2
Most i l l e g a l opium products smuggled i n t o t h e U.S. i n recent y e a r s have from Turkey v i a France, where morphine was converted t o heroin. However, Turkey has only accounted f o r about 5% of t h e world production, so c l o s i n g out opium c u l t i v a t i o n i n Turkey (subsidized by t h e U.S.) had little o r no e f f e c t on i l l i c i t heroin supplies i n t h e U.S., although it d i d cont r i b u t e t o a shortage of medicinal opium exacerbated by crop f a i l u r e s i n India. Furthermore, l e g a l c u l t i v a t i o n of opium i n Turkey i s about t o be r e i n s t i t u t e d f o r economic reasons. copne
Recent p r i c e s paid t o Turkish farmers f o r l e g a l opium have been about $7.00 per kilogram, but black market p r i c e s have been as high a s $250,000 per kilogram. A t t h i s p r i c e of crude opium, the c o s t of t h e heroin i n a $5.00 "bag" i n t h e U.S. i s less than one cent. Hence, because of t h e p r o f i t s made by farmers, i t was u n l i k e l y t h a t a u t h o r i t i e s would succeed i n completely choking o f f Turkish black market supplies, and even i f they did, t h e world black market has access t o even less expensive Southeast Asian opium. The l a t t e r source developed t o a high degree during t h e U.S. involvement i n t h e V i e t Nam war, and enormous amounts of heroin were smuggled i n t o t h e U.S. using m i l i t a r y p o s t a l systems. With t h e phasing out of U.S. m i l i t a r y a c t i v i t i e s i n Southeast Asia, a l t e r n a t i v e delivery systems w i l l doubtless be developed. An a d d i t i o n a l problem i n dealing with o p i a t e abuse i s t h a t i f opium prices should rise p r o h i b i t i v e l y , s y n t h e t i c a l t e r n a t i v e s l i k e methadone would be made a v a i l a b l e to s o p h i s t i c a t e d black market organizations. Methadone has been found by a d d i c t s t o be i n d i s t i n i s h a b l e from heroin on i n j e c t i o n i n double-blind experiments 103,216, 21r218,219. The e x t r a c t i o n of morphine from crude opium and i t s conversion t o heroin a r e r e l a t i v e l y simple processes t h a t r e q u i r e only rudimentary equipment o r t r a i n i n g . The synthesis of o p i a t e s de novo r e q u i r e s more equipmerc and t r a i n i n g , but should be q u i t e a v a i l a b l e t o the black market c o n s i d e r i m t h e economic rewards. Bearing i n mind t h e $25.00/kg p r i c e paid f o r Turki s h crude opium (which re r e s e n t s a c o s t of about $2.50/kg of morphine), it has been reported 128*p32 t h a t morphine base sells f o r up t o $2000/kg, t h a t 407. pure heroin sells f o r $20,00O/kg, and t h a t 1-37, pure heroin sells f o r $400,00O/kg on the 'street'. The l a r g e p r o f i t s from heroin production and d i s t r i b u t i o n underline the d i f f i c u l t y i n stopping smuggling of heroin. A look a t t h e l o g i s t i c s of i n t e r n a t i o n a l movement of f r e i g h t provides f u r t h e r discouragement s i n c e the e n t i r e U.S. heroin requirements are less than f i v e tons a year, which can e a s i l y be l o s t amid t h e more than 100,000,000 t o n s of cargo t h a t e n t e r the U.S. by sea each year 221 o r aboard t h e thousands of f l i g h t s t h a t e n t e r t h e U.S. from abroad each year carrying about 200,000,000 persons through customs. Since t h e d a i l y heroin requirement i s only about 1 2 kg, and considering t h a t a s i n g l e person can r e a d i l y c a r r y $500,000 worth of heroin on one t r i p , the problem of i n t e r d i c t i n g heroin smuggling can be appreciated. Government E f f o r t s . The epidemic of heroin abuse i n t h e U.S. has led t o considerable a c t i v i t y by Federal, S t a t e and Local Governments 144 t o d e a l with t h e problem. I n the White House a Special Action Office f o r Drug Abuse Prevention was established. The FDA has exerted considerable e f f o r t i n the area of policing drug treatment program~56,57,~04. The National
_ I _
40
Sect. I
-
CNS Agents
Gordon, Ed.
I n s t i t u t e s of Health mounted and funded considerable research e f f o r t i n t h e a r e a of 0 i a t e abuse 24,~5,~6,~6,49,76,134,135,136,138,143,160,166,167, 170*177918192p2 he Con r e s has contributed m n e and focussed attention on t h e problem 28,~3,8~,9~,1~1,118,129,144,157,159,~74,210, the kpartment of J u s t i c e has increased i t s e f f o r t s 97, and the c o u r t s have made use of devices l i k e c i v i l commitment t o encourage treatment 29,108. On the i n t e r n a t i o n a l scene, the UN has likewise addressed t h e problem of o p i a t e abuse 98,150,203.
Geographic
D i s t r i b u t i o n of Heroin Abuse. Although o p i a t e abuse o r i g i n a t e d i n China and Southeast Asia L14 i t has f i r s t of a l l spread t o the major population c e n t e r s of the U.S. 1,12,37,38,40,41,54,55,69,L21,180, p a r t i c u l a r l y New York 165, Puerto Rico 148 and California, where the HaightAshbury scene became infamous 195*140s 191 From the U. S. t h e heroin epidemic i n the past decade spread t o En land i 3 , t h e Continent 5 3 , 1 1 3 ~ 1 ~ O , e s p e c i a l l y Sweden 79, and t o Japan Ifo6, and t h e rest of the more a f f l u e n t p a r t s of t h e world l i k e Australia, South Africa, e t c . Opiate Antagonists. Martin e t a1 133 have shown t h a t an i n j e c t i o n of a n a r c o t i c antagonist i n t o a non-dependent s u b j e c t w i l l block t h e s u b j e c t i v e o p i a t e - l i k e e f f e c t s of a subsequent i n j e c t i o n of heroin o r o t h e r o p i a t e . Thus, he postulated t h a t a long-acting antagonist could "immunize" an addict from the subjective e f f e c t s of o p i a t e abuse. The e x i s t i n g antagon i s t s l i k e naloxone, cyclazocine and naltrexone have c e r t a i n drawbacks l i m i t t h e i r usefulness a s blocking agents i n t r e a t i n g heroin
Naloxone
Cyclazocine
Naltrexe.e_
Naloxone, although a "pure" antagonist, has a short duration and poor o r a l a c t i v i t y . Hence, a 24-hour o r a l blocking dose must be measured i n grams. Thus, considerations of cost and p a l a t a b i l i t y would tend t o r u l e out t h i s substance. Cyclazocine has a d e s i r a b l e duration of a c t i o n (about 24 hours) and good o r a l a c t i v i t y . However, i t s hallucinogenic l i a b i l i t y may prevent i t s a c c e p t a b i l i t y and widespread use. For example, an "induction" period of two weeks o r longer i s required t o build up t o a 24-hour o r a l blocking dose of 4 mg. Naltrexone has a duration of a c t i o n i n t e r mediate between naloxone and cyclazocine and i s r e l a t i v e l y devoid of "agonist" s i d e e f f e c t s . However, although i t has the most promising prof i l e of the t h r e e agents, i t s r e l a t i v e l y s h o r t duration of e f f e c t and i t s r a t h e r high o r a l dose requirement (approximately 60-100 mg f o r 24-hour blocking a c t i v i t y ) a r e disadvantages, e s p e c i a l l y i n considering i t for incorporation i n t o sustained r e l e a s e implants. Both naloxone and naltrexone s u f f e r frola the drawback t h a t they provide no "reinforcement" t o the heroin addict being t r e a t e d with them. Cyclazocine s u f f e r s from the serious disadvantage of dysphoric a c t i v i t y a t e f f e c t i v e dose levels. Thus, new agents which a r e devoid of these problems a r e d e s i r a b l e . Antagonists
Chap. 5
Abuse of CNS Agents
Gordon
41 -
Oxilorphan, a new t o t a l l y s y n t h e t i c antagonist synthesized by Monkovic e t a1 146,147, has many of the p r o p e r t i e s of t h e i d e a l antagonist agent. The s t u d i e s of J a s i n s k i e t a1 comparing cyclazocine t o oxilorphan 234 showed t h a t oxilorphan had a n o r a l potency about equal t o t h a t of cyclazoc i n e and a d u r a t i o n of e f f e c t a t least equal t o t h a t of cyclazocine, thus p r o j e c t i n g 24-hour heroin blocking a c t i v i t y f o r a 4 mg dose. A r e l a t i v e lack of hallucinogenic s i d e e f f e c t s a t 4 mg doses were seen i n former a d d i c t s 230. Thus, a projected 24-hour blocking dose of 4 mg can be given o r a l l y t o the post a d d i c t without any induction period and without any hallucinogenic e f f e c t . Additionally,oxilorphan produces some "euphoric" component which may assist i n keeping post a d d i c t s i n a n antag o n i s t program 230.
It should be mentioned t h a t oxilorphan d i f f e r s from cyclorphan only i n t h e presence of t h e 14-hydroxy group. Cyclorphan i s a potent analgesic as w e l l a s a potent hallucinogenic agent i n man, resembling cyclazocine. So it w i l l be seen t h a t introduction of a 14-hydroxy group i n t o cyclorphan 46,147 reduces i t s agonist and hallucinogenic e f f e c t s , much as is seen with naloxone i n comparison with, f o r example. nalorphine.
a6 Nalorphine
Cyclorphrn
Oxilorphan
lcvo-BC-2910
Oxilorphan has been subjected t o p a r e n t e r a l chronic t o x i c i t y and Phase I o r a l and p a r e n t e r a l t e s t i n g . I n a double-blind comparison of oxilorphan with cyclazocine 234 conducted a t t h e Addiction Research Center a t Lexington, Kentucky, oxilorphan was found t o have an hallucinogenic p o t e n t i a l one-fourth t h a t o f cyclazocine. Levo-BC-2910 an analog of cyclazocine, has been evaluated i n sub-acute t o x i c o l o g i c a l t e s t i n g by the NIMH i n preparation f o r Phase I c l i n i c a l t e s t ing. The findings comparing t h e antagonist a c t i v i t y of oxilorphan, LeVO-BC2910 and s e v e r a l reference agents are summarized i n Table I below 230. The most u s e f u l modality f o r dealing with t h e s o c i e t a l a s p e c t s of o p i a t e abuse (as w e l l as some of t h e medical and personal a s p e c t s ) has been methadone maintenance. I n consideration of t h e pharmacology o f o p i a t e dependence 4,17,45,58,87,88,131,140,172,185, Dole and Nyswander 51 proposed t h a t maintenance o f o p i a t e a d d i c t s on r e l a t i v e l y l a r g e doses of o r a l methadone would i n h i b i t drug seeking behavior, "block" t h e subjective e f f e c t s of p a r e n t e r a l heroin i n j e c t i o n because of t h e tolerance induced, break the needle h a b i t because of lack of reinforcement by t h i s route, and make the a d d i c t more a v a i l a b l e f o r p s y c h i a t r i c treatment and r e h a b i l i t a t i o n , breaking t h e cycle of crime and punishment. Methadone maintenance has been
Sect. I
-
Gordon, Ed.
CNS Agents
Table I Narcotic An:agonint and Agonist (Analgesic) A c t i v i t y o f OxilorDhan. . . levo-BC-2910 and Reference /.Pence ED5o rnglkg 8 . c .
Compound Oxilorphan levo-BC-2910 Nal trexone Cyclazocine Cyclorphan Levallorphan Nalorphine Pentazocine Naloxone HC1 Horphfne s u l f a t e
Narcotic Antagonist A c t i v i t y Oxymorphone -orphone Morphine Straub T a i l Narcosis Antag.-RTI 0.19 0.074 0.027 0.81 0.32 0.29 1.14 12.0 0.09
-
.
0.03 0.013 0.006 0.12 0.10 0.32 0.58 10.1 0.02
-
0.012 0.008 0.003
0.040 0.032 0.086 0.38 12.2 0.010
-
Agoaist (Analgesic) Activity Bat nouse Writhing Writhing 12.8
44 9 0
0.046 0.031 26.3 0.77 3.7 XI0
0.70
8.0 30 35.6 0.029 0.028
11.9 0.70 0.95 XI0 0.16
3, 43 947948,s 1,62,66,70, widely em lo ed in the u S 15 s 1 8 ~ 2 2 ~ 2 27~32,36342 72 73 5 78 8 2 91 100 101, i02,107,119, ip1423, 127,145,149,151,152,154,162, 163, l d , 168: 186,192,136 and elsewhere Addicts entering a methadone maintenance program commonly go through a detoxification program 34 and preinduction physical examination. Treatment is commonly started at low daily doses building up to a maintenance level of 40-120 mgfday, tailored to each individual. Most methadone is dispensed and ingested in clinic, since diversion of take-home supplies presents a problem discussed later in this review. Dose adjustment is important since too low a dose will permit heroin abuse, whereas too high a dose can lead to dangers while driving 112 or operating machiner , and can interfere with the rehabilitative process as well 62,65,196,191;. Most methadone treatment centers belong to city or state agencies and are federally funded, althou h private methadone maintenance clinics have been operated as well 15,f56,213 A number of drug free treatment programs also exist 46,161,162,163,164,176,192,196 under names like Synanon, Phoenix,etc. Complications arise due to multiple drug abuse 26,35,67,123, and these are countered by multi-modality treatment and comnunit partici ation and preventive 62 and education programs 1, 10,30,86,126,189*200,20f. The drug abuse of addicts while in treatment programs can usefully be monitored by urinalysis 8*158,176,186 at frequent but irregular intervals, and by following deaths or serious in uries that are reported on addicts by offiMonitoring of crimes, cial sources 7,89,90,115,116,114,130,137,155,179. especially burglaries, shoplifting and robberies, also provides a good quantitative index of heroin addict activity, and large scale treatment in centers like New York or Washington, D.C. has resulted in marked drops in arrest incidence, both in the case of individuals in treatment and for the community as a whole 44,153. Inevitably the epidemic of drug abuse has iven rise to unorthodox a ptoaches ranging from transcendental meditation to heroin maintenance 69991,173 which we deplore. Research on Less Abusable Forms of Methadone and Other Oral Opiates. As mentioned earlier, the diversion of methadone to street use from maintenance programs is a serious problem since Jasinski et a1 lo3 have shown in double blind trials in post addicts that methadone and heroin are indis-
Abuse of CNS Agents
Chap. 5
Gordon
43 -
tinguishable on injection. It has been found 32,103, 230, 224 that a 20:l mixture of methadone-naloxone is indistinguishable from methadone alone when taken orally for maintenance (or analgesia), but taken parenterally by the opium dependent subject it will precipitate abstinence and taken by the non-dependent subject the opiate effect will be eliminated, or postponed for several hours only to appear in an attenuated form. This combination relies on the fact that naloxone given orally is only about 1/100th as effective as it is parenterally. The methadone-naloxone dosage form has been further refined by the development of a gum-formulated tablet that resists dissolution and injection (thus preventing precipitation of severe abstinence in highly dependent subjects like methadone maintenance patients), and by the development of a color coding system for '"take home" methadone-naloxone tablets which permit s tracking diverted street" methadone to its diversion source. The gum formulation mentioned above, although giving identical methadone blood levels to those obtained from oral ingestion of a solution, 24 hours after dosing of each, produces less sedation and fewer "highs" than are seen with solutions. The addition of 1 mg of naloxone to 100 ml of paregoric 230 produces a product which is indistinguishable from paregoric alone when taken orally as intended. When boiled down, filtered, and injected, however, the combination will produce abstinence in the dependent subject, as does the methadone-naloxone. Other agonists are also being combined with naloxone t o deter oral abuse (e.g. oxycodone). Development of Totally Synthetic Analgesics and Antitussives. There has been a long standing interest in developing non-abusable analgetics and antitussives which do not depend on opium supplies s4955. As a result of limitations in cultivation of opium in Turkey, and crop failures in India, the U . S . has had to dip into opium stockpiles, and this has accentuated the interest in synthetic analgetics and antitussives. Two agents of current interest are butorphanol 1469147, 230 and nalbuphine 17. Butorpha-
Bu torphiu~: (levo-DC-2627)
Nalbuphine
no1 is approximately equivalent in analgesic potency to cyclazocine and approximately equal in antagonist potency to nalorphine. In animals, the analgesic activity of butorphanol is 4-10 times that of morphine, 25-70 times that of pentazocine and 1-2.5 times that of nalbuphine, which is chemically related to butorphanol. Butorphanol has antagonist activity which is approximately 30 times that of pentazocine and 4-6 times that of na lbuphine
.
Butorphanol demonstrated less physical dependence liability than pentazocine a determined in the mouse jumping test 131,172. In the Rhesus monkey 219 butorphanol did not suppress abstinence in the withdrawn mor-
44
Sect. I
- CNS Agents
Gordon, Ed.
phine dependent animal. I n a d d i t i o n , exacerbation of abstinence was observed. Physical dependence l i a b i l i t y t e s t i n g i s now i n progress by Dr.D. R. J a s i n s k i a t t h e Addiction Research Center, Lexington, Kentucky. Nalbuphine showed mixed agonist/antagonist e f f e c t s i n dependence t e s t i n g , with p r e c i p i t a t i o n of abstinence i n morphine dependent s u b j e c t s , but a l s o drugseeking behavior i n persons subjected t o d i r e c t a d d i c t i o n experiments. C l i n i c a l l y , butorphanol has been evaluated i n normal volunteers f o r s a f e t y and tolerance both o r a l l y and p a r e n t e r a l l y . Single intramuscular doses ranging from 0.1 t o 20 mg were studied. There was no i n d i c a t i o n of hallucinogenic a c t i v i t y even i n one volunteer who received the 20 mg dose 230. Butorphanol 230 and nalbuphine 231 have been t e s t e d c l i n i c a l l y f o r analgesia p a r e n t e r a l l y and found t o be approximately 10 times morphine and equipotent t o morphine respectively. I n summary, then, w e see t h a t progress has been made i n the a r e a of o p i a t e abuse by a p p l i c a t i o n of c l a s s i c a l medicinal chemical approaches of modifying various components of b i o l o g i c a l a c t i v i t y by s t r u c t u r a l modificat i o n , finding s y n t h e t i c s u b s t i t u t e s f o r n a t u r a l products which improve on nature, optimizing agonist and antagonist properties, etc. It is hoped t h a t these r e s u l t s w i l l encourage f u t u r e researchers t o make s i m i l a r prog r e s s i n d i f f i c u l t a r e a s l i k e b a r b i t u r a t e abuse, alcoholism, e t c . References 1. 2.
3. 4. 5.
c. 7. 8. 9.
10. 11. 12.
13. 14.
15. 16. 17.
18. 19. 20. 21. 22.
23. 24.
2s. 26.
A. Abrams, Contemporary Dmg P robl ems,Fal l 1973.p. 353 ( F e d e r a l Legal F’ublic a tions , N . ? . > J. R. A l l e n and L. J. West, Am. J . P s y c h i a t . , 125, 364 (1968). H. Andina, D. Kurg, L. E ergner, S . P a t r i c k and S. Whitman, Contemporary 3rug Problems, F a l l 1972, p. 707. H. L. Andrews and W. Workman, J. P h a m . & E x p t l . Therap.. 73, 99 (1941). B. A n g r i s t and S. Gershcn, in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and F e b i g e r , 1972. p . 2 6 3 . J . D. Armstrong. Am. J. Hosp. Pharm. g,149 (1965). I4. H. Baden, Human P at hol ., 3 , 9 1 (1972). S. L. Baker, Am. J . Pub. Heal t h, 62, 857 (1972). J . Becker, P. C o v g i l l , M. Drago, E . H e l t s l e y a nd B. Waters, Contemporary Drug Problems, Sunmer 1972, p. 413. E. L. B e l l i t o , i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea a nd P e b i g e r , 1972, p. 545. 8 . Bensnn and K. W al l ace, E,p. 369. T. H. Bevley. Bull. on Harcoc.rcs, 21, 13 (1969). T. H. Bewlsy, in Yearbook o f Drug Abuse, L. B r i l l and E. Harm, Eds., B e h a v i o r a l P u b l i c a t i o n s , N. Y. 1973 p . 207.Mahon, in Drug Abuse, Proc. I n t e r n . Conf., C . J . D . H Bewley, P. Jamr; and T * k r a f o n e t i s , Ea:, Lea and F e b i g e r , 1972, p . 73. 1. B i t z , J . Langrod and K . Colgan, Am. J . Pharmacy, Jan-Feb. 1972, p. 29. K. H. B l a c k e r , R. T. J o n e s , C. C . S t one and D. Pfefferbaum, Am. J . Psychtat..=, 361(1968). H. Blumberg, P. S. Wolfe and H. B. Dayton, Proc. SOC. Exp. B i o l . , 763 (1968). C. E. Bovling, A. D. H o f f e t f and W, J. R. T a y l o r , C l i n . Toxic ol. , 2, 66 (1972). P. Boyd, in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Zarafonetis. Ed., Lea a nd F e b i g e r , 1972, p. 399. 0. J. Braenden, Contemporary Drug Problems, Sunnner 1973, p. 257. J . H. Brenner, in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and P e b i g e r , 1972, p. 115. L. b r i l l and H. H e i s e l a s , in Yearbook o f Drug Abuse. L. B r i l l a nd E. H.m, Eds., L h a v i o r n l P u b l i c a t i o n s , N. Y., 1973, p. 49. E. B r i l l , G. Nash and J. L angrol , in Major M o d a l i t i e s i n t h e Treatment o f Drug Abuse. L. B r i l l and L. L i e b e m a n , Eds., B e h a v i o r a l P u b l i c a t i o n s , N. Y., 1972, p. 287. B. S. Brovn, C l i n i c a l Xesearch, 3,618 (1971). 8. S. Brown, N. Y. Lab! Journal, Mar. 27, 1972, p. 25. 8 . S. Brown, R. L . WPant, 1’. P. Sass, S. T. G le ndinninp, N. J. Kaeei and M. B. Meyors, Compr. P s y c h i a t r y , l3, 391 (1972).
118,
Chap. 5 27. 28.
29. 30. 31. 32.
33. 36.
35. 36. 37. 38. 39. 40. 41. 42. 43.
44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60 61. 62. 63. 60.
65. 66. 67. 68. 69. 70. 71.
Abuse of CNS Agents
Gordon
45 -
8. S. B r m , S. K. Gauvey. M. B. Meyers and S. D. S t a r k , I n t l . J . of A d d i c t i o n s , 5, 635 (1971). J. L. Buckley, N. I. Lpw Jouraal, Mar. 28, 1972. A. J . C a i l i o s t r o . J . R. Knop. I. Unx and R. G. Newman. Contemporary Drug, P r o b l e m . Slmmer 1972. p. 561. W. Cahn, J. Darney, A . H. Levine, R. Millman. H. Noulis and P. Wald, i b f d , F a l l 1972.p.829. D. C. Cameron, i n Drug Abuse. Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and P e b i g e r , 1972, p. 17. F. S. Caruso, M. Gordon, I. J . P a c h t e r , F i f t h N a t i O M l Conference on Methadone Treatment, 2, 1336 (1973). W. Cazalaa and A. G. Bucaro. C l i n . T o x i c o l . , 1, 7 0 (1972). C. D. Chambers, i n Major M o d a l i t i e s in t h e Treatment of Drug Abuse, L. B r i l l and L. Lieberman. Eds.. Behavioral P u b l i c a t i o n s , N. Y., 1972, p. 143. C. D. Chambers and L. B r i l l , *rf, p. 203. C. D. Chambers and A. D. N o f f e t t , in Yearbook o f Dtug Abuse, L. B r i l l and E. Harms, Eds., B e h a v i o r a l P u b l i c a t i o n s , N. Y . , 1973, p. 129. P. A. L. Chapple, D. E. Somekh and M. E. T a y l o r , B r i t . J . Addict., 2, 33 (1972). J . A. Cimino, R. M. Wad, H. S. Andim8 and S. A. West, Contemporary Drug P r o b l e m , P a l l 1973, p. 401. L. D. C l a r k and E. N. Nakashinu, Am. J. P s y c h i a t r y , 125, 379 (1968). S. Cohen, Contemporary Drug Problems, P a l l 1973. p. 431. S. Cohen. in Drug Abuse. Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s . Ed., Lea a n d Febiger. 1972, p. 333. T. Connor and E. Kremen, I n t e r n . J. of A d d i c t i o n s , 5. 279 (1971). A. T. Conrad, in Major M o d a l i t i e s in t h e Treatment of Drug Abuse. L. Brill a n d L. Lieberman. Eds.. Behavioral P u b l i c a t i o n s , N. Y., 1972, p. 23. P. Cushman. N. Y. S t a t e J . of Medicine, J u l y 1, 1972, p. 1752. F. E . D‘Amour and D. L. Smith, J. Pharm. L E x p t l . Therap., 72, 74, (1941). K. J . p e i a s l e r , Drug Dependence (5) O c t . 19’70. J . V. &Long, Dea1ir.q w i t h Drug Abuae. A Report t o t h e Ford Poundstion, P. M. Weld and P. Praexer P u b l i s h e r s , New York, 1972, p. 62. . B. - h t t . Eds.. J. V. &Long, i b c p. 173. J. Cenwn-Gerber, H. Wiener and R. Hochstedler, Contemporary Drug Problems, F a l l 1972, p. 783. A. H. Der Marderosian, K. H. Kensinger, J . M . Chao and P. J . G o l d s t e i n , Drug Dependence (NIMH) (5) Oct. 1970, p. 7 . V. P. Dole. e t e l . , Arch. I n t e r n . Ned. 118, 304 (1966). E. P. Domino. In Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i r , Ed., Lea and F e b i g e r . 1572, p . 30:. J . a r n b e r x-. .. The J c u r n a l , Addiction Research Foundation, Toronto, 2, 8 (1974). N. B. Eddy, Am. J. Hoap. Pharm. 22, 131 (1965). N. B. Eddy and D. Leimbach. J . Pharm. and Exptl. Therap., 107, 385 (1953). C. C. Edvards, H. Y. Law J c u r n a l , Mar. 27, 1972, p. 25. R. E. Edwards, Am. J . Hosp. Pharm. 22, 145 (1965). H. W. s l l i o t t . i n DYUR Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i a , Ed., Lea and F e b i g e r , 1972; p. 1371 C. P. E s s i g . An. 3. Hosp. Pharm. 22. 140 (1965). C.J.D. Z a r a f o n e t i s , Ed., Lea and F e b i g e r , C. F. Essig, - . i n 3rug Abuse, Proc. i n t e r n . Conf., 1972, p. 2 0 5 . C. F. E s s i g , Drug Dependence (IMH) (5) O c t . 1970, p. 24. M . Fink, Contemporaq Drug Problems, S p r i n g 1972, p. 245. M. Fink. Fall 1972, p. 875. M. P i n k , i n Drug Abuse, Proc. I n t e r n . Conf.. C.J.D. Z a r a f o n e t i a , Ed., Lea and P e b i g e r , 1972. p. 1 7 1 . L. P. Finnegan, J . F. Connauphton, J. P. Emich and W. F. Wieland, Contemporary Drug Problems, F a l l 1972, p . 795. G. S. Finney, i n Yearbook of Drug Abuse, L. B r i l l and E. R a m s , Eds., B e h a v i o r a l Publicat i o n s , N. Y.. 1973, D. 63. J . F o r t , i n Ecajor M o d a l i t i e s i n t h e Treatment of Drug Abuse. L. B r i l l and L. Lieberman, Eda., Behavioral P u b l i c a t i o n s , N. Y . , 1972, p. 237. J. F o r t , i n Yearbook of Drug Abuse, L. B r i l l and E. Harma. Eds.. B e h a v i o r a l P u b l i c a t i o n s , N. Y., 1973, p. 333. Z a r a f o n e t i a . Ed., Lea and 8. F. P r a s e r , i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. F e b i g e r , 1972, p. 141. A. M. Preednan, f’mptehcnsive P s y c h i a t r y , g,586 (1971). S. Freud, Dm3 Dependence (NIMH). (5) O c t . 1970, p. 15.
n.
s.
46 72.
73. 74. 75. 76.
77. 78. 19. 80.
81. 82 * 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 96. 95. 96. 97. 98. 99. 100. 101. 102.
103. 104. 105.
136. 107. 108. 109. 110. 111. 112.
113.
114. lls. 116. 117. 118. 119.
Sect. I
-
CNS Agents
Gordon, Ed.
J. 8. Prykmdn, i n Drug Abuse, Proc. I n t e r n . C o d . , C.J.D. Z a r a f o n e t i r , Ed., Lea and P e b i g e r , 1972, p. 527. C. R. Gay, Contemporary Drug Problems, P a l l 1972. p. 735. 1 . P. G a r f i e l d , I=, p. 953. F. R. Gearing, i!):~j, Sprinq 1972, p. 191. B. J. George, J r T n Drug Abuse, Proc. I n t e r n . Conf.. C.J.D. Z a r a f o n e t i a , Ed., Lea and F e b i g e r , 1962, p. 459. F. B. G l a s e r , I n t l . J. of Addictions, 6, 615 (1971). M. M. G l a t t , Brit. J . A d d i c t i o n s , 63, 111 (1968). L. Goldberg, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i r , Ed., Lea and P e b i g e r , 1972, p . 27. P. 8. Goldberg, 3eaiing w i t h Drug Abuse. A Report t o t h e Ford Foundation, Ed. by P. M. Wald and P. B. R u t t , Praeger P u b l i s h e r s , New York, 1972, p. 300. I. Goldenberg and E . Keatinae, Contemporary Drug Problems, F a l l 1973, p. 363. B. M . Goldsmith, W . C . Capel, K. J. Waddel and G. T. S t e w a r t , C l i n . Toxicol. 2 - 7 3 (1972). A. G o l d s t e i n , The Journal, Addiction Research Foundation, Toronto, 2, 7 (1974). C. W. Corodetsky. Drug Dependence (NMH)(51) Oct. 1970, p. 18. L. Grinspoon, Contemporary Crug Problems, F n l l 1972, p. 811. P. G. Hansnond, i>-L< , Summer 1973, p. 247. L. S. H a r r i s and A. K. P i e r s o n , J. Pharm. and E x p t l . Therap., 1 4). 141 (1964). L. S. H a r r i s , A. K. P i e r s o n , J. R. Dembinski and W. L. Dtwey. Arch. I n t . Pharmcodyn., 165, 165 (1967). T H e l p e r n , Buman Pathol., 2. 13 (1972). M. Helpern. N. Y. Lnw J o u r n a l , Mar. 28. 1972. R. M. Hochstedler, Contemporary !Jrug Problems, S m e r 1972, p. 517. J. F. Holahan, Dealing v r t h Drug Abuse. A Report t o t h e Ford Foundation, Ed. by P. @I. Walt and P. B. H u t t , Praeger P u b l i s h e r s , New York, 1972, p. 255. L. E. H o l l i s t e r , i n !kug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i e , Ed., Lea and F e b i g e r , 1972, p. 321. L. E. Hollfs:er, i-, p. 421. 8. Holmscedt and A . Linnarson. p. 291. C. M. IdestrClol. i n 2 u g Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i r , Ed., Lea and FebtgGr, 1972. p. 217. J. E . I n g e r s o l l , Committee on Problems o f Drug Dependence Mtg., May 22, 1972, Ann Arbor, Mich., p . 14. J. E . I n g e r s o l l , in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and F e b i q e r , 1972, p. 449. J. E. I n g e r s o l l , 14. Y. Law J o u r n a l , Mar. 2 7 , 1972, p . 25. C. E. I n t u r i s s i and K. Verebely, C l i n . Pharmacol. Therap. 2,633 (1972). J. H. J a f f e , i n Crug Abuse, Proc. I n t e r n . Conf.. C.J.D. Z a r a f o n e t i s , Ed.. Lea and F e b i g e r , 1972, p. 161.. J. H. J a f f e , in Yearbook of Drug Abuse, L. B r i l l and E. H a m , Eds., B e h a v i o r a l P u b l i c a t i o n s , N . Y. 1373, p . 103. D. R. J a s i n s k i e t a l . , Co!mfttce on Problems o f Drug Dependence, 442, (1972). D. R. J a s i n s k i , i n Yearbook of Drug Abuse, L. Brill and E. Harms, Eds., B e h a v i o r a l P u b l i c a t i o n s , N. Y. 1973, p. 37. Z a r a f o n e t i s . Ed., Lea and P e b i g e r , A. Koplan, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. 1972, p. 191. M. Kato, , p. 67. E. Kaufrnan. Contemporary Drug Problems, Spring 1972, p. 207. D. C. Kay, i n Yearbook of Drug Abuse, L. B r i l l and E. Harms, Eds., Behavioral P u b l i c a t i o n s , H. Y . 1973, p . 17. M. H. K e e l e r , Am. J . P s y c h i a t r y , 125, 386 (1968). K. H. Keeler, C. B. R e i f l e r and M. 8. L i p r i n , Am. J. P s y c h i a t . 384 (1968). E. M. Kennedy, N. Y. Law J o u r n a l , Mar. 28, 1972. P. K i e l h o l z , i n Drug Abuse, Proc. I n t e m . Conf., C.J.D. Z a r a f o n e t i r , Ed., Lea a n d P e b i g e r , 1972. p. 361. P. X i e l h e l z , Sb,p. 363. E. I. Koch, N. 1. Law J o u r n a l , Mar. 28, 1972. A. J . R. Koumans, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n o t i s , Bd., Lea and P c b i g e r , 1972. p. 331. A. J. R. Koumans, i 3 g , p. 385. J. C . Iramer, ibbi, p. 253. J. C. Kraner, i n Yearbook of Drug Abuse, L. B r i l l and E. Harm, Eds., B e h a v i o r a l Publicat i o n s , N. Y.. 1973, p. 265. M. J. Kreek, L. %dcs, 5 . Kane, J. Knoblcr and R. M a r t i n , 4nn. I n t e r n . Mod. 77,598 (1972).
!b-e,,
N,
Chap. 5
Abuse of CNS Agents
Gordon
47 -
120* T. b n d , che J o u r n a i , Addaction Research Foundation, Toronto, 3. 8 (1976). 121. J . 8 . b n g e r , Contemporary Drug Problemr, F a l l 1972. p. 8U. 122. J. Langrod, L. B r i l l . J. Lowinson and H. Joseph, in Major Modalities in t h e Treatment o f Drug Abuse, L. B r i l l and L. L i e b e m a n , Eds.. Behavioral P u b l i c a t i o n r , N.Y., 1972. p. 107. 123. L. Langrod , H. Joseph and K. Colgan. ibid, p. 167. Contemporary Drug Probtcmr, F a l l 1972. 124. D. L a r r i e r , M. C l i n e , P. Brophy and A. >=hen, p. 707. 125. D. Laskowitr, L. B r i l l and J. B. J a f f e , in Major M o d d i t i e s in t h e Treatment o f Dmg Abuse, L. B r i l l and L. Lieberman. Edr., Behavioral P u b l i c a t i o n s , N. Y . , 1972, p. 65. 126. L. b n s f o d . i n Yearbook of Drug Abure, L. B r i l l and E. Hams, Eds., B e h a v i o r a l P u b i i c a t i o n s , N. Y . 1973, p . 303. 127. H. L. b n n a r d , L. J. E p s t e i n and M. S. Rosenthal, Science, 176,881 (1972). 128* A. C. L e s l i e , H. Y. Law J o u t n a i , Uar. 28, 1972, p. 35. 129. L. Lieberman and L . B r i l l , in Yajor M o d a l i t i e s in t h e Treatment of Dmg Abuae. L. B r i l l and L. Lieberman, Eds., Behavioral P u b l i c a t i o n s , N. Y., 1972, p. 67. 130. D. 8. Louria, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i r . Ed., Lea and P e b i g e r , 1972. p. 505. 131. C. Maggiolo and F. Huidobro, Acta Phvsiol. Latinamer., y. 70 (1961). 132. S. T. Maidlow and A. Berman. Am. J . Pub. Health, 62, 1357 (1972). 133. W. R. M a r t i n & . W. Corodetsky and T. R. McClane, C l i n . Pharmacol.Ther.,L, 455 (1966). 134. W. R. M a r t i n , Am. J . Hosp. Pharm., 22, 133 (1965). 135. W. R. U a r t i n , in Dmg Abuse, R o c . I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed.. Lea and P e b i p e r , 1972, p. 153. 136. W. R. M a r t i n , in Yearbook of Drug Abuse, L. B r i l l and E. b m r , Edr., B e h a v i o r a l P u b l l c a t r o n . N. Y . , 1973, p . 1. 137. H. M. Mason, W. J. R. T a y l o r and M. V. Deming, C l i n . T o x i c o l . 2. 70 (1972). 138. D. W . Hatheson. S. J. Lynch and R. W. E a r l , Clin. T o x i c o l . , 2, 67 (1962). 139. E. May, a a l i n g w i t h W g Abuse. A Report t o t h e Ford Foundation, Ed. by P. M. Wdld and P. 8. h t t , Praeger F u b l i s h e r s , Nev York, 1972, p. 345. 140. E. W. Maynert, in Orug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i r , Ed., Lea and P e b f g e r , 1972, p. 199. 141. W. H. McClothlin, Contemporary Drug Problems, Summer 1972, p. 467. 142. W. H. McGothlin and L. U. Werc, Am. J . P s y c h i a t . , 125, 370 (1968). 163. J . Mendelson, The J o u r n a l , Addiction Research Foundation, Toronto, 2, 7 (1973. 164. P. H. Meyers, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea a n d P e b i g e r , 1972, p. 515. 145. A . D. M o f f e t t , I. H. Soloway and M. X . C l i c k , Clin. T o x i c o l . 5, 68 (1972). 146. I. Monkovic. A b s t r a c t s of 1 3 t h N a t i o n a l Med. Chem. Symp., ACS Div. Med. Chem., Iova C i t y , Iowa (1972). 147. I. Monkovic, T. T. Conway, H. Wang, Y. G. Perron, I. J. P a c h t e r and 8. B e l l e a u , J. Am. Cham. SOC. 95, 7910 (1973). 148. R. Morales-Boyer, in Yearbook of Drug Abuse, L. B r i l l and E. Harms. Eds., k h a v i o r a l P u b l i c a t i o n s , N. Y . 1973, p. 179. 149. J . C. Hunns, G. Geis and B. H. J u l l i n g t o n , i n Major M o d a l i t i e s in t h e Treatment of Dmg Abuse, L. B r i l l and L. L i e b e m a n , Eds., Behavioral R t b l i c a t i o n s , N. Y.,1972, p. 191. 150. J . Nepote. in Drug Abuse, W o e . I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed. Lea and F e b i g e r , 1972, p. 491. 151. R. G. Newman, Contemporary Drug Problems, Spring 1972, p. 183. 152. R. G. Newman, @, F a l l 1972, p. 605. 153. R. C. tiewman, S. Bashkow and M . C a r e s , i b f d , P a l l 1973, p. 417. 154. A. W. Nichols and P. R. Torrens, Arch. I r M e d . 127, 903 (1971). 155. W. W. Nichols, in Crug Abuse, Proc. I n t e r n . Conf.. C.J.D. Z a r a f o n e t i s , Ed., Lea and P e b i g e r , 1972, p. 93. 156. J . T. Nix, C l i n . T o x i c o l . 2. 62 (1972). ls7. J . W. O l i v e r , in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i a , Ed., Lea a n d F e b i g e r , 1972, p. 429, 158. K. D. P a r k e r , ;Sld , p. 129. 159. C. Pepper. N. Y. Law JOUrMl. Mar. 28. 1972. 160. C. C . - P e t e r s o n and M. R. Wilson, J r . , Mayo C l i n . Proc. 46, 468 (1971). 161. J. C. P o l l a r d , in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and P e b i g e r . 1972. D. 377. 162. T. G f a l s k y , Contemporary Drug Problems, SuPsler 1972, p. 399. 163. E. Ramiret. in Hajor k l o d a l i t i e s in t n e Treatment o f Drug Abuse, L. B r i l l and L. Lieberman, Eds., Behavioral P u b l i c a t i o n s , N. Y . 1972. p. 43. 164. E. Ramiret. i s , p. 55. 165. C. R. Rangel, N. Y. 5aw JOutM1, Mar. 20, 1972. I~
48
Sect.
L
166. 167. 168. 169.
170. 171. 172. 173. 174. 175. 176. 177. 178. 179.
180. 181. 182. 183. 184. 185. 186. 107.
186. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202 * 203. 204. 205. 206. 207. 208. 209. 210. 211. 212.
213.
I
-
CNS Agents
Gordon, Ed.
i n Major M o d a l i t i e s in t h e Treatment of Drug Abura, L. B r i l l and L. Lieberman, Edr., Behavioral P u b l i c a t i o n r , N. Y., 1972, p. 7. 0. S. Ray, C. V. Mosby Co.. S t . Louis, 1972. A. Richman. M. E. P e r k i n r , 8. B i h a r i and J. J. Pishman, Am. J. P u b l i c H e a l t h 62, 1002(1972). L. Robbine, B. S. Robhins and M. Stem, Druq IBwndmnce, (NMII) (5) O c t . 1970, p. 1. C. C. Rohrs, J . P. Murphy and J. Desen-Cerber, in D r u g Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and F e b i g e r , 1972, p. 571. M. S. Rosenthal. i n Yearbook of D r u g Abuse, L. B r i l l and E. Harrps. Eds., B e h a v i o r a l F u b l i c a t i o n s , N. Y. 1973, p. 83. J. K. S a e l e n s , P. R. Granat and W. K . Sawyer, Arch. I n t . Pharaucodya., E. 213 (1971). H. Samuels, Contemporary D r u g Problems, S m e r 1972. p. 517. J. 8 . Scheuer, i n Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed., Lea and P e b i g e r , 1 9 i 2 , p. 423. S. H. Schuman, p. 513. p. 233. J. W. Schweitzer and A. J. F r e i d h o f f , M. H. Seevers, , p. 9 . M. L. S e e v e r s , N. Y. Lav J o u r n a l , Mar. 28, 1972. S. 8. S e l l s , L. R. Chatham and R. L. Retka, Contemporary Drug Problems, P a l l 1972, p.665. R. P. S h a f e r , e t a l , Second Report o f N a t i o n a l C&ssion on Marihuana a n d Drug Abuse, March 1973. M. Shepherd, Lancet 1 (7636) 31 (1970). A. T. S h u l g i n , in Psychotomimetic Drugs, D. H. Efron. Ed., Raven Prarr, 1970, p. 21. A. T. S h u l g i n , T. Sargent and C. Naranjo, Nature, 221, 537 (1969). R. E. S h u l t e s . B u l l . N a r c o t i c s , 3.15 (1969). E. Siegmund, R. Cadnus and P. Lu, R o c . SOC. Exp. Biol., 9s. 729 (1957). J. M. Singh, M. D. C a a t e t and J. T. Nix, C l i n . Toxicol. 5, 72 (1972). C.J.D. Z a r a f o n e t i s , Ed., i c a a d D. - . E. Smith. i n Drug Abuse. Proc. I n t e r n . Conf., P e b i g e r , 1 9 j 2 , p. 271. D. E. Smith, i n Major M o d a l i t i e s i n t h e Treatment of Drug Abure, L. Brill and L. Lieberman, Eds., Behavioral P u b l i c a t i o m , N. Y., 1972, p. 267. D. E. Smith and A . J . Rose, i n Major M o d a l i t i e s i n t h e Treacment of h g Abuse, L. B r i l l 6nd L. Lieberman, Eds., Behavioral P u b l i c a t i o n s , N. Y., 1972, p. 257. D. E. Smith and D. Bentel, in Yearbook of Drug Abuse, L. B r i l l and E. Halmu, E d i . . Behavioral P u b l i c a t i o n s . N. Y., 1973. p. 157. R. C . Smith, in Drug Abuse, Proc. I n t e r n . Conf., C . J . 3 . Z a r a f o n e t i s , Ed., Lea and P e b i g e r , 1972, p. 455. R. C. SmFrn, =$ , p. 519. S. H. Snyder, L. A . ? a i l l a c a and H. W e i q a r t n e r , Am. J . P s y c h i a t . 125, 357 (1969). R. Stephens and E. C o r c r e l l , Brit. J . Addict. 67, 45 (1972). J. Sokol, i n Yearbook of Drug Abuse, L. B r i l l and E. Hams, Edn., Behavioral P u b l i c a t i o n s , N. Y., 1973. p. 169. W. J. R. T a y l o r , C . D. Chambers and C. E. Bowling, I n t l , J. C l i n . Pharmacol. Therap. T o x i c o l . 6, 28 (1972). D. A. T r e f i e r t , Contemporary D r u g Problems, Suxner 1973, p. 239. D. A. T r e f f e r t . l&, F a l l 1973, p. 393. J . T. U n g e r l e i d e r , in b h g Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n e t i s , Ed.. Lea arid Pebiger. - . 1972. D. 339. J. T. U n s e r l e i d e r , :I=, p . 501. J. T. U n g e r l e i d e r , D. D. F i s h e r , S . R. Goldsmith. M. Fuller and E. Forgy. Am. J . P s y c h i a t . 125, 352 (1958). T T . U n g e r l e i d e r and M. P u l l e r , in Yearbook of Drug Abuse, L. B r i l l and E. Harms, Eds., Behavioral P u b l i c a t i o n s , N. Y. 1973. p. 367. B. A . Van Der Kolk, Contemporary Drug Problems, Summer 1973, p. 263. P. M. Wald and P. B. Hutt, Dealing w i t h D r u g Abuse. A Report t o t h e Ford Foundation, Ed. by P. M. Wald and P. B. Hurt, P r a e g e r P u b l i s h e r s , New York, 1972, p. 3. P. M. Wald and A. Atrams, , p. 123. A. T. Weil, , p. 329. N. Weiner, in Drug Abuse, Proc. I n t e r n . Conf., C.J.D. Z a r a f o n c t i s , Ed.. Lea and P e b i g e r , 1972, p. 243. D. R. Uesson. C. R. Gay and D. E. Smith, Contemporary Drug Roblem6, Sunmer 1972, p. 453. J. H. Willis, Contemoorary D r u g Problems, Summer 1972. p. 501. L. L. Wolff, N. Y. Law J o u r n a l , Mar. 28, 1972. B. A. Wolfson and D. B. Louria, p. 225. S. F. Yoller, i n Yearbook of Drug Abuse, L. Brill and E. Harms, Ed.., B e h a v i o r a l Publicat i o n s , N. Y. 1973, p. 239. A. Zaks and M. Peldzmn. J . Am. Ned. Ansn. 222, 1279 (1972).
B. W. Rasor,
G,
m,
-.
w,
Chap. 5 214. 215. 216. 217, 718.
219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234.
Abuse of CNS Agents
Gordon
49 -
N. E. Zi a b e rg, Contemporary Drug Problems, S p r i n g 1972, p. 263. 1. E. Z in b e rg, ib:d , P a l l 1972, p. 747. W. R. M a r t i n and H. F. F r a s e r , J. Pharm. E xptl. Therap. 133, 388 (1961). J. R. J a f f e , Arch. Gen. P sychi at . 15, 525 (1971). It. Goodall, Psvchol. Today, 6 , 1 3 6 ( 1 9 7 2 ) . I. J . P a c h t e r , S ci ence, 179, (1923). M. Moore, P o l i c y Concerning Drug Abuse i n New York S t a t e , Vol. 111, t h e Hudson I n s t i t u t e (1970). pps. 67-73. E. A. P r e b l e and J . 3. Casey, I n t . J. Addi ction, 4 , 12 (1967). P. M. Brecher. (1972) " L i c i t and I l l i c i t Drugs" L i t t l e . Brown. p. 42. R. Dougherty, unpubl i shed d a t a . S. D. P a m a t i k a r and S. R. Knowles, Clin.Pharmaco1.Therap. 1 4 ,941 (1973). A. V. P i r c i o , H. Gordon and I. J . P a c h t e r , Pharmacologist 1 2,263 (1971). A. W . P i r c i o . Htg. Ned. Chem. 3 i v . Am. Chem. SOC., Iowa C i t y , June 1972. J . F . C a l i m l i n , W. :I. W ardel l , L. Lasagna, A. 3. G i l l i e s and H. T. Davis, C l i n . Pharmacol. Therap., I n P r e s s . H. Blumberg, H. 8. Dayton, and P. S . Wolf, Pharmacologist lo, 159 (1968). H. H. Swain, J . E. Villareal and H. H. S eeve rs , C o m t e on Problems of Drug Dcpendencc, 1973, p. 695, 696. M. Gordon, A. U. P i r c i o , F. S. Caruso, and I. J. P a c h t e r , Mtg. Cmte o n Problems of Drug Dependence, Mexico C i t y. March 11. 1974. R. W. Houde i n "Diagnosis and Management of Cancer," ed. by R. L. Cla rk, Yearbook M e d i c a l P u b l i c a t i o n , Chicago, I l l . (1971) p. 489, Vol. 111. U. H. F o r r e s t , Ccste on Problems of Drug Dependence. p. 247 (1971). N. 8 . Eddy, The N a t i o n a l Research Council Involvement i n t h e O pia te Problem, 192801971, N a t i o n a l Academy o f S ci ence, Vashington, D. C., 1973. D. J a s i n s k i , Mtg. Comte on Problems cf Drug Dependence, Mexico C i t y , M a r c h 11, 1974.
VL
S e c t i o n I1 Editor:
-
Pharmacodynamic Agents
Frank H. Clarke, Ciba-Geigy L t d . , A r d s l e y , New York Chapter 6 .
The E t i o l o g y of Hypertension
Donald W. DuCharme, The Upjohn Company, Kalamazoo, Michigan Hypertension i s one of t h e g r e a t e s t medical c h a l l e n g e s of o u r t i m e . I t i s e s t i m a t e d t h a t upwards of 40 m i l l i o n Americans a r e a f f l i c t e d by t h i s " s i l e n t disease",l Although g r e a t p r o g r e s s i n t h e t r e a t m e n t o f h y p e r t e n s i v e d i s e a s e u n q u e s t i o n a b l y h a s been made i n r e c e n t y e a r s , t h e u l t i m a t e t h e r a p y remains t o b e d i s c o v e r e d . The development of d r u g s which a c t s p e c i f i c a l l y upon v a r i o u s systems t o a m e l i o r a t e t h e symptom ( e l e v a t e d a r t e r i a l p r e s s u r e ) of t h i s d i s e a s e have, indeed, c o n t r i b u t e d a g r e a t d e a l t o c l i n i c a l management. They have enabled c l i n i c i a n s t o e f f e c t i v e l y lower blood p r e s s u r e i n t h e m a j o r i t y of p a t i e n t s , and minimize many of t h e a d v e r s e s i d e e f f e c t s which were a s s o c i a t e d w i t h e a r l i e r forms of therapy. There i s l i t t l e doubt t h a t s t i l l b e t t e r d r u g s can b e developed. For example, a d i u r e t i c which does n o t a l t e r potassium and u r i c a c i d e x c r e t i o n o r g l u c o s e metabolism, a c e n t r a l l y a c t i n g s u p p r e s s a n t of s y m p a t h e t i c v a s o c o n s t r i c t o r n e r v e f u n c t i o n which i s devoid of s e d a t i v e a c t i v i t y , a p e r i p h e r a l v a s o d i l a t o r which does n o t cause f l u i d r e t e n t i o n , a b e t a a d r e n e r g i c b l o c k i n g a g e n t which does n o t a f f e c t b r o n c h i a l smooth muscle f u n c t i o n , o r an a n t a g o n i s t of p e r i p h e r a l a d r e n e r g i c neurones which i s s p e c i f i c t o t h o s e neurones i n n e r v a t i n g blood v e s s e l s . The l i s t of pot e n t i a l improvements i n e x i s t i n g a g e n t s i s v i r t u a l l y e n d l e s s , and many would v e r y s i g n i f i c a n t l y improve c l i n i c a l therapy. The p o i n t remains, however, t h a t r e g a r d l e s s of how s p e c i f i c t h e s e a g e n t s become t h e y s t i l l p r o v i d e o n l y p a l l i a t i v e therapy. The r e a l c h a l l e n g e and hope i s t o d i s cover and develop a g e n t s which c o r r e c t t h e u n d e r l y i n g cause of t h e d i s ease. Before one can d e s i g n a r a t i o n a l program t o d i s c o v e r a g e n t s which w i l l "cure" h y p e r t e n s i o n , t h e c a u s e must b e d e f i n e d , While t h e c a u s e of h i g h blood p r e s s u r e can be d e f i n e d and c o r r e c t e d s u r g i c a l l y o r t h e r a p e u t i c a l l y i n a s m a l l p e r c e n t a g e of t h e h y p e r t e n s i v e p o p u l a t i o n , f o r t h e v a s t m a j o r i t y i t cannot, This l a r g e group of p a t i e n t s w i t h h y p e r t e n s i o n of unknown e t i o l o g y a r e c a t e g o r i z e d a s having " e s s e n t i a l " h y p e r t e n s i o n . I t i s t h i s group of p a t i e n t s which d i c t a t e s t h e need f o r a major r e s e a r c h e f f o r t t o uncover t h e cause o r causes of t h e d i s e a s e p r o c e s s and t o d i s cover and develop a g e n t s which w i l l e f f o r d o p t i m a l t h e r a p e u t i c c o n t r o l . I n t e r e s t i n g l y , i t h a s been p o s s i b l e t o induce h y p e r t e n s i o n i n l a b o r a t o r y animals a t w i l l by a v a r i e t y of methods f o r n e a r l y f o r t y y e a r s 2 , y e t t h e primary d i s t u r b a n c e which promotes t h e h i g h blood p r e s s u r e i n t h e s e a n i mals remains an enigma,
-
Vascular R e s i s t a n c e The major hemodynarnic a b n o r m a l i t y i n h y p e r t e n s i v e p a t i e n t s and l a b o r a t o r y animals i s an e l e v a t e d p e r i p h e r a l v a s c u l a r res i s t a n c e . Suggested e t i o l o g i c f a c t o r s which may c o n t r i b u t e t o t h e i n c r e a s e d v a s c u l a r r e s i s t a n c e a r e enhanced humoral v a s o c o n s t r i c t o r s u b s t a n c e s , d e c r e a s e d humoral v a s o d i l a t o r s u b s t a n c e s , enhanced neurogenic v a s o c o n s t r i c t o r a c t i v i t y , expanded e x t r a c e l l u l a r f l u i d volume, "auto-
Chap. 6
Etiology of Hypertension
DuCharme
51 -
regulatory" vasoconstriction and structural changes in the arterial walls. There is little question that the composition of arteriolar walls in hypertensive animals is modified. The wall is thickened in relation to the l ~ m e n 3 - 7 ~Furthermore, resistance to flow in hypertensive vessels is increased even after maximal vas~dilatation~,~, and reactivity of hypertensive vessels to vasoconstrictor stimuli is enhanceds,l0. Although most investigators believe the structural changes in the vessel walls are secondary to the increased intravascular pressure, some question remains as to whether the functional changes represent primary or secondary events'
Renin-Angiotensin-Aldosterone System - The major unresolved problem is the mechanism responsible for initiation of the abnormal vascular resistance. Humoral vasoconstrictor substances released from the kidney have been prime suspects since it was through restriction of renal blood flow that Dr. Goldblatt first induced hypertension in laboratory animals? The subsequent discovery and elucidation of the renin-angiotensin-aldosterone system, and the participation of this system in the hypertensive process has occupied the minds and efforts of many researchers and has been reviewed frequentl?l2 - I 4 . Recent studies which employed immunologic techniques to render animals insensitive to the vasoconstrictor action of angiotensin or specific angiotensin receptor blocking agents have demonstrated that the renin-angiotensin system is involved in the development of some but not all forms of experimental hypertension. Animals made hypertensive by restricting blood flow to one kidney and leaving the contralateral kidney intact generally exhibit a lowered blood pressure in response to angiotensin I1 blockade15'le. This is particularly true during the first weeks after onset of the hypertensive process. After the hypertension is well established, however, the blood pressure response to angiotensin I1 antagonism is much less consistent. On the other hand spontaneously hypertensive animals, metacorticoid hypertensive animals or animals rendered hypertensive by unilateral renal artery constriction and contralateral nephrectomy generally fail to demonstrate a decreased blood pressure in response to angiotensin I1 blo~kade~~'~~. Interestingly, immunization with a crude renal cortical extract markedly lowered the blood pressure of dogs with renal hypertension (bilateral renal artery constriction or unilateral renal artery constriction and contralateral This observation, coupled nephrectomy) of several years duratioli?o'2'. with those in which a specific angiotensin I1 antagonist was employed, suggests the possibility that the animals were immunized against a substance of renal cortical origin other than renin. This possibility is supported by more recent work which demonstrated that passive transfer of renin immunity to dogs with chronic renal hypertension did not restore blood pressure to n~rmal"~.Furthermore, active immunization of rabbits against angiotensin I1 failed to prevent the development of either perinephritic hypertension or single kidney Goldblatt hypertensionz4," 5. It is apparent that the results obtained with immunization procedures have varied considerably depending upon the animal species, the specific immunization technique, and the type of experimental hypertension employed. The causative role of the renin-angiotensin-aldosterone system in the genesis of hypertension, therefore, remains in question.
52
Sect. I1
-
Pharmacodynamic Agents
Clarke, Ed.
Other Renal Prohypertensive Factors - The lack of agreement between in-vestigators as to the etiologic significance of the renin-angiotensin system in experimental hypertension has prompted some to search for other renal factors which might be involved. Grollman has described a substance designated nephrotensin which was isolated from renal venous blood of patients with surgically remediable hypertension and from animals with renal ischemia hypertension?6'"7. Nephrotensin is presumably a polypeptide different from angiotensin I or I1 which exerts a potent vasoconstrictor action, and appears to be causally related to the hypertension associated with renal ischemia. The participation of this substance in human essential hypertension remains to be determined. Several investigators have suggested that the increase in vascular resistance associated with hypertension is a secondary, "autoregulatoryll response triggered by an increase in cardiac outpu?""l. If this is true, then the factors responsible for the increased cardiac output could become of greater etiologic importance than those which increase only vascular resistance. Cardiac output may be increased because of a change in renal function which promotes fluid retention and thereby enhances venous return to the heart?". Alternatively, venous return and cardiac output may be enhanced in response to increased venous smooth muscle tone-?-?.A vasoconstrictor material of renal origin different from angiotensin I1 which markedly contracts vascular capacity has been demonstrated ,35. ~ ~ The chemical in dogs subjected to severe hypovolemic h y p ~ t e n s i o n nature of this material and its role in the pathogenesis of hypertension remain to be determined.
-
Kallidin-Kinin System Recent work has also suggested a role for the kallidin-kinin system in the pathogenesis of hypertensiod 6 . Significant increases in urinary excretion of kallikrein were found in spontaneously hypertensive and DOCA-salt hypertensive rats, while levels found in rats with renal hypertension and patients with essential hypertension were lower than those in respective controls. Additional data suggests that the kallidin-kinin system may be intimately involved in the regulation of salt and water excretion by the kidnef6, ,?',
-
Renal Antihypertensive Factors In addition to a prohypertensive mechanism it has been recognized for many years that the kidney possesses an antihypertensive mechanism. Loss of the antihypertensive function may be as important to the pathogenesis of hypertension as activation of the hypertensive mechanism. Work in this area has been kindled in recent years by the demonstration that explants of renomedullary tissue will prevent the onset of renoprival hypertension or lower the blood pressure of Extracts of renal medullary tissue animals with renal hyperten~ion~"'~' have been shown to lower the blood pressure of animals with experimental hypertension by a number of investigators. Extracts possess both an acute transient hypotensive action and a slow onset, protracted effect. The The substance acute effect is due to the presence of prostaglandin^^'^^^ responsible for the delayed response is also lipid in character, however, it appears to be a neutral lipid and not in the prostaglandin fa~nily~"~~.
_ I _
.
.
Chap. 6
E t i o l o g y of Hypertension
DuCharme
53
The s o u r c e of t h e r e n a l medullary a n t i h y p e r t e n s i v e s u b s t a n c e s app e a r s t o be t h e i n t e r s t i t i a l c e l l s l o c a t e d p r i m a r i l y i n t h e p a p i l l a . G r a n u l a t i o n of t h e s e c e l l s and presumably s e c r e t i o n h a s been demonstrated t o r e f l e c t changes i n blood p r e s s u r e of animals s u b j e c t e d t o e x p e r i m e n t a l hyperten~ion~~~ R e~c'e.n t l y , r a b b i t i n t e r s t i t i a l c e l l s have been grown i n t i s s u e c u l t u r e * 9 . The c e l l s were o b t a i n e d from a u t o t r a n s p l a n t s of r e n a l medulla which prevented r e n o v a s c u l a r and r e n o p r i v a l t y p e s of h y p e r t e n s i o n . E x t r a c t s of t h e c u l t u r e d c e l l s were shown t o c o n t a i n t h e t h r e e r e n a l medullary p r o s t a g l a n d i n s PGE2, PG% and PGF2 The p o s s i b l e r o l e of p r o s t a g l a n d i n s i n t h e p a t h o g e n e s i s of a r t e r i a l h y p e r t e n s i o n i s of g r e a t i n t e r e s t , s i n c e some p r o s t a g l a n d i n s n o t o n l y d i l a t e p e r i p h e r a l r e s i s t a n c e v e s s e l s but a l s o possess n a t r i u r e t i c a c t i v i t y 0 . I t i s t h e r e f o r e tempting t o s p e c u l a t e t h a t a d e f i c i e n c y of r e n a l p r o s t a g l a n d i n s might lead t o a r t e r i a l h y p e r t e n s i o n . R e l e a s e of p r o s t a g l a n d i n s i n t o t h e r e n a l venous blood has been demonstrated i n r e s p o n s e t o vasoc o n s t r i c t o r s t i m u l i o r r e n a l i ~ c h e m i a ' ~ ' ~ ~Most . s t u d i e s have suggested t h a t t h e primary v a s o d i l a t o r p r o s t a g l a n d i n r e l e a s e d from t h e kidney i s PGE2, b u t because of i t s r a p i d metabolism by t h e lungs PGE2 could n o t f u n c t i o n a s a g e n e r a l v a s o d i l a t o r hormone. A l t e r n a t i v e l y , r e n a l p r o s t a g l a n d i n s may e x e r t an a n t i h y p e r t e n s i v e a f f e c t through an a c t i o n w i t h i n t h e kidney t o m a i n t a i n normal r e n a l r e s i s t a n c e and p r e v e n t sodium and water accumulation. Lee has suggested t h a t PGAs, on t h e o t h e r hand, may be c i r c u l a t i n g a n t i h y p e r t e n s i v e hormones, s i n c e t h e y a r e much more r e s i s t a n t t o m e t a b o l i c d e g r a d a t i o n on p a s s i n g through t h e lungs55. There i s c o n t r o v e r s y , however, p e r t a i n i n g t o t h e a b i l i t y of t h e kidney t o form A prostaglandin^^^. Nonet h e l e s s , two groups have r e p o r t e d t h a t c i r c u l a t i n g l e v e l s of PGA a r e lower i n h y p e r t e n s i v e t h a n normotensive i n d i v i d u a l s , and a r e v i r t u a l l y a b s e n t i n t h e blood of a n e p h r i c 5y. While t h e h y p o t h e s i s t h a t p r o s t a g l a n d i n s f u n c t i o n a s a n t i h y p e r t e n s i v e hormones i s c e r t a i n l y a t t r a c t i v e , i t i s obvious t h a t much a d d i t i o n a l work i s n e c e s s a r y f o r v e r i f i c a t i o n .
-
The autonomic nervous system a l s o i s i m p l i c a t e d Autonomic Nervous System i n t h e p a t h o g e n e s i s of h y p e r t e n s i o n . S e v e r a l i n v e s t i g a t o r s have suggested t h a t heightened s y m p a t h e t i c nerve a c t i v i t y may u n d e r l i e t h e i n i t i a l l a b i l e phase of hypertension6"' 'O. This h y p o t h e s i s i s supported by e x p e r i m e n t a l s t u d i e s which demonstrated t h a t removal of t h e sympathetic nervous system c h e m i c a l l y o r immunologically prevented t h e o n s e t of g e n e t i c o r mineraloc o r t i c o i d hypertension60, 61. On t h e o t h e r hand, t h e s e p r o c e d u r e s were i n e f f e c t i v e i n r e d u c i n g t h e blood p r e s s u r e of animals i n which t h e hypertension w a s established p r i o r t o Conversely, t h e o n s e t of r e n a l h y p e r t e n s i o n i s n o t prevented by sympathectomy, b u t maintenance of t h i s form of e x p e r i m e n t a l h y p e r t e n s i o n a p p e a r s t o be dependent upon a n i n t a c t , f u n c t i o n a l s y m p a t h e t i c nervous system64. Involvement of t h e sympat h e t i c nervous system i n h y p e r t e n s i v e d i s e a s e i s a l s o suggested by t h e a n t i h y p e r t e n s i v e e f f i c a c y of t h e many sympathetic s u p p r e s s a n t drugs. Many c l i n i c a l s t u d i e s have been conducted i n an a t t e m p t t o q u a n t i t a t e t h e d e g r e e of s y m p a t h e t i c n e u r o n a l involvement i n v a r i o u s forms of human h y p e r t e n s i o n . These s t u d i e s have shown t h a t n e u r a l l y mediated v a s o c o n s t r i c t o r t o n e i s en-
54 -
Sect, I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
hanced i n most h y p e r t e n s i v e s u b j e c t s , b u t i t s r o l e i n t h e maintenance of t h e h y p e r t e n s i v e s t a t e i s c o n t r o v e r s i a l . The r e a d e r i s r e f e r r e d t o two . r e c e n t a r t i c l e s which a d d r e s s t h i s q u e s t i o n i n g r e a t e r d e t a i l 6 5 Y ~ ~There would seem t o be l i t t l e doubt t h a t t h e autonomic nervous system i s i n volved i n t h e h y p e r t e n s i v e process. Whether i t p l a y s a primary o r p e r missive r o l e i n t h e p a t h o g e n e s i s of t h e d i s e a s e , however, i s i n q u e s t i o n .
-
Genetic F a c t o r s The f a c t t h a t t h r e e independent groups have s u c c e s s f u l l y bred s t r a i n s of h y p e r t e n s i v e r a t s i n d i c a t e s t h a t g e n e t i c f a c t o r s a r e a l s o e x t e n s i v e l y involved i n t h e g e n e s i s of h y p e r t e n ~ i o n ~ ~ ' ~Many ". investig a t o r s b e l i e v e t h a t t h e spontaneously h y p e r t e n s i v e r a t (SHR) i s t h e model of e x p e r i m e n t a l h y p e r t e n s i o n which most c l o s e l y resembles e s s e n t i a l human h y p e r t e n ~ i o 70. n ~ ~ ~The e t i o l o g y of t h e h y p e r t e n s i o n which occurs i n t h e s e s t r a i n s , however, has n o t been d e f i n e d . The r e s u l t s of many s t u d i e s which have been conducted w i t h SH r a t s a r e h i g h l y q u e s t i o n a b l e , because app r o p r i a t e c o n t r o l animals a r e u n a v a i l a b l e . Normotensive r a t s of even t h e same s t r a i n o b v i o u s l y a r e g e n e t i c a l l y d i f f e r e n t from t h e i r h y p e r t e n s i v e r e l a t i v e s , and, t h e r e f o r e , a r e q u e s t i o n a b l e c o n t r o l s . The one e x c e p t i o n appears t o be t h e Dahl s t r a i n . These animals r e q u i r e a d m i n i s t r a t i o n of s a l t t o induce t h e hypertension. Therefore, one can have g e n e t i c a l l y s i m i l a r animals w i t h and w i t h o u t h y p e r t e n s i o n . Renal t r a n s p l a n t a t i o n experiments w i t h t h e Dahl SH r a t s have shown t h a t t h e kidney i s d e f i n i t e l y involved i n t h e p a t h o g e n e s i s of t h e h y p e r t e n ~ i o n ~ ~ - ~The ' . specific etio l o g i c f a c t o r s , however, have n o t been d e f i n e d . Although many f a c t o r s undoubtedly modify t h e p a t h o g e n e s i s of hypert e n s i o n , t h e b u l k of evidence p o i n t s toward t h e kidney a s t h e f o c a l p o i n t . F u t u r e s t u d i e s d i r e c t e d toward a c a r e f u l d e f i n i t i o n of r e n a l prohypert e n s i v e and a n t i h y p e r t e n s i v e f a c t o r s coupled w i t h r e n a l e x c r e t o r y f u n c t i o n and autonomic nerve a c t i v i t y would appear t o be most l i k e l y t o y i e l d t h e u l t i m a t e s o l u t i o n t o t h i s complex problem. References 1. 2.
3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14.
E. D. F r o h l i c h , Ann. I n t . Med., 78, 7 1 7 , 1973. H. G o l d b l a t t , S. Lynch, R. F. Hanzel and W. W. Summerville, J. Exp. Med., 5 9 , 347, 1934. L. Tobian, J. Janecek, A. Tomboulian and D. F e r r e i r a , J. C l i n . I n v e s t . , 40, 1922, 1961. L. Tobian, R. Olson and G. Chesley, Amer. J. P h y s i o l . , 216, 2 2 , 1969. L. Tobian and G. Chesley, Proc. SOC. Exptl. Biol. Med., 340, 1966. L. Tobian and J. T. Binion, C i r c u l a t i o n , 5 , 754, 1952. D. S h o r t , B r i t . Heart J . , 28, 184, 1966. B. Folkow, Clin. S c i . , i l , 1, 1971. R. S i v e r t s s o n , Acta Physiol. Scand., Suppl. 343, 1970. P. Redleaf and L. Tobian, Circ. Res., 6 , 185, 1958. D. F. Bohr, Fed. Proc., 33, 1 2 7 , 1974. S. Koletsky, I n t . Rev. Exp. Path., 2, 203, 1973. J. H. S t e i n and T. F. F e r r i s , Arch. I n t . Med., 860, 1973. J. H. Laragh, L. Baer, H. R. Brunner, F. R. Buhler, J. E. S e a l e y and E. D. Vaughan, Amer. J. Med., 52, 633, 1972.
-
121,
131,
Chap. 6
E t i o l o g y of Hypertension
DuCharme
55
15. A. R. C h r i s t l i e b , T.U.L. B i b e r , and R. B. H i c k l e r , J. Clin. I n v e s t . , 48, 1506, 1969. 16. 7 Bing and K. Poulsen, Acta Path, Microbiol. Scand., 7 8 , 6, 1970. 17. H. R. Brunner, J. D. Kirshman, J. E. S e a l e y and J. H. Laragh, Science, 174, 1344, 1971. 18. T T . P a l s , F. D. Masucci, G. S. Denning, F. Sipos and D. C. F e s s l e r , C i r c . Res., 2, 673, 1971. 19. F. M. Bumpus, S. Sen, R. R. Smeby, C. Sweet, C. M. F e r r a r i o and M. C. Khosla, Circ. Res., 32, Suppl. 1, 150, 1973. 20. G. E. Wakerlin, R. B. B i r d , B. B. Brennan, M. H. Frank, S. H. Kremen, I. Kuperman and J. H. Skom, J. Lab. Clin. Med., 4 l , 708, 1953. 2 1 . S. H. Kremen and G. E. Wakerlin, Proc. SOC. Exptl. B i o l . Med., 90, 9 9 , 1955. 22. E. Haas and H. G o l d b l a t t , Amer. J. P h y s i o l . , 197, 1303, 1959. 23. R. W. H i l l , J. E. Chester and P. E. Wisenbaugh, Lab. I n v e s t . , 22, 404, 1970. 24. I. Eide and H. Aars, Nature (London), 222, 571, 1969. 25. W. J. Louis, G. J. Macdonald, V. R e n z i n i , G. W. Boyd and W. S. P e a r t , Lancet, 1, 333, 1970. 26. A. Grollman, Proc. Soc. Exptl. Biol. Med., 1120, 1970. 27. A. Grollman and V. S. R. Krishnamurty, Amer. J. P h y s i o l . , 221, 1499, 197 1. 28. J. M. Ledingham and R. D. Cohen, Clin. S c i . , 22, 69, 1962. 29. J. M. Ledingham and R. D. Cohen, Can. Med. Assoc. J., 90, 292, 1964. 30. C. M. F e r r a r i o , I. H. Page and J. W. McCubbin, Circ. R e s . , 27, 799, 1970. 31. T. G. Coleman, H. J. Granger and A. C. Guyton, Circ. Res., 28, Suppl. 11, 76, 1971. 32. T. G. Coleman, J. D. Bower and H. G. Langford, C i r c . , 42, 509, 1970. 33. J. Brod, M. Cachovan, H. -U. Pixburg and P. Harmjanz, Therapiewoche, 45, 4258, 1973. 34. W. DuCharme and L. Beck, J. Pharmacol. Exp. Ther., 177, 56, 1971. 35. J. R. Powell and D. W. DuCharme, Amer. J. Physiol., 2,168, 1974. 36, H. S. Margolius, R. G. Geller, W. deJong, J. J. P i s a n o , and A. Sjoerdsma,Circ. Res., 2, Suppl. 11, 125, 1972. 37. M. Marin-Grez, P. Cottone and 0. A. C a r r e t e r o , Amer. J. P h y s i o l . , 9, 794, 1972. 38. E. E. Muirhead, J. A. Stirman, W. Lesch and F. Jones, Surg. Gynecol. O b s t e t . , 103, 673, 1956. 39. E. E. Muirhead, F. Jones and J. A. Stirman, J. Lab, Clin. Med., 56, 1 6 7 , 1960. 40. E. E. Muirhead, J. A. Stirman and F. Jones, J. Clin. I n v e s t . , 39, 266, 1960. 41. E. E. Muirhead, G. B. Brown, G. S. Germain and B. E. Leach, J. Lab. Clin. Med., 7 6 , 641, 1970. 42. R. B. H i c k l e r , D. P. L a u l e r , C. A. S a r a v i s , P. I. Vagnucci, G. S t e i n e r and G. W. Thorn, Can. Med. Ass. J., 90, 280, 1964. 43. E. G. D a n i e l s , J. W. Hinman, B. E. Leach and E. E. Muirhead, Nature (London), 215, 1298, 1967. 44. E. E. Muirhead, J. W. Hinman, E. G. D a n i e l s , M. Kosinski and B. Brooks, J. C l i n . I n v e s t . , 41, 1387, 1962.
134,
56
Sect. I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
45. J. B. Lee, R. B. H i c k l e r , C. A. S a r a v i s and G. W. Thorn, C i r c . Res., 13, 359, 1963. 46. E. E. Muirhead, B. Brooks, M. K o s i n s k i , E. G. Daniels and J. W. Hinman, J. Lab, Clin. Med., 67, 778, 1966. 47. R. C. Muehrcke, A. K. Mandal, M. E p s t e i n and F. I. V o l i n i , J. Lab. C l i n , Med., 7 3 , 299, 1969. 48. L. Tobian, M. I s h i i and M. Duke, J. Lab. Clin. Med., 73, 309, 1969, 49. E. E. Muirhead, G. Germain, B. E. Leach, 3. A. P i t c o c k , P. Stephenson, B. Brooks, W. L. B r o s i u s , E. G. D a n i e l s and J. W. Hinman, C i r c . Res., 31, Suppl. 11, 161, 1972. 50. 7 C. McGiff and H. D. I t s k o v i t z , Circ. Res., 33, 479, 1973. 51. J. C. McGiff, K. Crowshaw, N. A. Terragno and A. J. Lonigro, Circ. Res., 27, Suppl. I , 121, 1970. 52. J. C. McGiff, K. Crowshaw, N. A. Terragno, K. U. Malik and A. J. Lonigro, Clin. S c i . , 42, 223, 1972. 53. E. W. Dunham and B. G. Zimmerman, Amer. J. P h y s i o l . , 219, 1279, 1970. 54. J. C. McGiff, K. Crowshaw, N. A. Terragno, A. J. Lonigro, J. C. S t r a n d , M. A. Williamson, J. B. Lee and K. K. F. Ng, Circ. Res., 27, 765, 1970. 55. J.' B. Lee, New Engl. J. Med. , 277, 1073, 1967, 56. R. M. Zusman, B. V. Caldwell, P. J. Mulrow and L. S p e r o f f , P r o s t a g l a n d i n s , 2 , 679, 1973. 57. J. B. Lee, A. A t t a l l a , V. K. Vance, C. Elwood and A. Prezyna, J. Clin. I n v e s t . , 52, SOa, 1973. 58. E. D. F r o h l i c h , V. J. Kozul, R. C. T a r a z i and H. P. Dustan, Circ. Res., 27, Suppl. I , 55, 1970. 59. B. Folkow, M. H a l l b i c k , Y. Lundgren, R. S i v e r t s s o n and L. Weiss, C i r c . Res., 32, Suppl. I , 2 , 1973. 60. G. H a e u s l e r , L. Finch and H. Thoenen, E x p e r i e n t i a , 28, 1200, 1 9 7 2 . 61. B. Folkow, M. Hallbxck, Y. Lundgren and L. Weiss, Acta P h y s i o l . Scand., 84, 512, 1972. 62. Ayitey-Smith and D. R. Varma, B r i t . J. Pharma., 40, 175, 1970. 63. D. W. C l a r k , C i r c . Res., 28, 330, 1971. 64. L. D. Dorr and M. J. Brody, Proc. SOC. Exptl. B i o l . Med., 123, 155, 1966. 65. R. C. T a r a z i and H. P. Dustan, Clin. S c i . , 44, 1 9 7 , 1973. 66. P. I. Korner, J. Shaw, J. B. Uther, M. J. West, R. J. McRitchie and J. G. Richards, Circ. 48, 107, 1973. 2 2 7 , 1969. 67. K. Okamoto, I n t . Rev, Exp. Path. , 7 2 7 , 1958. 68. F. H. Smirk and W. H. H a l l , Nature (London), 69. L. K. Dahl, M. Heine and L. T a s s i n a r i , Nature (London), 3,480, 1962. 70. S. Udenfriend and S. S p e c t o r , Science, 1155, 1972. 71. L. K. Dahl, K. D. Knudsen and 2. J u n e c h i , Circ. Res., 27, Suppl. 11, 277, 1970. 7 2 . L. K. Dahl, M. Heine and K. Thompson, C i r c . Res., 34, 94, 1974. 73. L. Tobian, Am. J. Med., 52, 595, 1972.
1,
182,
176,
Chapter 7.
A n t i h y p e r t e n s i v e Agents
John E . F r a n c i s , R e s e a r c h Department, P h a r m a c e u t i c a l s D i v i s i o n CIBA-GEIGY C o r p o r a t i o n , A r d s l e y , N. Y. 10502 New P r o d u c t s - I n F e b r u a r y 1973, S c h e r i n g C o r p o r a t i o n i n t r o d u c e d d i a z o x i d e ( I ) as H y p e r s t a t I . V . l , t h e f i r s t a n t i h y p e r t e n s i v e a g e n t t o r e a c h t h e U. S . market i n t e n y e a r s . I t was a l s o marketed t h i s y e a r i n S w i t z e r l a n d and Germany? S u g g e s t e d u s e i s f o r emergency i n t r a v e n o u s a d m i n i s t r a t i o n t o h o s p i t a l i z e d p a t i e n t s w i t h m a l i g n a n t h y p e r t e n s i o n , f o r which i t i s claimed t o b e a welcome and e f f e c t i v e t r e a t m e n t ? I n a r e c e n t c l i n i c a l s t u d y i t was o r a l l y e f f e c t i v e , sometimes combined w i t h a B - a d r e n e r g i c b l o c k e r , i n some p a t i e n t s w i t h s e v e r e and r e f r a c t o r y forms of h y p e r t e n s i o n : Debrisoquin ( D e c l i n a x , 11) w a s i n t r o d u c e d i n October i n S w i t z e r l a n d by HoffmannLaRoche? Long known f o r i t s u t i l i t y i n s e v e r e h y p e r t e n s i o n , t h i s d r u g gave good r e s u l t s i n a r e c e n t s t u d y o f m i l d t o m o d e r a t e l y s e v e r e hypert e n s i v e s ? P r o p r a n o l o l ( I n d e r a l , 111) t h e o n l y @ - b l o c k e r a v a i l a b l e on t h e U. S . m a r k e t 6 , i s n o t y e t i n d i c a t e d f o r t h e t r e a t m e n t of h y p e r t e n s i o n i n t h e U.S.A!
CI
Me 9” OCHzCHCI$ NH-CH /
aye
I
Me
P”
0“ “0
II
NH
I
I1
-
111
Drups i n C l i n i c a l I n v e s t i g a t i o n Although many s i n g l e d r u g s were e v a l u a t e d , c l i n i c a l s t u d i e s i n 1973 r e f l e c t e d a growing t r e n d t o c o m b i n a t i o n t h e r a p y . C l o n i d i n e ( C a t a p r e s , ST-155 , IVa) , marketed i n Europe, w a s found t o b e e f f e c t i v e a t low d o s e s w i t h o u t p o s t u r a l h y p o t e n s i o n o r l a s t i n g s e d a t i v e s i d e e f f e c t s i n two l o n g term s t u d i e s ? y g A comparison w i t h r e s e r p i n e i l l u s t r a t e d c l o n i d i n e ’ s l a c k of d e p r e s s i v e r e a c t i o n s ” and t h e c o m b i n a t i o n w i t h c h l o r t h a l i d o n e (Combipres) w a s even more e f f e c t i v e t h a n c l o n i d i n e alone:’ The d a n g e r o f h y p e r t e n s i v e rebound and o t h e r s i d e e f f e c t s on One s t u d y d e s c r i b e d t h e sudden w i t h d r a w a l from c l o n i d i n e was n o t e d ? ,1 d r u g as s a f e and e f f e c t i v e f o r emergency t r e a t m e n t 1 4 whereas a n o t h e r r e p o r t e d s e r i o u s p r e s s o r e f f e c t s when p a t i e n t s w i t h a c c e l e r a t e d h y p e r t e n s i o n were t r e a t e d i n t r a v e n o u s l y ! New p h a r m a c o l o g i c a l s t u d i e s ’ 6 - 2 1 on t h e d r u g and i t s m a j o r m e t a b o l i t e , 4 - h y d r o x y - c l o n i d i n e Y s u p p o r t a mode of a c t i o n i n v o l v i n g s t i m u l a t i o n o f c e n t r a l a - r e c e p t o r s . These r e c e p t o r s may b e c o n n e c t e d t o a n i n h i b i t o r y n e u r o n , t h e a c t i v a t i o n of which c a u s e s a d e p r e s s i o n of p e r i p h e r a l s y m p a t h e t i c a c t i o n and a b l o o d p r e s s u r e f a l l ? ’ The r e l a t e d compound IVb, i n p h a s e I o f c l i n i c a l t r i a l s i n Europe, i s a c t i v e a t 0.2-0.4 mg./day i n man w i t h maximal h y p o t e n s i o n a t 4-5 hoursZ3
58 -
Sect. I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
The mechanism of a c t i o n o f indoramine ( V ) has been r e ~ i e w e d ? A~ r e c e n t c l i n i c a l t r i a l , however, was d i s a p p o i n t i n g due t o t h e s i d e e f f e c t s ~bserved?~ Guanabenz (WY 8678, BR 750, FLA 137, V I ) i n a n i m a l s shows a potency l e s s t h a n c l o n i d i n e b u t g r e a t e r t h a n g u a n e t h i d i n e w i t h a mechanism I n i t i a l c l i n i c a l t r i a l s showed showing s i m i l a r i t i e s t o b o t h d r u g s ? 6,2 t h e same potency r a n k i n g ? 8 y 2 9 The d r u g w a s e f f e c t i v e and f u r t h e r improved by h y d r o c h l o r t h i a z i d e a d d i t i o n T 8 The p r i n c i p a l s i d e e f f e c t w a s d r o w s i n e s s .
Ar=2 ,6 - d i c h l o r o p h e n y l N-CO- CGH5 Ar-3-( 2-chloro-4-methyl) V H VI th ieny 1 Guanadrel (U-28288D, V I I ) , e q u i p o t e n t t o g u a n e t h i d i n e i n t h e c l i n i c , a p p e a r s t o o f f e r more s t a b l e b l o o d p r e s s u r e c o n t r o l d u r i n g t h e day w i t h less f r e q u e n t d i a r r h e a ? ' S t u d i e s on g u a n c y d i n e ( V I I I ) c o n t i n u e d t o s u p p o r t t h e mechanism of a d i r e c t v a s c u l a r e f f e c t 3 ' w i t h p a r t i a l d e p l e t i o n o f norepinephrine s t o r e s observed only a f t e r high c h r o n i c d o s i n g under certain conditions?' I
IVa: IVb:
NH
V II
VIII
IX
M i n o x i d i l (U-10,858, I X ) i s a u s e f u l h y p o t e n s i v e a g e n t i n uremic p a t i e n t s w i t h s e v e r e h y p e r t e n ~ i o no~r ~ t h o s e w i t h m a l i g n a n t o r a c c e l e r a t e d h y p e r t e n s i o n r e f r a c t o r y t o c o n v e n t i o n a l d r u g s ? 4 Compared t o h y d r a l a ~ i n e ? ~ t h e d r u g was more p o t e n t , l o n g e r a c t i n g and showed no s i g n s o f t o l e r a n c e development. It c a u s e s a marked i n c r e a s e i n serum r e n i n a c t i v i t y , 3 6 ' 3 7 c a r d i a c h y p e r a ~ t i v i t y qand ~ sodium r e t e n t i o n 3 4 ' 3 5 b u t c o - a d m i n i s t r a t i o n of a @ - b l o c k e r and a d i u r e t i c c o u n t e r a c t s t h e s e s i d e effect^$'^^-^^ The pharmacological p r o f i l e i s t h a t of a p o t e n t , o r a l l y e f f e c t i v e , long a c t i n g h y p o t e n s i v e i n r a t s , dogs and monkeys w h i c h works p r i m a r i l y by a p e r i M i n o x i d i l i s n o n - t o x i c i n r a t s , monkeys p h e r a l v a s o d i l a t o r mechanism? and m i n i p i g s b u t c a u s e s a d e g e n e r a t i v e l e s i o n i n t h e r i g h t a t r i u m of dogs a f t e r p r o l o n g e d d a i l y d o s i n g . D i s c r e p a n c y between t h e p r o l o n g e d a c t i o n and r a p i d c l e a r a n c e from plasma was e x p l a i n e d by s p e c i f i c r e t e n t i o n of t h e I t may i n t e r f e r e w i t h some c e l l u l a r comd r u g i n v a s c u l a r smooth muscle. ponent ( c a l c i u m ? ) of t h e c o n t r a c t i l e p r o c e s s ? ' Another p e r i p h e r a l d i l a t o r , p r a z o s i n (CP-12299-1, X ) gave good r e s u l t s i n a r e c e n t t r i a l (1.5 t o 15 mg./day) even w i t h o u t a d i u r e t i c 4 ' i n m o d e r a t e l y s e v e r e hypert e n s i v e s . A n o t h e r member o f t h i s s t r u c t u r a l t y p e , t r i m a z o s i n (CP-19106, X I )
Chap. 7
A n t i h y p e r t e n s i v e Agents
Francis
59 -
showed a s t a t i s t i c a l l y s i g n i f i c a n t a n t i h y p e r t e n s i v e e f f e c t a t 50-150 mg/ day i n a group of p a t i e n t s w i t h e s s e n t i a l h y p e r t e n s i o n t 2 The combination drug B r i n e r d i n e ( dihydroergocr i s t i n e -c lopamide -res e r p i n e ) i s c 1i n i c a 1l y e f f e ~ t i v e and ~ ~ more , ~ ~ a c t i v e than any o f i t s s e p a r a t e i n g r e d i e n t s o r combination of two.
Recent c l i n i c a l t r i a l s of p r o p r a n o l o l (111) c o n t i n u e t o i l l u s t r a t e i t s u t i l i t y a s a h y p ~ t e n s i v ew~i t~h a c t i v i t y improved by a d d i t i o n of a v a s o d i l a t o r such as h y d r a l a z i n e i n s e v e r e h y p e r t e n ~ i o no~r ~w i t h hydroc h l o r t h i a z i d e i n mild t o moderate h y p e r t e n s i o n t 7 There i s i n c r e a s i n g evidence t h a t t h e drug reduces plasma r e n i n t 8 - 5 1 Combining p r o p r a n o l o l w i t h a d r e n e r g i c b l o c k e r s and a d i u r e t i c has a l s o been recommended?2 Int r a c e r e b r o v e n t r i c u l a r ( i c v ) s t u d i e s of p r o p r a n o l o l i n animals by a number of investigator^^^-^^ have l e d t o t h e view t h a t i t s hypotensive a c t i v i t y i s c e n t r a l l y mediated and depends on t h e i n t e g r i t y of n o r a d r e n e r g i c neurons. Blockade of p-adrenoceptors i n t h e b r a i n i s claimed t o cause hypotension and b r a d y ~ a r d i a ? ~However, i t i s noteworthy t h a t p r a c t o l o l which does n o t ( E r a l d i n , I C I 50172, X I I ) , a c a r d i o s e l e c t i v e c r o s s t h e b l o o d - b r a i n b a r r i e r 5 lowers blood p r e s s u r e v e r y w e l l i n This i s a l s o t r u e f o r a l p r e n o l o l ( A p t i n , X I I I ) 6 2 - 6 5 and I . C . I . 66082 Other p-blockers shown t o lower blood p r e s s u r e i n c l i n i c a l (XIV)$6'67 t r i a l s t h i s y e a r were p i n d o l o l (Visken, LB-46, XV) f 8 - 7 1 t i m o l o l (MK-950,
R-OC$
HChN-C(Meh " H
Li
X I I I : R'=Allyl
XII
XIV
CONH2
X V I I : R'=Allyloxy
0
n
O U N W OCH2F$NH- C(Me& OH N N
's'
XVI
-CH2FHCH2NCH&4 OH H
QO
Me XVIII
60 -
S e c t . I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
X V I ) j 2 - 7 4 ~ h i w~ ahs c o n s i d e r a b l y more p o t e n t t h a n p r o p r a n o l o l i n animals 7 5 ~ 7 6 and man, and o x p r e n o l o l ( T r a s i c o r , X V I I ) j 7 - 7 9 w h i c h w a s a l s o v e r y s u c c e s s f u l when combined w i t h c y c l o p e n t h i a z i d e s O i n a l a r g e s c a l e s t u d y . Tolamolol (m 6558, XVIII) c a u s e d a pronounced b l o o d p r e s s u r e f a l l i n 3 o f 4 normot e n s i v e humans?' Many a n a l o g s have b e e n d e s c r i b e d Though c a r d i o s e l e c t i v e @ - b l o c k e r s a r e a n improvement o v e r n o n - s e l e c t i v e @ - b l o c k e r s , f o r example, i n p a t i e n t s w i t h a s t h m a , e a c h r e d u c e s c o n t r a c t i l e f o r c e a l o n g w i t h h e a r t r a t e . A " c h r o n o s e l e c t i v e " B-blocker i s s t i l l t o b e f o u n d . 8 3
N a t u r a l P r o d u c t s and R e l a t e d Compounds - A v a s o d e p r e s s o r f a c t o r (VDF) was i s o l a t e d from c a n i n e plasma and a o r t i c t i s s u e and human plasma.84 The p o l y p e p t i d e , m o l e c u l a r w e i g h t -G!OOO, c o n t a i n i n g g l u t a m i c a c i d , p r o l i n e and g l y c i n e as p r i n c i p a l components , r a p i d l y lowers b l o o d p r e s s u r e i n r a t s when g i v e n i . v . VDF l e v e l s i n c r e a s e i n dogs d u r i n g induced hemorrhagic shock and h i g h l e v e l s a r e s e e n i n p a t i e n t s w i t h d i f f e r e n t t y p e s o f shock. A t r i d e c a p e p t i d e c a l l e d n e u r o t e n s i n i s o l a t e d from b o v i n e h y p o t h a l a m i i s composed o f Lys, Arg,, Asx, Glx,, P r o 2 , I l e u , L e u 2 , T y r Z a 5 and i s a c t i v e i n r a t s a t 100 pmoles/kg. S y n t h e t i c p e p t i d e s o r i g i n a l l y i s o l a t e d from Bothrops jararaca venom, s p e c i f i c i n h i b i t o r s of a n g i o t e n s i n - c o n v e r t i n g enzyme, c o n t i n u e t o a p p e a r p r o m i s i n g as d i a g n o s t i c t o o l s and p e r h a p s i n t r e a t m e n t o f r e n a l h y p e r t e n s i o n ? 6 - 8 8 A s t u d y of 57 r e l a t e d p e p t i d e s i n d i c a t e s t h a t t h e C-terminal sequence Pro-Gln-Ileu-Pro-Pro is r e q u i r e d f o r The significant i n h i b i t i ~ n . ~ ~ a n g i o t e n s i n I1 a n t a g o n i s t e f f e c t o f S a r 1 - a l a 8 - a n g i o t e n s i n I1 was confirmed i n dog m o d e l s g 0 ,91 and i n man.92 Hypotension w a s a c h i e v e d i n h y p e r t e n s i v e p a t i e n t s w i t h h i g h r e n i n l e v e l s b u t n o t i n t h o s e w i t h low o r normal l e v e l s . In vitro studies indicate ( I l e u 8 ) - a n g i o t e n s i n I1 t o b e t h e most p o t e n t a n t a g o n i s t y e t d e v e l o p e d , b u t s u b s t i t u t i o n o f s a r c o s i n e f o r a s p a r t i c a c i d i n t h e one p o s i t i o n i n c r e a s e s i n v i v o a ~ t i v i t y . ' The ~ p e p t i d e from t h e n a t i v e r e n i n s u b s t r a t e Asp-Arg-Val-Tyr-Ileu-His-Pro-Phe-His-Leu-Leu-Val-wr-Ser has b e e n m o d i f i e d s l i g h t l y t o produce c o m p e t i t i v e i n h i b i t o r s of r e n i n . 9 4 The s h o r t e r p e p t i d e His-Pro-Phe-His-Leu-D-Leu-Val-wr is a l s o a potent i n h i b i t o r . 95 A r a c h i d o n i c a c i d is h y p o t e n s i v e i n s p o n t a n e o u s h y p e r t e n s i v e r a t s l i k e l y due t o c o n v e r s i o n t o PGE, s i n c e a c t i v i t y i s i n h i b i t e d by a n t i i n f l a m matory a g e n t s ? 6 The a n t i h y p e r t e n s i v e e f f e c t of PGA, i n man i s t h o u g h t m a i n l y due t o i t s e f f e c t on r e n a l c i r c u l a t i o n where it c a u s e s v a s o d i l a t a t i o n and e x c r e t i o n o f water and sodium. I t a l s o i n h i b i t s a n g i ~ t e n s i n . ~ ~ The h y p o t e n s i v e a c t i v i t y o f A 9 - t e t r a h y d r o c a n n a b i n o l ( X I X ) i n a n i m a l s s u g g e s t s i t as a new l e a d . 9 8 , 9 9 Development of t o l e r a n c e t o t h i s e f f e c t may i n v o l v e a n immunogenic r e a c t i o n . ' O O Methylapogalanthamine ( X X ) , h y p o t e n s i v e i n c a t s , dogs and r a b b i t s , has a d r e n o l y t i c , s p a s m o l y t i c and s e d a t i v e p r o p e r t i e s . I t h a s b e e n approved f o r w i d e c l i n i c a l u s e i n t h e U.S.S.R?" A naphthoquinone ( X X I ) from t h e fungus Corynespora c a s s i c o l a i n h i b i t s catechol-o-methyltransferase i n v i t r o and i s a h y p o t e n s i v e o f l o n g d u r a t i o n ( 2 4 h r s . ) i n s p o n t a n e o u s h y p e r t e n s i v e r a t s a f t e r 12.5 mg/kg i . p . l o 2 F u s a r i c a c i d ( 5 - n - b u t y l p i c o l i n i c a c i d ) a n a l o g s w i t h c h l o r i n e o r bromine i n t h e 3- a n d / o r 4 - p o s i t i o n o f t h e s i d e
Chap. 7
A n t i h y p e r t e n s i v e Agents
Francis
61
c h a i n a r e more p o t e n t dopamine-@-hydroxylase i n h i b i t o r s t h a n t h e p a r e n t compound!03,104 The 4 ' - c h l o r o a n a l o g (FD-008) c a u s e s marked s u s t a i n e d h y p o t e n s i o n i n s p o n t a n e o u s h y p e r t e n s i v e r a t s a t 12.5-25 mg/kg. p . o . I o 5
OH M e I- C H C H $ % q O HOH
Me= (=@ Me
Me0
C5H11
Me
Nhle
xx
xI X
XXI
-
O t h e r Compounds A f f e c t i n g A d r e n e r g i c T r a n s m i s s i o n The p r e d o m i n a n t l y c e n t r a l mode of a c t i o n o f a-methyldopa h a s r e c e i v e d s t r o n g support106-110 and t h e mechanism has been more p r e c i s e l y d e f i n e d . The d r u g is m e t a b o l i z e d i n t h e CNS t o a - m e t h y l n o r e p i n e p h r i n e which may a c t on b r a i n a - a d r e n o c e p t o r s t o c a u s e h y p o t e n s i o n , as do o t h e r p o t e n t a - s t i m u l a n t s g i v e n i c v , 2 2 y 1 1 1 o r may a c t i n d i r e c t l y by r e l e a s i n g n o r e p i n e p h r i n e from a d r e n e r g i c n e u r o n s . The h y p o t e n s i o n c a u s e d by p-hydroxynorephedrine (PHN) i n man i s more l i k e l y due m a i n l y t o a p e r i p h e r a l f a l s e t r a n s m i t t e r mechanism s i n c e t h i s compound d o e s n o t p e n e t r a t e t h e b l o o d - b r a i n b a r r i e r . l 1
*
The p o t e n t a - b l o c k e r 12473JL ( X X I I ) has been s e l e c t e d f o r c l i n i c a l t r i a l from a number o f o x a z o l i d o n e s w i t h a n t i h y p e r t e n s i v e , a n t i a r r h y t h m i c and a n a l g e s i c a ~ t i v i t y . ' ~ Compound ~ , ~ ~ ~ X X I I I i s reported t o be a potent a - b l o c k e r w i t h prolonged action.'15 The p i p e r a z i n e X X I V , p r o b a b l y a n
Et XXII
I
O 1NHOH XXIII
XXIV
@ H
a - b l o c k e r , i s a c t i v e a t 0.2 mg/kg S . C . i n m e t a c o r t i c o i d r a t s 1 1 6 b u t d i s p l a y s CNS d e p r e s s a n t p r o p e r t i e s . Methoxyl s u b s t i t u t i o n i n t h e i n d o l e nucl e i r e d u c e s a c t i v i t y . The t r i c y c l i c s t r u c t u r e XXVa, o r a l l y a c t i v e a t low d o s e s i n h y p e r t e n s i v e r a t s and n e u r o g e n i c d o g s , shows a - b l o c k i n g and n o r e p i n e p h r i n e r e l e a s i n g p r o p e r t i e s : l 7 Several r e l a t e d t r i c y c l i c compounds a r e q u i t e a c t i v e though none a s a c t i v e i n a l l models as XXVa.118y119 L i n e a r i t y of t h e t r i c y c l i c system a p p e a r s e s s e n t i a l f o r a c t i v i t y .
62 -
Sect. I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
R e l a t e d compounds r e p o r t e d as a c t i v e i n animal models are XXVb'20 ( a l s o a p l a t e l e t a g g r e g a t i o n i n h i b i t o r ) and XXVI?21 W-9465-2 (XXVIIa), a c t i v e i n r e n a l and DOCA h y p e r t e n s i v e rats a p p e a r s g u a n e t h i d i n e - l i k e : 2 2 b u t may a l s o r e l e a s e a n t i d i u r e t i c hormone.'23 The most a c t i v e member of a s e r i e s of 48 a n a l o g s i s XXVIIb.lZ4
XXVa
R'H,
XXVb
R=CH3, X=O
X=Hz
XXVIIa
X=H
XXVIIb
X=C1
\S-2395 ( X X V I I I ) , though a n o n - s p e c i f i c p - b l o c k e r , i s much more p o t e n t than p r o p r a n o l ~ l ~ CP-240-S ~~ ( X X I X ) i s more a c t i v e t h a n p r o p r a n s l o l a s a h y p o t e n s i v e i n spontaneous h y p e r t e n s i v e r a t s though less B-blocking.126 The D C I v a r i a n t XXX i s t h e most p o t e n t i n a s e r i e s of @ - b l o c k e r s showing p o s i t i v e i n o t r o p i c and h y p o t e n s i v e a c t i v i t y o r a l l y i n r a t s and d o g s ? 2 7 A s t u d y of t h e a-methyl a n a l o g s of p r o p r a n o l o l and p r a c t o l o l shows t h a t t h e s u b s t i t u t i o n reduces potency b u t i n c r e a s e s c a r d i o s e l e c t i v i t y . '
OH OCH~CHCH~NHCH(M~)~
a XXVIII
OH
Me
xxx
XXIX
-
P e r i p h e r a l V a s o d i l a t o r s and Other A n t i h y p e r t e n s i v e s L-6150 ( X X X I ) , which has h y d r a l a z i n e - l i k e a c t i v i t y w i t h l e s s t o x i c i t y , shows no lupus erythemat o s u s - l i k e syndrome i n C o l l i e dog s t u d i e ~ . ~A ~group ~ , ~of ~3-amino-4~ halosydnone imines r e l a t e d t o PR-G-138 ( X X X I I ) show comparable o r a l a c t i v i t y t o t h e p a r e n t compound i n h y p e r t e n s i v e r a t s (ca. 10 mg/kg).13' Diazoxide a n a l o g s w i t h t h e benzene r i n g r e p l a c e d by t h i o p h e n e , e.g. XXXIII, a r e a c t i v e i n DOCA r a t s and i n dogs.132 The n i c o t i n i c a c i d ester H - 1 ( X X X I V ) i s a h y p o t e n s i v e and v a s o d i l a t o r i n spontaneous h y p e r t e n s i v e rats.l33
n
XXXIII
Ant i h yp er t e n s i v e Ag en ts
Chap. 7
Francis
63 -
XXXV lowers b l o o d p r e s s u r e i n h y p e r t e n s i v e r a t s m a i n l y by a p e r i p h e r a l mechanism.134 Abbott 41596 ( X X X V I ) , t h e b e s t o f a s e r i e s of amino a c i d amides o f dopamine, c a u s e s r e n a l v a s o d i l a t i o n o f 3 h o u r s d u r a t i o n a t 12 mg/kg p.0. i n d o g s ? 3 5 It w i l l b e t e s t e d c l i n i c a l l y f o r p o t e n t i a l p r o p h y l a c t i c u s e i n h y p e r t e n s i o n and i n r e n a l d i s e a s e s . A s e r i e s o f phosp h o d i e s t e r a s e i n h i b i t o r s from Merck show c a r d i o s t i m u l a n t , b r o n c h o d i l a t o r and h y p o t e n s i v e p r o p e r t i e s i n a n i m a l s , I n t h i s s e r i e s , compound X X X V I I shows good h y p o t e n s i o n a t d o s e s t h a t show no c a r d i a c ~ t i m u 1 a t i o n . l ~The ~ c l o n i d i n e a n a l o g X X X V I I I i s a c t i v e a t 0.5 mg/kg p . o . i n r e n a 1 h y p e r t e n s i v e
0
OH
o$ O C H 2 & H C0IH 2
xxx I V
M ee0o a i > , C O M e
HOp , & M e
xxxv
.I
CI
HO
0
Et
J!
AN AN H
XXXVII
XXXVIII
xxx I X
rats? Sandoz 44-549 (XXXIX) c a u s e s s u s t a i n e d h y p o t e n s i o n and bradycardia i n n o r m o t e n s i v e and DOCA rats a t v e r y low d o s e s b u t s l i g h t s t r u c t u r e modif i c a t i o n s d e c r e a s e a c t i v i t y markedly? 3 8 The h y d r o x y g u a n i d i n e s XL, a c t i v e i n low d o s e s i n r e n a l h y p e r t e n s i v e r a t s and h y p e r t e n s i v e d o g s , a p p e a r t o a c t by a d i r e c t c e n t r a l e f f e c t . 1 3 ’ W-1984 ( H C 1 s a l t : W-2587) ( X L I ) i s o r a l l y a c t i v e i n h y p e r t e n s i v e r a t s , dogs and monkeys and i t , t o o , i s t h o u g h t t o a c t ~ e n t r a 1 l y . l C~e~r t a i n 2-carbamoyl-4-nitropyridine-N-oxides a r e h y p o t e n s i v e i n r a t s , dogs and humans. The b e s t of t h e s e a p p e a r s t o b e ~
~
1
1
.
~
4
~
@ N b
I
(MekNCH2CO XL
XLI
XLI I
64 -
Sect.
TI
- Phanwcodynamic
Clarke, E d .
Agents
References 1. 2. 3. 4. 5. 6. 7. 8. 9.
10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36.
37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49.
P. DeHaen, New Product Surveya, 13 (1973) P. DeHaen, ibid.. 70 (1973)
J.ArenaandD.C.McLeod,Drug Intell.,Z,459(1973) P. Kincaid-Smith, Arner. J. Cardiol., 32,575 (1973) A. Buckert, E. Schweda andV. Vich., Schweiz. Rdsch. Med. (Praxis), @, 1453 (1973) M.E. Kosrnan,J. Arner. Med.Ass., 225,1380 (1973) “Physician’s Desk Reference”, B.B. Huff, Ed., Medical EconornicsCo., Oradell, N.J. (1974) S.W. Hoobler, Univ. Mich. Med. Cent. J.,38,98 (1972) J.Raftos,G.E. Bauer, R.G. Lewis, GSStokes, A.S. Mitchell,A.A.Youngand I.MacLachlan, Med. J.Aust.,1,786(1973) D.Schwarz, D.Micheland F. Strain,Arch. Psychiat. Nervenkr.,=8,41 (1973) M. C. Igloe, Curr. Ther. Res., Clin. Exp., 15,559 (1973) S.N.Hunyor, L. Hansson,T.S. Harris0nandS.W. Hoobler, Brit. Med. J.2,209(1973) , 605 (1973) i ! L. Hansson, S.N. Hunyor, S. Juliusand S.W. Hoobler, Arner. Heart J., 8 A.P. Niarchos,andA.K. Baksi, Postgrad. Med. J.42,908 (1973) W.J. Mroczek, M. Davidovand F. A. Finnerty, Jr., Clin. Pharmacol. Ther., 14,847 (1973) J.D. Ehrhardt, Therapie&7,947 (1972) T.J. Bucher, R.E. Buckingharn. L. Finchand R.A. Moore, J. Pharrn. Pharmacol.2_5(Suppl.) 139P (1973) C.T. Dolleryand J.L. Reid, Brit. J. Pharmacol.4_7,206(1973) G. Haeusler, Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharrnakol.. 278,231 (1973) J.R. Reid, R.H. Briantand C.T. Dollery, Life Sci. 12,459 (1973) H. Schrnitt, H. Schrnitt and S. Fenard, Arzneirn.-Forsch. 3 , 4 0 (1973) P.A. VanZwieten, J. Pharrn. Pharrnacol.s.89 (1973) F. Kersting, Arzneirn.-Forsch, 23,1657 (1973) T. Baurn, A.T. Shropshire, D. K. Eckfeld, N. Metz, J. L. Dinish, J.R. Peters, F. Butzand M.I. Gluckrnan, Arch. int. Pharrnacodyn. Ther., &4,390 (1973) P. J. Lewis, C. F. Georgeand C.T. Dollery, Europ. J. Clin. Pharrnacol.,G_,211 (1973) P. Bolrne. H. Corrodi and K.Fuxe, Acta pharrnacol. toxicol.,a (Suppl. I)65 (1972) R. K. Saini, A.P. Caputi and E. Marrno, Farrnaco, Ed. Prat., 359 (1973) F.G. McMahon and P.A. Cole, Clin. Pharrnacol. Therap., 14,142 (1973) D.T. Nash, J. Clin. Pharrnacol. 13,416 (1973) L. Hansson, A. Pascualand S. Julius, Clin. Pharrnacol. Therap. 14,204 (1973) C. Russoand M. Medlowitz, Clin. Pharrnacol. Therap. 13,875 (1973) L. Ellenbogen, P. S. Chan and J. R. Curnmings, Federation Proc.a,522Abstr., Abstr. 1739 (1972) C. J. Lirnasand E. D. Freis, Arner. J. Cardiol.3_!,355 (1973) W.A. Pettingerand H. C. Mitchell, New Engl. J. Med.=9,167 (1973); Clin. Pharrnacol. Therap., 14, 143 (1973) C.D.Chidsey,Clin.Sci.Molec.Med.Q(Suppl. I),171s(1973) W. A. Pettinger, W. B. Campbell and K. Keeton, Circulation Res.a,82 (1973): Federation Proc.32. 765Abstr., Abstr. 31 10 (1973) K. O’Malley, M.Velascoand J.L. McNay, Clin. Res.,a, 953 (1973) W. A. Pettingerand K. Keeton, Clin. Res. 21,472 (1973 D.W. DuCharrne.W. A. Freyburger. B.E. Graham and R.G. Carlson, J. Pharmacol. Exp. Therap., 184, 662 (1973) R.G. Pluss, Orcuttand C.A. Chidsey, J. Lab. Clin. Med., 639 (1972) P. Kincaid-Smith, P. Fang and M.C. Laver, Clin. Sci. Molec. Med.45 (Suppl. I)75s (1973) D. DeGuia, M. Mendlowitz, C. Russo, N. D. Vlachakisand S. Antrarn, Curr. Ther. Res. 12,339 (1973) Y. Goto, K. Hagino,and K.Hara. J. Int. Med. Res. 1,71 (1973) A. N. Britovand L. M. Grebeshkova, Kardiologiya 12,46 (1972) G. Berglund, 0.Andersson, L. Hansson and R . Olander, Acta. Med. Scand. 194,513 (1973) L. Hansson,and A.J. Zweifler, Mich. Med. 72,695 (1973) P. D. Nigarn, R. Ravishankar, K. A. Rarnachandren and P.C. Sikand, J. Int. Med. Res. 1,616 (1973) L.Hansson,Acta.Med.Scand.,Suppl.&0,36 (1973) P. Harnet, 0. Kuchel, J.L.Cuche, R. Boucherand J. Genest,Can. Med. Assoc. J. 1099 (1973)
a,
a,
lm,
Chap. 7
Antihypertensive Agents
Francis
65
50. F. R. Buhler, J.H. Laragh, E. D.Vaughan, H. R. Brunner, H.Gavrasand L.Baer,Amer. J.Cardiol.,Z, 511 (1973) 51. E. L. Bravo, R.C.Taraziand H. P. Dustan, J. Lab. Clin. Med. 83,119 (1974) 52. F. O.Simpson, Curr. Ther. 14,91 (1973) 53. C.T. Dollery, P.J. Lewis, M.G. Myersand J.L. Reid, Brit. J. Pharmacol.a,343P (1973) 54. N. Winer. Clin. Res.2,15A (1974) 55. M. D. DayandA.G. Roach, Federation Proc.a,724Abstr.,Abstr.2879(1973) 56. N. Ram and H.L. Garvey, Federation Proc. g,724Abstr., Abstr. 2880 (1973) 57. R.K. Srivastava,V. K. Kulshrestha, N. Singh and K.P. Bhargava, Eur. J. Pharmacol.a,222 (1973) 58. B.L. Bayer, P. Mentzand W. Foerster, Arch. Int. Pharmacodyn. Ther.a0,341 (1972) 59. L. Offerhausand P.A. Van Zwieten, Europ. J. Clin. Invest.,& 258 (1973) 60. M.D. Eslerand P. J. Nestel, Brit. Heart J.%,469 (1973) 61. R.A. Wood,T.M. Forrester, A.W. Johnstonand K.N.V. Palmer,Clin. Trials J. lJ,53 (1973) 62. J.A. Vedin, C.-E. Wilhelmsson and L. Werko, Brit. Heart J. 1285 (1973) 63. G. Berglund and L. Hansson, Acta Med. Scand. 193,547 (1973) 64. J.Castenfors, H. Johnsson and L. Oro, Acta. Med. Scand., 193,189 (1973) 65. C. FarsangandZ. Nagy,Orv. Hetil.,l-, 196 (1973);C.A.B, 143784e(1973) 549 (1973) 66. L. Hansson, H. Aberg, S. Jameson, B. Karlberg and R. Malmcrona, Acta. Med. Scand. 67. B.R.Graham, D.W. Littlejohns, B.N.C. Pritchard, B.Scalesand P. Southorn, Brit. J. Pharmacol.,@, 154 P (1973) 68. S. deMuckadell and F. Gyntelberg,Europ. J. Clin. Pharmacol.,S, 210 (1973) 69. I. Persson and J. Ulrich, Europ. J. Clin. Pharmacol.5,151 (1973) 70. M. Safar. Y. Weiss, A. Sobel, G. Lagrue and P. Milliez, Nouv. Presse Med. 2,2685 (1973) 71. P.E. Van Coller, J. Int. Med. Res. 1,561 (1973) 72. G. Lohmolleand E. D. Frohlich, Europ. J. Clin. Invest.& 251 (1973) 73. J.A. Franciosa, E.D. Freisand J. Conway, Circulationg, 118 (1973) 74. P.A. Poole-Wilson, J. Int. Med. Res. 1,580 (1973) 75. A.Scriabine,M.L.Torchiana, J.M.Stavorski,C.T. Ludden, D.H. MinskerandC.A.Stone,Arch. Int. Pharmacodyn.a5,76 (1973) 76. R.A.Hall, R.D. Robsonand N.N.Share, Proc. Canad. Fed. Biol.Sci.,lL3,113(1970) 77. A.J. Marshall and D.W. Barritt, Brit. J. Clin. Pract.z,337 (1973) 78. J.Tuckman, F. Messerli and J. Hodler, Clin. Sci. Molec. M e d . , g (Suppl I),159s (1973) 79. G. Muiesan, M. Motoleseand A. Colombi, Clin. Sci. Molec. M e d . 9 (Suppl I),163s(1973) 80. W.A. Forrest, Brit. J. Clin. Pract.,z, 331 (1973) 81. R.H. Briant, C.T. Dollery, T. Fenyvesi and C. F. George, Brit. J. Pharmacol. @, 106 (1973) 82. J. Augstein, D.A. Cox, A.L. Ham, P.R. Leeming and M. Snarey, J. Med. Chem 11,1245 (1973) 83. R.E. Goldstein, Circulation 4_2,443 (1973) 84. J. Rosenthal, J. Paddock and W. Hollander, Circulation Res. 32/33,Suppl. I, 1-169 (1973) 85. R. Carrawayand S.E. Leeman, J. Biol. Chem. 6854 (1973) 86. H.S. Cheung and D.W. Cushman, Biochem. Biophys. Acta, 23,451 (1973) 87. H.F. Loyke, J. Lab. Clin. Med. 82,406 (1973) 88. A. Bianchi, D.B. Evans, M. Cobb, M.T. Peschka.T. R. Schaefferand R.J. Laffan, Europ. J. Pharmacol. 23,90 (1973) 89. D.W. Cushman, J. Pluscec, N.J. Williams, E.R. Weaver, E.F.Sabo, 0.Kocy, H.S. Cheungand M.A. Ondetti, ExperientiaD, 1032 (1973) 90. D.T. Palsand F.D. Masucci, Europ. J. Pharmacol. 23,115 (1973) 91. B.G. Zimmerman, J. Pharmacol. Exp. Therap. l-,486 (1973) 92. H.R. Brunner, H. Gavras,J.H. Laragh and R. Keenan, Lancet W/11,1045 93. F.M. Bumpus, S.Sen, R.R. Smeby, C.Sweet, C.M. Ferrarioand M.C. Khosla, Circulation Res.32/33, SUPPI.I, 1-150 (1973) 94. I . Parikhand P. Cuatrecasas, Biochem. Biophys. Res. Commun.,&I, 1356 (1973) 95. E. Haber, K. Poulsen and J. Burton, Clin. Res. 716 (1973) 96. M. Cohen, J. Sztokalo and E. Hinsch, LifeSci. 13,317 (1973) 97. A. Hornych, M. Safar, N. Papanicolaou, P. Meyerand P. Milliez, Ann. Med. interne I.%, 355 (1973) 98. R.B. Williams, K.R. Lamprecht and I.J. Kopin, Psychopharmacologiaa, 269 (1973) 99. I.Cavero,T. Solomon, J.T. Buckleyand B.S. Jandhyala, Res. Commun, Chem. Pathol. Pharmacol. 6. 527 (1973)
s,
m,
w,
a,
_-66
Sect. I1 - Pharmacodynamic Agents
Clarke, Ed.
100. G. Nahas, I.Schwartz, J. Palacekand D.Zagury, C.R.Acad. Sci., Ser. D , m , 6 6 7 (1973) 101.U. B. Zakirov, Kh. U. Alievand I.M. Karnilov, Farrnakol. Toksikol.tj, 708 (1972) 102.H. Chimura, T. Sawa, Y. Kumada, F. Nakamura, M. Matsuzaki,T.Takita, T.Takeuchi and H. Umezawa, J. Antibiot.z, 618 (1973) 103. H. Hidaka,T,Asanoand N.Takernoto, Mol. Pharmacol.,Q,172 (1973) 104. H. Umezawa,T.Takeuchi, K. Miyano,T. KoshigoeandH.Harnano,J.Antibiot.,& 189(1973) 105. Y. Ishii, Y. Fujii,and H. Urnezawa,Jap. J. Pharrnacol.a, Supp1.,53,Abstr. 76 (1973) 106. M. D. Day, A.G. Roach and R.L. Whiting, Europ. J. Pharrnacol., 21,271 (1973) 107. L. Finchand G. Haeusler, Brit. J. PharrnacoI.,a,217 (1973) 108. A. Heiseand G. Kroneberg, Naunyn-Schrniedebergs Arch. Pharrn.279,285 (1973) 109. M.L.Torchiana,V.J. L0tti.C. M. Clarkand C.A.Stone,Arch. Int. Pharrnacodyn.2&5,103(1973) 110. M.J.Antonaccio, R.D. Robson and R. Burrell, Europ. J. Pharrnacol.,a, 9 (1974) lll.T.BaurnandA.T.Shropshire, NeuropharrnacologyQ,49(1973) 112. R. E. Rangno, J. S. Kaufrnan, J. H. Cavanaugh, D. Island, J. T. Watson and J. Oates, J. Clin. Invest., 52,952 (1973) 113.TMaillard, M.Langlois,V.V.Tri, P. Delaunay, R. Morin, M. Benharkate, C. Manuel and F. Motosso. Chim.Ther.8,393 (1973) 114. J. Maillard, M. Langlois, P. Delaunay, T. V. Van, J. Chenu, R. Morin, M. Benhartake, C. Manuel and F. Motosso, J. Med. Chern. 13,1123 (1972) 115. L. I.Wiebe,R.T.CouttsandA.A. Noujaim,Arzneirn.-Forsch.,a,466 (1973) 116. K. Brewster, D.M. Green, R. M. Pinderand P.B.J.Thornpson, Clin. Ther.,& 169 (1973) 117. J.P. Buyniski, R.L. Cavanaugh and M.E. Bierwagen, Res. Cornrnun. Chern. Pathol. Pharmacol.5, 647 (1973) 118.T. Jen, P. Bender, H. Van Hoeven, B. Loev, J. Med. Chern. 16,407 (1973) 119. T. Jen, B. Daniel, F. Dowalo, H. Van Hoeven, P. Bender and 8. Loev, J. Med. Chern. 12,633 (1973) 120. Bristol-Myers Co., Ger. Offen. 2,305,575 (9.22.72) 121. G.V. Kovalev,S.M. Gofrnan,S.V. Ivanovskaya, M.V. Punshina,V.I. Petrov,A.M. Sirnonovand I. N. 88 (1973) Tyurenkov. Farrnakol. Toksikol. 122. D. Deitchrnan, A. W. Gornoll and G. R. McKinney, Federation Proc. =,750Abstr., abstr. 3021 (1973) 123.D.Deitchrnan and A.W. Gornoll, Proc. SOC.Exp. Biol 144,203 (1973) 124. W.L. Matier, D.A. Owens, W.T. Comer, D. Deitchrnan, H. C. Ferguson, R.J. Seideharnel and J.R. Young, J. Med. Chern. 13,901 (1973) 125. M. Laubie, H. Schrnitt, P. Mouille, G. Cheyrnol and J.C. Gilbert, Arch. Intern. Pharrnacodyn. 201,334 (1973) 126.J. Roba, G. Larnbelin and A. F. deschaepdryver, Arch. Inter. Pharrnacodyn. 200,182 (1972) 127. E. Bellasio and F. Cristiani, Ger. Offen 2,220,337 (11.23.72) 128. B. Levy, Brit. J. Pharmaco1.@,514 (1973) 129. E. Baldoli,A.Sardi, V. Dezulian, M. Capelliniand G. Bianchi,Arzneirn.-Forsch.,a, 1591 (1973) 130. A. Sardi, A. M. Caravaggi and E. Baldoli, Naunyn-Schrniedebergs Arch. Pharrnacol. 279,301 (1973) 131.M.Gotz,K.GrozingerandJ.T.Oliver, J.Med.Chern. 13,671 (1973) 132. Schering Corporation, US. 3,641,017 (2.8.72); U S . 3,733,409 (5.15.73) 133. K.Tsururni, H. FujimuraandY. Suzuki,OyoYakuriZ, 175 (1973) 134. E. Bellasio, A. Carnpi, A. Trani, E. Baldoli, A. M. Caravaggi and G . Nathansohn, Farmaco, Ed. Sci., 164 (1973) 135. P.H. Jones, J.H. Biel, C.W. Ours, I.L. Klundt and R. L. Lenga, 165th A.C.S. Metting, Dallas (April) MEDI-9 (1973); F.N. Minard, J.C. Cain and D.S. Grant, ibid., MEDI-10; P. Sornani, R. Hollingerand F.N. Minard, ibid., MEDI-11. 136.J.H. Jones,W.J. Holtz and E.J.Cragoe, J. Med. Chern 16,537 (1973) 137.WanderAG.,Ger.Offen.2,258,318 (10.12.72) 138. L.D. Boyajy, R.E. Manning, R. Mclntosh, F. Schaefer, M. Herzig, J. Schaafand H.H.Trapold, 166th A.C.S. Meeting, Chicago (August), MEDI-22 (1973) 151 (1973) 139. D.M. Bailey,C.G.DeGrazia,H.E. Lape,R. Frering,D. FortandT.Skulan, J. Med.Chern. E, 140.J.F. SchaeferJr., R.R. Loetzer, G. B. Phillips, B. J. Kletzkin and F.M. Berger, Federation Proc. 32,750 Abstr.,abstr. 3020 (1973) 141.J.M.D. Aron-Samueland J.J. Sterne, Ger. Offen. 2,213,843 (10.12.72)
s,
a,
Chapter 8. Antiarrhythmic and Antianginal A g e n t s Gilbert W. Adelstein and Richard R. Dean, Searle Laboratories, Chicago, 111.
ANTIARRHYTHMIC AGENTS Introduction - Cardiac arrhythmias generally result from enhanced automaticity or disturbances in conduction. These disturbances cause alterations in cardiac rate, regularity, origin of cardiac impulse or sequence of activation of the atria and ventricles.1-6 8-Receptor Blocking Agents - Current synthetic efforts in @-blockers has focused mainly on compounds of generic structure 1. By alteration of the ArOCH2CH (OH)CH2NHCH (CH3)2
3,4-dihydro-1(2H)-naphthalenon-5-yl 4-ACNHCgHq4-MeOCH2CH2C6H44-MeOCH2CH20C6H42-CH2=CHCH2C6H48-thiochromanyl 1,2,3,4-tetrahydro-l,4-ethano-5-naphthyl 2-acetyl-7-benzofuranyl 7-indenyl 5-methyl-8-coumarinyl 2,3-Me2CgH34-CgHqCONH2 2,3,4,5-tetrahydro-1H-2-benzazepin-l-on-7-y1 4-indolyl 4-CH2=CHCH2C&-
nature of Ar-, compounds of greater cardioselectivity and lesser cardiac depressant activity have been sought. Schwender and co-workers studied the effects of aromatic substitution7 and carbonyl-containing analogs8 on the 8-blocking properties of bunalol (la) and concluded that no enhancement of cardioselectivity could be obtained. Tolamolol (2) - was the most cardio-
OCH2CH (OH)CH 2NHCH (R) (CH2) no
-2
(R=H, n=1, RV=4-CONH2)
selective member of a series of @-blockers and clinical studies indicated negligible myocardial depression9 Practolol (Ib) was effective in treating supraventricular tachyarrhythmias in patients who could not tolerate
.
-68
Sect. I1
-
Pharmacodynamic Agents
Clarke, Ed.
propranolol because of i t s bronchoconstrictor a c t i v i t y . 1 ° The (-) - isomer of p r a c t o l o l r e t a i n s t h e 6-blocking a c t i v i t y and, u n l i k e p r o r a n o l o l , l i t t l e The a b s o l u t e anti-arrhythmic a c t i v i t y i s r e t a i n e d i n t h e (+) -enantiomer.lf c o n f i g u r a t i o n of ( + ) - p r a c t o l o l w a s determined t o be (R) by t o t a l s y n t h e s i s . 1 2 H 93/26 ( l c ) and H 87/07 ( l a ) were r e p o r t e d t o possess considerable c a r d i o s e l e c t i v i t y and H 87/07 had i n t r i n s i c a c t i v i t y s i m i l a r t o a l p r e n o l o l ( l e ) and p r a c t 0 1 o l . l ~ N o improvement i n anti-arrhythmic a c t i v i t y over prop r a n o l o l w a s seen f o r 5-2395 (lf)14, K-4423 (Lg)15, BFE-60 (1h116, o r YB-2 (li) 17. Greater potency and less c a r d i a c depressant p r o p e r t i e s than prop r a n o l o l were a s c r i b e d t o CS-359 (1j)18 and D-32 (1k).19 N o improvement over p r a c t o l o l could be obtained f o r a r e v e r s e amide (11) o r c y c l i z e d r e v e r s e amide (l m ) .20 A s e r i e s of N-substituted-2-amino-l-(thienyl)ethanols were evaluated a s $-blockers and found t o be less p o t e n t than propranolol a s i n h i b i t o r s of t h e tachycardic response t o i s o p r o t e r e n o l . 21 A s e r i e s of h e t e r o c y c l i c propanolamines had 6-blocking a c t i v i t y , t h e most p o t e n t ( 3 ) having t e n times t h e a c t i v i t y of propranolol on t h e guinea p i g a t r i a l
ArCH2CH (OH) CH2NHC (CH3)3
3 (Ar=6-phenanthridinyl) C l i n i c a l e v a l u a t i o n of b u n i t r o l o l (Koe 1366)23 and t i m o l 0 1 ~shows ~ no c l e a r advantages over propranolol f o r i n c r e a s i n g e x e r c i s e t o l e r a n c e o r t r e a t i n g arrhythmias. I n dogs, p i n d o l o l (LB 46, _In) produced no depression of v e n t r i c u l a r function and increased myocardial performance, while K8 592 depressed myocardial performance and propranolol produced an even g r e a t e r depression i n v e n t r i c u l a r function. 25 Thus , s u b t l e changes i n s t r u c t u r e confer s u b t l e changes i n pharmacological p r o f i l e whose s i g n i f i c a n c e i s n o t r e a d i l y understood. Vaughan-Williams has suggested t h a t p - s u b s t i t u t e d phenyl groups tend t o make a 6-blocker more c a r d i o s e l e c t i v e , s i n c e t h e orthos u b s t i t u t e d isomer of p r a c t o l o l has no c a r d i o s e l e c t i v i t y , whereas 2-oxprenolol The r o l e ( l o ) w a s h i g h l y c a r d i o s e l e c t i v e and more p o t e n t than p r a c t o l o l . 26 o T metabolism i n d e l i n e a t i n g t h e p r o f i l e of a c t i v i t y of a 6-blocking agent i s not c l e a r , b u t evidence f o r s e p a r a t i o n of 6-blocking a c t i v i t y and a n t i arrhythmic a c t i v i t y v i a m e t a b o l i t e s e x i s t s . l 9
-
Quaternary Ammonium Derivatives Quaternization of arnine-containing a n t i arrhythmic agents has sometimes r e s u l t e d i n improved a c t i v i t y with a r e duction i n c e r t a i n s i d e e f f e c t s . UM-272 ( 4 ) , t h e dimethyl d e r i v a t i v e of propranolol , e x h i b i t s n e i t h e r t h e 6-blocking p r o p e r t i e s nor t h e l o c a l a n e s t h e t i c p r o p e r t i e s of propranolol. UM-272 is e f f e c t i v e a g a i n s t d i g i t a l i s and myocardial i n f a r c t i o n arrhythmias i n t h e dog. 27 128 I n a d d i t i o n , UM-272 was shown t o s i g n i f i c a n t l y i n c r e a s e v e n t r i c u l a r f i b r i l l a t i o n threshold29 1 3o and reduce t h e occurrence of v e n t r i c u l a r f i b r i l l a t i o n following a c u t e occlusion of t h e l e f t a n t e r i o r descending coronary a r t e r y and i t s subsequent de-occlusion. Miura and co-workers have found t h a t t h i s compound e x h i b i t s e l e c t r o p h y s i o l o g i c a l e f f e c t s s i m i l a r t o propranolol on i s o l a t e d canine
Chap. 8
Antiarrhythmic, Antianginal Agents
Adelstein, Dean
3
Purkinje fibers and rabbit atria.31 Quaternized lidocaine (methyl lidocaine) exhibited the therapeutic efficacy of lidocaine without the CNS side effects of the latter.32 On the other hand, the dimethyl ammonium quaternary salt of bunalol exhibited only weak anti-arrhythmic activity with pronounced myocardial depression. 33
Bretylium tosylate, a neuronal blocking agent, has generated interest as an anti-fibrillatory agent.34 Counsel1 and co-workers have synthesized a series of bretylium analogs and found that 2-iodobenzyltrimeth lammonium iodide showed high uptake by myocardial tissue. 35 Ring-labeled I3lI bretylium analogs (RIBA) were useful as myocardial scanning agents.36 Miscellaneous Agents - Clinical studies indicate that disopyramide phosphate (?a, R=CONH2, Norpace@) was effective in treating both atrial and ventricular arrhythmia~.37-~0Adelstein found that replacement of the amide by heterocyclic rings (rb, 5c) did not significantly enhance activity.41 Cusic and co-workers found that substitutions on phenyl or pyridyl groups did not improve the therapeutic index of disopyramide.42 Aprindine (6) is a new anti-arrhythmic agent that is 20 times more potent than lidocaine as a local anesthetic. Clinical studies have shown that aprindine is a long-acting, orally effective anti-arrhythmic agent which compares favorably with intravenous lidocaine in preventing ventricular arrhythmias after acute myocardial infarction.43
-5
a) R=CONH2 b) R=5-tetrazolyl c) R=2-methyl-1,3,4-oxadiazol-5-yl
6 -
Diphenidol (1) was recently shown to effectively protect dogs against digitalis into~ication.~~ Its mechanism of action was found to result from a shortening of the atrium-to-His bundle conduction time and a suppression of ventricular automaticity. Studies on a group of patients exhibiting digitalis-induced arrhythmias confirmed the animal data and strongly suggest a clinical role for diphenid01.~~ A similar type of action has been suggested for the steroidal antialdosterone agent, potassium canrenoate.46
DCAA (17,21-di-monochloroacetyl ajmaline) abolished digitalis-induced arrhythmias in the majority of dogs and significantly reduced mortality rate. No adverse effect on myocardial function was 0bserved.~7
Sect. I1
70 -
-
Clarke, Ed.
Pharmacodynamic Agents OH
Verapamil (iproveratril) was shown to be an anti-arrhythmic agent several years ago48 I 49 and Singh and Vaughan-Williams postulated that this drug acts by a unique mechanism of action; namely, blockade of the calciumcarrying depolarizing current.50 Recent studies have confirmed the electrophysiological characteristics and effectiveness of verapamil both in vitro and in ouabain intoxicated dogs. In each case, the effect of verapamil was readily reversed by administration of calcium, thus lending support to Singh and Vaughan-Williams ' hypothesis.51 52 In isolated guinea pig atria, BL-3676 and BL-3677 (isomers of 5-endobenzoyloxy-N- (dimethylaminopropyl)-bicycle (2.2.1) heptane-2 ,3 - e dicarboxylic acid hide HC1) increased stimulus threshold but did not alter the resting membrane potential.53 In dogs, W36095 (2-amino-2',6'-propionoxylidide) was an orally effective, long-acting anti-arrhythmic agent with little depressant effect on the cardiovascular system. 54 CRD-401, the benzothiazepine derivative 2, reversed epinephrine-induced arrhythmias in guinea pigs, but failed to reverse arrhythmias due to twostage coronary ligation.55 LL-1530 (10) , whose structure is reminiscent of propranolol, was not a &blocker and was found to have a better therapeutic index and anti-arrhythmic activity of longer duration than quinidine in dogs56 and was effective clinically with minimal myocardial depressant effects.57 OCH2CH (OH)CH2C (=NOH)NH2'HC1 I
10 -
CH CH NMe2.HC1 2 2 PGF7, is reportedly effective in reversing ouabain-induced arrhythmias in ~ a t s ~ ~ - aanclinical d study verified the therapeutic effects.59 The mechanism of action has not been studied. ANTIANGINAL AGENTS Angina pectoris is the result of a disparity between myocardial oxygen demand and oxygen supply. Factors which determine oxygen demand include heart ratelarterialpressure, preload, ventricular volume and mass, and contractility.60 Oxygen supply is determined by the caliber of the coronary arteries, arterial p02, oxygen carrying capacity of the blood, affinity of hemoglobin for oxygen and viscosity of the blood. 61
Chap. 8
Antiarrhythmic, Antianginal Agents
Adelstein, Dean
2
Current a n t i a n g i n a l therapy i s aimed a t reducing oxygen demand and/or i n c r e a s i n g oxygen supply. The n i t r i t e s and organic i n t r a t e s reduce preload by causing venous pooling of blood. These agents have a l s o been shown t o r e d i s t r i b u t e myocardial blood flow, thereby improving oxygen d e l i v e r y t o ischmic areas even though t o t a l coronary blood flow i s n o t increased. 62163 Nitrates continue t o b e drugs of choice i n a l l e v i a t i n g a n g i n a l pain, b u t c o n t r o v e r s i e s e x i s t as t o the e f f i c a c y of long-acting n i t r a t e s . 6 4 A r e c e n t study i n d i c a t e d t h a t cutaneous absorption of n i t r o g l y c e r i n from an oiniment base may be d i s t i n c t l y s u p e r i o r t o t h a t of s u b l i n g u a l o r o r a l n i t r a t e s i n angina pro phyla xi^,^^ suggesting t h a t t h e search f o r more e f f e c t i v e n i t r a t e s might be b e t t e r served by exploring new r o u t e s of administrat i o n f o r nitroglycerin.
Propranolol reduces oxygen needs through a 6-adrenergic blocking a c t i o n which r e s u l t s i n reduced h e a r t r a t e , blood p r e s s u r e and c o n t r a c t i l i t y . 66 ,67 Propranolol a l s o decreases t h e a f f i n i t y of hemoglobin f o r oxygen a t low oxygen tension.68 This increased P50 r e s u l t s i n a greater r e l e a s e of oxygen i n hypoxic t i s s u e s . A study comparing t h e e f f e c t i v e n e s s of propranolol, oxprenolol, and p r a c t o l o l i n anginal p a t i e n t s suggests similar a n t i a n g i n a l a c t i v i t y f o r a l l t h r e e drugs. 69
The p r e v i o u s l y described dimethyl quaternary analog of p r o p r a n o l o l , UM-272, i s n o t a 6-adrenergic blocker. Like propranolol, UM-272 was r e c e n t l y shown t o reduce t h e ST segment s h i f t s observed i n canine e l e c t r o c a r d i o grams d u r i n g c a r d i a c ischemia. 70 This f i n d i n g i n d i c a t e s t h a t 6-adrenergic blockade per se may n o t be necessary f o r e f f e c t i v e a n t i a n g i n a l a c t i o n . The e f f e c t of UM-272 on t h e hemoglobin-oxygen d i s s o c i a t i o n curve has n o t been studied. L 8040 (ll), an analog of t h e coronary v a s o d i l a t o r amiodarone, w a s shown t o b e e f z c t i v e i n decreasing myocardial oxygen consumption by an adrenergic blocking e f f e c t , b u t n o t by competitive 6-blockade. 71 Cardiac o u t p u t w a s n o t reduced.
Br
Chlorthalidone (Hygroton@), a d i u r e t i c , has an a n t i a n g i n a l e f f e c t u n r e l a t e d t o i t s hypotensive e f f e c t . 72 A double-blind study of perhexilene @exid@) i n angina p a t i e n t s showed improved e x e r c i s e t o l e r a n c e . 7 3
Although t h e s e a r c h f o r b e t t e r a n t i a n g i n a l drugs continues, t h e r e is no consensus of opinion regarding t h e most d e s i r a b l e mechanism of a c t i o n .
72 -
Sect. I1
-
Pharmacodynamic Agents
Clarke, Ed.
The controversy over t h e a c t i o n s of n i t r o g l y c e r i n and propranolol continues and, t h e r e f o r e , t h e r e l a t i v e importance of s e l e c t i v e d i l a t a t i o n of coll a t e r a l coronary a r t e r i e s compared t o reduction i n myocardial oxygen needs p e r s e has n o t been e s t a b l i s h e d . While propranolol appears e f f e c t i v e i n t h e p r o p h y l a c t i c therapy of angina p e c t o r i s , concern has been r a i s e d over t h e apparent "rebound" i n c r e a s e i n anginal a t t a c k s a f t e r c e s s a t i o n of therapy. Therefore, f u r t h e r i n v e s t i g a t i o n i s needed before propranolol i s accepted a s t h e s i n e qua non of a n t i - a n g i n a l drugs.
--
References
1. 2. 3. 4. 5. 6.
7. 8. 9. 10.
11. 12. 13. 14.
15. 16.
17. 18. 19. 20.
21.
s. -.
G. W. Adelstein and R. R. Dean, Ann. 9. , 1972, R. V. Heinzelman, ed., p. 63, Academic Press, New York, 1973. P. F. C r a n e f i e l d , A. L. W i t , and B. F. Hoffman, C i r c u l a t i o n 47, 190 (1973). B. F. Hoffman and P. F. Cranefield, Am. J. Med. 37, 670 (1964). D. H. Singer, R. Lazzara, and B. F. Hoffman, Circ. R e s . 21, 537 (1967). S. Weidmann, J. Physiol. 213 (1955). B. F. Hoffman, P. F. Cranefield, and A. G. Wallace, Mod. Conc. Cardiov. D i s . 35, 103 (1966). C. F. Schwender, R. E. Pike, and J. Shavel, Jr., J. Med. Chem. 2, 254 (1973). C. F. Schwender, R. E. Pike, B. R. Sunday, and J. Shavel, J r . , i b i d , 16, 585 (1973). J. Augstein, D. A. Cos, A. L. Ham, P. R. Lemming, and M. Snarey, 16, 1245 (1973). P. Van Durme, L. Bossaert, P. Vermeire, and R. Rannier, Am. Heart J. 86, 284 (1973). G. J. K e l l i h e r and J. Roberts, Eur, J. Pharmacol. 20, 243 (1972). J. C. Danilewicz and J. E. G. Kemp, J. Med. Chem. 16,168 (1973). B. Ablad, E. Carlsson, and L. Ek, L i f e S c i . I , 107 (1973). M. Lauble, G. Cheymol, P. Mouille, J. C. G i l b e r t , and H. Schmitt, Arch. I n t . Pharmacodyn. Ther. 201, 323 (1973). M. Bergamaschi, V. Mandelli, R. Tommasini, C. Turba, and M. M. Usardi, 667 (1972). Boll. Chim. Farm. Y. Maruyama, T. I s h i h a r a , I. H i r a k i , M. Nozaki, and F. Takenaka, Jap. J. Pharmacol. 23, Suppl. 35 (1973). H. Kato, Y. Noguchi, K. Nakao, and K. Takagi, H ISuppl. 39 (1973). T. Oshima, S. Krimakura, H. Koike, and K. Nakayama, E l497 (1973). A. Izumi, M. Mieda, S. Nishida, and Y. Hiramatsu, Suppl 37 (1973). G. Shtacher, M. Erez, and S. Cohen, J. Med. Chem. 16, 516 (1973). C. C o r r a l , V. Darias, M. P. Fernandez Tome, R. Madronero, and J. d e l 882 (1973). Rio, H I R. F. Meyer, C. D. S t r a t t o n , S. G. Hastings, and R. M. Corey, H I 16, 1113 (1973). W. Klempt and F. Bender, Arzneim.-Forsch. 23, 1064 (1973). J. A. Franciosa, E. D. F r e i s , and J. Conway, C i r c u l a t i o n 48, 118 (1973). R. D. Smith and C. B. Nash, Arch. I n t e r n . Pharmacodyn. Ther. 203, 151 (1973). E. M. Vaughan-Williams, Schweiz. Med. Wochenschr. 262 (1973). F. J. Kniffen, D. P. Schuster, and B. R. Lucchesi, C i r c u l a t i o n , Suppl. 11, 46, 177 (1972).
127,
g,
12,
111,
g,
16,
22.
23. 24. 25. 26. 27.
103,
Chap. 8
Antiarrhythmic, Antianginal Agents
Adelstein, Dean
73
28. D. P. Schuster, B. R. Lucchesi, N. L. Noven, M. N. Mimnaugh, R. E. Counsell, and F. J . Kniffen, J. Pharmacol. Exp. Ther. 213 ( 1 9 7 3 ) . 29. F. J. Kniffen, D. P. Schuster, and B. R. Lucchesi, J. Pharmacol. Exp. Ther. 260 ( 1 9 7 3 ) . 30. F. J. Kniffen and B. R. Lucchesi, Am. J. Cardiol. 142 (1973). 475, 31. D. S. Miura, A. B. Hodess, and M. R. Rosen, Fed. Proc. a b s t r . #1491 (1974). 32. R. A. G i l l i s , F. H. Levine, H. Thibodeaux, A. Raines, and F. G. S t a n d a e r t , C i r c u l a t i o n 47, 697 ( 1 9 73). 33. H. R. Kaplan, J. Barker, D. Dugan, J . Fox, and E. Giardino, Pharmacologist 192 (1973). 34. G. Sanna and R. Arcidiacono, Am. J. Cardiol. 32, 982 (1973). 35. R. E. Counsell, T. Yu, V. V. Ranade, and A. Buswink, J. Med. Chem. 16, 1038 (1973). 36. E. A. C a r r , Jr., R. E . Counsell, and M. C a r r o l l , C l i n . Pharmacol. Ther. 14, 132 (1973 ) . 37. D r e i f u s , Am. J. Cardiol. 1 2 9 (1973). 38. R. B. Kalmansohn and R. W. Kalmansohn, Cardiov. R e s . , V I World Congr. Cardiol. , 179 ( 1 9 7 0 ) . 39. L. Vismara, J. Lies, R. MaSSumi, R. Z e l i s , D. T. Mason, and E. A. Amsterdam, C l i n . Res. 456 (1973). 40. B. B e f e l e r , A. C a s t e l l a n o s , Jr., D. E. Wells, M. C. Vagueiro, B. K. Yeh, and R. J. Myerburg, Am. J. Cardiol. 31, 119 (1973). 41. G. W. Adelstein, J. Med. Chem. 16, 3 0 9 (1973). 42. H. W. Sause, J. W. Cusic, and K . .P Yonan, Abstr. Papers, Am. Chem. SOC. 165 Meet. MEDI 1 2 ( 1 9 7 3 ) . 43. F. Hagemeijer and P. G. Hugenholtz, Am. Cardiol. 33, 142 (1974). 44. W. J. Mandel, H. Hayakama, J. K. Vyden, M. Carvalho, W. W. Parmley, and E. Corday, Am. J. Cardiol. 2, 67 (1972). 45. A. F e l i p e and S. Cecgna, Am. J. Cardiol. 33, 130 (1974). 915 (1972). 46. B. K. Yeh, P-K Sung, and A. K. Saha, CircTRes. 47. M. Dalmastro, T-W Lang, S. Rubins, C. C o s t a n t i n i , and S. Merrbaum, Am. J. Cardiol. 133 (1974). 48. K.. I. M e l v i l l e , H. E. S h i s t e r , and S . Huq, Can. Med. Assoc. J. 90, 76 (1964). 49. C. Hanna and J. R. Schmid, Arch. I n t e r n . Pharmacodyn. Ther. 1 8 5 , 228 (1970). 50. B. N . Singh and E. M. Vaughan-Williams, Cardiovasc. Res. 6, 109 ( 1 9 7 2 ) . 51. R. M. King, D. P. Zipes, A. N i c o l l , and J . Linderman, A m . J . Cardiol. 33, 1 4 8 (1974). 52. R. Rosen, J. P. I l v e n t o , and C. Merker, Am. J. Cardiol. 33, 166 ( 1 9 7 4 ) . 53. M. S. Strauch. R. W. Gardier, and P. B. Hollander, Pharmacoggist 192 (1973). 54. G. Gerstenblith. J. F. Spear, and E. N. Moore, C l i n . R e s . 419 (1973). 55. K. Yamada, T. Shimamura, and H. Nakajima, Jap. J. Pharmacol. 23, 3 2 1 (1973). 56. J. D u t e i l , J. Nadaud, M. Henry, E. ASSOUS, and R. Gompert, Therapie 28, 703 (1973). 57. R. T r i c o t , P. E. Valere, and A. C a s t i l l o Fenoy, 28, 7 2 1 (1973). 3, 895 (1973). 58. W. F o e r s t e r , H. J. Mest, and P. Mentz, Prostaglandins -
184,
187,
31,
33,
15,
-
2,
21,
J.
-
2,
33,
15,
21,
74 59. 60. 61. 62. 63. 64. 65. 66. 67. 68.
Sect. I1
70. 71.
Clarke, Ed.
2,
46,
C.
22,
-
201,
72. 73.
Pharmacodynamic Agents
Mann. H. G. Meyer, and W. F o e r s t e r , H, 905 (1973). K. Friedberg, C i r c u l a t i o n , 1 037 (1972). F. J. Haddy, Am. J. Med. 47, 274 ( 1969). W. M. Fam and M. McGregorTCirc. Res. 649 (1968). M. M. Winbury, B. B. Howe and M. A. Hefner, J. Phannacol. Exp. Ther. 168, 70 (19 6 9 ) . T E . Goldstein and S. E. E p s t e i n , C i r c u l a t i o n 48, 917 (1973). N. Reichek, R. E. Goldstein, M. Nagel, and S. E T E p s t e i n , Am. J. Cardiol. 31, 1 5 3 (1972). S. Aronow, Am. Heart J. 84 ( 1 9 7 2 ). H. Mueller, A. Religa, R. Evans and S. Ayres, Am. J. Cardiol. 33, 1 5 9 (1974). J. D. Schrumpf, D. S. Sheps, S. Wolfson and A. L. Aronson, Am. J. Cardiol. 170 (1974). U. Thadani, B. Shanna, M. K. Meeran, P. A. Majid, W. Whitaker, and S. H. Taylor, B r i t . Med. J., 138 ( 1 973). F. J. Kniffen, T. E. Lomas and B. R. Lucchesi, Fed. Proc. 33, 489 (1974). R. C h a r l i e r , G. Delaunois, and J. Bauthier, Arch. I n t e r n . Pharmacodyn. Ther. 234 ( 1 9 7 3 ) . C. B. Floyd and J. G. Domenet, P r a c t i t i o n e r 210, 559 (1973). C. M. Morgans and J. R. Reas, Am. Heart J. 8 6 , 3 2 9 (1973). D.
33,
69.
-
Chapter 9. Antithrombotic Agents J. Stuart Fleming and John E. MacNintch Bristol Laboratories, Syracuse, New York 13201
The medical problem of thrombosis encompasses three distinct physiological processes, platelet aggregation, coagulation and fibrinolysis. Drugs capable of influencing one or more of these processes are potentially useful from either a prophylactic or a therapeutic standpoint in various clinical situations. This review will attempt to highlight developments during the past year in this very active field of medicinal research. Platelet Aggregation Inhibitors A large number of compounds capable of inhibitin in vitro platelet aggregation (PA) have been reported in recent years.1-2 Some of these compounds, such as aspirin, dipyridamole and sulfinpyrazone were being used clinically for other purposes. Others are new compounds which were either developed particularly for their effect on PA or which possess this potential in association with another pharmacologic activity, e.g. the nonsteroidal anti-inflammatory agents. In either case, the demonstration of in vitro activity cannot be considered sufficient to qualify the compound as an antithrombotic agent. It should also be capable of inhibiting thrombosis in vivo in one or more of the available laboratory models. Many compounds possess potent in vitro activity but fail to be effective in vivo ’ either due to poor absorption, rapid metabolism or the presence of undesirable side effects.
-
-
Aspirin conAspirin and Other Non-Steroidal Anti-Inflatmatory ARentS tinues to receive the greatest attention of the compounds in this category. In 1971, Smith and Willis reported that aspirin interferes with prostaglandin production in human platelets.5 Recently, it has been reported that both aspirin and indomethacin administered to human subjects abolished platelet prostaglandin production as well as the second wave of epinephrine induced PA,6 Furthermore, the duration of the effect on prostaglandin production matched the duration of the effect on PA. It was suggested that the nonsteroidal anti-inflammatory agents exert their antihemostatic or antithrombotic effects through disruption of platelet prostaglandin production. It has also been demonstrated that aspirin and PGEl produce supra-additive effects on PA and experimental thrombosis,7,8 although conflicting evidence exists concerning in vivo potentiation. The implication is that platelet levels of two or more prostaglandins may act to modulate platelet adhesiveness. Additional experimental evidence has also been reported which substantiates the effectiveness of aspirin in preventing arterial thrombosis. The compound was active in a variety of animal models where mechanical, chemical, electrical or laser injury was used to induce arterial thromboais.10-14 In addition, studies in cats have demonstrated aspirin to be effective in reducing the incidence of thrombosis on catheters placed in the inferior venae cavae.15
76 -
Sect. I1 - Pharmacodynamic Agents
Clarke, Ed.
Three new synthetic anti-inflammatory agents have been reported which possess activity against collagen induced PA. Flurbiprofen (1)was effective in vitro in human, rat and rabbit platelet rich plasma (PRP) and in rats and rabbits following in vivo dosing.16 It produced significant inhibition of collagen induced PA in human PRP following a single oral dose of 10 mg/kg and had a duration of action in rats of nearly two days. Flurbiprofen did not affect platelet cyclic AMP levels but was capable of inhibiting platelet release of serotonin. It was effective in several other in vivo animal models which included the protection of mice from lethal thromboembolism resulting from collagen infusion. Sudoxicam (2) was also found to be a potent inhibitor of collagen induced PA both & vitro and in viv0.17 This compound demonstrated activity in humans following oral administration of 50 mg/kg and in animal models of thrombosis. The third agent, ditazol (2)was somewhat less potent in rabbit PRP but was also reported to produce some inhibition of ADP induced PA at high concentrations.18 Bleeding time in mice was prolonged at daily doses of 100 mg/kg P.o., but PA was only slightly inhibited in human PRP after subjects had received the compound for two days at a dose of 800 %/day.
-
Dipyridamole and Related compounds A variety of pyrimidopyrimidines and thienopyrimidines have previously been shown to inhibit the primary phase of ADP induced PA and to demonstrate activity in animal models of thrombosis. In addition, dipyridamole has been shown to normalize enhanced platelet consumption associated with a variety of clinical conditions, and it may be more effective when used in combination with an anticoagulant or another inhibitor of PA such as aspirin.19 There have been several attempts to clarify the mechanism of action of these agents but no clear cut theory has yet evolved.20,21 It would appear that these agents have some degree of phosphodiesterase inhibitory activity and that they are capable of potentiating the inhibitory activity of adenosine on PA. In view of the rather weak activity of dipyridamole, the conflicting reports of its clinical effects and the limiting side effects of more potent analogs, a good candidate for extensive clinical evaluation probably has not yet emerged from this series of compounds.
-
Adenosine Derivatives Adenosine and certain of its derivatives were among the first compounds described which were capable of inhibiting PA. Adenosine is not useful clinically due to its severe cardiovascular side effects and the fact that it is rapidly inactivated in vivo. 2-Chloroadenosine was found to be a powerful inhibitor of PA but was very toxic.22 2-Methylthioadenosine 5'-monophosphate was shown to be less toxic but also was considerably less potent.23 In searching for potentially useful analogs, a series of N6-substituted adenosine8 and N6-substituted adenosine 5 ' -monophosphates have recently been synthesized.24
Chap. 9
Antithrombotic Agents
Fleming, MacNintch
77
Compound 4 is an example of one of mc6H11 the more active members of this series. Studies in rabbits demonstrated that this N+N N p ) agent was also active following an intradN,q ) C6H11SkN N venous infusion of 8 mglkg. Additional 2-thioadenosine compounds were reported which also were effective in v i t r ~ . ~ ~ Compound 2 is an example of one of the HO OH HOOH more active members of this series. However, no in vivo data were reported for these compounds and it is not known if either series possesses activity in animal models of thrombosis.
-4 Hmd -
-
-
It has been reported that high concentrations of Miscellaneous Agents penicillin G are capable of inhibiting ADP, collagen and thrombin induced PA as well as the platelet release reaction in human PRP and in suspensions of washed platelets from rabbits or pigs.26 Clofibrate and related compounds have been used extensively as lipid lowering agents in patients with various forms of hyperlipemia and atherosclerosis. In addition to lowering serum lipid levels, these compounds have been reported to affect all three aspects of the problem of thrombosis being considered in this review. Two recent reports further describe the ability of these compounds to decrease PA in hyperlipemic patients. 27,28 A series of substituted 3,4-pentadienyldiamines was reported to inhibit ADP induced PA both in vitro and in vivo.29 Compound 5 was one of the more potent members of the series and was effective in guinea pigs administered 30 mg/kg p.0. for four days. However, 100 mg/kg for four days was lethal. The lower dose also had a slight effect on ADP induced fall in guinea pig platelet count. A series of N-diethylaminoethylaryloxyacetamides were also reported. Compound L was one of the more active members of the series and inhibited both collagen 72H5 and ADP induced PA in vitro.30 However, this agent did not demonstrate activity in (CH3)2C=C=CHCCH2NH(CH2)3NH2 I rabbits after an intravenous dose of 10 6 C4H9 mg/kg. The compound B-(2-p-chlorophenylthiazole-4yl)acrylic acid (WY-23,049) (8) 000CH2CmcH2cH2NEt2 has been reported to inhibit ADP-induced I thrombocytopenia in rats and to significantly prolong clotting time.31 The comC10-7;N SACH=CHCO2H 8 pound AY-16,804 (9) was found to have & I vitro activity in rat PRP and was nearly equipotent to sulfinpyrazone but markedly 9 less active than PGEl in vivo.32 &(CH2 16C02H
-
. 1
-
-
-
General Considerations The spectrum of potential clinical uses for an effective compound in this area is continuing to broaden. During the past year a number of reports have appeared which tend to substantiate the role of PA in the hyperacute rejection of tissue transplants. It has been known for some time that antigen-antibody complexes are capable of aggre-
78
Sect. I1
-
Pharmacodynamic Agents
Clarke, Ed.
gating blood platelets and that intravascular coagulation has been shown to play a major role during the hyperacute rejection of allografts. Recently Claes has shown that during such a rejection process involving dog kidney, labelled platelets aggregate and are removed as blood perfuses the transplanted organ.33 Furthermore, it was demonstrated that this platelet accumulation in the allograft could be abolished with the use of platelet anti-aggregation substances such as cyproheptadine or dextran and that transplant rejection was postponed in treated animals.34 Similarly, it has been shown that PA plays a role in hyperacute rejection of heterotropic cardiac allografts in presensitized dogs.35 Once again, an anti-aggregation agent, sulfinpyrazone, proved effective in postponing rejection. A novel model for the study of allograft rejection was reported in which the rejection process was followed microscopically in a segment of kidney allgrafted into the ear chamber of a rabbit.36 When a whole kidney was allografted into an animal with an established ear chamber allograft, both grafts rejected simultaneously within seven days. It has been suggested that although platelet participation is dramatic in the case of hyperacute rejection, PA may play a more subtle, though important,role in more chronic forms of rejection. It was found that cyproheptadine added to the therapeutic regimen had a beneficial effect on the post-transplant course of rejection crisis in human renal transplant patients.37 It was also reported that heterologous antithymocytc globulin and antilymphocyte globulin, which are often used as part of the therapeutic regimen in transplant patients, have platelet activating activity in vitro and may have thrombogenic properties when administered in vivo. 3g-Thus, an anti-aggregation agent may be useful in post-transplant therapy in counteracting the thrombogenic properties of these globulins, as well as preventing both antigenantibody-induced hyperacute rejection and more subtle platelet involvement leading to the endothelial thickening associated with chronic forms of reject ion.
A number of rather limited trials have been reported with agents such as aspirin, dipyridamole, sulfinpyrazone and cyproheptadine in a variety of clinical conditions. An example is a rather dramatic effect seen with aspirin and dipyridamole in a case of thrombotic thrombocytopenic purpura.39 Variable results with these agents have also been previously reported in transient cerebral ischemia,40,41 platelet consumption following prosthetic heart valve s u r g e r y , 4 2 ~and ~ ~ postsurgical venous thrombosis.44 Certainly results from clinical studies of a larger scale, such as those currently underway in the United States and Canada, will have to be completed before a valid assessment of the potential clinical utility of these agents can be made.45~46 Anticoagulants Anticoagulant therapy in recent years has involved the use of either heparin or the oral anticoagulants, coumarin and indandione derivatives, on venous thrombosis. The only newer agents with clinical potential appear to be several snake venoms or venom fractions which act either through defibrinogenation or inhibition of prothrombin activation. In view of the growing body of laboratory and clinical evidence
Chap. 9
Antithrombotic Agents
Fleming, MacNintch
2
which implicates platelet aggregation as the initiating event in most forms of arterial thrombosis, the emphasis of anticoagulant therapy is focusing more and more on conditions such as postoperative venous thrombosis and pulmonary embolism. Currently, the use of subcutaneous heparin in low doses is receiving a great deal of attention. Numerous studies and opinions have been published in the past two years regarding this form of therapy. Gallus et al. reported a prospective study of 350 high risk surgical and medical patients.47 The thrombosis rate was lower in those patients treated with the lov-dose heparin regimen, regardless of whether they had elective surgery, emergency hip surgery or were suspected of having myocardial infarction. Overall, the rate of thrombosis in heparin-treated patients was 3.6 X as compared to 21.5 X in the untreated group. While there have been some studies which have not demonstrated a beneficial effect of 8ubcutaneous heparin in low doses, the predominant opinion is that venous thrombosis and pulmonary embolism can be delt with effectively by combining the latast diagnostic techniques such as 1125 fibrinogen scans with the proper use of currently available anticoagulant agents .48 The anticoagulant properties of several snake venoms have previously been reported.4 The venom of Ankistrodon acutus contains a procoagulant principle as well as an anticoagulant fraction, both of which have been purified and studied. It has recently been found that the anticoagulant factor inhibits prothrombin activation by interfering with the interaction between prothrombin and its activation factors.49 Fibrinolytic Agents Potential for the application of fibrinolytic therapy lies in two distinct areas. One area involves the concept of curative therapy directed primarily toward dissolution of thrombi formed in cases of vascular obstruction. The other area i s based on the concept that the endogenous fibrinolytic system of the body is responsible for clearing fibrinous deposits from the circulation as soon as they are formed and this concept involves prophylactic therapy as accomplished by chronic enhancement of the endogenous fibrinolytic activity. Evidence for diminished fibrinolytic activity in patients suffering from diseases which have a thrombotic component has been recently reviewed. 50 With respect to clinical effectiveness, success has been restricted to the curative aspect and has involved the intravenous infusion of direct activators which convert plasminogen to plasmin. 51 The greatest success has been achieved with streptokinase, a potent activator which is believed to exert its effect through activation of both circulating plasminogen and intrinsic thrombus plasminogen by formation of an activator complex with the plasminogen molecule itself. The current literature contains an excellent comprehensive review of the clinical pharmacology, mechanism of acticm and therapeutic uses of streptokinase. 52 Streptokinase, however, has been faulted on three major points: (A) its induction of pyrogenic side effects, (B) it@ induction of a refractory state with respect to fibrinolysis because of the ability of this agent to act as an antigen and (C) its low se-
80
Sect. I1
-
Pharmacodynamic Agents
Clarke, Ed.
lectivity in causing activation of gel phase plasminogen within thrombi in preference to soluble phase plasminogen in the general circulation which New deoften leads to hyperplasminemia and a hemorrhagic state.52 velopments include the synthesis of compounds, notably substituted benzylamines for the purpose of potentiation of urokinase fibrinolytic activity, 53 and the development of a streptokinase-plasminogen mixture (molar ratio 2:l to 1:2) as an activator of the fibrinolytic system which is not affected by natural inhibitors in the blood.54 The principle behind the latter concept is that the plasminogen masks the antigenic groups of streptokinase, consequently the mixture can be injected without risk of reaction even if the patient has antibodies against streptokinase resulting from prior contact with streptococci or prior injection with streptokinase. Clinical 8uccess in clot dissolution without the concomitant problems of pyrogenicity and antibody formation with associated development of resistance and titration problems has been achieved with urokinase. The high cost of urokinase, which is now approximately $ 1000 per patient per day, precludes this agent from becoming the drug of choice. Unless current attempts to reduce the cost of urokinase production are successful, the future for acute fibrinolptic therapy lies in the preparation of a synthetic plasminogen activator. However, because of the enzymatic nature of the conversion of plasminogen to plasmin, development of a low molecular weight direct activator of a nonenzymatic nature is essentially precluded. Although the search for agents which might reduce the level or block the action of natural inhibitors of plasmin or of plasminogen activation continues, as yet no agent with an effective efficacy/toxicity ratio has been found.55 The greatest efforts have been directed towards the search for low molecular weight agents which induce the release of endogenous plasminogen activator. The goal is to obtain a non-toxic, orally effective agent capable of producing either a modest but prolonged increase in the level of circulating plasminogen activator for prophylactic purposes or a strong, relatively prolonged fibrinolytic response of sufficient magnitude to be effective acutely in dissolving preformed thrombi. Since no concrete evidence presently exists that such indirect activation of the endogenous fibrinolytic system is either powerful enough or prolonged enough to dissolve preformed thrombi, the greatest potential for indirect activators of fibrinolysis undoubtedly involves the prophylactic approach to the problem. It has been suggested that a $-type of adrenergic receptor may be wholly56-58 or partially59 involved in the fibrinolytic response to infusion of such agents as epinephrine. However, substantial evidence also exists that this is not the case and thata- and $-blocking drugs do not inhibit the fibrinol tic response to agents such as serotonin, bisobrin to exercise-induced fibrinolytic responses63 or to and epinephrine, fibrinolytic responses induced by venous stasis.64 Fibrinolytic responses induced in humans by oral or parenteral administration of the B-receptor have been reported. 5 8 ~ 6 5 ~ 6 6 agonist salbutamol (lo) This not only suggests the possibility of a new lead for orally OH HOCH2 active non-toxic fibrinolytic agents but also H /cH3 HO~-{-CH2-N-C-a3 may serve to shed some light on the implication \ of $-receptors in the endogenous fibrinolytic H CH3 sequence. Salbutamol, a synthetic saligenin 10
60-6q
-
Chap. 9
Antithrombotic Agents
81
Fleming, MacNintch
analogue of isoprenaline, is a selective $2 receptor stimulant, which acts selectively on smooth muscle of bronchi, uterus and arteries in preference to heart and intestinal muscle. Consequently, salbutamol produced a fibrinolytic response without the problems of tachycardia associated with the administration of $1 receptor stimulants such as epinephrine and isoprenalineS8, 66 and provides evidence that plasminogen activator responses may be $2 receptor mediated.58 However, it has been recently reported in humans treated chronically with orally administered salbutamol (4 mg/kg qid) that a profound depression of the plasminogen activator, factor VIII and pulse rate responses to epinephrine infusion occurred.66 In addition, there was no evidence of significant change in the resting levels of these parameters indicating a lack of prophylactic fibrinolytic potential for prolonged salbutamol administration at this treatment level. Promising results have been reported con. q O C H 3 cerning the induction of fibrinolytic actiJ CH2 -CHz vity in humans and experimental animals by -CH2-CH2 OCH3 11 the bis-tetrahydroisoquinoline EN-1661 bisobrin) (11) and related compounds. 67s 6 These investigat ions have led to the synthesis of other isoquinoline deriv a t i v e ~ ’and-a ~ series of 1,w-diphenyl-l,@-alkane diamines of comparable general activity.71 However, it has been demonstrated that the fibrinolytic activity induced by bis-6,7-dimethoxy isoquinoline derivatives is reduced significantly with prior administration of the antihistaminic promethazine.70 It is postulated that this type of fibrinolytic agent acts by inducing the release of histamine which in turn is able to activate the fibrinolytic system by mediating the release of plasminogen activators localized in the vascular endothelium. 70s72-74 The fibrinolytic activity elicited by dimethaxpisoquinoline derivatives and related compounds appears to be limited in duration and effect and not adequate for an effective thrombolytic action in cases of massive vascular occlusions. 55 m3°J3& CH-0
6
The well known association of anti-inflammatory and fibrinolytic activities continues to be reported as indicated by evidence of comparisons of fibrinolytic activity of flufenamic acid with niflumic acid, mefenamic acid, azapropazone dihydrate and some trifluromethyl analogues of azapropazone in the hanging plasma clot test.75 A number of dlcl-4-isobutyl(cyc1ohexen-1-y1)alkanoic acids and their derivatives, some of which have anti-inflammatory properties, were reported to have fibrinolytic activity in the standard hanging plasma clot teat.76 The most active compound (l2) was reported to decrease fibrin monomer levels after intravenous infusion into rabbits and to decrease the H euglobulin clot-lysis time in rat blood after daily iC4Hg~-Co0H oral administration for prolonged periods with no evidence of tachyphylaxis. Results in this area are 12 CH3 sometimes confounded by the fact that elevated plasma fibrinogen levels observed in the inflammatory state can exert a marked influence on the fibrinolysis values obtained by standard clot-lysis method^^^,^^ and may mask the true fibrinolytic activity. This frequently makes results difficult to interpret as observations of increased fibrinolytic activity may be secondary to decreases in plasma fibrinogen content. It should also be emphasized here that Baillie and Sim79 maintain
-
82
Sect. I1
-
Pharmacodynamic Agents
Clarke, Ed.
that the effects of acidic anti-inflammatory agents (such as those of Von Kaulla) on enzyme systems are accomplished as a result of their combination with substrate protein rather than by the enzyme itself. Consequently, the enzyme activating effect of such compounds in the hanging clot system should be interpreted with caution since the possibility exists that neither plasmin nor plasminogen are directly involved. These authors reported that flufenamic acid and 3-bromo-4-tertiarybutyl benzoic acid were not only highly active in the hanging clot test but also were both potent inhibitors of plasmin. They also found a positive linear correlation between fibrinolytic and antiplasmin activities (rs-0.81, p<.05) using this test
.
The literature contains equivocal results concerning the beneficial effects of prolonged clofibrate treatment of fibrinolysis.80-83 The most recent study involved treatment of elderly arteriosclerotic patients with a combination of two clofibrate derivatives, diisopropylamine p-chlorophenoxyisobutyrate and 2-dimethylaminoethanol p-chloro-phenoxyisobutyrate (GerobrekR) for a period of 30 days. A statistically significant increase in fibrinolytic activity was observed along with a significant reduction of platelet aggregation and a potentiation of the anticoagulant activity produced in patients receiving an indirect anticoagulant.28 Although studies have suggested that clofibrate exerts a protective effect against sudden death and myocardial infarction unrelated to its lipidlowering action,B4 the effect of GerobrekR in elevating fibrinolytic activity is in all probability secondary to hypolipemic effects. It is well documented that in humans, low density of lipoproteins and chylomicrons inhibit the fibrinolysis of plasma euglobulin in vivo.85-87 In the same context, treatment of hyperlipemic patients orally with a combination of nicotinic acid and the synthetic heparin-like polyanion S P 5 4 R has been reported to reduce the hypercoagulable state by increasing fibrinolytic activity, reducing platelet aggregation and reducing both cholesterol and triglyceride levels in the blood over a 9-week period.87 Increased fibrinolytic activity associated with decreased blood lipids in humans was also reported subsequent to oral diethanolamine treatment .a9 Compounds causing enhancement of fibrinolytic activity over extended periods of time by increasing concentrations of circulating plasminogen activator still fall mainly into the group of anabolic steroids such as ethylestrenol and stanozolol and the glucose-lowering agents such as tolbutamide and phenformin. Treatment with orally administered phenformin in conjunction with either ethylestrenol or etanozolol continues to give evidence of prolonged improvement of overall fibrinolytic activity ae evidenced by the results of a nine month study in patients with cutaneous vasculit is having impaired fibrinolytic a~tivity.9~The oral ant idiabetic was reported to drug gliclazide (S1702) (2) H O H induce fibrinolytic activity in dogs and rats after both oral and parenteral administration. c H / 3-10s o 2 - ~ - : - ; - N ~ g1 Infusion of prostaglandin Eg into female 13 patients for the termination of pregnancy was reported to increase plasma antithrombin concentration and increase fibrinolytic activity. 92
-
Chap. 9
Antithrombotic Agents
Fleming, MacNintch
83
Heparin-serotonin complexation to form an entity with anticoagulant activity and lytic activity different from that of plasmin with respect to the fact that it lysed unstabilized fibrin clots in the presence of EACA has been reported.93 Evidence of a protective action of vitamin C in deep vein thrombosis has also been reported.94 A potential area of interest which has as yet had no clinical application is the approach of rendering a thrombus fibrin more susceptible to fibrinolysie, and is treated in a comprehensive review on factor XI11 inhibit ion.95 -.-I_ I t 1 3 I \Ireiic e
s
1. J. Y . S c h o r , Ann. Rrporte in bled. Chem., 1 9 6 9 , C . K. Caln, Ed., Academic P r e s s , New York, N. Y., 1 9 7 0 , p 2 7 7 . 2 . L. J. C Z U b B , Ann. R cport s i n Mcd. Chem., 1 9 7 0 , C . K. Gain, Ed., Academic P r e s s , New York, N. Y . , : 9 7 1 , p. 6 0 . 3 . L. J . Czuba, Ann. Report s i n Med. Chem. 1 9 7 1 , R . V. Heinzetman,Ed., Academic P r e s s , New York, N. Y . , 197.2. p. 70. 4 . R . G . Herrmann and W. 8. L a c e f i e l d . Ann. R eports i n Med. Chem., 1 9 7 2 , It. V Heinzelman, Ed., Asndrmic Prefin, New York, N . Y . , 1 9 7 3 , p. ? 3 . 5 . J. B. S d t h and A . L. Willis, Nature New Dlol., 231, 2 3 5 ( 1 9 7 1 ) . 6 . J. J . Kocais, J . Hernandovich, M. J. S i l v e r , J. R. Smith and C . Ingernun, P r o s t a g t a n d l n s , 3 , 141 ( 1 9 7 7 ) . 7. Rall, G. C. Breveton, M. Fulwood, D. M. I r e l a n d and P. Yatea. Bioc he mJ . , 1 2 0 , 7 0 9 ( 1 9 7 0 ) . 8 . J . S. FLcrnlng, J . 0. Buchanan, S . P. King, R. T. C o r n i s h and M. E. Bierwagen i n " F l a t e l e t s and T1-rombosia", Ed. A. S c r i a b t n e and S. Shorry, Untv. Pa rk P r r r s , I n Pre e n. 9 . M. G . Emsser, Biomedicine, 19, 9 0 ( 1 9 7 3 ) . 10. M. L. Dylcen, R. L. Campbell, J . W l l e r , 11. Peue r, T. Horner, R. King, 0 . Kolar. E. Solow and F. H. .Tnncn, S t r o k a , 5, 387 ( 1 9 7 3 ) . 11. M. G . Bnusser and C. L e r r u b l e r , La Nouv. P r e s s e Med., 23, 1687 ( 1 9 7 3 ) . 1 2 . I . B. Kova'cs, I.. Csal ay and r . C&gg, Microvasc. Rer., 6 , 1 9 4 ( 1 9 7 3 ) . 1 3 . J. P, Mayer, 0 . L. Harmond, Ann. Surg.. E , 108 ( 1 9 1 3 ) ; 1 4 . C , 8. M O ~ C ~ O S K. , L a h i r l . M. Lyons, A. 8. Welsse, II. A. O lde w orte l and T. J . Regan, Am. Heart J . , n-6, 61 ( 1 9 7 3 ) . 1 5 . I . I . K r i c b e f f , ti. B. Zucker, T. B. Tschopp and A. K o t o d j i e z , Diagn. Radiology, 1 0 6 . 4 9 ( 1 9 7 3 ) . 16. E. B. Nlshfzawa, D. J. Wynalda, D. E. Suydam and B. A. Molony, Thromb. Res., 3, 577 ( 1 9 7 3 ) . 1 7 . J . W. C o n s t a n t i n e and I. M. P u r c e l l , J. Pharm. Ex?. The r. , 187, 653 ( 1 9 7 3 ) . 18. L. C a p r ln o , F. B o r r e l l f and R. F a l o h c t t i , Arzneim. F o r e r h . , 23, 1777 ( 1 9 7 3 ) . 1 9 . J . F. Mcstard and M. A. Packharn, Blochem. Pharm., 22, 3151 ( 1 9 7 3 ) . 2 0 . M. C . ltozenherg and C. M. Walker, Brit. J . Haematology, 24, 409 ( 1 9 7 3 ) . 2 1 . P. L. R i f k i n and M. B. Zuckcr, Throinbos. Di at he a . haemorrh., 2,694 ( 1 9 7 3 ) . 2 2 . G. V. I?. Born, A. J. Honour and J. R . A. M i t c h e l l , N a ture , 202, 9 5 ( 1 9 6 4 ) . 2 3 . F. Michal, M. H. Maguire and C. Cough, Nature. 222, 1073 ( 1 9 6 9 ) . 24. K. Kikupawa, K. I i z c k a end M. Ichfno, J . Med. Chem., l6, 358 ( 1 9 7 3 ) . 2 5 . K . Klktiaawcl, I I . S u e h i r o and M. Ichi no. J . Med. Chem., .l6, 1381 ( 1 9 7 3 ) . 2 6 . J. P. Carenclvc, M. A. Packham, M. A. Guccione and J. F. Mts ta rd, Proc. SOC. Exp. B t o l . Med., 1 4 2 , l5Y ( 1 9 7 3 ) 2 7 . A . C a r v ~ I I i o , R. V a i l l a n c o u r t , R. C a b r a l , R . W. Colman and R. S. Lees, C i r c u l a t i o n , 48, I V - 1 5 (1973). 2 8 . T. L. S p r r a f l c o , G. F r n n d o l i and G. Turazza, Arznetm. Pors c h. , 23. 2 3 6 ( 1 9 7 3 ) . 2 9 . K. D . HacKrnzie, T. R . Dlohm and J. M. C r i s a r , J . Med. (:hem., 688 (1973). IT.. Farmaso. 28. 511 ( 1 9 7 3 ) . 3 0 . F. Dc.'di-chi, $. F , T amgnure and F. Dorato. 7 1 . I). L. renirtirl and 11. K. Alburn, C t r c u l a t L o n , 48, I V - 1 5 2 ( 1 9 7 3 ) . 3 ? . C . R. Yuirhead. T'lrOmbOR. D i n t h e s . h a e n o r r h . , 30, 138 ( 1 9 7 3 ) . 3 3 . G . C l a r s . Acta C h t r . Scan:l., 139, 1 7 3 ( 1 9 7 3 ) . 3 h . G . C l n e s . Bcla C h l r . Scaiid.. 127 ( 1 9 7 3 ) . 3 5 . H. M. Sharma, J. Rocerrsweig, S. C h a t t e r f e e , S. Moore and M. I..dechamplatn, Am. J. P a th o l o g y , 125 (1Y73). 3 6 . J. B. Hobha and W . J. C l t f f , J . Exp. Med., 137, 7 7 6 ( 1 9 7 3 ) . 3 7 . L. Burrows, M. Ilaimov. L. A l e d o r t , E. L e i t e r , C. Nirmul, H. Shanzur, R. Taub and S . Cla bman, T r a n s p l a n t a t i o n P roc., 157 ( 1 9 7 3 ) . 3 8 . J . Thnnns, P. Thoman, R. M u r c r . J . Caul and D. M. Hum. Organ T r a n s p l a n t a t i o n , l3, 288 (1972). 3 9 . J. Amir and S. Krousn, B1ood. 42. 27 ( 1 9 7 3 ) .
.
c.
-
2,
I?,
84 -
Sect. I1
- Pharmacodynamic Agents
Clarke, Ed.
SO. G. Evans, Can, Med. Assoc. J., E, 463 (1973). 4 1 . B. Boneu, B. Guiraud and D. Fernet, Nouv. Presse. 863 (1972). 4 2 . H. S. Weily and E. Genton, Circulation, 42, 967 (1970).
L
43. L. A. Harker and S. J. Slichter. New Eng. J. Hed., 283, 1302 (1970). 4 4 . J. R. O'Brien, V. Tulevski and M. Etherington, lancet, L, 399 (1971). 45. Drug Research Reports, 2,1 (1972). 4 6 . H . J. M. Barnett, Can. Med. Assoc. J., 138, 462 (1973). 4 7 . A. S. Gallus. J. Hirsh, R. J. Tuttle, R. Trebilcock, S. E. O'Brien, J. J. Carroll, J. H. Minden and S. M. Hudecki, New Eng. J. Md., 285. 545 (1973). 48. J. J. Skillman, Surgery, 75, 114 (1974). 49. C. Ouyang and C. M. Teng, Toxicon.. 2,287 (1973). 50. c. M. R. Prentice and J. F. Davidson. Clinics in Haematology, 2. 159 (1973). 5 1 . G. P. McNicol and J. A. Davies, Clinfcs in Haematology, 2, 23 (1973). 52. R. N . Brogen, T. M. Speight and G. S. Avery. Drugs, 2, 3 5 (1973). 53. R. P. Johnson and J. Harold Short, Abbott, U. S. Patent 3726969-5, 10 April 1973; D e w a n t 23852U-B. 54. A. Hemburger. H. Ronneberger and M. Schick, Behringwerke, German Patent DT-214886)-Q, 5. April 1973; D e m e n t 21388U-B. 55. M. verstraete, Drugs, 5, 353 (1973). 56. H. Yarnazaki, T. Sand. T. Odakura, K. Takeuchi, T. Nasmura. S. Hosaki and T. Shimamto, Thromb. Diach. haemorrh. 26, 251 (1971). 57. J. G. Kral, B. Ablad, G. Johnason and KOrSPn-BengtSen, Eur.J. Clin.Pharrrmcol., 3 1 4 4 (1971). 5 8 . A . M. A. Gader, A. R. Clarkson and J. D. Cash, Thromb. Res., 2, 9 (1973). 59. J. D. Cash, D. G. Wooafield and A. G. E. Allan, Brit. J. Haematol., l8, 487 (1970). 60. 0. Ponari, A. Giannini. M. Squeri and A. G. Dettori, Coagulation, 2, 249 (1970). 61. Y . Sasaki and S. Takeyam, Jap. J. Pharmacol., 22 (Suppl.), 120 (1972). 375 (1964). 62. A. R. Transer and H. Smellie, Clin. Sci., 63. R. J. Cohen, S. E. Epstein, L. S. Cohen and L. H. Dennis. Lancet, 2, 1264 (1968). 6&. 0. Ponari. E. Civardi, A. Elegha, M. P h i , R. Pot1 and A. G. Dettori, Brit. J. Ilaem., 463 (1973). 65. J. D. Cash and A. Gader, 111. Congrerr on Thrombosis and Haemostasis, Warhington, D. C., 1972, Abstr. p. 280. 66. A. M. A. Gader, S. Parker, G. K. Crompton and J. D. Cash, Thrombosis Res., 2, 137 (1973). 67. L. J. Flieaner, Jr.. J. M. Schor. M. J. Myers and I. J. Pachter, J. Med.Chem., &,580(1971). 68. Chemical Control of Fibrinolysis Thrombolysis, ed.by J. M. Schor, Wiley-Interscience, New York, N . Y., 1970. 5 9 . P. Rajagopalan, 164th National ALS Meeting, New York. N. Y., 1972. 70. P. Markwardt, H. P. Kliicking, J. H. Hauptwnn and G. Paust, Thrombosis Res., 2, 383 (1973). 71. L. J. Fliedner, Jr., M. J. Myers, J. M. Schor and I. J. Pachter, J.Med.Chem.. 16,749 (1973). 72. M. H. Cho and W. Choy. Thrombos. Diathes. haemorrh. (Stuttg.), II, 372 (1964). 73. R. Holemans and R. D. Langdell, Proc. SOC. Exp. Biol. (N.Y.), 115, 584 (1964). 7 4 . R. Holemans, American J. Physiol., 208, 511 (1965). 75. J. T. Wagner, U. Jahn and W. Buerlimann, Arzneim. Porsch., 911 (1973). 76. M. Vincent, C. Remond, P. Desnoyers and J. Labaume, J. Med. Chem., l6, 710 (1973). 77. J. A. Hickman, Brit. J. Haem., 20. 611 (1971). 78. J. A. Hickman, I. C. Gordon-Smith, P. F. Whitfield and S. J. Godfrey, J. Clin. Path., 189 (1973). 351 (1972). 79. A. J. Baillie and A. K. Sim, Thrombos. Diath. haemorrh. (Stuttg.), 80. S. C. Srivastava, M. J. Smith and H. A. Dewar, J. Atheroscler. Res., 3, 640 (1963). 81. E. H. Jepson and D. C. 0. J6ae6, J. Atheroscler. Res., 3, 554 (1963). 62. A. Gibelli, G. Frandoli. P. Giarola and P. Denicola, Hemostase, 285 (1966). 83. R. C. Cotton and E. G. Wade, Lancet, 1, 263 (1969). 8 4 . i. R. Kransno and G. J. Kidera, J. Amer. Hed. Assoc., 219, 845 (1972). E 5 . S. F. Chopin and E. L. Beard, Thrombosis Diath. naemorrh. (Stuttg.), 29. 286 (1973). b6. J. fidsiatwicz. 2. Skrzydlevski and M. Bielecki. Lxperentia, 274 (1967). 87. 2 . Skrzvdlweski, S. Niewiarwski and J. Skrzydlewska, Atherosclerosis Res., 5 273 (1966). @a. G. Turazza,,P. L. Spreafico and G. Frandoli, Arz. Porsch., 23, 654 (1973). 89. D. C. itoehm, Clin. Res., 240 (1973). 40. 8 . Dodman, W. J. Cuncliffe, B. E. Roberts and R. Sibbald, Brit. Mea. J., II, 82 (1973). 31. P. Desnoyers, J. Labaume, H. Anstett, M. Herrera, J. Pesquet and J. Sebastien, A r m . Forscn.. 22, 1691 (1972). 92. P. K . H w i e , A. A. Calder, C. D. Forbes and C. M. R. Prentice, J.Clin.Path., 2 3 3 5 4 (1973). 93. B. A. Kudrjashov, T. M. Kalishevskayo and L. A. Lyaprna, Vopr. 3ed. Khirn., l9, 269 (1973). 44. C. R. Spittle and U. K. Wakefield, Lancet, & 199 (1973). 95. The BioloRical Role of the Clot Stabilizing Enzymes: Transglutamase and Factor XIII, K. Laki, Ed., AM. New York Acad. Sci., 202. 1-348 (1972).
a,
a
-
a
a,
a
z.
Chapter 10:
Pulmonary and A n t i a l l e r g y Drugs
Ralph E. Giles and David J. Herzig Warner-Lambert Research I n s t i t u t e , Morris P l a i n s , N . J. This review covers p a p e r s p u b l i s h e d i n t h e p e r i o d 1971-1973 w i t h a few o l d e r c i t a t i o n s when t h e y were needed f o r t h e a p p r o p r i a t e d i s c u s s i o n of a concept. The main emphasis of t h e review is t h e p r e s e n t o r p o t e n t i a l therapy of asthma o r r e v e r s i b l e airways d i s e a s e . A s e c t i o n i s devoted t o emphysema, an " i r r e v e r s i b l e " airways d i s o r d e r . Asthma i s a t y p e of r e v e r s i b l e , o b s t r u c t i v e pulmonary d i s e a s e due t o widespread narrowing of t h e b r o n c h i a l airways and edema of t h e b r o n c h i a l mucosa, caused by s p e c i f i c a l l e r g i c and/or n o n s p e c i f i c i r r i t a t i v e s t i m u l i ls2. A s p e c i f i c immunoglobulin, IgE, i s produced i n t h e a t o p i c o r allerg i c i n d i v i d u a l , i n response t o t h e a p p r o p r i a t e exposure t o a n t i g e n s . An important predisposing f a c t o r t o the asthmatic a t t a c k is t h e acute sensit i v i t y of t h e b r o n c h i a l tree t o pharmacologic a g e n t s , i r r i t a n t s and spec i f i c allergens. Therapy of r e v e r s i b l e airways d i s e a s e i n c l u d e s symptomatic r e l i e f of t h e a t t a c k , c o n t r o l of s p e c i f i c c a u s a t i v e f a c t o r s as w e l l as g e n e r a l i z e d care of t h e p a t i e n t . Drugs are employed t o relax and d i l a t e b r o n c h i o l e s (beta-sympathomimetics and p h o s p h o d i e s t e r a s e [PDE] i n h i b i t o r s ) , reduce i n flammation ( s t e r o i d s ) , l i q u e f y mucus ( a c e t y l c y s t e i n e ) , d e c r e a s e mucous membrane c o n g e s t i o n (alpha-sympathomimetics) and p r e v e n t mediator release (cromolyn sodium). I n i t i a l c l i n i c a l s t u d i e s of a n t i c h o l i n e r g i c s i n a s t h matics and b r o n c h i t i c s are under way.3-5 Beta Adrenoceptor Agonists - Beta a d r e n o c e p t o r s have been d i v i d e d i n t o s u b c l a s s e s based on t h e r e l a t i v e a c t i v i t i e s of v a r i o u s sympathomimetic m i n e s on d i f f e r e n t t a r g e t t i s s u e s . 6 For example, beta-1 r e c e p t o r s a r e found i n t h e h e a r t and beta-2 r e c e p t o r s are found i n b r o n c h i o l a r and o t h e r smooth muscle. The p o t e n t beta adrenoceptor s t i m u l a n t i s o p r o t e r e n o l , a common agent f o r t h e t r e a t m e n t of asthma, i s n o n s e l e c t i v e and may cause u n d e s i r a b l e c a r d i a c s t i m u l a t i o n a t doses which r e l a x b r o n c h i o l a r smooth muscle. Besides d i r e c t e f f e c t s on b r o n c h i a l smooth muscle, t h e s e compounds i n h i b i t mediator release from s k i n 7 o r p a s s i v e l y s e n s i t i z e d human lung' and a l s o i n h i b i t a n t i g e n - s t i m u l a t e d h i s t a m i n e s y n t h e s i s i n human leucocytes.
Chemical m o d i f i c a t i o n s of t h e catecholamine s t r u c t u r e by a ) r e p l a c e ment of t h e 3-hydroxyl group, b ) replacement of t h e 3,h-dihydroxy configu r a t i o n by a 3,5-dihydroxy c o n f i g u r a t i o n , c ) attachment of a l a r g e r subs t i t u e n t on t h e a l k y l n i t r o g e n and d) a l t e r a t i o n of t h e ethanolamine s i d e c h a i n have y i e l d e d compounds w i t h g r e a t e r b r o n c h o s e l e c t i v i t y , i o n g e r d u r a t i o n of a c t i o n and g r e a t e r o r a l a c t i v i t y t h a n i s o p r o t e r e n o l . D i f f e r ences i n d u r a t i o n of a c t i v i t y and o r a l potency a r e probably r e l a t e d t o a l t e r a t i o n s of t h e 3,4-dihydroxy c o n f i g u r a t i o n ; l a c k of t h e 3,4-dihydroxy c o n f i g u r a t i o n p r e c l u d e s metabolism by catechol-0-methyl t r a n s f e r a s e (COMT)
86 -
S e c t . II
-
Pharmacodynamic Agents
C l a r k e , Ed.
and a p p e a r s t o i n t e r f e r e w i t h s u l p h a t e c o n j u g a t i o n i n t h e major m e t a b o l i c pathways f o r i s o p r o t e r e n o l .
9
both
Compounds r e p o r t e d t o b e more s e l e c t i v e and l o n g e r a c t i n t h a n i s o proterenol include s a l b u t a m o l ~ ' - ' k e r b u t a l i n e , l5-I6 Th 1165a, K7-1 salmefahexoprenaline,21 trimeto s o t e r e n 0 1 , ~r~i m i t e r o l , 2 6 c a r b u t e r o l , 27-29 and p y r b u t e r o l . 39 I s o e t h a r i n e , a l s o more b r o n c h o s e l e c t i v e than i s o p r o t e r e n o l , h a s been t e s t e d u s i n g a s u s t a i n e d release system t o p r o l o n g d u r a t i o n . 31 The b r o n c h o d i l a t o r a c t i v i t y of a group of monofluorom e t h a n e s u l f o n a n i l i d e s was r e c e n t l y r e p o r t e d ; 32 u n f o r t u n a t e l y t h e b e s t a g e n t i n t h i s series caused i r r e v e r s i b l e e y e changes i n c a n i n e s .
R i m it e r o 1
H
A common c l i n i c a l problem of t h e o r a l o r p a r e n t e r a l r o u t e of adminis t r a t i o n of t h e newer b e t a - s t i m u l a n t s , such as s a l b u t a m o l and t e r b u t a l i n e , adrenoce t o r s of t h e i s d i g i t a l tremor.16,3?his e f f e c t i s mediated beta-2 s u b c l a s s . I n c i d e n c e of tremor may b e as h i g h as 40%. No subs t a n t i a l s e p a r a t i o n between b r o n c h o d i l a t o r and tremorogenic a c t i v i t y h a s been r e p o r t e d . 3 3 A d e c r e a s e i n t h e t e n s i o n and d e g r e e of f u s i o n of incomp l e t e t e t a n i c c o n t r a c t i o n s of t h e slow c o n t r a c t i n g s o l e u s muscle of t h e c a t i s used as a l a b o r a t o r y model p r e d i c t i v e of tremor i n man.35
"
Use of p r e s s u r i z e d a e r o s o l s c o n t a i n i n g beta a d r e n o c e p t o r a g o n i s t s was i m p l i c a t e d i n i n c r e a s e d d e a t h s among a s t h m a t i c s i n England. 36 However, S t o l l e y r e c e n t l y showed a s t r o n g c o r r e l a t i o n between c o u n t r i e s having an e l e v a t e d d e a t h r a t e i n a s t h m a t i c s and c o u n t r i e s marketing a s t r o n g prepar a t i o n of i s o p r o t e r e n o l . 37 However, i n t h e U.S. , where t h e s t r o n g prepar a t i o n w a s n o t marketed, t h e d e a t h r a t e from asthma d e c r e a s e d d u r i n g t h e y e a r s 1958-1969 w h i l e t h e number of p r e s s u r i z e d a e r o s o l s s o l d i n c r e a s e d 60% between 1964 and 1968.38
Chap. 1 0
Pulmonary, A n t i a l l e r g y Drugs
G i l e s , Herzig
87
P r o s t a g l a n d i n s - P r o s t a g l a n d i n s are found i n n e a r l y a l l t i s s u e s ; PGE2 i s t h e dominant p r o s t a g l a n d i n i n b r o n c h i a l t i s s u e , w h i l e PGF2, p r e d o m i n a t e s i n l u n g parenchymal t i s s u e . 39-40 However, p r o s t a g l a n d i n s are n o t s t o r e d as s u c h i n t i s s u e . A l a r g e number of s t i m u l i can t r i g g e r p h o s p h o l i ase A which c l e a v e s a r a c h i d o n i c a c i d from c e l l membrane p h o s p h o l i p i d s . 41-e2 A r a c h i d o n i c a c i d i s r a p i d l y c o n v e r t e d t o p r o s t a g l a n d i n s by t h e enzyme p r o s t a g l a n d i n s y n t h e t a s e . Thus measurement of t i s s u e l e v e l s of p r o s t a g l a n d i n s may b e i n d i c a t i v e of s y n t h e t i c a b i l i t y a t t h e t i m e of measurement r a t h e r than b a s a l t i s s u e values. A e r o s o l a d m i n i s t r a t i o n o f PGEl o r PGE2 p r o d u c e s b r o n c h o d i l a t a t i o n i n a n i m a l s 4 3 and man44 w i t h minimal c a r d i o v a s c u l a r s i d e e f f e c t s . 45-46 BY t h i s r o u t e PGEl o r PGE2 w a s 1 0 t i m e s more p o t e n t on a w e i g h t b a s i s t h a n i s o p r o t e r e n o l , b u t had a s l o w e r o n s e t of a c t i o n ; 4 7 d u r a t i o n o f a c t i v i t y w a s i n t h e r a n g e of i s o p r o t e r e n o l and t h e r e f o r e c o n s i d e r a b l y less t h a n t h e l o n g a c t i n g b e t a - 2 s t i m u l a n t s . A l i m i t i n g s i d e - e f f e c t of t h e a e r o s o l a d m i n i s t r a t i o n of PGEl o r PGE2 i s l a r y n g e a l i r r i t a t i o n and coughing. 46 Furthermore, some a s t h m a t i c s have developed an a t t a c k of asthma a f t e r i n h a l a t i o n o f PGE1, p o s s i b l y due t o i r r i t a n t e f f e c t s i n t h e a b s e n c e of a b r o n c h o d i l a t o r r e s p o n s e . 48 While PGEl h a s been r e p o r t e d t o i n c r e a s e CAMP l e v e l s i n i s o l a t e d l u n g t i s s u e , f u r t h e r mechanism s t u d i e s are i n o r d e r . 4 9 P G F ~ Bc a u s e d b r o n c h o d i l a t a t i o n i n t h e c a t and g u i n e a p i g . 5 o PGF2, produced b r o n c h o c o n s t r i c t i o n i n man. 51 Human a s t h m a t i c s were 8000 t i m e s more s e n s i t i v e t o t h e b r o n c h o c o n s t r i c t o r e f f e c t s of PGF2, t h a n were normals and o n l y 10 times more s e n s i t i v e t o h i s t a m i n e - i n d u c e d bronchospasm.52 I t h a s been s u g g e s t e d t h a t t h e endogenous PGF/PGE r a t i o may b e c r i t i c a l i n a s t h m a t i c s , b u t t h i s awaits d e f i n i t i o n . 5 3 C e r t a i n a n a l g e s i c , a n t i i n f l a m m a t o r y d r u g s such as a s p i r i n , indomethac i n , f l u f e n a m i c a c i d and mefenamic a c i d i n h i b i t p r o s t a g l a n d i n s y n t h e s i s . 54 A s p i r i n and t h e fenamates a l s o a n t a g o n i z e d t h e d i r e c t c o n s t r i c t o r e f f e c t s of PGF2a, b u t n o t t h e r e l a x a n t e f f e c t s of P G E z , ~on ~ i s o l a t e d human bronc h i a l t i s s u e . 5 4 Indomethacin and a s p i r i n reduced t h e b a s a l t o n e of i s o l a t e d t r a c h e a , d e c r e a s e d t h e e f f e c t of s m a l l d o s e s and i n c r e a s e d t h e e f f e c t of l a r g e d o s e s of h i s t a m i n e o r a ~ e t y l c h o l i n e . ~These ~ latter s t u d i e s suggest a modulating i n f l u e n c e f o r t h e p r o s tag lan d in s i n t r a c h e a l smooth muscle. High m o l e c u l a r w e i g h t a n i o n i c p o l y e s t e r s of p h o s p h o r i c a c i d and p h l o r e t i n , c a l l e d p o l y p h l o r e t i n p h o s p h a t e (PPP) have a n t a g o n i z e d t h e c o n s t r i c t o r e f f e c t s of PGF2, on human b r o n c h i . Yet n e i t h e r t h e d i l a t o r r e s p o n s e t o P G E z ~n o~ r t h e c o n s t r i c t o r r e s p o n s e t o c a r b a c h 0 1 ~were ~ a l t e r e d , s u g g e s t i n g s e l e c t i v e antagonism. PPP a l s o i n The d i f f e r e n t h i b i t s a l k a l i n e p h o s p h a t a s e , h y a l u r o n i d a s e and u r e a s e . m o l e c u l a r w e i g h t c o n s t i t u e n t s of t h e m i x t u r e of PPP polymers have been s e p a r a t e d t o y i e l d t h e P G - i n h i b i t o r y component i n t h e low m o l e c u l a r w e i g h t f r a c t i o n s and t h e enzyme i n h i b i t o r y a c t i v i t y i n t h e h i g h molecul a r w e i g h t f r a c t i o n s . 59 Asthmatics have f a i l e d t o show an improvement i n airway r e s i s t a n c e a f t e r 5 mg d o s e s of PPP were i n h a l e d . 1 8
88
S e c t . I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
P r o s t a g l a n d i n s i n h i b i t e d immunologic release of h i s t a m i n e from human l e u c o c y t e s 0 and human l u n g f r a g m e n t s ; 6 1 t h i s i n h i b i t i o n w a s a s s o c i a t e d w i t h i n c r e a s e d CAMP levels. PDE I n h i b i t o r s - CAMP i s r a p i d l y metabolized by a PDE which h y d r o l y t i c a l l y c l e a v e s t h e 3'phosphate bond t o y i e l d a 5 ' phosphate e s t e r of adeno s i n e (AMP). A similar r e a c t i o n o c c u r s f o r cGMP. CAMP r e l a x e s smooth muscle such as i s o l a t e d t r a c h e a . 6 2 The d e m o n s t r a t i o n of a Ca4-dependent i n c r e a s e i n cGMP i n smooth muscle i n response t o c h o l i n e r g i c a g e n t s , h i g h K+ c o n c e n t r a t i o n s , and h i s t a m i n e s u g g e s t s a r o l e of t h i s n u c l e o t i d e i n smooth muscle c o n t r o l . 6 3 However, d i b u t y r l cGMP and 8-bromo-cGMP r e l a x e d t r a c h e a l smooth muscle. 64 A b i p h a s i c c o n t r a c t i o n and r e l a x a t i o n have a l s o been r e p o r t e d .
Theophylline and o t h e r m e t h y l x a n t h i n e s are PDE i n h i b i t o r s and are f r e q u e n t l y used t o t r e a t asthma. I n a comparative s t u d y u s i n g f r o g eryt h r o c y t e c y c l i c n u c l e o t i d e PDE, t h e o p h y l l i n e ( 4 ~ 1 0 - ~ Mwas ) a potent inh i b i t o r of t h e h y d r o l y s i s of CAMP b u t w a s a much less e f f e c t i v e i n h i b i t o r of t h e h y d r o l y s i s of c G M F ' . ~ ~ Compounds c a p a b l e of i n h i b i t i n g PDE' s from v a r i o u s s o u r c e s have been t e s t e d f o r b r o n c h o d i l a t o r e f f i c a c y . A t r i a z o l o p y r a z i n e ( I C I 58,301) and a t r i a z o l o p y r i m i d i n e (ICI 63,197) p r o t e c t e d g u i n e a p i g s from t h e l e t h a l e f f e c t s of h i s t a m i n e ( r e s p e c t i v e ED50 v a l u e s were 0 . 5 and 0.05 mg/kg).67 Propranolol did not block the antibronchoconstrictor e f f e c t s i n v i t r o but d i d i n v i v o . The a p p a r e n t blockade i n v i v o could be due t o antagonism of r e f l e x l y - r e l e a s e d catecholamines which c o n t r i b u t e t o t h e p r o t e c t i v e response.
S t u d i e s u t i l i z i n g r a t e r y t h r o c y t e PDE l e d t o t h e d i s c o v e r y of 4(3butoxy-4-methoxybenzyl)-2-imidazolidinone (RO 20-1724; IBM).6 8 T h i s a g e n t w a s 5000 t i m e s more p o t e n t than t h e o p h y l l i n e i n t h e e r y t h r o c y t e p r e p a r a w a s about 400 times more p o t e n t t h a n t i o n , w i t h an 150 of 0 . 1 pM. IBM t h e o p h y l l i n e i n r e l a x i n g t h e i s o l a t e d guinea p i g t r a c h e a and i t s e f f e c t S i m i l a r r e s u l t s were n o t e d u s i n g i s o l a t e d w a s n o t blocked by p r o p r a n o l o l . w a s a v e r y poor PDE i n human t r a c h e a and b r o n c h i . I n t e r e s t i n g l y , IBM h i b i t o r i n dog t r a c h e a l smooth muscle o r i n whole guinea p i g t r a c h e a . Thus i t s mechanism o f t r a c h e a l r e l a x a t i o n cannot be e x p l a i n e d i n terms of
Chap. 10
Pulmonary, A n t i a l l e r g y Drugs
Giles, Herzig
89
PDE i n h i b i t i o n . The p u r i n e compound i n o s i n e h a s a l s o been r e p o r t e d t o i n h i b i t PDE and i n h i b i t b r o n c h o s p a s t i c r e s p o n s e s i n guinea p i g s . 6 9
A n t i c h o l i n e r g i c s - I n b o t h animals and man, s t i m u l a t i o n of e p i t h a l i a l i r r i t a n t r e c e p t o r s i n t h e airways by a n t i g e n i c and n o n a n t i g e n i c y h y s i c a l o r pharmacological a g e n t s r e s u l t e d i n r e f l e x b r o n c h o c o n s t r i c t i o n . This b r o n c h o c o n s t r i c t i o n could be blocked by a t r o p i n e i n humans71 and by a t r o p i n e o r vagotomy i n a n i m a l s , 72 i n d i c a t i n g a p a r a s y m p a t h e t i c m e d i a t i o n . Vagal blockade reduced t h e i n c r e a s e i n pulmonary r e s i s t a n c e caused by h i s t a m i n e ( i n j e c t e d i n t o t h e pulmonary c i r c u l a t i o n ) from 800% t o 100%.7 3 B r o n c h o c o n s t r i c t i o n caused by a n t i g e n i n h a l a t i o n i n a s t h m a t i c s h a s been blocked by a t r o p i n e . These experiments have c h a l l e n g e d t h e t r a d i t i o n a l concept of mediator-induced d i r e c t muscle c o n t r a c t i o n as t h e primary e v e n t i n bronchospasm. Atropine h a s h i s t o r i c a l l y been viewed as dangerous t o a s t h m a t i c s because of t h e p o t e n t i a l of d r y i n g e f f e c t s and mucous p l u g s . I n one a c u t e t r i a l , i s o p r o p y l a t r o p i n e (Sch 1000) was found supeAcute r i o r t o salbutamo1,‘l w h i l e i n a n o t h e r t h e reverse was r e p o r t e d . ’ s t u d i e s may n o t be t h e most a p p r o p r i a t e means t o e v a l u a t e t h e problem of mucous p l u g s . It h a s r e c e n t l y been r e p o r t e d t h a t a few s e l e c t e d p a t i e n t s were t r e a t e d w i t h a e r o s o l i z e d a t r o p i n e f o r up t o 6 months w i t h o u t observi n g mucous problems. 7 4 Emphysema - Emphysema i s an anatomic a l t e r a t i o n of t h e l u n g c h a r a c t e r i z e d by an abnormal enlargement of t h e a i r s p a c e s d i s t a l t o t h e t e r m i n a l , nonr e s p i r a t o r y b r o n c h i o l e , accompanied by d e s t r u c t i v e changes of a l v e o l a r walls. S i n c e B r ~ w n - S e q u a r d ~f i~r s t d i s c u s s e d t h e p r o d u c t i o n of e x p e r i m e n t a l emphysema i n t h e l a t e n i n e t e e n t h c e n t u r y , r e p o r t s of v a r i o u s exp e r i m e n t a l procedures t o induce t h i s c o n d i t i o n have appeared i n t h e l i t e r a t u r e . Emphysema-like c o n d i t i o n s have been produced by phosgene, 76 c i g a r e t t e smoke, 7 7 t r a c h e a l l i g a t i o n and ph t o h e m a g g l u t i n i n , 7 8 p a p a i n , adm i n i s t e r e d i n t r a t r a ~ h e a l l y ~o’ r by polymorphonuclear-enriched l e u k o c y t e homogenates, 8 1 and cadmium c h l o r i d e a e r o s o l . 82 U t i l i z a t i o n of p r o t e o l y t i c materials, such as p a p a i n , t o produce an e x p e r i m e n t a l emphysema-like s t a t e may be of p e r t i n e n t v a l u e i n l i g h t of r e c e n t e v i d e n c e t h a t a d e f i c i e n c y of an a n t i p r o t e o l y t i c f a c t o r , a 1 - a n t i Many i n v e s t i g a t o r s t r y p s i n , i s a s s o c i a t e d w i t h p a n l o b u l a r emphysema. have i n d i c a t e d t h a t papain-induced emphysema i s similar morpholo i c a l l y , p a t h o l o g i c a l l y and p h y s i o l o g i c a l l y t o human emphysema. 79 3 8 o 9 8 4 - 8 F Cadmium i s of s p e c i a l i n t e r e s t because of i t s p r e s e n c e i n c i g a r e t t e smoke. P r o g e s t e r o n e a n t a g o n i z e d t h e development of emphysema induced by i n t r a t r a c h e a l l y - a d m i n i s t e r e d papain and t r a c h e a l l i g a t i o n B 8 and by papain a e r o s o l i n male r a t s , 8 9 9 9 0 as w e l l as t h e development of an emphysema-like c o n d i t i o n produced by phytohemagglutinin and t r a c h e a l l i g a t i o n . 7 8 D i m e t h i s t e r o n e and m e g e s t r o l acetate were e f f e c t i v e a g a i n s t an emphysemal i k e c o n d i t i o n produced by papain a e r o s o l and t r a c h e a l l i g a t i o n . 88 Medroxyprogesterone acetate p r e v e n t e d t h e development of an emphysema-like l e s i o n caused by t h e m i c r o b i a l p r o t e a s e , thermolysin. 91 Reasons f o r i n i t i a l l y s t u d y i n g p r o g e s t e r o n e i n e x p e r i m e n t a l emphysema i n c l u d e d t h e obs e r v a t i o n s t h a t a ) t h e r e w a s a lower i n c i d e n c e of pulmonary emphysema i n
90 -
S e c t . I1
-
Pharmacodynamic Agents
C l a r k e , Ed.
females t h a n i n males, 92 b ) female emphysematous p a t i e n t s improve d u r i n pregnancy when t h e blood t i t e r o f p r o g e s t a t i o n a l hormones i s e l e v a t e d . 9 g The mechanism of t h e b e n e f i c i a l e f f e c t of p r o g e s t e r o n e i s unknown. S i n c e p r o g e s t e r o n e and o t h e r p r o g e s t a g e n s are e f f e c t i v e i n s e v e r a l t y p e s of emphysema-like c o n d i t i o n s , i t seems u n l i k e l y t h a t t h e b e n e f i c i a l e f f e c t i s due t o antagonism of papain-induced p r o t e o l y s i s . S t u d i e s t o a ) d e f i n e t h e dose r e s p o n s e r e l a t i o n s h i p of p r o g e s t e r o n e i n e x p e r i m e n t a l emphysema and b ) e v a l u a t e t h e r e l a t i o n s h i p between p r o g e s t a t i o n a l a c t i v i t y and "antiemphysema" a c t i v i t y seem a p p r o p r i a t e . C o r t i c o s t e r o i d s - C o r t i c o s t e r o i d s have a number of s i d e e f f e c t s t h a t can r e s t r i c t t h e i r u s e i n asthma. The most troublesome of t h e s e i s t h e supp r e s s i o n of normal a d r e n a l f u n c t i o n and t h e development of Cushingoid symptoms. Recently beclomethasone-17,21-dipropionate h a s been used c l i n i c a l l y w i t h r a t h e r good r e s u l t s as a replacement f o r o r a l s t e r o i d therapyB4-?Z p a t i e n t s w i t h moderately severe c h r o n i c b r o n c h i a l asthma t h a t were n o t on o r a l s t e r o i d s , beclomethasone a e r o s o l (100 pg, 4 times a day) improved l u n g f u n c t i o n tests and reduced b r o n c h o d i l a t o r usage w i t h o u t a s i g n i f i c a n t e f f e c t on plasma c o r t i s o l l e v e l s . 9 8 The l a c k of s u p p r e s s i o n s e e n w i t h t h e a e r o s o l may b e due t o t h e l o c a l i z e d a p p l i c a t i o n and l a c k of a b s o r p t i o n . I n p a t i e n t s a l r e a d y on maintenance o r a l s t e r o i d s , a e r o s o l beclomethasone reduced b u t d i d n o t r e p l a c e p r e d n i s o l o n e P 6 This l i m i t e d response may be due t o a ) t o o low a dose of a e r o s o l s t e r o i d o r b ) o t h e r n e c e s s a r y s y s t e m i c a c t i v i t i e s of c o r t i c o i d s d i s c u s s e d below t h a t cannot b e r e p l a c e d by t o p i c a l a p p l i c a t i o n .
Although p a r t of t h e e f f e c t of s t e r o i d s i n asthma may b e due t o t h e well-known a n t i i n f l a m m a t o r y a c t i o n and s t a b i l i z a t i o n of lysozomal memb r a n e s , t h e r e a l s o appear t o be e f f e c t s of t h e s e compounds on t h e immune system. The s t i m u l a t i o n o f i n v i t r o immunoglobulin s y n t h e s i s by epinep h r i n e on p e r i p h e r a l l e u c o c y t e s from normal humans could be augmented by 10-6M h y d r o c o r t i s o n e , w h i l e lymphocytes from a s t h m a t i c s d i d n o t respond t o e p i n e p h r i n e o r t o augmentation w i t h h y d r o c o r t i s o n e . loo
'',
C o r t i c o s t e r o i d s have a l s o been shown t o augment t h e e f f e c t of c a t e cholamines on b r o n c h i a l t i s s u e , such t h a t g u i n e a p i g s , c h r o n i c a l l y treated w i t h h y d r o c o r t i s o n e , were more s e n s i t i v e t o i s o p r o t e r e n o l . Lungs from such guinea p i g s t o o k up l e s s e p i n e p h r i n e and n o r e p i n e p h r i n e i n v i t r o w i t h o u t changing catecholamine metabolism. l o 1 , I o 2
Chap. 10
Pulmonary, A n t i a l l e r g y Drugs
Giles, Herzig
91
S p e c i f i c I n h i b i t o r s of Anaphylactic Mediators - Slow r e a c t i n g s u b s t a n c e of a n a p h y l a x i s (SRS-A), a c o n s t r i c t o r of b r o n c h i a l smooth muscle, has been shown t o d i f f e r from any of t h e o t h e r known p h y s i o l o g i c a l l y a c t i v e a g e n t s (MW of 350-450; p I = 4 . 7 ) . Diethylcarbamazine i n h i b i t s t h e release of SRS-A from rat and human t i s s u e s b u t i t h a s n o t been e f f e c t i v e i n amelior a t i n g b r o n c h i a l c o n s t r i c t i o n i n a s t h m a t i c s , perhaps because of t o x i c l i m i t a t i o n s . FPL 55712 a c t s i n v i t r o as a h i g h l y s p e c i f i c a n t a g o n i s t o f SRS-A-induced c o n t r a c t i o n s of g u i n e a p i g ileum, b e i n g s e v e r a l t i m e s less a c t i v e a g a i n s t o t h e r c o n t r a c t o r s . l o 4 FPL 55712 a l s o r e v e r s e d an ongoing SRS-A-induced c o n t r a c t i o n of guinea p i g ileum. The c l i n i c a l u t i l i t y of t h i s compound i s unknown. A n t i h i s t a m i n e s , which u s u a l l y e x e r t t h e i r e f f e c t s by b l o c k i n g h i s t a mine a t end-organ r e c e p t o r s , are e f f e c t i v e i n u r t i c a r i a and a l l e r g i c r h i n i t i s b u t a r e of q u e s t i o n a b l e e f f i c a c y i n asthma. Troublesome s i d e e f f e c t s of t h e c l i n i c a l l y u s e f u l a n t i h i s t a m i n e s i n c l u d e b o t h CNS stimul a t i o n and d e p r e s s i o n . R M I 9918 h a s been r e p o r t e d t o be an e f f e c t i v e H I s p e c i f i c a n t i h i s t a m i n e i n r a t s , mice and guinea p i g s w i t h no o b s e r v a b l e CNS a c t i v i t y . 1 0 5 Anaphylactic I n h i b i t o r s - Cromolyn sodium i n h i b i t s t h e release of a l l e r g i c m e d i a t o r s such as h i s t a m i n e and SRS-A from s e n s i t i z e d t i s s u e s , b u t does n o t i n t e r f e r e w i t h t h e combination of a n t i g e n and a n t i b o d y . Like i t s p r e c u r s o r a z a t a d i n e , a z a n a t o r maleate (Sch 15,280) h a s s i g n i f i c a n t a n t i m e d i a t o r a c t i v i t y . O 6 I t also i n h i b i t s rat r e a g i n i c p a s s i v e cutaneous a n a p h y l a x i s (ID50=3 mg/kg p . 0 . ) and i n v i t r o a n a p h y l a c t i c h i s t a m i n e release from r a t p e r i t o n e a l m a s t c e l l s ( I C 5 0 = lO-'M). This drug a l s o r e l a x e s guinea p i g t r a c h e a l smooth muscle ( n o t mediated v i a b e t a a d r e n o c e p t o r s ) and p r e v e n t s a n a p h y l a c t i c b r o n c h o c o n s t r i c t i o n i n s e n s i t i z e d rats. Other " a n t i - a l l e r g y " compounds shown e x p e r i m e n t a l l y t o i n h i b i t a l l e r g i c r e a c t i o n s i n a wide range of i n v i t r o t e s t models i n c l u d e t h r e e xanthones, (AH 6556) (AH 7079) (AH 7 7 2 5 ) ~ 0 ~ s e r i of e sxanthone-2 c a r b o x y l i c a c i d s a n t a g o n i z e d p a s s i v e cutaneous a n a p h y l a x i s i n t h e r a t . a There h a s been g r e a t i n t e r e s t i n s t u d y i n g mechanisms f o r p r e v e n t i n g a l l e r g i c r e a c t i o n s a t t h e l e v e l of t h e antigen-antibody t a r g e t c e l l . When i n c u b a t e d w i t h cromolyn sodium i n v i t r o r a t p e r i t o n e a l mast c e l l s and human l u n t i s s u e s become s t o i c h i o m e t r i c a l l y a u t o d e s e n s i t i z e d t o The c l i n i c a l i m p l i c a t i o n s of t h i s o b s e r v a t i o n are uncromolyn. log-K1l known. Chrysotherapy h a s been used f o r a r t h r i t i s and some r e l a t e d d i s e a s e s , and r e p o r t s e x i s t of some v a l u e i n asthma. SK&F-39162 a p p e a r s t o be a s p e c i f i c i n h i b i t o r of a n a p h y l a c t i c h i s t a m i n e release i n r e a g i n i c a l l y sens i t i z e d animals. Y e t t h e compound h a s no d i r e c t antagonism t o known m e d i a t o r s . 112 It i s n o t known whether t h i s compound h a s t h e same l i a b i l i t i e s of o t h e r g o l d s a l t s i n humans, such as kidney and s k i n l e s i o n s .
92
1. 2. 3. 4.
Sect. XI
- Pharmacodynamic Agents
Clarke, Ed.
W.B.
Sherman, Asthma, I n &cil-Loeb Textbook of Lbdicine, ed. by F.E. iieeson, and k . ?hDermott, pp. 53E539, H.B. Saimdzrs Co., PhilaBeluhia, 1973. A.W. ~ r a ~ k l a n dI,n Clinical Aspects of h m o l o g y , ed. P.G.K. LelL and R.A. Coombs, F.A. CQ,, Philarlslphia, 1968.
D.Y.C. Yu, S.P. ( r l e n t and V+.M. Gold, J. Apul. FhJrsiol. 32, R23 (1972). H. Poppiue and Y. L a l o r i m e , !kit. Ihd. J. 4, 134 (1973)T
U d o r s u o , 9.6. V i l j a n e n , and A. l l u i t t u r i , %end. J. of Clin. and k h . I n v e s t , 31, Suppl. 13,16 (1973). 6. Z L : . Lands, A. Arnold, J.P. lIcAuliff, F, P. Ludumaand %& &own, N i t i r e (London) 214, 597 (1967). 7. A s s e m and A.V. X i c h t e r , & r u n o b g y , a 729 (19-1). Z.S.A. Assem and H.Q. S c h i l d , Nature (London! 224, lG2e (1959). 63. Assem and J.J.I. Feigenbaum Br. 3. P h a r x c o l . 46, 519 (1372). 9. 2.S.K. 10, 1i.D. domay, I. Minatoya, A.M. Lands and J.;'. S h e k o s l n r J . Fharm. Sci. 57, 1135 (1968) 11. d.2. Liles, and J.;r. M i l l q J. Pharmacol. Exp. Ther. 156 201 (1967). 12. P.S. Davics, C.P. fhrgan, !d.i. Conolly, J.\ E a t t e r s o F L s J . Sandler and C.T. Dollery Fed. ROC.28, 797 (1969). &lm, J.B. iGm, D. Jack and G.?. Levy, S it. J. P h : r a c o l . 35, 1 4 13. f.A. (1969) 14. C.L. S n i d e r and R. Laguardie, J. J.A.MbA. 221, 682 (1972). 15. .!1 Persson and T'. Ollsson, Acta Med. S c a n d ~ s u r p l . 512 1 (1970). 16. P. Glass and !..J. h l f a n o , C u r r . Ther. Res. 15, 141 m 3 { . 17. S.R. O'Donnell, 6ur. J, Ejharm. 12, 35 (1970)T F i n k e l , J. Pharmacol. Exp. Ther. 472 l o . H.S. L i l e s , J.C. Williams and (1973). 19. Y,. J o r d e and YI. K e i s t e n , E-kd. Klin. 68, 961 (1973). Kededy and C.H. Dash, Acta m a r g o 1 27, 22 20. M.C.S. (19721. 21. J.C. Vermak, h1.A. deKooE- and J.1,. J o u b a r t , S . A f r o ZPd. Z. 46, 1999 (1972). 22. 1. Iwasawa and A . Kiyomoto, Jap. J. rharmacol. l7, 143 (1967)T 23. h. Yamamoto, Asian Med. J. 13, 165 (1970). 24. F.K. Lish, J.k. L e i k e l a n d r 3ungan, J. Fharmacol. Sxp. Tier. 149, 161 (1965). 25. J.P. L r i f f i n and P. I'urner, J. Clin. Pharrxtcol. 280 1971 26. H.C. Bowman and 1.W. Rodger, B-. J. Fharmacol. 574 119721. 27. J.R. Viardell, Jr., D. C o l e l l a , C. Kaiser and S . T o a s , Xbs. of Yolunteer Papers, 5 t h I n t l . Congress on Pharmacology, San Francisco, C - d i f . , July 2x28, 1972, p. 246. 28. J.2. Wardell, Jr., D.F. Colella, A. S h e t z l i n e and F.J. Yowler, J. Pharmacol. bxp. Ther., 189, 167 (1974). 29. C. Kaiser, D.F. C o l e l l a , IL.S. Schwartz, 3. Carvey and J.R. Yardell, Jr. J. hkd. Chem. 17,49 (1974).
5.
m.X.
.
s,
.
8:
.
Chap. 10
Pulmonary, Antiallergy Drugs
Giles, Herzig
93
225, 521 (1973). 30 United S t a t e s hdopted lJa~ii?s,J.A.M.A. Lees, =to J. Dis. Shest. 67, 6 1 (1973). 31. 3.N. Sinha, G.W. Allen and C.N. J. Lled. ;hem. 2, l.!&urran and J.2. Robertson, 32. 2.H. B a n i t t , K.E. Soyne, K.P. 116 (1974). 33 U. Jack, In, Asthma: Physioloty, I-minopherirmecology and Treatment, ed. by K . T . Austin anTL.34. Lichtenstein, Academic &ess, New York, p. 351 (1973). , 1367(m). 34 Soh. Spstein, J.A. Biirnaxd and T.T. Zsoter, h e r . Rev. Resp. X s . 9 %man and lL7+.Nott, Br. J. Fharmacol. 38 37 1970). 35 9i.C. 36. F.3. 6peizer and 3. Doll, Bit. l&d. J. 3 247t1968 37 P.D. Stolley, Am. ilev. Hesp* 92s. 105, E85 (1972). 5 O m 7 1 ) . 38 N.C. H a r r i s , Ann. Allergy 29, 2 K a r b , ld. Sandler 3.D. Williams, Er. J. Pharmacol. 31, 340 (1967). 39 .:.!.S Cuthbert, In Frostaglandbw: Pharnxicoloty and Thera e u t i c z ed. by M.F. 40. !.F. Ckthbert, Heinemann !led. aook, London, pp. 251-2e2 (19727. 41 J. ifakaiio and J.X. Kessinger, Froc. Soc. Exp. 3.01. ibd. 133, 1314 (1970). ., Plemrn 42. J. Nakano, I n Prostaglandins ed. by PbTiJ, Ramell and J.3. ‘sE;z;w, vol. l p. 239 (1975). Press, l?ew=k, 43. 1d.2. Hosenthale, A. Dervinis, A.J. Begany, M. Lapidus and i.1.1. G l u c h n , ixperentia, 26, 1119 (1979. 44. &F. C u t h b e r c Proc. Ray. SOC. l&d. 6 4 , s (1971). 45. L1.9. Rosenthale, A. Delervinis and J. E s s a r i c h , J. Fharmacol. Exp. Ther. 178, 541 (1971). 46. 1vl.F. Cuthbert, Bit. >led. J. 4, 723 (1969). 47 A.P. Smith, and 1ul.F. Cuthbert, kit. Med. J. 2, 212 (1972). 48 A.P. Smith, I n Asthma: Physiolody, h u n o p h a r m c o l o g y and Treatment, ed. by K.F. 267 (1973). ATJstin and Liahtenstein, Acaienic h-PraSS, Kew York, Baird and S.W. Sutherland, I n F r o s t a g f h i i n Syclrosium of the 49 R.N. &tcher, C.2. Worchester foundation f o r d x p e r b n t a l Biolo,yTed. by F.K. Famiell and 5.3. ShaA’, Interscience Publishers. New York (1967). 50. id.$. Rosenthale, A. D e r h n i s and MiI. G i u c b n , Prostaglandins 3, 767 (1973). 51. A.P. Smith and bl.F. Cuthbert, *it. !dear J. 3, 212 (1972). N. Tvanborg, Brit. Med. J. 2, 193 (1973). 52. &A. Mathe; P. riedqvist, A. 53.
.. . .
f.
a
.. .
.
Lx.
54. 55 56 57 58
.
59. 60
61. 62. 63.
J. Grphek, I..^-.-.
68 0
63. 70 71. 72. 73. 74. 75. 76 77. 78.
Douglas,
(Lond) 219, 864 (1968). Bouhuys’;-mat. New Biol.,
(Mf3l.
z, P4
hthe’; K. Strandbsrg and A. Astrom, Nature (Lond) 230, 215 (1971). K.E. ERkins, J.9, bBller and S.M.M. K a r i m , J. PhermacorExp. Ther. 176, 441 (1971). K.E. Eakins, Ann. N.Y. &ad. Sci., le0, 386 (1971). Lob:. Lichtenstein and C. Henney, 11,Tostaglavdins i n Cellular 8iolofy, ed. by P.W. Hatnwell, Plenum Fublishing %, N.Y., p. 293 (1972). Austin, J. A’lergy and Clin. k.1. Tauber, Id. K a l i n e r , D.J. Stechschulte and K.F. Irmunol. 51, 106 (1973). P.Y. Moore, L.C. I o r i o and J.M. hlci.lanus, J. Pharm. Pharmacol. 20, 36@ (1966). G. Schultz, J.C. Hardman and 3.W. Sutherland, In Asthma: Physixogy, Inn-inoLichtenstein, hcademic pharmacoLogy ai;rl Treatment ed. by X.F. AustinTnd L.! Press, Inc., N.Y., p. 123 11973). L. bzaduykisSzadiiski, and I’. Berti, Phasmacol. Pes. Connun. 4 , 53 (1972). A.J. Lerris, J.S. Douglas and A. r’ouhuys, J. Pharm. Pharmacol. 75, 1071 (1973). 0M .. Rosen, Arch. Bioc’ilea. Siophys. 139, U 7 (1973). L E O Davies, J. Pharm. Pharmacol. z5el (1973). H. Sheppard, I n Asthma: FLLysiolofy,Z-mnophwmacoloy’y and !Creatm#>nt, ed. by K.F. Austir. and L.M. Lichtaastein, Acadellic Press, p. 235, N.Y. (1973). A. B e r t e l l i , C. 3ianchi and L. b a n i , J. Pharm. Pharmacol. 25, 60 (1973). J.G. Widdicomband Go:!. Sterliw’, Arch. Intern. lied. 126, 3 n (1970). 3.G. Simonsson, F.’:. Jacobs and J.A. Nadel, J. CZin. I n v e s t . 46 182 (1967). U.V. Gold, G.F. Kesslm and 1.Y.C. Yu, J. Appl. Physiol. 33, (1972). 1A.A. DeKock. J.A. Iiadel. S. M . H.J.Y. Colebatch and C . x Olsen. J. A.. m l .physiol. 21; 185 (1906): J.A. N a d e r I n A s t h n a : Physiology, hmnopharmacoloFy and Treatment, ed. bj K.’!. Austin and LT- Licbtenstein. Academic Press. N.Y.. D. 3. 1973. C.2. &own-Sequard, C.?. Soc: €601. 37, 354 [1085): J.R. Clay, and H.C. flossink, m h n l . 78 544 (1964). J.A. Zernandez, h e r . €rev. fieL2:hiis. 93, 7811966). S. I t o and D.% Aviada, J. Pharmacol. ,xp. - + e r . 161, 197 (1968). A.A.
.
64 65. 66 0 67
J.S.
.
n6
Sect. I1
94 -
.
- Pharmacodynamic Agents
Clarke, Ed.
79 P. Gross, E.A. E f i t s e r , E. Tolker, Id. Babyak and 1:. Kaschak, Arch. 3nviron. h e a l t h 11, 50 (1965). ao. h.2. C i s s , !!.P. k i n k e l and 2.. Leeds, R.oc. 5oc. 4xp. Biol. ? i d . 134 157 (1970). 81.. V, -0 B Ilhss D.X. l'eranzg, f lieinhavm and P. 'imhel, h e r . R e c f i e s p . ?is. 104, 5% 719711. S n i d e r , J.A. Hayes, A.L. Korthy and L.P. Lowis, Amer. i{ev. Reap. D S s . 100, 820
.
n 40 11973).
133. C.3. Laurell, and S. k i k s s o n , Scand. J. Clin. Lab. I n v e s t . 15, 132 (1963). Aviado, &oh. dnviron. H e z t h , 15, 332 (1367). 84. P. Palecek, 1.1. Palecekovs and Arch. Z w i r o n . Heanh 35., 332 85 I.P. G o l d r i n g , I. Gresnburg and L T i . Ratner.,
.
86 0
87 88. 89. 90.
(1967)
f.'UahDakOm, J.C. Hog A.J. Wooloock, A,?, fm us, P.T. bhcklem and Wdd. f h w l b e c k , h r . Rev. &sp. Dis, 102, 77P, (19707. 458 (1971). E.J. Caldwell, J. Appl. Physiol. D.M. Aviado, and G.R. MDXinnq$ P h a r a Res. Corn. 1, H.S. Giles and J.C. \ i i l l i a m s , Lne Pharmacologist 17, ii.i. G i l e s , 5.2. l r i l l i a m s and M.F. E'inkel, k o c . ?&.
H,
(1973) 91. 2. Ivjandl, S. Keller, T. Xosannah and C. Blackwood In: Pilmonary 3Fphyaem and P r o t e o l y s i s , ed. by C. Mittman, pp. 439-447, A c a d k c Press, New York, 1972. StuartHarris
92. C.H.
and T. Sanly, O x o n i c Ih-ooohitis .?mphysema and C n r PulTonale.
J o b 'Aright and Sons, Ltd. 3 i s t o 1 , h g l a n d , 1957. Bickerman, Fulmonary Emp\Ayserna, The Viilliams and b i l k i n s 93. A.L. Barach and K.A. Co., Baltir?ore, 1956. Clark, Lancet, I, 1361 (1972). 94. T.H.H. Rhalla, S.N. Singha1 and A.L. B:t,lPr, Bit. Meed. J. 95. S. Lal. D,t& Harris, 311, 3j4 (1972). 96 -- $""ran, P.J. Cooper, !I,?. Home and T.ti,B, Crant, Brit. :led. J. 2, 205 (lY/JJ* Ashurst, V. Kirton, Y+.T. SiTpson, HalL-Smith, R.A. h b i n P.J 37 I.w, Caldwel1, S.P. G.h. V i i l l i a m s , &it. J. Dermatol. 80, 11. 13.966). S i n c l a i r , C. Skinner and K.'$;.V. 98. J.W. Laddie, G.R. P e t r i , I.W. Heid';-d.J.kI. Pa-, Lancet, I691 (1973). ii.s, Smith and E. h!iddleton, J. Allergy Clin. I~munol., 52, 13 A.ASherman, 99 N,? $. LIYISlr
m.
.-
-
.
100.
his.
k t h , N.A.
Sherman and E. I'iddleton,
J. A l l e r g y Clin.
Impunol.,
2, 328
(1973). 101. L.Q. Pun, M.W. McCulloch and 1d.J. Rand, Em. J. Phnrmacol. 22, 162 1973). 102. &A. Idathe', and B. Levine, J. A l l e r g y Clin. h u n o l . , 53, 1% (19741. 103. k.P. &a 'e, H.C. Murphy, M.L. Karnovsky and K.Y. Austen, J. Lmunol. E, 760 (1978. 104. 5. Augstein, J B. Famner, !.B Lee, I.. Sheard and %To T a t t e r s a l l , Mature New Biol. 245, 215 11373). 105. C.R. m s o l v i n g N.L. ~.$.uro and A.A. C a r r , T!ie D h a r m c g l o g i s t , 15, 221 (1973). 106. Lor,. Smith, S. f o z z i and J. P e t i l l o , J. Allerp i l i n . +mnmol. 84 (1974). 107. E.S.K. Assem, Int. Arch. Allergy 45, 708 (19733. 108. J.R. P f i s t e r , Rob. F e r r a r e s i , I . n a r r i s o n , 1t.H. Rooks, A.P. Doszkovski, A. ?2n Horn and J.H. F r i e d , J. Bded. Cham. 15, 1033 (1972). lC9. 2.J. Kusner, 3. Dubnick, and D.J. G e i g , J. Fharmacol. Expo Ther., 2 4 , 41 (19731. 110. 3 . S . Thomson and D.P. Zvans Clin. gxp. I m u n o l . 13, 537 (1973). 111. H.G. Johnson, and C.R. van &out, Proc. SOC. Cxp. n o l . h:ed., 143, 427 (1973). lPr L.W. Chakrin, 3.T. Walz, A. b!isher, J, Mengel, D. Yo.mg, V. m o r n e and J.R. Wardell, The Pharmacologist l5, 220 (1973).
z,
Section 111
- Chemotherapeutic Agents
George H. Warren, Wyeth Laboratories, Inc., Philadelphia, Pa.
Editor:
Chapter 11. Antibiotics
F. Leitner and C. A. Claridge, Bristol Laboratories, Syracuse, N. Y.
-
General The molecular basis of antibiotic action was discussed in a monograph1 and at a symposium.2 The proceedings of several symposia were published, each devoted to a single antibiotic3'5 or drug combination.6 A collection of papers on the clinical evaluation of amoxicillin7 and a preliminary report on the pharmacokinetic properties and therapeutic efficacy of pivampicillin8 appeared. An issue of "Seminars in Drug Treatment"9 contains reviews on adverse effects of antibiotics98 and the treatment of various bacterial infe~tions.9~'~A therapeutic guide to selection of systemic antibacterial agents was prepared.10 A review appeared on the nephrotoxicity of antibiotics and the therapy of infections in patients with impaired renal function.1l The synthesis of B-lactams12, the allergenicity of penicillinsl3, the biological properties of semisynthetic penicillinsl4, and the chemical and biological properties of ansamycinsl5 were reviewed. Several antibiotics16a-d and antibacterial agents16esf are included in the first two volumes of a new serial publication16 on physical, chemical, and biological properties of selected drugs. The concentration of antibacterial drugs in interstitial fluid was determined by a new experimental technique.17 The molecular properties of R-factorsl8-20 and the biochemical mechanisms of resistance to antibiotics21 were discussed.
-
Infectious resistance to antibiotics Plasmid-borne antibiotic resistance was demonstrated in Streptococcus faecalis22-24 and Bordetella bronchisepand evidence for its conjugal transfer was adduced.24,25 The curing of an R-factor from Escherichia by trimethoprim was achieved.26 R-factors carrying multiple copies of a penicillinase gene were identified.27 An R-factor mediated resistance to penicillins not involving p-lactamase occurred under anaerobic conwas described.28 R-factor transfer in E. ditions simulating those prevailing in the mammalian gastrointestinal tract.2b Transfer of R-factor in the human gut from an ingested donor strain to resident organisms was detected, but on1 when the host was treated with therapeutic doses of a relevant antibiotic. 50 The authors confirmed the identity of the plasmid in the donor and recipient strains by DNA/DNA hyb r i d i ~ a t i o n .The ~ ~ transfer of a plasmid carrying a €3-lactamase marker from Klebsiella aerogenes to Pseudomonas aeruginosa occurred in the burns of a patient .-32
-
a
-
An intense effort of late to devInfections caused by obligate anaerobes elop anaerobic methodology €or use in the clinical laboratory resulted in numerous publications on the c ~ l l e c t i o n ~and ~ - transportation33-36 ~~ of specimens, the c ~ l t u r e ~ sand - ~ i~ d e n t i f i ~ a t i o n ~of ~ r or ~ ~ enisms, and the determination of their antibiotic susceptibility profile.82-47 Several lab-
96 -
Sect. I11
- Chemotherapeutic
Agents
Warren, Ed.
oratory manuals48-50 appeared on this subject and part of the proceedings of the Second International Symposium of MicroecologyS1 was devoted to the discussion of anaerobic techniques. Two drugs were tested against infections with anaerobes. Clindamycin 2-phosphate, recently approved for parenteral use, was highly effective against various infections caused by Bacteroides, such as septicemia, peritonitis and abscesses, including a brain abscess.52-54 During acute meningitis, the drug reached bactericidal concentrations in the CSF. 54 Metronidazole was bactericidal for all 77 strains of Bacteroides fragilis against which it was tested, at concentrations obtainable in the serum following normal therapeutic dosee.55,56 Initial clinical experience with this drug in treating deep-seated anaerobic infections showed promise. 57
-
The effect of FL 1060 (la), a 60-amidinopenicillanic acid, on @-Lactams was intensely investigated. The morphological changes elicited b E,. this compound differ from the classical penicillin-induced response.58t58 The three enzymes sensitive to penicillins, i.e., peptidoglycan transpeptidase, D-alanine carboxypeptidase, and endo eptidase, were not inhibited at bactericidal concentrations of FL 106060~6, but the formation of peptidoglycans covalently bound to the cell wall or to lipoproteins was impaired.60 A number of pivaloyloxymethyl 6-W1-cyanoamidinopenici11anates (lb) were prcpared.62 The antibacterial activity of the corresponding free acids, obtained by enzymatic hydrolysis of the esters, resembled that of structurally analogous penicillins.
P
V (&) was resistant to Bacillus cerand moderately active against gram-positive organisms.63 Several 2-acetoxymethyl penicillins ( 2 a . 9 6 4 and 2-spirocyclopropyl cephalosporins (3)65 were prepared. Various chemical procedures were developed for the 7(6ya-methoxylation of p-lactam antibiotics.66-72 Conversion of penicillins to cephalosporins was achieved by new synthetic routes. 73-76 Some [2,3]-fused tricyclic cephem derivatives (&-Q were synthesized.77,78 Compound 4c displayed significant antibiotic activity, 78 Racemic cephalothin, 7-methoxyce halothin, and cefoxitin were obtained by total synthesis of a novel type.yy-81 A nuclear analogue of a 7-methylcephalosporin prepared by total synthesis, lacked antibiotic activity.82 A carbon analogue of penicillin
eus p-lactamase
(z),
The asymnetric incorporation of valine into penicillins N and V and cephalosporin C was demonstrated by incubating the producing cultures with 3-chiral ~ a l i n e s84 . ~ ~The Pa-methyl of the penicillins and the cephalosporin 3-methylene derive from the same methyl group of the amino acid. The activity of selected cephalosporins against Mycobacterium tuberculosis H37Rv was correlated with their structure.85 Two other studies relating activity to structure were undertaken, one on 7(R)-mandelamidocephalosporanic acid&, the other on a-sulfopenicillins.8~ AmoxLcillin was effective and well tolerated in a variety of infections: chronic respiratory diseases caused by Haemphilus influenzae i n children88; urinary tract infections due to gram-negative bacilli or S,.
Chap. 11
Antibiotics
-H b
NC-N=CR-NH-
Leitner, Claridge
97
-H
a
-CHiOCOC(C;H,S
COOH
3
5
faecelis89,90; uncomplicated gonorrhoea (when administered in combination with probenecid).9l The serum concentrations of ticarcillin after parentera1 administration to patients suffering from neoplastic diseases were comparable to those obtained with cerbenicillin.92 However , the serum inhibitory activity against p. aeruginosa in vitro was greater with ticarcillin. Given by iv infusion, ticarcillin was effective in 18 of 20 patients with Pseudomonas infections, even in the presence of severe granulocytop e n i a y
Sect. I11
98 -
-
Chemotherapeutic Agents
Warren, Ed.
Cefamndole was more active in vitro than cephalothin, cephaloridine or cephalexin against Haemophilus and gram-negative bacilli. Moreover, its spectrum covered many organisms resistant to the other cephalos orins, such as strains of Enterobacter and indole-positive Proteus species. 84 Cefoxitin is highly resistant to degradation by most 0-lactamases from gram-negative organisms.95,96 In human volunteers the mean serum concentrations of cefoxitin reached peak values of 10.9 and 22.5 Bg/ml after im administration of 0.5 and 1 g, re~pectively.9~About 90% of the administered dose was recovered in the urine. Cefazolin was approved for use in the U.S. Recent reports confirm the high efficacy and tolerance of this compound in the treatment of a variety of severe infections, including staphylococcal and bacillary endo~arditis.~7-99
-
Amikacin (BB-K a), when compared to other aminoglycosides, Aminoglycosides shows a broad spectrum of activity100 that includes a number of strains of E. Klebsiella, Enterobacter, Pseudomonas and Serratia resistant to tobramycin, gentamicin and kanamycin.101 It may present no advantage & vitro over gentamicin.102 However, in a study involving amikacin, gentamicin, tobramycin, sisomicin and butirosin, determination of an inhibitory index (ratio between mean peak serum levels and concentration required to inhibit 213 of each species) showed that the index for amikacin was the largest (with the exception of 11. aeruginosa, where all agents were equally effective).l03 S ectinomycin was the least active when compared to these aminoglycosides~~4 and its major value may be in the treatment of gonorrhoea in patients allergic to penicillin.105 Pharmacokinetic studies on amikacin and tobramycin were reported. 106-108
e,
Mixtures of a penicillin with tobramycin or gentamicin were synergistic in vitro against enterococci109,110 and a spectrum of gram-negative clinical isolates.111 A similar combination therapy with a penicillin or cephalosporin and these aminoglycosides has been reported efficacious in gram-negative infections of cancer patients. 112 However, there were two reports of acute renal failure associated with combined gentamicin-cephalothin therapy in patients with normal renal function.113,114 The chemical procedures for the synthesis of 4"-deoxygentamicin C115 , configurational and positional isomers of amikacinll6 butirosin B117, 5"amino-5"-deoxybutirosin~~~, 3 ' ,4' -dideoxybutirosin Bli9 , 3 -deoxykanamycin B (tobramycin)l*O, 6'-amino-6' -deoxylividomycin B, 6'-deoxy-6'-methylaminolividomycin B and 6 ' -deoxy-6 ' (2-hydroxyethylamino)lividomycin B12 1 have been described. l-N-(L-T'-Amino-a-hydroxybutyryl) derivatives of kanamycin B, 3' ,4'-dideoxykanamycin B122, lividomycin A123 and 3' ,4'-dideo~yneamine12~ were also synthesized. The total syntheses of dihydrostreptomycinl25 and of kasugamycinl26, the latter through the methyl N,N' -diacetyl-a-d-kasugaminide, were described. Degradation of butirosin yielded l-N-aminohydroxybutyrylneamine, a compound having antimicrobial activity. Substitution of the aminohydroxybutyric acid in butirosin with other acyl groups produced a new 8 eries of active compounds. 1 2 7
-
New active aminoglycosides were produced biosynthetically from mutant cultures of Bacillus circulans (butirosin)128 and Streptomyces ribosidificus
Antibiotics
Chap. 11
Leitner, Claridge
99 -
(ribostamycin). 129 These mutants could form antibiotic only when Z-deoxystreptamine (2-DOS) was added exogenously. Substitution of the 2-DOS with streptamine and streptidine in the former culture and with 1-N-methyldeoxystreptamine, streptamine and 2-epi-streptarnine in the latter culture yielded new antibiotics. A similar mutant of Streptomyces kanamyceticus (kanamycin) yielded two new kanamycin analogues by the addition of 1-N-methyldeoxystrep tamine and 2 epi - 8 treptamine. 129 The successful incorporation of str eptidine by the B. circulans mutant and 1-N-methyldeoxystreptamine by 2. &sidificus and g. kanamyceticus is in contrast to the production of hybrimycins, where a rigid requirement for an unsubstituted 1,3-diamino function on the aminocyclitol was reported.130 The scope of enzymes which inactivate aminoglycosides has been widened with the reports that neomycin-kanamycin which phosphorylates the 3'-hydroxyl phosphotransferase I (from &. group of the kanamycins, also phosphorylates the 5"-hydroxyl group of lividomycin A.131 An enzyme in p. aeru inosa was found to phosphorylate only the 5"-hydroxyl group of ribostamycin 3-N-Carboxymethylation of ribostamycin was induced by the producing culture (5. ribosidificus)l33, where the acetic acid is introduced via the methyl group, the first biochemical report of this reaction. Gentamicin acetyltransferase 11 catalyzes the acetylation of the 2'-amino group of the aminohexose ring of gentamicin, tobramycin, kanamycins and related antibiotics.134 Another new enzyme, discovered in E. & resistant to gentamicin, acet lates the 3-amino group of the 2-deoxystreptamine moiety of gentamicin C1.1$5 Antibiotic inactivating enzymes have also been discovered in actinomycete cultures.136 Two antibiotics related to the butirosins were reported as minor components in that fermentat ion. 137
-
w),
+
The elucidation of the structures of the members of the nebramycin complex has continued. Factor 2 (now called apramycin) has the unique structure (g)l38, factor 4 ( 7 a ) is 6"-O-carbamoyl kanamycin B, factor 5 is kanamycin B (7b), factor 5' is 6"-O-carbamoyl tobramycin (7c) and factor 6 (E)is tobramycin. Factor 5 and tobramycin are not normally detected in fermentation broths but arise from the acid- or base-catalyzed hydrolysis of their carbamoyl derivatives.139
Sect. I11 - Chemotherapeutic Agents
.-100
Warren, Ed.
The structure-activity relationships among the aminoglycoside antibiotics, based on bacterial inhibition and misreading of polypeptide synthesis, was discussed.140
A thin layer chromatographic assay for the separation and quantitation of the members of the gentamicin complex was detailed.141 In addition, biological142 143 and radioimmune assays144 for the measurement of members of this group were reported. A rapid assay for serum levels of amikacin and all aminoglycosides with a free 6'-amino group using the kanamycin acetylstrain carrying thc R-factor for this enzyme transferase from an E_. was de~cribed.1~5
-
Rifampicin appears to have imnunosuppressive effects in some Ansamycins tubercular patients when used in conventional doses.146 However, it is still a highly useful drug in the treatment of tuberculosis i n combination with ethambutoll47 or streptomycin plus isoniazidl48, but long term treatment of chronic infections such as trachoma with rifampicin as the sole drug appears undesirable because of the emergence of resistant mutants. 149 Rifampicin action was shown to be caused by its tight binding to RNA polymerasel50, but no genetic effects were shown in Drosophila or in human leukocyte chromosomes i n vitro.151 Rifamycin biogenesis probably occurs through a condensation of propionate and acetate units.152
-
Chloramphenicol is considered the drug of choice for Chloramphenicol treatment of typhoid fever, but recently R-factor mediated resistant strains of Salmonella typhi have appeared in epidemics in Mexico1S3, Los Angelesl54 and Viet Nam.155 In staphylococci, chloramphenicol resistance has been shown to be caused by acetyltransferases of 4 distinct types, each existing as a tetrameric protein with a molecular weight of 80,000 and an identical subunit size of 20,400.156 Studies on the biosynthesis of chloramphenicol by Streptomyces v s zuelae, based on a carbon-by-carbon degradation of the antibiotic using labeled glucose were consistent with the shikimate pathway of aromatic biosynthesis. 15$ The structure-activity relationships of 37 chloramphenicol derivatives were studied. The trifluoro derivative is 1.7 times more active than the parent.158 against g.
-
Lincomycin A detailed pharmacokinetic study of clindamycin 2-phosphate i n man was reported.159 Both lincomycinl60 and clindamycin161 were shown to cross the placental barrier in pregnant women in therapeutic concentrations. Intrathecal administration of lincomycin was successful in treatment of 86% of patients with meningitis of gram-positive and gram-negative origin.162 Reports on the successful use of clindamycin 2-phosphate in a variety of infections continue to mount.163-167 An oral dosage form, clindamycin 2palmitate, was re orted to be well tolerated by man168 and useful in pediatric practice. 169, 170 2-Deoxylincomycin has the same spectrum as the parent but only 1% of the activity. Its P-anomer and 2-0-methyllincomycin were only marginally active.171 However, 7-0-methyllincomycin has the same antibacterial spec-
Antibiotics
Chap. 11
Leitner, Claridge
101
trum as lincomycin and 1.3 to 1.8 times the in vitro activity. It showed equivalence to lincomycin in mouse rotection tests against Staphylococcus aureus on subcutaneous inje~tion.17~A series of lincomycin 2-monoestersl73 and 2,7-di(alkyl carbonate) esters174 was synthesized. Good antibacterial activity was observed with monoesters of chain lengths from C 4 to C16. All of the 2,7-diesters were inactive in vitro although many were hydrolyzed by the esterase in rodent serum but not by human serum. N-Demethyllincomycin was produced by Stre tom ces lincolnensis in fermentations to which sulfonamides were added
TrK-y-
New celesticetins, members of a class of antibiotics related to the lincomycins, have been produced by mutants of Streptomyces caelestis. NDemethylcelesticetin and N-demeth 1-7-O-demethylcelesticetin were less active than celesticetin itself.lq6 A procedure for separation by gas chromatography of closely related members of this family as the trimethylsilyl ethers was described. 177
-
Macrolides Chemical modifications of erythromycin A yielded the 8-hydroxy derivative, having one-half the antibacterial activity of the parent compound but 500-600 times greater acid stability.178 A similar derivative of erythromycin B was also less active.179 In vitro and in vivo antibacterial activities of 9(S)-erythromycylamine (the C9 amine counterpart of 9(S)-dihydroerythromycin), of a series of aliphatic and aromatic aldehyde condensation products of 9(S)-erythromycylamine, and of 9(R)-erythromycylamine were reported. N-Benzylidene-9(S)-erythromycylamine was absorbed better than erythromycin after oral administration in mice and dogs, but gave lower blood concentrations in human subjects.180 Chemical modifications of the 17-membered macrocyclic antibiotic lankacidin group showed that some of the lankacidin C monoesters (particularly the propionate) had little in vitro but good in vivo activity, with wide tissue distribution. 181* 182-&ridomycin has also been described183 and modified in a similar manner, with the 9-propionyl derivative being the most effective for in vivo use.184 The structures of megalomicins A, B, C1 and C2 have been elucidated along with the description of a new dimethylamino sugar, 2,3,6-trideoxy-3-dimethylamino-D-lyxo-hexopyranose, c o m n to all of them. 185-187 The biosynthetic pathway to the platenomycins was studied through the use of blocked mutants and cosynthesis experiments.188
-
Peptide antibiotics The structures of a m p h ~ m y c i n ' ~and ~ the enduracidinsl9U were elucidated, and the complete chemical synthesis of etamycin was accomplished. 191 A new ring closure method involvin diethyl phosphite was reported useful for the synthesis of valinomycin. lgl The 3-hydroxypicolinic acid fraction of this antibiotic was shown to originate biosynthetically from L-ly~ine.19~The total cell-free biosynthesis of bacitracin A was accomplished in a reaction mixture containing urified enzyme from Bacillus licheniformis, ATP, Mg*, and 10 amino acids.164 This synthesis was not affected by blockers of ribosomal protein synthesis. Edeine D, one of the complex of 4 edeine antibiotics, was shown to contain glycine, 2-hydroxy-3-aminopropionic acid, 2,6-diamino-7-hydroxy-
Sect. I11
102
-
Chemotherapeutic Agents
Warren, Ed.
azelaic acid, 2 ,6-diamino-A7-azelaic acid, 2,3-diamino ropionic acid, spermidine and B-phenyl-P-alanine, a rare amino acid. 185 A new spectrophotometric assay more suitable than the microbiological assay for measurement of the gramicidin and tyrocidine components of tyroA gas chromatographic procedure for the assay of thricin was described. colistin was 0ut1ined.l~~ Polymyxin given prophylactically by aerosol was found to reduce significantly the incidence of colonization of the upper respiratory tract by nosocomial gram-negative bacteria in post-operative patients and in patients wi th respiratory failure .I98 Endurac id in, administered im, was effect ive against urinary tract and dermatological infections, but not against chronic osseus infections, caused by methicillin-resistant S. aureus. 199
-
Doxycycline was reported effective in treatment of urinary Tetracyclines tract inf ections200, chronic trachoma201, typhus202, and respiratory tract i n f e ~ t i o n s . 2 ~Minocycline, ~ likewise, was useful in the treatment of tetracycline-resistant staphylococcal infections204,205 and urinary tract infections.206 It was proposed that minocycline is effective against tetracycline-resistant staphylococci because of its ability to penetrate the cells more readily and to reach inhibiting concentrations at sensitive reaction sites .207 Increas ed incidence of tet racycline-resis t ant pneumococci has been reported.208 A tetracycline-novobiocin combination proved syner istic in the treatment of melioidosis caused by Pseudomonas pseudomallei.2 9 Doxycycline, and presumably other tetracyclines, were shown to interfere with the bactericidal effect of human complement in vivo.210
8
The total syntheses of anhydrochlorotetracycline211 , d,l-7-chloro-6-deoxyand d, 1-4tetracycline, d, l-7-chloro-6-demethyl-6-deoxytetracycline~~~, amino-7-chloro-2-N-methylcarbamyl-2-decarbamyl-4-dedimethylamino-6-deoxytetracycline213 were reported. A new fluorometric assay for oxytetracycline in blood and plasma using thiol reagents to prevent decomposition was described. 214
-
The structures of a- and $ - l i p ~ m y c i n ~oleficin2", ~~, and Miscellaneous manumycin21/, polyene antibiotics active against gram-positive organisms, were elucidated. Two pigments with growth inhibitory activity for positive bacteria were isolated: roseoflavin from a Stre tom cea2lfz; AB-64 from a variant of Actinomadura roseoviolacea. 2 The structure of the former was fully and that of the latter partially determined. Oxamicetin, closely related to amicetin, was isolated from Arthrobacter oxamicetus sp. n. and its chemical and biological properties were described.220,221 The compound is moderately active against a variety of organisms, including acid-fast bacteria. A study on kinamycins, correlating activity to structure, was done.222 The total synthesis of nybomycin and deoxynybomycin was accomplished.223
Chap. 11
Antibiotics
Leitner, Claridge
103 -
REFERENCES
1. E.F. G a l e , E . C u n d l i f f e , P.E. Reynolds, H.H. Richmond h H.J. Wsrlng, "The Molecular B a a i 5 of A n t i b i o t i c Action", John Wiley h Sons, London, (1972) 2. K o l e c u l s r Hecnanisns of A n t i b i o t i c Action on Protein Bioaynrheais and Membranes, GraMda, Spain, .!unr_ 1 - 4 , 1971, B. Eunoz, F. G a r c i a - F e r r a n o i z h D . Vazquez, Eds., E l s e v f e r . A n s t e r dam,(1972) 3. ?he F i r s t Nordic Centanicir! Symposium, Stockholm, Sweden, S e p t . 29-30, 1972, J.B. Bang, Ed., Act. P a t h . M i c r o b l o l . Scand. 8 , Suppl. 2 d , ( 1 9 7 3 ) 4 . Symposium on Oral Indsriyl C s r b e n i c i l l i n i n t h e T r e a t n e n t of Ilrlnary-Tract I n f e c t i o n , Yew Orleans, L a . , Jilne 6 , 1972, C . E . Cox & D . Kaye, E d s . , J . I n f e c t . D i s . , Suppl. 127. > b y , 0773) 5 . C l i n i c a l S y n p o s i m on Ceftzolin, Key Siscaync, F l a . , March 29-30, 1973, X. F f n l a n d , D . Kayc 6 H. T u c k , E d r . , J . Infec:. D i s . . S U D ? ~E . , Oct.,(1973) 6 . T r l m c t h o p r l ~ - S u l f i ~ ? c t h o x a z o l e ,Loston, ?!ass., Dec. 7-8, 1972, H. F i n l a n d h E.H. Rase, Eds., J. I n f e c t . D i s . , S u p p l . LZl, Nov.,(197?) 7. C l i n i c a l E v a l u a t i o n of Amoxycillln (P.?.L 2333). J.P. van M a r d h u i z e n , Ed., Chemotherapy, Suppl. 12,(1973) 8 . J . B . U l l c o x , R . N . Brqdcn & G . S . A v t r g , Druss, 6.?4,(1973) 9. Seminars I n Drug T r e c t m n t , 2 , ( 3 ) , ( 1 9 7 2 ) : a / A . H . Johnson, p. 331; b/ W.E. F a r r a r . J r . , p. 259; c / U . E . F a r r a r , Jr., p. 275; d / A . H . Johnson, p . 289; e l V.E. Del k n e h i4.E. F a r r a r , Jr.. p. 295 LO. Anonymus, Drugs, 5 , 1 3 2 , (1972) 11. P. Kovnat, E. Labovitz h S . P . I c v i s o n , Xed. C l i n . No. Amr., 57.1045,(1973) 12. A.K. 1:ukerjee h B.C. Siiv?tscfiva, S y n t h e s i s . p . 327,(1973) 13. C.T. S t e w a r t , Ann. F.ev. P i - . a m c o l . . i 3 , ? 0 9 , ( 1 9 7 3 ) 14. G . N . Rolinson & R . S u t h e r l a n a , Adv. Ftarmacol. Chemother.. l l , 1 5 1 , (1973) 15. V. von Prelog & W. Opbolzer, Hrlv. Chlm. Acta. 56,2279,(1973) 16. " A n a l y t i c a l P r o f i l e s of D r q Substances", K. Flcrey, Ed., Academlc P r e s s , flew York; Vol. 1, (1972): a / Erythromycin e s t o l s t e , p . 101; b / Potassium phenoxynethyl p e n i c i l l i n , p . 249; c/ Sodim c e p h a l o t h l n , p . 319; Vol. 2,(1373): d l A m p i c i l l i n , p . 1; e / Sulfamethoxazole. p . 467; f / ~ ~ i f i ~ o x a ~ Do. i 487 e, 17. G . D . Chisholm, P.H. Watervorth, J . S . Calnan h L . P . Ganod. B r l t . Mcd. J., ?_,569,(1973) 18. D.R. H e l l n s k l , Ann. Rev. H i c r o b l o l . , z . 4 3 7 , ( 1 9 7 3 ) 19. D . H . Wuanchrtud, B u l l . Ins:. P a s t e u r , 7 l , L 9 , (1973) 20. C.G. H e y n e l l , "Cacterlsl P l a m i d s " , T h e 24.1.11. P r e s s , Cambridge, Haars., (1973) 21. Ii. W n v e n i s t e h J . Davles, Ann. P.ev. Blochem., 42.471,(1373) 22. P.M. C o u r v a l i n , C . C a r l l e r 6 Y.A. Chabbert, Ann. I n s t . P a s t e u r , =,755,(1972) 23. D . B . Clewell, Y. Yagi, 6.13. Dunny 6 S.K. S c h u l t z , J. Bflct., = , 2 8 3 , ( 1 ? 7 & ) 24. A.E. Jacob h S . J . Hobbs, J. a c t . , 117,360, (1974) 25. El. Tcrakado, R. Azechl, 1. Nlnomiya h T. Shimiru, Aatlmicrob. Ag. C h e m t h c r . (AAC), 2 , 5 5 5 . (1973) 26. R . J . Pinncy h J.T. Smlth, A M , 2,670,(1973) 27. Y. Cdakura. T . Tanaka. H. €?ashimto h S. H l t s u h a s h l , AAC. 3,315,(197?) 28. N.A.C. C u r t i s , W.H. Rlchmond h V. S t a n i s l c h , J . Gcn. H i c r o b i o l . , 79,163,(1973) 29. E.L. Moodie h D.R. Koods, J. Gen. H i c r o b i o l . I 76,437, (1973) 30. J . D . Anderson, W.A. C i l l e s p i o h N.H. Richmond, J. Hcd. Microblol.. 6-,461,(1973) 31. J.D. Anderson, L.C. Inqr23, 11.8. Rlchwnd d B. Wlcdemenn, J. Med. X l c r o b l o l . , 6,475,(1973) 32. L . C . Iceram, N.H. R i c h n o d b 5.1. Sykes, AAC, 2,279, (1973) 33. X.E. Lovison. Ned. C l i n . No. A m e r . . S7,1015.(1973) 34. S.H. F i n e g o l d h J.E. R o s e n b l a t t . Medicine, 52,311.(1973) 35. J.E. R o s e n b l a t t . A. Fallon & S.M. Fi?leZold, A p p l . H i c r o b i o l . . 25,77,(1973) 36. A.P. Bsrton h J.A. k'inzar, J . C l i n . P a t h . . .:L,238.(1973) 37. J.C. C o l l e a , B. W a t t , E.B. Fowler h R . Brown, J. A p p l . E a c t . , 35,71,(1972) 38. J . A ; Washington I1 6 W.J. ,?artin, Appl. M i c r o b l o l . , 2>,7C,(1973) 39. C.E. Davls, U . J . Niinter, J.L. Ryan h A . I . Bcaucie, h c n l . H i c r o b l o l . , 25,216,(1973). 4 0 . P . D . E l l n e r , P.A. Granato h C.B. Kay, Az-pl. H i c r o b i o l . . 26,904, (1973) 41. S . E . S t a r r , F.S. Thor?son, V.R. Dwell, Jr. h A . b l o w s , h p p l . H i c r o b l o l . , 25,713,(1973) 42. V.L. S u t t e r , Y.-Y. Wok h S.H. F i n e g o l d , Appl. H i c r o b i o l . , 2 , 2 6 8 , ( 1 9 7 2 ) b3. T.D. Wilklns. L.V. Holdenan, I.J. Abransoa 6 U.E.C. Moore, AAC. 1,451,(1972) 44. S.J. Bodner, M.G. Koenig. L.L. Tremor h J.S. G o o d a n , A X , &57,(1972) 65. P . L . Sapico, Y.-Y. Rwk, V . L . S u t t e r & S . H . Ffnexold. M C . 2,320,(1472) 46. V . L . S u t t c r . Y.-Y. Xvok 6 S.H. P i n e g o l d , MC, 3 1 8 8 , ( 1 9 7 3 ) 47. T.D. Wllkins C T. Z i i e l , AAC, 2.350,(19:3) 48. ''Anaerobe Laboratory N . w u a l " , L.V. Boldeman 6 W.K.C. Moore, Eds., V.P.I. L State Vnlv., Blacksburg, Va.,(1972) 4 9 . V.L. S u t t c r , H.R. Attebery, J.E. R o r e n b l a t t . K.S. B r l c h e l l h S . X . Plncgold, "Aoaerobic
104 50.
51. 52. 53. 54. 5s. 56. 57 58. a
59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84.
85. 86. 87. 88. 89. 90. 91. 92. 93.
94. 95. 96. 97. 98.
99. 100. 101. 102.
103. 104. 105. 106.
Sect. I11
-
Chemotherapeutic Agents
Warren, Ed.
bacteriology Manual", U. of C a l i f . , Lo8 Angelcs.(1972) V.R. D w e l l , Jr. h T.M. Hawkins, "Laboratory Methods in Anmrobic Iiacteriology", C'JC laboratory manual, CDC. Arlantr. G a . , (1973) Am. J. Clin. Nutrition, 25,(12), Dec..(1972) E.V. Aaldane & C.B. van Kooycn, CUA J.. ~ . 1 1 7 7 , ( 1 9 7 2 ) R.L. Douglas h J.W. Kislak. J . I s i e c t . Dis., %559,(1973) N. Khuri-Bulos, K . Hcfnto6h 61 J. Zhret, Am. J . Die. Child., 126,96,(1973) L.J. Nastro b S.M. Pinegold, 3. I n f e c t . his., 12fr,l04,(1972)J.P.F. ' h e l a n h J . H . Hale, J. Clin. T i t h . . %,393,(1973) F.P. T a l l y , V.L. S u t t e r h S.M. Pinegold, C a l i f . Hed., Il7,22,(1972) N.B. Helchior, J. B l s m , L. Tybriag & A . Birch-Amlerscn, A t t i Path. Wicrobiol. S c a d . B, 81,393, (1973) Greenwood 6 P. O'Grady, J. Clin. Path., 26,1,(1973) J.T. Park h L. B u m n , Biochem. Biophys. Res. Comm., &863,(1973) S. M t s u h a s h i , T. Kaairyo, P . M . Blumberg, P. Linnett, E . Willoughby h J.L. Stromingcr, J. Bact., 117,578, (1974) B.J. P r t e r s t n , J. Fed. Chem., u,lO1,(1974) J . C . Sheehan h Y . S . Lo, J. Drg. Chem., 38,3227,/1973) D.O. Spry, JCS Chem. Corn., p . 259.(1973) D.O. Spry, T e t r a . L e t t . , p . 2413,(1973) J.E. b l d w i n , F.J. Urban, R.D.G. Cooper & P.L. Jose, JACS, %,2401,(1973) G.A. Koppel & R.E. Koehlcr, JACS, 9S,2403,(1973) W.A. S p i t z e r h T. Coodson. T e t r a . L e t t . , p . 273,(1973) L.D. Canu 6 B.G. Christensen, T e t r a . Lett., p . 3505,(1973) W.A. Slusarch7k. H.E. Appleqate, P. P u n k , W. Koster, M.S. P u a f , M. Young h J.E. D o l f i n i , J. Org Chem., 38,9&3,(1973) R.A. Firestone 6 B.G. Christensen, J . Org. Chen., =.1436,(1973) T. Jen, J. Praree 15 J.R.E. Hoover, J. Org. Chem., 2,2857,(1973) H. h'umata. Y . Imashiro, I. Minauida & M. Yaraoka, Tetra. L e t t . , p . 5097,(1972) T. Ramiya. T. T e r a l i , I. S a i t o h H. Hasnimoto, Tetra. Lett., p . 3001,(1973) S. Kukoiji h S.R. ia&rt, Angew. Chem. I n t e r n . E d i t . , J2,67,(1973) R.R. C h a w c t t c & P . A . Prnnington, J. O r E . Chen., g,2994,(1973) D.O. Spry, J C S Chen. Corn., p. 671,(1973) J.C. Sheehan, H.C. D a l z e l l , J.M. Greenwod h D.R. Ponzi, J. Org. Chem., g , 2 7 ,(1974) R.W. p t c l i f f e & B.G. Christensen, Tetra. Lett., p . 4645,(1973) R.W. R a t c l i f f e 6 B.G. Christensen, T e t r a . L c t t . , p. 4649, (1973) R.W. R a t c l i f f e 6 B.G. Christensen, T e t r a . Lett., p. 4653,(1973) D.M. Brunvin 6 G. Lowe, JCS Perkin I, p . 1321,(1973) N. Neuss, C.H. Nash, S.E. B l d w i n , P A . Lemke 6 J.B. Crutzner, JACS, 95,3797, 1973) 8 . Kluender. C.H. Bradley, C . J . Sih. P. Faucett & E.P. Abraham. JACS, 95,6149 (1973) H. Mirick, A.J. Mascs, T;A. Pursianb, 1 . Lcitner h K . E . Rice, J . A n t i E o t . , 6 , 7 3 7 (1973) J.R.E. Hoover, G.L. Dunn, D.R. J a b s , L.L. Lam, J.J. Taggart. J.R. Grurini h L. Phi l i p s . J. Hcd. Chem., l 7 , 3 4 , (1974) S. Morimto, H. Nomura, T. Fugono, I. MiMmi, T. Iahiguro h T. Msuda, J. Antibiot. 26, 146, (1973) Z.G. Weinberu, S.C. Shore 6 C. White, S.A. Med. J., Q,717,(1973) F.G. Kiddleton, D.M. Poretz & R . J . Duma, MC, 4,25,(1973) J. Sabto. P. Carson h T. Xorgan. >:ed. J. Aust., 2.537.. (1973) . C.D. Alergant, B r i t . J. Veacr. b i n . , g,274,(197Tj V. Rodriguez, J. Inagaki h G.P. BoGey, AAC, &,31,(1973) V. Rodriguez. G.P. W e y , N . Horikoshf, J. IMgaki 6 K.B. McCredie, AAC, &,427,(1973) S. Eykyn. C. Jenkins, A . King h I. P h i l l i p s , AM, 3%657,(1973) R.R. Onishi, D . R . Daourt, S.B. Zfm=ctmrn. D. Hcndlin h E.O. Stapley, M C , 5,38,(1974) J. Kosmidis, J.M.T. I
.
Chap. 11
Antibiotics
Leitner, Claridge
105 -
V.K. Si-wn, E.U. Hosinger 6: V. M l e r c z 7 , AAC, 3.445,(1973) X.C. h'nber, S.R. Kestenfelder & P.O. ?udsen, AAC, 2,469,(1973) R.D. L i t k c , C . Reganry, J.T. Clarke h U . M . M . Kirby, MC, 4,5b4,(1973) R. Moellering, Jr., C . jlennersten Q A . J . Veinstein, M C , 3.526,(1973) 111. J. Klasterskg, A . Henri & L. Vandenborre, Am. J. Ned. S c i . , =,13.(1973) 112. J. Klastersky, R . Canpel h D. Daneati, Cancer, 2,331,(1973) 113. J.P. P i l l a s t r c , R . Lauwnler, C. €iumbert, D . Dubols, J. Metayer, A . Dclpech, J. Leroy & Y. Robert, B r i t . Mcd. J.. 2,346, (1973) 114. D. Kleinknechc, D . Caneval h D. Groz, Lancet, 1,1129,(1973) 115. A.K. Kmllams, H.P. Verruy, D.P. Crow, G. Detrs, M. Tanabe C D.H. Yasuda, J. A n t i b i o t . ,
107. 108. 109. 110.
116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126, 127. 128. 129.
UO
.
131. 132.
u3. 134. US. 136. 137.
138. 139. 140.
141. 142. 143.
144. 145. 146. 147. 148. 149. 150.
151, 152. 153. 154. 155. 1%. 157.
158. 159. 160. 161. 162. 163.
26,782, (1973) Naito, S. U b g a w a , Y. A b e , S. T d a . K. PUjiSdWa. T. Hiyaki, 8 . Koshiyama, H . O h k m 6 8 . Kawaguchi, J. Antlbiot.. 26,297,(1973) E. Akita, I . Horluchi 6 S . Yasuda, J . Antibiot, 26,365,(1973) T.P. Culbertson, G.R. khtson & T.H. Hnakell, J. A n t i b i o t . , 26,790,(1973) D. Ikeda, T. Tstrchlya, S. :'u?rawa, H . Ihezawa h H. Ilanoda, J. A n t i b i o t . , 26,307,(1973) I. Takagi, T. Hiyoke, T. Tsuchiys, S. Lkezawa C H. W t a w a , J . A n t l b i o t . , 26,403,(1973) I . Wetanabe. T . fsuchign. S. U z a w a 6 H. Ihrezawa, J. Antibiot., 25,802,( 1 f i 3 ) S. Kondo, K. Iinrrsa, 11. I n s a m t o , K. U c d a 6 H. Wzawa, J. Antiblot., g , 4 1 2 , ( 1 9 7 3 ) I. Watanabe, 'I. Tsucbiya, S. Wezawa & H. llmezawa, J. Antibiot., 211,31O,(i973) S. Umezawa, D. Ikeda, T. Tsuchiya 6 H. Vsczawa, J. Antlbiot.. 2&,304,(1973) S . I b u w a , 2. Tsuchiya, T. YdasSaki, H . Sano h 1. T a b h a s h i , JACS, 96,920.(1974) S. Yasuda, T . Ogaoawara. S . KJvaDlta, I. Iwataki 6 T. Natsrrmoto, Tetrahedron, %,3141,(1973) R. Tsukiura, K. Fujlsawa, !4. Konlshi. K. Saito. K. Numata, R. Ishlkava, T. Mlyakl, K. Tomita 6 8. Kawaguchi, J. A n t i b i o t . , 26,351.(1973) X.D. DePuria & C.A. Claridge, Abst. Ann. Meeting Am. Soc. Uicrobiol., Mami Beach, P l a . , 6-11, 1973 U. Kojima 6 A . Satoh, J. A n t i b i o t . , 26,784,(1973) Y.T. S h i e r , S, Ogaua, M. Hickens 6 K.L. Rinehart, Jr., J. Antibiot., 26.551,(1973) 8. Uwzava, H. Tamamoto, X. Yagisawa, S. Kondo, T. Takeuchi h Y.A. Chabbsrt, J. A n t l b i o t . , 26,407, (1973) Kida, S . I g a r a s i , T. O h t a n i , T. Asako, K. l i r a g a & S. n i t s u b a s h i , AAC, &92,(1974) S. Omoto, S. Inouye, M. Kojinm h T. N i i d a , J. Antibiot.. 26,717,(1973) Y. Chevereau, P . J . L . Daniels, J. Davies 6 F. LeGoffic. Blochem., l3,538,(1974) 8 . Ilhmzrwa. H. Tagisawn, I. Hatsuhashl, R. NaagaMW, R. Yamamto. S. Kondo, T. Takeuchi 6 Y.A. Chabbert, J . A c t f b i o t . , 26,612.(1973) A. Benveniste 6 J. Cavies, Proc. Nat. Acad. Sci. USA, 70,2276,(1973) R. Tsukfurr, K . S s i t o , S. Kokaru, H. Konishl h It. Kowaguchi, J. Antlbiot., 26,386,(1973) S. O'Connor 6 L.K.T. Lam, Abst. 165th ACS Meeting, Dallas. Texas, A p r i l 8-13, 1973 K . I . Koch, F A . Davis 6 J . A . Rhoades. J. Antibiot., 26,745,(1973) R. Eenveniste h J. Davies, AAC. &,402,(1973) U.L. Wilson, C. Richard & D.W. Rcqhes, J. Fharm. S d . , 62,282,(1973) D.V. Alcid 6 S.J. Seligrcan, AAC, 2.559,(1973) X.E. Lund. D . J . Blarevic 6 J . H . Fatsen, AAC, 4,%9,(1973) W.A. Mahon, J. Ezer h T.W. Wilson, AAC, 2,585,(1973) N.J. Hnas 6 J . DEVieS, AAC. 4,497,(1973) P. Xukerjee, S . Schuldt 6 J.E. Kasik, AAC, 4.607,(1973) Anonymous, Brit. Ned. J.. 4,568, (1973) Anonymous, Lancet, 1,1331, (1973) A. Kcshishyan, L. HanM & E. Javetz, Nature, =,173,(1973) U.I. L i l l & C.R. Haitriinn, Eur. J. Bio:hem., 38,336,(1973) E. Vogel 6 G . Obe, Zxperiantia, 29,124,(1973) R . J . White. E. M a r t i n e l l i . G.G. Gallo, G. Lancini 6 P. Beynon. Nature, =,273,(1973) R.N. Lawrence, E. C c l d s t e i n 6 P.D. Hoeprich, J A M , 3 , 8 6 1 , (1973) C . Overturf, K . I . Ydrton 6 A.W. Hathien, Jr., Nev Eng. J. Med., 289,463,(1973) T. Butler, N.C. Linh, K. Arnold & M. Pollack, Lancec, 2,983, (1973) L.C. Sands C W.V. Sbaw, AAC. 2,299,(1973) W.P. O'Neill, R.F. Nystrom, K.L. Rinehart. Jr. 6 D. G o t t l i e b , Biochem., 2 . 4 7 7 5 , (1973) C. Reosch, K. NakaaUtO, M. Gorin, P. Denlsevlch, E.R. Garrett, S.H. Henurn-Ackah & C.H. Won, J. Hed. Cham., l6,917.(1973) R.U. DeIiaan, C.H. Mettler, D. Schellenberg h W.D. Vandenbosch, J. Clin. Phsrmacol., 2 , 1 9 0 , (1973) W.H. DuigMn, J. Andrevs & J.D. W i l l l a s r , Brrif. ?fed. J . , 2.75,(1973) A. Philipson, L.D. SaabPth 6 D. Charles, New E n g . J. Med. 2&1219,(1973) I. H i y a u k i , Artne1m.-Porsch., Z3,940,(1973) D. Mildvan, U. Ravreby, B.R. )(eyers 6 S . Z . HirschmPn. H t . Slnnl, J. Mad., 40,7M, (1973)
106 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 1%. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223.
Sect. I11
-
Cher*otherapeutic Agents
Warren, Ed.
W. Sshumer, R.L. Nichols, B . Killer, E.T. %met 6 G.O. HcDorsrld, Arch. Surg., =,578,(1973) A.H. Pontifex & D.R. HcNHuqht, ChA J . , ~ ~ , l O 5 , ( 1 9 7 3 ) V. B a l s c h n d a r , P.J. C o l l i p p h B . J . RLeinq, Clin. Fled., 80,(4),2&,(1973)
A.T. Edmirdson, Ann. Surg., %.637,(1973) A.A. P o r i s t , R.U. DcKaan 6 C.H. W t z l e r , J . Pharmecakin. Biopharm., 1.89, (1973) R.T. P f e i f e r , K . M . CeHaan, W.D. Vandentbsch 6 D. Schtllenberg. Clin. Hed. , 80,(5),21. (1973) W.C.L. Csrr. Curr. Ther. Res., 1',,630,(1573) B. Bannister, JCS Perkin I. p . 3025,(1972) B. Ennnister, JCS Perkin I , p . 1676,(1973) W. Moroaovich, A.A. Sfnkule, P.A. HacKellar 6 C. Levis, J. Pharm S c i . , 62,1102.(1973) A.A. Sinkula & C. Lewis, J . Phai-m. S c i . , J2,1757,(1973) A.D. Argoudclir, L.E. Johnaon h T.R. e k e , J. Antibiot., 26,429,(1973) A . D . Argoudelis, J.H. C o a t s , P.C. LEmaw h O.K. Sebek, J. Antibiot., &7.(1973) T.F. Erodasky C A.D. Argoueelir, J. Antrbiot ., 2 . 1 3 1 , (1973) K. K r w i c k i h A . Zamojski, J. A n t i b i o t . . ?fi,575,(1973) R. Krovicki & A. Zamo]skl, J. A n t i b i o t . , 22,587,(1973) E.H. Hassey, B.S. % i t c h e l l . L.D. Martin h h . Gerzon, J. Hed. Chem., ~ ~ , 1 0 5 , ( 1 9 7 4 ) S. Earada, T. Yaeulzaki, K. Aatano, K. Tsuchiya 6 T. Kishi. J. A n t i b i o t . , 26,647,(1973) S . Harada, S. Tanayarm 6 T. Kiohi, J. A n t i b i o t . , 26,658.(1973) 8 . Ono, T. Rasegnwa, E. Efqashide 6 M. Shibata, f. Actibiot, 26,191.(1973) H. Kondo, K. Ishifuji, K. Tsucniya, S. Goto h S. Kuwahara, M C , &,156,(1973) A . K . Mallams, JCS Perkin I, p. 1369,(1973) R.S. J a r e t , A.K. M 8 l h a S h H. Reinann, JCS Perkin I, p. 1374,(1973) R.S. Jaret, A.K. Mallams h H.P. Vernay, JCS Perkln I, p. 1389.(1973) T . Furumai, Y. Seki, K. Takeda, A . Kinurraki 6 H. Suzuki, J. Antibiot., 26,708,(1973) M. Bodanszky, G.P. S i g l e r 6 A . 3odansrky. JACS, 9S,2352,(1973) A. I v a s a k i , S. Horli, M. h s a i , K. Nftuno, J. Uayaoagi & A . niyaka, Chem. Phara. Bull., 2, 1184, (1973) J.C. Sheehan h S.L. k d i r , JACS, 95,875,(1973) H. Rothe 6 W. Kreiss. Angev, Chem. I n t e r n a t . E d i t . , lZ,lO12,(1973) D . J . Hook & L.C. Vining, JCS Chem. Corrm., p. 185, (LE73) P. Pfaender, D. Spccht, G. lieinrich, E. Schwarr, E. Kuhnle h M.M. Simlot, PEBS Letters, 32,100, (1973) Wojciechovska, J. Ciarkarski, H. Chmra 6 E. b r o w s k i , Experientfa, 28.1423, (1972) E.. Ivashkiv, Biotech. Bi0er.g.. lS.821, (1973) A.A. Al-Khayyat & A.L. Aronson, Chemotherapy, l9.75, (1Y73) S . G r e e n f i e l d , D. Teres, L . S . Burhnell, J. Hedley-khyca h D.S. Peingold, J. Clin. Invest., 52,2935, (1973) H. Peromct, E. Schoutcns h 1 . Yourascowsky. Chemotherapy, l9,53.(1973) C.E. Cox, C l i n . )led., 8f),(10),30,(1973) I. Hoshivara, H.B. Ootlcr, L. Ram, F. C i g n e t t i , V.R. Colermn & E. Jawetr, JAHA, 224.220, (1973) J. Huys, J. Kayihigi, P. Preyens h G . Vanden Berghc, Chemotherapy, l8,314,(1973) G.A. Pankey, C l i n . Ned., 80, (9),12,(1973) H. Lades, C l i n . Xed., 80, (9),31. (1973) A . Hoagland h L.G. Smith, Clin. Ued., 60,(4),22,(1973) P. Veysoier, Y . Bouasougant & C. Mariel, Path. Biol., 2l,59,(1973) N.A. Kuck C H. Forbes, AAC, 2,662,(1973) K.V. Copalakrishna & P . I . Lerner, Amr. Rev. Resp. Die., ~ , 1 0 0 7 , ( 1 9 7 3 ) 0. Calabi, J. M d . H i c r o b i o l . , 5,293,(1973) A. Forsgren h H. Cnarpe. Nature New Blul., 3 + , 8 2 , ( 1 9 7 3 ) R. Muxfoldt, H. Capp, J.E. Kaufran, J . Schneider, P.E. Hanren, A . .%saki h T. Geiscr, Angew Chm. I n t e r n a t . E d i t . , &497.(1973) W. Martin, H. Gartung, H. t i r h c h 6 W. Ddrckhcirrrr, T e t r a . Lett., p. 3513,(1973) H. Urbach, H. Bartunq. W. E a r t i n h W. Durckheinrr, T e t r a . Lett., p. 4907,(1973) B . S c a l e s ti D . A . Assinder, J . %am. S c i . , 62,913.(1373) K. Scbabacher 61 A . b e c k . T e t r a . Lett., p . 2691.(1973) G. Horvith, J. Gyimesi h 2. H6:hesfalvi-Va~na. T e t r a . Lett., p. 3643.(1973) K. Schrdder h A . Zeeck. T e t r a . Lett., p. 4935,(1973) S. Otani, H. Takatsu, M. Nakano, S, Kasai, R. Hiura h K. t!atiui, J. Antibiot., 27,88,(1974) A . Tanura, R. Puruta, H. Kotnni h S. Naruto, J. A n t i b i o t . , 26,492,(1973) M. Konishi, M. Ximeda, H. Tsukiura. H. Ysmmoto, T. IIoshiya, T. n i y s k i , K. Pujioam, 8 . Koshiyama 6 H. Kawaguchi, J. A n t i b l o t . , 26,752,(1973) H. Konishi, M. F a r u i s h i , T . Tsuno, B. Tsukiura h H. Kawaguchi, J. Antiblot., 26,757,(1973) S. h u r a , A . Nakagawa, H. Yameda, T . Hat., A . Purusaki 6 T. Watanabe, Chem. Pharm. l u l l , 21.931, (1973) E M . Forbis h K.L. R i n e b r t , Jr., JACS, 95,5003,(1973)
Chapter 12. Antifungal Agents Smith Shadomy, Medical College of Virginia, Richmond, Virginia
-
Reviews The changing clinical setting and etiology of fungal endocarditis was reviewed, with particular reference being made to the changing pattern of this disease as seen in narcotic addicts and following cardiac surgery.192 The renal toxicity of antibiotics, including that of amphotericin B, also was reviewed. The therapeutic indications, pharmacology, and mode of action of amphotericin B y nystatin and candicidin were the subject matter of a new text on fundamentals of ~hemotherapy.~ Methods - A standardized procedure for in vitro susceptibility testing with 5-fluorocytosine (Ancobon) which ermitted both more accurate and more reproducible results was described.! Two new experimental in vivo models were reported; one dealt with cladosporiosis in mice treated with 5-fluorocytosine6 and the second with experimental urinary tract infections in rats In the former model, 5-fluorocytosine procaused by Candida albicans tected experimentally infected animals against cerebral disease caused by Cladosporium trichoides but did not clear the tissues of infection; in the albicans were treated successfully with latter model, infections due to 5. ~-~amphotericin B, and the model appears useful in the study of anticandidal agents.
.
Improvements were reported in cultural techniques available for the detection of candidemia in man by use of a lysis-filtration procedure.' Improved serologic diagnosis of fungal infections was the subject of several reports. A slide latex agglutination test for use in sporotrichosis was described as being specific, sensitive and rapid.9 Similarly, an immunodiffusion test capable of detecting approximately 80 per cent of proven cases of blastomycosis was reported .lo Reevaluation of a previously reported medium for identification of dermatophytic fungill revealed that several nondermatophytic fungal pathogens could be misidentified as dermatophytes thus possibly resulting in the selection of totally inappropriate therapy.i2 A method for coupling antibiotics, including amphotericin B, to cellulose and cellulose carbonate to produce active, insoluble agents was described.l3
-
Clinical Experience Amphotericin B continued to be the drug of choice in treatment of serious or systemic fungal infections. It was reported earlier that while either 2-hydroxystilbamidine or amphotericin B was effective in treatment of noncavitary pulmonary blastomycosis, the latter drug was the more effective agent in treatment of this infection in those cases with cavitary disease or with systemic organ involvement.I4 Amphotericin B also was described as useful in the treatment of canine blastomycosis.15 A brief comparative study of the pharmacology of amphotericin B failures in treatment of cryptococcal meningitis, histoplasmosis and blastomycosis was reported.16 The authors of this study attribute the higher failure and relapse rates observed in patients with cryptococcal disease treated with am-
108
Sect. I11
-
Chemotherapeutic Agents
Warren, Ed.
photericin B to the lower ratios of in vitro minimal inhibitory concentration (MIC) to serum drug level as compared with similar ratios recorded in the other, more successfully treated infections. Continuous bladder irrigation with amphotericin B was reported to be useful and without toxicity in management of candidal urinary bladder infections.I7 Low nontoxic doses of amphotericin B (10-355 mg given over 4-18 days) were reported as efficacious in treatment of mucocutaneous and systemic Candida infections exclusive of meningitis and endocarditis.I8 There was continued interest in the clinical use of clotrimazole (Bay b 5097), a compound previously described as being broad-spectrum and effective vitro, but without effect orally in vivo against systemic fungal pathogens.l’ssz6 In one study, topical clotrimazole was reported to be well tolerated and superior to a drug-free vehicle in treatment of dermatophytic infections.21 In contrast, it also was reported as being ineffective and associated with gastrointestinal side effects when given orally in the treatment of mycetoma due to Madurella mycetomi and paranasal aspergilloma, although it was said to be effective topically in treatment of candidal paronychia.22 Other investigations reported late in 1972 described limited but successful results with clotrimazole in treatment of urinary tract infections due to Candida albicans23 and chronic mucocutaneous candidiosis24 in infants and children. Miconazole, a 8-substituted l-phenethyl-imidazole (R 14889, 1-{2,4dichloro~-[(2,4-dichlorobenzyl)oxy]phenethyl~imidazole) with broad spectrum antifungal activity25 was evaluated both. in normal individuals and clinically. It was reported as being effective topically in treatment of both dermatophytic infections26 and locally in treatment of vaginal candidiasis.26,27 Pharmacological studies showed that oral miconazole, 3 g/day, produced no hematologic, biochemical or cardiac abnormalities and was capable both of reducing the fungal flora of sputum and feces and of producing moderate blood levels; it was not absorbed through skin or mucous membranes.28 Studies continued with two other topical agents for use in treatment of dermatophytoses. Tolnaftate (Tinactin), as a 1 per cent powder, was found effective in both prevention and treatment of tinea pedis caused by Candida, Trichophyton and Epidermophyton.29 Haloprogin (Halotex), used topically as either a 1 per cent solution or as a cream, was found to be more effective than a placebo30 and comparable to tolnaftate3l in the treatment of experimental dermatophytic infections (Trichophyton rubrum) and naturally occurring human infections. Additional experience was gained both in the clinical use of and pharmacology of 5-fluorocytosine, Oral 5-fluorocytosine was found beneficial in treatment of both meningeal and pulmonary aspergillosis although relapses occurred in some patients with chronic cavitary disease and some resistance to the drug was observed.32 It was reported to be effective in treatment of urinary tract Candida infections and without side effects at dosages of 100 mg/kg/day in children with congenital anatomical abnormali-
Chap. 12
Antifungal Agents
Shadomy
109 -
ties.33 It also was reported effective in treatment of pulmonary Candida infections.34 Pharmacological studies revealed a direct relationship between the status of renal function, as measured by serum creatinine clearance rates, and retention of the drug; guidelines for determination of appropriate dosages in patients with impaired renal function were presented35 Contrarily, hepatic function failed to influence 5-fluorocytosine serum levels, either in experimental animals with CC14-induced hepatic insufficiency or in a patient with postnecrotic cirrhosis.36 Preliminary data were reported on the successful use of combinations of amphotericin B and 5-fluorocytosine in treatment of human cryptococC O S ~ S . This ~ ~ mode of therapy, based on the earlier demonstration of a synergistic action between the two drugs in vitro against yeasts,38 was validated experimentally in animals. In one study in mice infected with Candida albicans, CD50 dosages of amphotericin B were reduced in the presence of an otherwise inactive dose of 5-fluorocytosine.39 An additive effect for the two drugs was observed in mice infected with Cryptococcus neoformans .40 New Antifungal Agents - New sources of antifungal agents were investigated. One of these, the passion fruit, Passiflora spp., yielded an active agent following aqueous extraction of cut rind."l This agent, with UV absorption max. at 340, 358 and 375 to 377 nm, was active against a variety of fungi including both yeasts and dermatophytes.42 Antifungal compounds also were detected in cowpea tissues following infection with tobacco necrosis virus43 and in cuticle of the coffee berry.44 Polifungin, a complex of tetraene antibiotics similar to nystatin was isolated from Streptomyces noursei var. polifungini ATCC 21581.45 This complex was best recovered by paper chromatography at pH 8.2 and was developed with a chloroform-methanol-ammonia solvent system; it appeared to consist of three fractions. Another heptaenic antibiotic, cryptomycin, was isolated from a new species of actinomycete, Actinomyces bulgaricus.46 This antibiotic, consisting of a complex of 6-7 heptaene antibiotics, was highly active against yeasts and filamentous fungi including C. neoformans. Preliminary data were reported on U-42,126, an antifungal antibiotic produced by fermentation of %. sviceus.47 This compound was active in vitro against fungi and in vivo against L1210 leukemia in mice. Actinomyces voloviolaceus spp. nov., isolated from a soil sample, was found to produce a polyenic heptaene identical to component A3 of the levarin complex.48
s-
Various synthetic antifungal compounds were examined. A series of polyhalophenyl esters of p-sulfamoylcarbanilic acid were tested against yeast and fungi and were found to be active against C. albicans, Penicillium notatum and Aspergillus f u m i g a t ~ s . ~The ~ most active compounds, in order, were the pentachloro, tribromo and triiodophenyl esters. N-trisubstituted methylimidazoles related to clotrimazole and 2 congeneric compounds with 2-pyrrylmethylidenimino and 2-pyrimidinyl amino groups substituted for the imidzaole nucleus were tested;50 three compounds were found
110
Sect. I11
-
Chemotherapeutic Agents
Warren, Ed.
active against a variety of pathogenic fungi in vitro and one was active C. neoformans.
-in vivo against C. albicans, A. fumigatus and
An alkaloid, 6,6'-dihydroxythiobinupharidine isolated from Nupar, was described.51 It was reported as being active against several of a variety of human fungal pathogens, including Histoplasma capsulatum, Blastomyces dermatitidis, Trichophyton mentagrophytes, Microsporum gypseum, g. canis, C. neofonnansand 5. albicans.51 Optimal conditions were reported for fermentation of A9145, a water soluble antifungal containing adenine.li2 Production was stimulated by cottonseed oil, adenine, various nucleosides, and tyrosine. The antifungal properties of 2-alkenoic acids and 2-bromoalkanoic acids were studied .53 Antifungal activity of these compounds and of analogous alkanoic and 2-fluoroalkanoic acids were affected by chain length, pH and presence or absence of absorbents. The relative antifungal activity of the compounds was: 2-alkenoic acids > 2-fluoroalkanoic acids > 2-bromoalkanoic acids > alkanoic acids. Biological Studies - One of the more important areas of study with antifungal agents involved the synergistic action of amphotericin B with other antifungal or even antibacterial compounds. This developed from earlier -in vitro studies with amphotericin B and 5-fl~orocytosine~~ in which combinations of the two drugs were found to be additive or synergistic. Amphtericin B was found to potentiate the antitumor activity of 5-fluorouracil and of chromomycin A3 on RNA synthesis in transformed fibroblastic cells while polymyxin B potentiated bleomycin 2 in its action on both DNA and RNA syntheses.55 Combinations of amphotericin B and rifampin were found to be fungicidal for yeast-phase cells of 11. capsulatum at low concentrations, whereas either drug alone was only fungistatic and only at higher concentrations.56 RNA synthesis was inhibited by the combination of the two drugs. Combinations of amphotericin B and 5-fluorocytosine were additive or synergistic in vivo in mice infected with 2. albicans and C. neoformans. 39 3 40 The effect of polyenes of membranes of susceptible and resistant fungi was the subject of several investigations. Mutants of 2. albicans resistant to nystatin, amphotericin B and filipin were isolated following exposure to N-methyl-N'-nitro-N-nitrosoguanidine; they apparent1 were stable and differed from the parent yeasts primarily in morphology57 Changes in cell membrane chemistry were studied in these organisms; new sterols were detected in membranes of nystatin-resistant mutants of 5. albicans and Saccharomyces cerevisiae, and there also were increases in ergosterol levels ' 8 in the polyene-resistant mutants. Three compounds, SKF 525-A (B-diethylaminoethyldiphenylpropyl acetate), SKF 3301-A (2,2 diphenyl-l-dimethylaminoethoxyl]-pentane) and SKF 16467-A (N-dimethylaminoethyl-a, a-diphenyl valeramide, HC1) which inhibited cholesterol biosynthesis were inhibitory for both the polyene-resistant mutants and the parent y e a ~ t s . 5 ~ Electron micrographic studies of yeast phase cells of E. capsulatum and 5. dermatitidis exposed to amphotericin B and hamycin revealed degenerative changes in both plasma membranes and mitochondria followed by plasmolysis within 6 hours of exposure.60 Mutants of Neurospora crassa with blocks in
.
Chap. 12
Antifungal Agents
Shadomy
111
the earlier stages of ergosterol synthesis were resistant to various polyene antibiotics.61 Lyposomes were used as models for the study of the action of polyene antibiotics.62 It was noted that changes in permeability were related to the composition of membrane phospholipid fatty acid chains, and that the distribution of double bonds in the sterol nucleus determined the selective toxicity of the polyenes for natural sterol-containing membranes. These observations were confirmed in studies on natural memb r a n e ~ . Similar ~~ differences in binding affinity of amphotericin B and another polyene, vitamin A, were measured in a study of the enhancement by these compounds of the specific actions of rifampin fusidic acid and 1,3bis (2-chloroethyl)-l-nitrosourea on mouse L cells.b4 Additional data regarding 5-fluorocytosine were provided. In one study, it was noted that premature reading of inhibitory endpoints could be misleading in terms of missed resistant strains; percentages for primary resistance to the drug in several species of pathogenic yeasts also were reported.65 Cytosine, uridine and adenine were found to be antagonistic for both 5-fluorocytosine and 5-fl~orouracil,6~ thus supporting the suggested pathway and mode of action for 5-fluorocytosine; i.e. intracellular deamination of the former with incorporation of the latter in 5fluorouridylic acid. Data regarding 5-fluorocytosine resistance in C. Eformans suggested the existence of a similar pathway in this latter organism.6' Several other studies were concerned with the effect of antibacterial and antifungal agents on nucleic acid synthesis. For example, nalidixic acid was noted to cause a transient inhibition of RNA, DNA and protein synthesis in cells of 5. cerevisiae.68 Lomofungin was found to have a specific inhibitory effect on synthesis of both r osomal and messenger RNA preIt also was inhibitory for cursors in protoplasts of Saccharomyces spp." purified Escherichia DNA-dependent RNA polymerases.70 The sterol binding activity of the polyene filipin was studied.71 Two forms of the drug were demonstrated; an "active form" which binds with cholesterol and an "inactive form" which does not bind with cholesterol. Inactive filipin was converted to the active form by incubation at 50' for 2 hours. An alcoholic extract of bark of the walnut tree, Juglans regia, was found to contain a fungistatic agent active against many common dermatophytic pathogens.72 The stabilities of nystatin and amphotericin B in the presence of phosphate buffers were studied and it was found that both drugs were stable at a pH of 5 to 8; it also was noted that nystatin was more active at a lower temperature (30-25'C) while amphotericin B was more active at a higher temperature (41OC) .73 Intravenous solutions of this drug in 5% dextrose were found to be stable for up to 24 hours when exposed to light at 25OC; addition of hydrocortisone or heparin had no effect on stability.74 5-Fluorocytosine was found to increase survival in immunosuppressed mice injected with C. albicans.75
112 -
Sect. I11
-
Chemotherapeutic Agents
Warren, Ed.
References
1. D. Kaye, "Infectious Disease Reviews, William J. Holloway , Ed. , Futura Publishing Co., Mount Kisco, New York, 2, 99 (1973). 2. D. Kaye, "The Medical Clinics of North America", J. Katz and D. Kaye. Eds., W.B. Saunders Co. 5J:4,941 (1973). 57:4, 1045 (1973). 3. P. Kovnat, E. Labovitz and S.P. Levison, 4. W.B. Pratt, "Fundamentals of Chemotherapy," Oxford University Press, New York (1973). 5. E.R. Block, A.E. Jennings and J.E. Bennett, Antimicrob. Ag. Chemother., 5 , 392 (1973). 2, 95 (1973). 6. E.R. Block, A.E. Jennings and J.E. Bennett. 2, 474 (1973). 7. G.J. Miraglia and K.J. Renz, 8. R.A. Komorowski and S.G. Farmer, Amer. J. Clin. Path. 3,56 (1973). 9. S.O. Blumer, L. Kaufman, W. Kaplan, D. McLaughlin and D.E. Kraft, Appl. Microbiol., 26, 4 (1973). 244, 10. L. Kaufman, D.W. McLaughlin, M.J. Clark and S. Blumer, (1973). 11. D. Taplin, N. Zaias, G. Rebell, and H. Blank, Arch. Dermatol., 2, 203 (1969). 12. I.F. Salkin, Appl, Microb., 26, 134 (1973). 3, 575 (1973). 13. J.F. Kennedy and H.C. Tun, Antimicrob. Ag. Chemother. 14. J.F. Busey, Amer. Rev. Resp. Dis., 105, 812 (1972). 15. W.J. Stubbs, Can. Vet. J., 2, 125 (1973). 16. B.T. Fields, J.H. Bates and R.S. Abernathy, Amer. Rev. Resp. Dis. 105, 997 (1972). 17. G.J. Wise, S. Wainstein, P. Goldbern - and P.J. Kozinn, J. Amer. Med. ASSOC., &, 1636 (1973). 18. G. Medoff, W.E. Dismukes, R.H. Meade, 111, and J.M. Moses, Arch. Intern. Med. 130, 241 (1972). 19. S . Shadomy, Infec. Immun., 5, 143 (1970). 20. S . Shadomy, Antimicrob. Ag. Chemother., -1970, 169 (1971). 21. L.M. David, N.K. Veien, J.D. Schmidt, W. Murtishaw and E.B Smith, Curr. Therap. Res., IS, 133 (1973). 22. E.S. Mahgoub, Sabouraudia, 10,212 (1972). 23. R.J. Holt and R.L. Newman, Develop. Med. and Child Neurology 14 (Supp. 27), 70 (1972). 24. W. Meinhoff and D. GGnther, Arch. Derm. Forsch. 242, 293, (1972). 25. J.M. Van Cutsem and D. Thienpont, Chemother., 17,392 (1972). 26. A.A. Botter, Mykosen, 15,179 (1972). l5, 35 (1972). 27. M. Thiery, B.M. Mrozowski and H. Van Kets, 28. J. Breigmans, J. Van Cutsem, J. Heykauts, V. Schuermans and D. Thienpont, Europ. J. Clin. Pharmacol. 5 , 93 (1972). 29. P. Charney, V.M. Torres, A.W. Mayo and E.B. Smith, Int. 3. Dermatol., 2, 179 (1973). 30. H.W. Herman, Arch Dermatol., 106,839 (1972). 106,837 (1972). 31. R. Katz, and B. Cohn, 32. G.W. Atkinson and H.L. Israel, h e r . J. Med., 55, 496 (1973).
u,
m,
w,
z,
e,
u,
Chap. 1 2 33. 34. 35.
Antifungal Agents
113
Shadomy
R.J. Holt and R.L. Newman, Develop. Med. and Child Neurol. 14 (Supp. 2 7 ) , 70 ( 1 9 7 2 ) . P.C. Bartley, Aust. N.Z.J. Med. 2, 1 8 9 ( 1 9 7 3 ) . J. Schgnbeck, A. Polak, M. Fernex and J.J. Scholer, Chemother. 18, 321 ( 1 9 7 3 ) .
36. 37 * 38.
E.R. Block, Antimicrob. Ag. Chemother., 2 , 1 4 1 ( 1 9 7 3 ) . I.L. Garriques, M.A. Sande, J.P. Utz, G.L. Mandell, J.F. Warner, R.F. McGehee and S . Shadomy, abst., 13th ICAAC, 239 ( 1 9 7 3 ) . G. Medoff, M. Comfort and G.S. Kobayashi, Proc. SOC. Exp. Biol. Med.,
138, 571 (1971). 39.
E. Titsworth and E. Grunberg, Antimicrob. Ag. Chemother. 4 , 306
40.
E.R. Block and J.E. Bennett, Proc. SOC. Exp. Biol. Med, 142, 476
41. 42. 43. 44. 45.
Birner and J.M. Nicolls, Antimicrob. Ag. Chemother. 3 , 1 0 5 ( 1 9 7 3 ) . J.M. Nicolls, J. Sirner and P. Forsell, 3 , 110 ( 1 9 7 3 ) . J.A. Bailey, J. Gen. Microbiol., 75, 1 1 9 ( 1 9 7 3 ) ; J.F. Lampard, Ann. Appl. Biol., 73, 3 1 ( 1 9 7 3 ) . D. Kotiuszko, Acta Microbiol. Pol, Ser. A., Microbiol. Gen., A, 201
46.
V.A. Tsyganov, A.F. Morgunova, Yu. E. Konev, S.N. Solovev and M.A. Malyshkina, Antibiotiki, 17,1 0 6 7 ( 1 9 7 2 ) . L.J. Hanka and A. Dietz, Antimicrob. Ag. Chemother., 2, 425 ( 1 9 7 3 ) . Yu. E. Konev. V.A. Tsygonov, E.D. Etingov, N.M. Zavalnaya and A.I. Filippova, Antibiotiki, 18,354 ( 1 9 7 3 ) . G. Moktat, N. Rezvani, M. Emami and L. Lalezari, J. Pharm. Sci62,
(1973).
(1973). J.
u.,
(1972).
47. 48. 49.
485 ( 1 9 7 3 ) . 50. 51.
S . Casadio, A. Donetti and G. Coppi, J. Pharm. Sci., 62, 7 7 3 ( 1 9 7 3 ) . W.P. Cullen, R.T. La Tonde, C.J. Wang and C.F. Wong, 62,
w.,
826 ( 1 9 7 3 ) . 52. 53. 54. 55. 56. 57. 58. 59. 60.
L.D. Boeck, G.M. Clem, M.M. Wilson and J.E. Westhead, Antimicrob. Ag. Chemother. 3 , 4 9 ( 1 9 7 3 ) . H. Gershon, M-WTMcNeil, R. Parmegiani, P.K. Godfrey and J.M. Baricko, ibid., 4, 435 ( 1 9 7 3 ) . G. Medoff, M. Comfort and G.S. Kobayashi, Proc. Soc. Exp. Biol. and Med. 1 3 8 , 5 7 1 ( 1 9 7 1 ) . M. K u G o , T. Kamiya, H. Endo and S . Komiyama, Antimicrob. Ag. Chemother., 2, 5 8 0 ( 1 9 7 3 ) . G.S. Kobayashi, G. Medoff, D. Schlessinger, C.N. Kwan and W.E. Musser, Science, 177,7 0 9 ( 1 9 7 2 ) . J.M.T. Hamilton-Miller, J. Med. Microbiol., 2, 425 ( 1 9 7 2 ) . J.M.T. Hamilton-Miller, J. Gen. Microbiol., 2, 201 (1972). J.M.T. Hamilton-Miller, Chemotherapy, 18,1 5 4 ( 1 9 7 3 ) . J.W. Love, R.G. Garrison and D.R. Johnson, Mycopathol. Myco. Appl.,
4 8 , 289 ( 1 9 7 2 ) . 61. 62.
M. Grindle, Mol. Gen. Genet., 120, 283 ( 1 9 7 3 ) . Chuen-Chin Hsuchen and D.S. Finegold, Antimicrob. Ag. Chemother.,
4 , 309 ( 1 9 7 3 ) . 63. 64.
u.,
Chuen-Chin Hsuchen and D.S. Finegold, 4 , 316 ( 1 9 7 3 ) . G. Medoff, C.N. Kwan, D. Schlessinger and G.S. Kobayashi,
u., 3
114
Sect. 111 441, (1973).
65. 66. 67. 68.
-
Chemotherapeutic Agents
Warren, Ed.
e,
S . Shadomy, C.B. Kirchoff and G. Wagner, 2, 9 ( 1 9 7 3 ) . A. Polak and H.J. Scholer, Pathol. Microbiol., 3 9 , 1 4 8 ( 1 9 7 3 ) . E.R. Block, A.E. Jennings and J.E. Bennett, Antzicrob. Ag. Chemother. , 2, 649 ( 1 9 7 3 ) . C.A. Michels, J. Blamire, B. Goldfinger and J. Marmur, 2,
s,
562 ( 1 9 7 3 ) .
69. 70. 71.
S-C. Kuo, F.R. Cano, J.O. Lampen, M y 3, 716 ( 1 9 7 3 ) . F.R. Cano, S-C. Kuo and J.O. Lampen, ?bid., 3, 723 ( 1 9 7 3 ) . F. Schroder, J.F. Holland and L.L. Bieber, Biochem., 12, 4785
72.
S . Ahmad, M.A. 3, 436 ( 1 9 7 3 ) .
(1973).
Wahid and A.Q.S. Bukhari, Antimicrob. Ag. Chemother.
73. 74.
J.M.T. Hamilton-Miller, J. Pharm. Pharmacol., 25, 4 0 1 ( 1 9 7 3 ) . E.R. Block and J.E. Bennett, Antimicrob. Ag. Chemother., 5 , 6 4 8
75.
J.A. Linquist, S . Rabinovich and I.M. Smith,
(1973).
w.,4 , 5 8
(1973).
115 Chapter 13.
Antiparasitic Agents
W. C. Campbell and H. Mrozik, Merck Institute for Therapeutic Research, Rahway, New Jersey 07065 Agents - The -Antiprotozoal comprehensively reviewed.l
chemotherapy of protozoan diseases was The Abstracts of the Ninth International Congress on Tropical Medicine and Malaria2 contain many articles on protozoan and helminthic diseases. Many aspects of parasite biochemistry and drug action were presented at a recent meeting and have been published. 3
-
The current state of malaria chemoAntimalarial Drugs. General therapy, with special emphasis on drug resistance, was reviewed by the WHO scientific group.4 This survey contains a summary of the structures of 24 antimalarial drugs from 8 chemical classes in general use, of 16 experimental compounds receiving clinical trials, and of 9 experimental compounds so far used only in animal models. A general review on antimalarial drugs and their,actions, acridine antimalarials, and diagnosis and treatment of malaria became available.
-
The phenanthrene methanol WR33063 cured a high perClinical Data centage of human volunteers infected with several Plasmodium falciparum strains, including chloroquine-resistant ones, without evidence of phototoxicity or other serious side effects, although occasionally a treatment failure occurred, even at the largest doses used in therapy; such failures might be due to drug resistance.8 In another study, WR33063 did not protect volunteers from chloroquineand pyrimethamine-resistant P. falciparum infection when given prophylactically.9 The quinolize methanol WR30090 likewise demonstrated effective antimalarial action, with low toxicity, against multi-drug-resistant P. falciparum and P. vivax in human volunteers.l0 Contrary toexpectation, the Tnduced photosensitivity was judged by these investigators to be rare, of minor degree, and easily reversed by drug withdrawal. Prophylactically, this drug provided suppressive cures to 75% of volunteers exposed to P. falciparum, but not to P. vivax.9 Although these two drugs exemElify a major advance in tge cure of P. falciparum infections, they are only suppressive against P. vivax zhere the drug of choice still remains primaquine. l1 Amodiaquin appears curative against P. falciparum infections resistant to the structurally closely reiated chloroquine. This surprising observation was supported by new experiments showing no apparent difference in binding of 14C-amodiaquin by erythrocytes of monkeys infected with chloroquine-susceptible and chloroquine-resistant P. falciparum, whereas erythrocytes of chloroquineresistant infections have a deficiency of 14C-chloroquine binding. l2 The triple combination of chloroquine, sulfamethoxydiazine, and pyrimethamine (ratio 30:lO:l) showed a high degree of potentiation of the drug effects upon P. berghei infections in mice.13
-
116
Sect. I11
-
-
Chemotherapeutic Agents
Warren, Ed.
Drua Modifications The success of suinoline methanols and Dhenanthrene methanols in the cure of p. falciparum malaria caused the recent synthesis of many analogs intended not only to increase the activity but also to reduce the phototoxicity. The more active quinoline methanols are the adamantyl derivative I (curative in mice against P. berghei at 100-320 mg/kg), 14 the phenoxy derivative 40-80 mg/kg),15 and the 7,8-benzo derivative I11 I1 (curative A low phototoxicity was observed only (curative at 100 mg/kg).16 for I. The bis-trifluoromethyl phenanthrene methanol IV (curative at 40 mg/kg)rand the naphthylthiophene V (curative at 100-320 mg/kg)18 are interesting new versions of this lead. An analysis of 107 phenanthrene methanols for the contribution of polar and partition effects of substituents according to Hansch and of a smaller number according to the Free-Wilson Additivity Scheme was reported.19 Two highly active pyridine methanols were VI (curative at 2040 mg/kg)20 and VII (curative at 20-80 mg/kg).21 The quinacrine analog VIII (curative at 80 mg/kg) is more active and less toxic than quinacrine itself.22 DHDS (X), a suspected metabolite of diaminodiphenylsulfone (DDS, IX), had no antimalarial activity but caused marked methemoglobinemia, a side effect also of DDS chemotherapy. The tetraacetyl derivative TAHDS (XI), however, had antimalarial activity (curative at 160 mg/kg) superior to DDS (TAHDS) without causing formation of methemoglobin. It is not known if TAHDS is metabolized to DDS or another active metabolite or is active in its own right, but it is clear that DHDS is not responsible for the antimalarial action of either DDS or TAHDS.23 The acylaminonitrodiphenylsulfone XI1 had curative action on the order of DDS.24 The pyrimidinylaminobenzimidazole XI11 was selected from a group of 38 compounds with curative action against 5. berghei; it is well tolerated in mice. This benzimidazole was synthesized as one of the hypothetical active metabolites of the antimalarial guanidinopyrimidine (XIV), which is toxic and less active than XIII.25 The synthetic effort in the coenzyme Q antimetabolite area produced two new quinolinequinones with antimalarial activity: XV (curative at 320 mg/kg)26 and XVI (prophylactic in chicks against P. gallinaFor inhibition of coenzyme Q enzGes by 6 ceum at 120 mg/kg).27 hydroxy-7-alkyl quinolinequinone analogs of CoQ and for antimalarial activity, an alkyl chain length of 15 carbon atoms appears optima1.28 An optimal range for the enzrgy of the lowest empty molecular orbital as calculated by the Huckel technique as well as an appropriate partition coefficient, was determined for many of the antimalarial naphthoquinones. 29 A reexamination of 295 of these compounds showed that variation of the alkyl substituent according to Topliss' scheme (methyl, isopropyl, cyclopentyl, and cyclohexyl) would lead to some of the most active analogs after synthesis of only these four compounds.30 A compound related to hetol and twice as active (curative of P. berghei in mice after a single S.C. dose of 320 mg/kg) is XVII.3f 6
zt
-
Chap. 13
Antiparasitic Agents
Campbell, Mrozik
R6m
117
HOCHCH 2NH E t
2
R8
1-11 I R2 = 1 - a d a m a n t y l , -cH (OH ) c H 2 N ( N -Bu ) 2 ,
v
F3c%
I11
HOqHCH2NH ( 4 - h e p t yl )
V
IX, X, XI, XII,
DDS, X i = X 2 = N H 2 DHDS, Xi=X2=NHOH TAHDS, X1=X2=N( O A c ) A c X1=N02,
c1
a 3 H
XIV 0
-
Coccidiosis Two v e r y c o m p r e h e n s i v e and up-to-date reviews of cocc i d i o s i s appeared. 32, 33 The c u r r e n t c o m m e r c i a l c o c c i d i o s t a t s were c l a s s i f i e d i n t o 1 2 groups according t o t h e i r m o d e of action.34 It
118
Sect. I11 - Chemotherapeutic Agents
Warren, Ed.
was p o i n t e d o u t t h a t c o c c i d i a r e s i s t a n t t o one drug of a group a r e a l s o r e s i s t a n t t o t h e o t h e r d r u g s of t h e s a m e group and t h a t a s w i t c h i n medication must be t o a d i f f e r e n t group t o overcome t h i s resistance. T i s s u e c u l t u r e s of E i m e r i a t e n e l l a have been used t o detect a n t i c o c c i d i a l a c t i v i t y , 3 5 mode of drug a c t i o n , 3 6 growth f a c t o r antagonism,37 and e f f i c a c y of drug combinations,38 and t h i s e x c i t i n g new t e c h n i q u e w a s reviewed.39 The now f a m i l i a r a s s a y of chicken embryos i n f e c t e d w i t h E. t e n e l l a c o n t i n u e s t o g i v e i n t e r e s t i n g i n s i g h t s i n t o t h e a c t i v T t y and mode of a c t i o n of c o c c i d i o s t a t s .40, 41 The c o n t i n u i n g appearance of d r u g - t o l e r a n t c o c c i d i a s t r a i n s and t h e concomitant problems f o r p r o p h y l a c t i c chemotherapy were r e f l e c t e d i n t h e h i g h a c t i v i t y aimed a t d i s c o v e r y of new a n t i c o c c i d i a l s , a s w e l l as i n numerous s t u d i e s of t h e s e n s i t i v i t y of newly i s o l a t e d f i e l d s t r a i n s t o e x i s t i n g drugs. While m e t i c l o r p i n d o l w a s e f f i c a c i o u s a g a i n s t i n f e c t i o n s by E. t e n e l l a s t r a i n s t o l e r a n t t o other a n t i c o c c i d i a l agents, a metiTlorpindo1-tolerant s t r a i n w a s not c r o s s - r e s i s t a n t t o 14 other c o c c i d i ~ s t a t s . ~ An~ o b s e r v a t i o n t h a t a m e t i c l o r p i n d o l - t o l e r a n t s t r a i n of E. a c e r v u l i n a showed g r e a t e r t h a n expected s e n s i t i v i t y t o decoq;finate43 l e d t o a s y n e r g i s t i c drug combination of a 4-hydroxyquinoline c o c c i d i o s t a t p l u s m e t i c l o r p i n d o l , which w a s e f f e c t i v e a t lower l e v e l s t h a n t h o s e used f o r e i t h e r c o c c i d i o s t a t alone. Although b o t h classes of d r u g s a r e similar i n s t r u c t u r e and b o t h i n h i b i t t h e growth of s p o r o z o i t e s a t t h e same s t a g e of t h e l i f e c y c l e , no c r o s s - r e s i s t a n c e i s p r e s e n t between them and i t w a s concluded t h a t t h e y p r o b a b l y a c t upon c l o s e l y r e l a t e d b u t n o n i d e n t i c a l m e t a b o l i c pathways.44 An E. t e n e l l a s t r a i n r e s i s t a n t t o Novastat t r e a t m e n t w a s developed aEd shown t o b e c r o s s - r e s i s t a n t t o t r e a t m e n t w i t h nihydrazone, n i t r o f u r a z o n e , T r i t h i a d o l , U n i s t a t and z o a l e n e , b u t not t o 9 o t h e r COCcidi0stats.~5
-
-
The s t r u c t u r e of t h e ionophore a n t i b i o t i c A204A w a s d e s cribed.46 The conformation of X537A, a p o l y e t h e r a n t i b i o t i c , i n complexes w i t h metal s a l t s and amines i n d i f f e r e n t s o l v e n t s w a s d i s c ~ s s e d ; ~t h7 e g e n e r i c name l a s a l o c i d h a s been adopted f o r i t , and t h e o p t i m a l d o s e a g a i n s t mixed E i m e r i a i n f e c t i o n s i n c h i c k e n s w a s determined t o b e 0.0075% i n f e e d . 4 8 The a c t i v i t y of monensin w a s s t u d i e d i n b r o i l e r s 4 9 and cal~es.~B o r o i l e r s r a i s e d on a monensin-medicated d i e t developed o n l y a low immunity t o Eimeria i n f e c t i o n s . 5 1 The b i o s y n t h e s i s of monensin w a s d i s c u s s e d . 3 2 Robenedine a t 30 g/ton of f e e d p r o t e c t e d chickens from c o c c i d i o s i s caused by 8 E i m e r i a s p e c i e s . 5 3 A t e t r a hydro analog of robenedine i s claimed i n t h e p a t e n t l i t e r a t u r e f o r u s e of c o n t r o l of malaria and c o c c i d i o s i s . 5 4 Residue and metabolism of robenedine i n r a t s was s t u d i e d . 5 5 I t w a s shown t h a t b u q u i n o l a t e does n o t i n t e r f e r e w i t h t h e h o s t ’ s development of immunity a g a i n s t c o c c i d i a l species, 56 a l t h o u g h such i n t e r f e r e n c e c o u l d have been
Chap. 13
Antiparasitic Agents
Campbell, Mrozik
119 -
expected because of the drug's mode of action upon the sporozoites in the very early part of the life cycle.34 3,5-Dinitrobenzamides substituted in the 2-position with an amino or ethoxy group appeared to be active in experimental chicken c o c c i d i ~ s i s . ~The ~ 6-hydroxy2H-pyran-3(6H)-one derivative XVIII was active against E. tenella iKfections i ; chicks at 0.05% in the feed.58 The recenF patent literature mentions 4-nitro-5-cyanoimidazole derivatives further substituted at the 1- and 2-positions,59 cinnamylideneaminobenzylideneaminoguanidines,60 6-aminopurines and their N1-oxides with further substitution at the 9-position,61 aminoethylcarbazole,62 indazolylphenylureas,63 3-amino-2,4-diarylthiophene-l, l-dioxides,b4 and a new antibiotic, salinomycin (C39H6501Na) as potential coccidiostats.65
8
-
Trypanosomiasis A review series on animal H trypanosomiasi s is being published. 66 A O a m C H 3 monograph on Chagas's disease67 contains a description of the disease, its diagnosis, XVIII and the authors' extensive experience with nifurtimox therapy of acute and chronic cases in the clinic. With a 90- to 120-day treatment using nifurtimox, a high cure N -0 0 2 N q c 3 = L H < N 4 N H 2 rate of Chagasls disease could be obtained. XIX The 2-nitroimidazole derivative Ro-7-1051 showed high efficacy in laboratory studies against T. cruzi.68 The nitrovinylfuran derivative SQ 18,506 (XIX) had curaTive action in mice infected with T. brucei and T. rhodesiense at a dosage of 200 mg/kg every 12 hours for 3 days.69 Some tetracyclic diamidines were synthesized but did not approach the high trypanocidal activity of diminazene. 70 Amoebiasis - Inhibition of Entamoeba histolytica protein synthesis was correlated with the amoebicidal activity of a number of alkaloids and antibiotics. 71 Toxoplasmosis This subject was r e ~ i e w e d . ~ The ~ , ~cat ~ was implicated as the definitive host of Toxoplasma gondii with small mammals and birds as essential intermediFte hosts.74 The therapeutic effect of several sulfa drugs and DDS, alone and in conbination with pyrimethamine or trimethoprim, in T. gondii-infected mice was reported. The effect can be reversed by F-aminobenzoic acid, and trimethoprim alone has no activity.75 T. gondii infections in mice have been cured by clindamycin and Nrdemethyl-4l -pentyl ~ l i n d a m y c i nand ~ ~ by sulfameter plus pyrimethamine or spiramycin. 77
-
-
-
Antiprotozoal Nitrofurans and Nitroimidazoles Ipronidazole at 0.00625% in feed had antihistomonal activity equivalent to that of dimetridazole and ronidazole at their recommended levels and was more effective than carbazone, nitarsone or 2-acetylamino-5-nitrothiazole in preventing mortality in turkeys.78 2-(4-Carbostyryl)-5nitro-1-vinylimidazole, a urinary metabolite of 2-(4-methylstyryl)5-nitro-l-vinylimidazole, was curative in calves against T. vivax
--
120
Sect. 111
-
Chemotherapeutic Agents
Warren, Ed.
upon multiple dosing; this compound and several carboxylic acid derivatives also showed activity against T. vaginalis, E. histol tica, T. rhodesiense, T. cruzi, T. gambieke and T. concolense. ---d c
_
- - -
-
-
-
-
Antiprotozoal Antibiotics Antibiotics with antiprotozoal activity that have been mentioned in the recent literature are G-41880 (Entamoeba), dactylarin81 (Leishmania and Entamoeba) , and viomycin82(Trichomonas )
.
-
Drugs Active Against Nematodes, General Three major reviews of this subject appeared.83-83 Methodological contributions were made to the screening of anthelmintics86,87 and to their evaluation in ruminants.88,89 The role played by fumarate reductase inhibition in the mode of action of anthelmintics was further studied. Enzyme isolated from thiabendazole-sensitive Haemonchus was inhibited by thiabendazole, cambendazole, levamisole, morantel tartrate and disophenol, but not by mebendazole. Enzyme from a thiabendazole-resistant strain was similarly affected, except that the inhibitory effect of cambendazole was reduced and that of thiabendazole was not demon~trable.~ In~ lambs, after 4 generations of Haemonchus strain BPL-2 had been exposed successively to single doses of cambendazole at 5, 5 , 10 and 20 mg/kg, this parasite was less susceptible to cambendazole than it had been initially.91 Studies on the effect of mebendazole on Trichinella larvae in vitro or in rats suggested that the mechanism of anthelmintic action is similar to that observed in certain other helminths, i.e., mebendazole reduced the parasite's uptake of exogenous glucose thus apparently depleting the endogenous energy resource (glycogen).92 Studies with Ascaris also showed a primary inhibition of glucose uptake or transport, with secondary reduction in the uptake of other nutrients.93 The physiological distribution of dichlorvos, when administered to pigs in polyvinyl chloride pellets, was studied. Radioisotope measurements indicated that certain components of the polyvinyl chloride were incorporated into the tissues, but no dichlorvos or its metabolites were found.g4 Dinitro henol inhibited the uptake of arginine by Ascaris in vitro.!9
--
-
-
0
N
xx
CH3 e C C l = N N H
H XXI
s o
I I Ii NHCNHCOEt
=I1
NHCNHCOEt II II
s
0
0
The structure-activity relationships of piperazine derivatives were studied by measuring their relative potentiation of the acetylcholine response in nervemuscle preparations from Ascaris.
MrNkEt eN,)d XXIII
Chap. 13
Antiparasitic Agents
Campbell, Mrozik
121
The results suggested that diethylcarbamazine inhibits cholinesteraseSg6 Bephenium hydroxynaphthoate gave variable and often unsatisfactory results against Necator in man, even though a high dosage was used. It was suggested that the local strain of Necator may be partially resistant to the drug.g7 Diphetarsone (a pentavalent arsenical) was reported to be highly efficacious and well tolerated when used for the treatment of Trichuris infections in man.98
-
The latest of the benzimidazole anthelmintics, oxibendaNew Drugs zole ( X X ) , was reported to have a broad spectrum of activity and a good margin of safety. The drug is insoluble in water and only slightly soluble in most organic solvents. In sheep, single oxibendazole doses of 5-10 mg/kg were highly effective against immature and adult worms of the genera Haemonchus, Ostertagia, Trichostrongylus, Strongyloides, Nematodirus, Cooperia, Bunostomum, Oesophagostomum and Chabertia. In cattle, doses of 5-20 mg/kg were 80-100% effective in removing worms of the genera Haemonchus, Ostertagia, Trichostrongylus, Cooperia and Oesophagostomum. In swine exposed to Ascaris infection, the feeding of diets containing 0.05-0.10% oxibendazole provided protection against clinical signs of disease. Radioisotope studies in sheep showed that at 53 mg/kg, the peak plasma concentration was reached in 6 hours. Approximately 34% of the drug was recovered in the urine within 24 hours after dosing, and an additional 6% was recovered within 216 hours. In toxicologic studies, sheep tolerated a dose of 300 mg/kg; and a dose of 30 mg/kg, given at various intervals during gestation in sheep or rats, did not adversely affect fetal d e v e l ~ p m e n t . ~ ~ A new anthelmintic, p-toluoyl chloride phenylhydrazone (XXI), at 40 mg/kg p.0. was at least 97% effective against Haemonchus, Ostertagia, Trichostrongylus, Cooperia and Oesophagostomum in was 87% effective against Nematodirus and inactive against Trichuris. loo P
-
Thiophanate (XXII), diethyl 4,4'-0-phenylene-bis-( 3-thioallophanate), at 50 mg/kg, was at least 97%'-effective against Haemonchus, Ostertagia and Trichostrongylus in sheep and cattle. At 100 mg/kg it was highly active against Nematodirus and Cooperia, but variable against Dictyocaulus in sheep.lul Synergistic action against Dirofilaria was claimed for a combination of 3,3'-[[[4-[(4,6-diamino-l, 3,5-triazin-2-yl)amino]phenyl]arsinidine]bis(th~o)]b~s-D-val~ne (F151) and p-[ 5-[5-(4-methyl-1-piperazinyl)-2-benzimidazolyl]-2benzimidazoly1)-phenol (HOE33258). lo2 In rodents infected with Litomosoides, 3-ethyl -8-methyl-l ,3,8-triazabicyclo[4,4,O]decan-2one (XXIII) caused a transient reduction in microfilaremia but did not kill the adult worms.lo3
-
-
-
Drugs Active Against Trematodes Major reviews of anti-trematode drugs appeared.u',lu4 A new Technical Report from W.H.O. briefly reviewed the anti-schistosome drugs that are currently in use105 (a much more comprehensive account of these drugs appeared in
Sect. I11
122 -
-
Chemotherapeutic Agents
Warren, Ed.
197 2 ) .lo6
A method for screening compounds for fasciolicidal activity was described and was used to study the efficacy of many known f a s c i o l i ~ i d e s . ~A~way ~ of automatically measuring the movement of Schistosoma in response to drugs in vitro was reported and was proposed as a method for screening compounds for anti-schistosome activity.lo8 Transfer of immature flukes from the parenchyma to the bile ducts of goats gave results which suggested that the drug susceptibility of Fasciola is more dependent on degree of maturation than on location.109 The effect of bithionol on the glycolytic and oxidative metabolism of Paragonimus was studied.110 In a series of novel salicylanilides, fasciolicidal action required electron-withdrawing substituents on both the salicylic acid and aniline rings, together with a lipophilic group such as tert-butyl in the 3-position. However, not all such compounds were .___ fasciolicidal; compounds with a plasma half-life of less than 36 hours in sheep were inactive against fluke; those with a half-life of 48-84 hours were active; and those with a half-life of 5-6 days were very active. The last group included rafoxanide and several di -substituted 3-ter t -butyl -5-nit 1-0-6 -methylsalicylanilides '11
.
-
Fasciolicidal action was also reported for another series of salicylanilides in which an electronegative substituent was introduced in the 3-position. The choice of substituents in the aniline ring was restricted to halogens, methyl groups and tri-halogenated methyls (which improve lipid solubility). The most effective compounds were 3-nitro-2,6-dihydroxybenzoic acid anilides. The inhibition of succinate dehydrogenase from liver flukes has been corthe distribution of the compound between lipid and aqueous phase and not electronic or steric factors within the series is responsible for the activity. 113,114
in vitro by 25 substituted 2,6-dihydroxybenzanilides -related with the Hansch parameter*, suggesting that
-
The evolution of diamphenethide (XXIV) from 4-tert-butoxyacetanilide was recounted. Efficacy and safety of diamphenethide appear to depend on deacylation (probably to the diamino analog) by liver deacylases. Diamphenethide is not active against liver flukes in vitro unless incubated in the presence of enzymatically functional liver cells. Further, the diamino analog is rapidly effective in vitro in the absence of such cells. It was suggested that the production of this metabolite in the liver parenchyma, and its rapid destruction in the liver and dilution in the bloodstream, account for the high activity observed against immature, tissuedwelling flukes and the low activity against mature, duct-dwelling flukes.115 The unique relationship between efficacy of diamphenethide and age of F. -hepatica in shee was described and related to pathogenesis and Fontrol measures. 1
Le__
- L _ _
&
Chap. 13
O ,
Antiparasitic Agents
Campbell, Mrozik
123
xxv
0
72-MZ/
cH2-cH2, 0
XXIv
The structure-activity relationships of fasciolicidal thiobisphenol derivatives were described.l17
-
Drugs Active Against Schistosomes The level of serotonin in Schistosoma mansoni was increased when hycanthone (or a benzothiopyranoindazole) was given to the host mouse. '18 Hycanthone caused morphological transformation of virus-infected rat cells in culture'" and caused mutations in Salmonella. 120 However, no mutations were observed in thousands of offspring of male mice treated with a high dosage of hycanthone.121 Successful clinical use of hycanthone continued.122 The effect of the drug on liver enzymes of infected and noninfected hosts was studied.123 Oxamniquine ( X X V ) was highly active against S. mansoni in man and was well tolerated except for pain at the siteof injection.124 The antischistosome activity of nitrofuran compounds was further investigated. Comparison of 3-( 5-nitro-2-fur yl ) -substituted derivatives of propionic,